METHODS FOR MODIFYING RNA SPLICING CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. provisional application No. 62/519,226, filed on June 14, 2017, which is incorporated by reference herein in its entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0002] This application incorporates by reference a Sequence Listing submitted with this application as a text file in ASCII format entitled "10589-277-228_Sequence_Li sting.txt" created on June 13, 2018 and having a size of 1,200,491 bytes.

INTRODUCTION

[0003] In one aspect, described herein is a recognition element for splicing modifier (REMS) present in an intron (i.e., an "intronic REMS" or "iREMS") that can be recognized as a 5' splice site by the Ul snRNP and/or other components of the pre-mRNA splicing machinery in the presence of a small molecule splicing modifier, wherein gene expression is modified by inducing alternative splicing of intronic exons (iExons) in the transcribed RNA. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, a branch point and a 3' splice site, and the methods utilize a small molecule compound described herein to induce alternative splicing of iExons, More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene via alternative splicing of iExons, wherein a precursor RNA transcript transcribed from the gene comprises an endogenous or non-endogenous intronic REMS, and the methods utilize a compound described herein to induce iExon alternative splicing. In another aspect, provided herein are artificial gene constructs comprising an intronic REMS (including an endogenous or non-endogenous intronic REMS), and uses of those artificial gene constmcts to modulate protein production via iExon alternative splicing in the presence of a small molecule splicing modifier compound. In another aspect, provided herein are methods for altering genes to comprise a non- endogenous intronic REMS, and the use of a small molecule compound described herein to induce alternative splicing of iExons, subsequently modulating the amount and modifying the type of protein produced from such altered non-endogenous gene transcripts. BACKGROUN D

[0004] Diseases associated with expression of an aberrant quantity (lower or higher than normally required) of gene product or of an aberrant gene product (e.g., where the production of an aberrant RNA transcript or protein causes a disease) are often treated with a focus on affecting aberrant protein expression. However, targeting components of the splicing process responsible for production of aberrant RNA before the aberrant protein or aberrant quantity of protein is expressed by using a small molecule may affect the underlying cause of a disease or disorder, and thus more efficiently prevent or ameliorate the disease or disorder caused by expression of the aberrant gene product or aberrant quantity of gene product. Accordingly, there is a need for methods of modulating the expression of aberrant RNA transcripts encoded by certain genes using small molecules to prevent or treat diseases associated with expression of aberrant RNA transcripts or associated proteins or associated with expression of an aberrant quantity of RNA transcripts or associated proteins.

SUMMARY

[0005] In one aspect, provided herein is a recognition element for splicing modifier

(otherwise referred to as "REMS") present in an intron (i.e., an "intronic REMS" or "iREMS") capable of being recognized by the Ul snRNP and/or other components of the pre-mR A splicing machinery in the presence of a small molecule splicing modifier, whereby elements of the splicing reaction are affected as further described herein. In a specific aspect, the intronic REMS comprises the nucleotide sequence GAgurngn found in an intronic sequence at the RNA level, wherein r is A or G (i.e., a purine nucleotide carrying adenine or guanine) and n is any nucleotide. In another specific aspect, the intronic REMS comprises the nucleotide sequence GAguragu found in an intronic sequence at the RNA level, wherein r is adenine or guanine. In a specific aspect, the intronic REMS comprises the nucleotide sequence NNGAgurngn (SEQ ID NO: 1) found in an intronic sequence at the RNA level, wherein r is A or G (i.e., a purine nucleotide carrying adenine or guanine) and n or N is any nucleotide. In another specific aspect, the intronic REMS comprises the nucleotide sequence NNGAguragu (SEQ ID NO; 2) found in an intronic sequence at the RNA level, wherein r is adenine or guanine and N is any nucleotide. In one or more of such specific aspects provided herein, N is adenine or guanine.

[0006] In another aspect, in addition to the iREMS sequence, the intron of an RNA transcript comprises a branch point and a functional 3' splice site. One aspect described herein relates to iExons, wherein the RNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site (also referred to as an iExon 3' splice site), an intronic REMS sequence, a second branch point and a second 3' splice site (see, for example. Figure 1 A). In this aspect, in the presence of a compound described herein, the intronic REMS sequence functions as a 5' splice site and will undergo splicing with the second 3' splice site, causing the NNGA nucleotides of the iREMS sequence and the intronic nucleotides downstream from the first 3' splice site to be retained and spliced as an intronic exon to provide a non-wild-type mRNA. Another aspect described herein relates to eExons (extended exons), wherein the RNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an intronic REMS sequence, a branch point, and a 3' splice site (see, for example, see Figures IB and 1 C: Exon le and Exon 2e, respectively). In this aspect, in the presence of a compound described herein, the 5' splice site upstream of the iREMS splice site does not undergo splicing with the downstream 3' splice site. Instead, in the presence of a compound described herein, the iREMS sequence, in the presence of the downstream branchpoint, undergoes splicing with the downstream 3' splice site. In this aspect, the exon is extended from the 5' splice site by including one or more nucleotides into the mRNA transcript downstream of the annotated 5' splice site to the iREMS splice site.

[0007] In certain aspects, one or more sequence elements necessary to form an iExon may be present endogenousiy or non-endogenousiy, wherein the sequence elements are selected from the group consisting of an intronic REMS, a branch point and an iExon 3' splice site. In other aspects, one or more additional sequence elements necessary to form an iExon may be present endogenousiy or non-endogenousiy, wherein the sequence elements are selected from the group consisting of a 5' splice site, a second branch point and a second 3' splice site for an exon. In another aspect for an iExon, the sequence elements necessary to form an iExon include an upstream iExon 3' splice site sequence, an intronic REMS sequence, a downstream branch point sequence and a downstream 3' splice site sequence. In another aspect, where an eExon

(extended Exon) is formed, the sequence elements necessary to form an eExon include an intronic REMS sequence, a downstream branch point sequence and a downstream functional 3' splice site sequence. In certain aspects, one or more snRNPs and trans factor elements necessaiy for splicing may be present beyond endogenous levels as a result of the presence of a compound described herein at any of the various splice inducing sequence combinations described herein. Without being bound by any theory or mechanism, the small molecule compounds described herein, in conjunction with the iREMS sequence, initiate the assembly of a splicing-competent spliceosome around a weak or incompletely defined exon (i.e., a nascent iExon). Splicing modifier compounds most likely enable a functional Ul snRNP - REMS interaction and, at least, have been shown to increase the affinity of one or more snRNPs and trans factor elements necessary for splicing, including Ul, U2, U4, U5 and U6, whereby the interaction between the Ul snRNP, as well as other components of the pre-mRNA splicing machinery, and the nucleotides NNGA of the REMS (which will be retained as part of the iExon or eExon) are enhanced. In fact, we have discovered that the interaction of the Ul snRNP, the iREMS and the small molecule splicing modifier compounds described herein serve to define nascent exons by increasing the binding affinity of the pre-mRNA splicing machinery to the iREMS sequence, stabilizing Ul binding with the iREMS sequence, activating the iExon 3' splice site upstream from the iREMS (in the case of iExons) and recruiting U2 snRNP and other trans-acting splicing factors such as U2AF (U2AF65 and U2AF35) and SF3A (SF3A1, SF3A2 and SF3A3) to the downstream branch point and 3' splice site. The branch point and 3 'splice site may or may not necessarily be partially or fully occupied by trans factors in the absence of the compound but have been shown to become more occupied after the compound has enabled the formation of a functional Ul snRNP - iREMS complex. We have elaborated on the interaction of these key splicing machinery elements, showing that, in the presence of small molecule splicing modifier compounds such as, but certainly not limited to, those described herein, the mechanism of spliceosome assembly on a nascent iExon can be mediated by interaction of the iREMS sequence with such compounds, such that the intronic REMS sequence functions as a Ul snRNP binding site, resulting in intronic nucleotides spliced in the mature RNA transcript as a non-wild type intronic exon.

[0008] In Figure 1A, the intronic REMS is located in Intron 1 downstream from an

Exon 1 5' splice site {i.e., a 5' splice site at the 3' end of Exon 1), a first branch point (BP) sequence and a first iExon 3' splice site sequence and upstream from a second branch point sequence and a second 3' splice site sequence of Exon 2 in an RNA transcript (i.e., a precursor mRNA). In the presence of a small molecule splicing modifier compound described herein the iREMS sequence functions as a 5' splice site, whereby the nucleotides between the Exon 1 5' splice site and the first iExon 3' splice site are removed between Exon 1 and a nascent mtronic exon and the nucleotides between the intronic REMS and the second 3' splice site are removed between iExon la and Exon 2, thus allowing Exon 2 and the portion of the intron comprising nucleotides from the first 3' splice site up to and including NNGA of the intronic REMS to be joined, thus introducing an intron-derived iExon la, generating a non-wildtype mRNA, In certain aspects of Figure 1 A, one or more elements necessary to induce splicing may be present endogenously or introduced and may be in any confi guration capable of recognition by the splicing machinery as an "exon," wherein the one or more elements are selected from the group consisting of the intronic REMS, the first branch point, the first 3' splice site, the second branch point and the second 3' splice site. While illustrated for Intron 1 here, where the configuration in this instance results in a non-wild type iExon, this concept is generally applicable to any other intron in an R A transcript.

[0009] In Figure I B, the intronic REMS is located in an intron of an RNA transcript downstream from an Exon 1 5' splice site (i.e., a 5' splice site at the 3' end of Exon 1) and upstream from an Intron 1 branch point sequence and a 3' splice site sequence of Exon 2 (i.e., a 3' splice site at the 5' end of Exon 2). In the presence of a small molecule splicing modifier compound described herein, the nucleotides between the Exon 1 5' splice site and the intronic REMS are retained and those between the intronic REMS and the Intron I 3' splice site sequence (except the NNGA nucleotides of the intronic REMS) are removed, allowing Exon 1 and the portion of the intron comprising nucloeotides from those adjacent to the Exon I 5' splice site up to and including NNGA of the intronic REMS and the Exon 2 nucleotides to be joined. While illustrated for Exon 1 here as an example of a particular configuration, this concept is generally applicable to any other exon that has another downstream exon. The elements necessary to induce splicing of an eExon may be present in any configuration capable of recognition by the splicing machinery as an "exon." Accordingly, in the presence of a splicing modifier compound, the splieeosome recognizes the elements as exonic boundaries for removal of intervening intronic nucleotides between those boundaries. The configuration in this instance results in an eExon, with an extension of the upstream exon at its 3' end. [0010] In Figure 1C, the intronic REMS is located in Intron 2 downstream from an Exon 2 5' splice site (i.e., a 5' splice site at the 3' end of Exon 2) and upstream from an Intron 2 branch point sequence and a 3' splice site sequence of Exon 3 (i.e., a 3' splice site at the 5' end of Exon 3) in an RNA transcript. In the presence of a small molecule splicing modifier compound described herein, the nucleotides between the intronic RE S and the Exon 3 3' splice site sequence are removed, allowing Exon 3 and the portion of the intron comprising nucloeotides from those adjacent to the Exon 2 5' splice site up to and including NGA of the intronic REMS to be joined. In this example, the endogenous splicing reaction between Exon 1 and Exon 2 is unaffected by the presence of a compound described herein, resulting in the complete removal of Intron 1. While illustrated for Exon 2 here, this concept is generally applicable to any other nascent exon, i.e., an exon that is located between at least one upstream exon and one

downstream exon of the same pre-mRNA transcript.

[0011] As used herein, an "exon 5' splice site" or the like refers to a 5' splice site at the 3' end of the exon upstream from the iREMS sequence, while an "exon 3' splice site" or the like refers to a 3' splice site at the 5' end of the exon downstream from the iREMS sequence.

[0012] In the presence of a small molecule splicing modifier compound described herein, the iREMS nucleotides retained in the formation of an iExon or eExon are selected from the group consisting of ANGA, CNGA, GNGA, UNGA, NAGA, NCGA, NGGA, NUGA, AAGA, ACGA, AGGA, AUG A, CAGA, CCGA, CGGA, CUGA, GAGA, GCGA, GGGA, GUGA, UAGA, UCGA, UGGA and LIUGA. The inclusion of an iExon or the formation of an eExon may result in an RNA transcript having an altered or truncated open reading frame due to the inclusion of a frame-maintaining sequence, frameshift, premature stop codon, or internal insertion or deletion (as a result of mutually exclusive alternative splicing) within the open reading frame. In other aspects resulting from non-mutually exclusive alternative splicing, the inclusion of an iExon or the formation of an eExon may result in the mature mRNA having a functional open reading frame, producing a novel protein which may or may not be functional or may be unstable and rapidly degraded. RNA transcripts having an altered or truncated open reading frame are expected to be present in low abundance and can be substrates for nonsense-mediated decay, nonstop-mediated decay, no-go decay, translation-dependent decay, iExon-mediated decapping, alternative 3 'end formation and polyadenylation and thus have low abundance. Any intronic REMS-mediated alternative splicing modified RNA transcripts may also have altered stability, altered intracellular transport, altered 3' end formation efficiency and altered translation efficiency. In aspects described herein, the term "frame-maintaining sequence" refers to the inclusion of a sequence that alters the open reading frame but maintains nucleotide trimers between start and stop codon in the mature mRNA. In aspects described herein, the term

"mutually exclusive alternative splicing" refers to the choice between two exons or exon groups of which exon or exon group of the two will be spliced. In other words, mutually exclusive spli cing events are not independent, leaving only one of the exons or exon groups in a RNA to be spliced but not both (i.e., "mutally exclusive"). For example, inclusion of an iExon, per se, cannot result in a deletion. However, in a mutually exclusive alternative splicing event, such an inclusion may also result in exon skipping up or downstream of the iExon and a deletion when one exon or the other is spliced out. In other aspects described herein, the term "non-mutually exclusive alternative splicing" refers to independent splicing events in which one or the other or both exons or exon groups in a RNA may be spliced.

[0013] Accordingly, in one aspect, provided herein are methods for modulating the amount of RNA transcripts produced from precursor RNA containing an endogenous or non-endogenous intronic REMS. In another aspect, provided herein are artificial gene constructs comprising an endogenous or non-endogenous intronic REMS, which may be used in the context of, e.g., gene therapy or reporter assays. In another aspect, provided herein are methods for altering endogenous genes so that they contain an intronic REMS or an additional intronic REMS.

[0014] In another aspect, provided herein are methods for modulating the amount of one or more RNA transcripts {e.g. , mRNA transcripts) or proteins thereof expressed as the product of one or more genes, wherein precursor RNA transcripts transcribed by the one or more genes comprise an intronic REMS, the methods comprising contacting a cell with a compound of Formula (I):

CO

[0015] or a form thereof, wherein W, X, A and B are as defined herein.

[0016] In one aspect, provided herein is a method for modulating the amount of an RNA transcript produced from precursor RNA containing an Intronic Recognition Element for Splicing Modifier (iREMS), the method comprising contacting a cell containing the precursor RNA with a compound of Formula (I) or a form thereof, wherein the intronic REMS comprises the sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, wherein the precursor RNA is a gene described herein. In another aspect, provided herein is a method for modulating the amount of an RNA transcript produced from precursor RN containing an intronic recognition element for splicing modifier (REMS), the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof, wherein the intronic REMS comprises the sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, wherein the precursor RNA is a gene described herein. In some aspects, the intronic REMS comprises the sequence NNGAguragu (SEQ ID NO: 3) at the RNA level, wherein r is adenine or guanine and N is any nucleotide. In certain aspects, the intronic REMS comprises a sequence selected from the group consisting of ANGAgurngn (SEQ ID NO: 4), CNGAgurngn (SEQ ID NO: 5), GNGAgurngn (SEQ ID NO: 6), UNGAgumgn (SEQ ID NO: 7), NAGAgurngn (SEQ ID NO: 8), NCGAgumgn (SEQ ID NO: 9), NGGAgumgn (SEQ ID NO: 10), NUGAgurngn (SEQ ID NO: 1 1), AAGAgumgn (SEQ ID NO: 12),

ACGAgumgn (SEQ ID NO: 13), AGGAgumgn (SEQ ID NO: 14), AUGAgumgn (SEQ ID NO: 15), CAGAgurngn (SEQ ID NO: 16), CCGAgurngn (SEQ ID NO: 17), CGGAgurngn (SEQ ID NO: 18), CUGAgumgn (SEQ ID NO: 19), GAGAgumgn (SEQ ID NO: 20), GCGAgurngn (SEQ ID NO: 21 ), GGGAgurngn (SEQ ID NO: 22), GUGAgurngn (SEQ ID NO: 23), UAGAguragn (SEQ ID NO: 24), UCGAgurngn (SEQ ID NO: 25), UGGAgurngn (SEQ ID NO: 26) and UUGAgurngn (SEQ) ID NO: 27), wherein r is adenine or guanine and n or N is any nucleotide.

[0017] In some aspects, the intronic REMS comprises a sequence selected from the group consisting of ANGAguragu (SEQ ID NO: 28), CNGAguragu (SEQ ID NO: 29), GNGAguragu (SEQ ID NO: 30), UNGAguragu (SEQ ID NO: 31), NAGAguragu (SEQ ID NO: 32),

NCGAguragu (SEQ ID NO: 33), NGGAguragu (SEQ ID NO: 34), NUGAguragu (SEQ ID NO: 35), AAGAguragu (SEQ ID NO: 36), ACGAguragu (SEQ ID NO: 37), AGGAguragu (SEQ ID NO: 38), AUGAguragu (SEQ ID NO: 39), CAGAguragu (SEQ ID NO: 40), CCGAguragu (SEQ ID NO: 41 ), CGGAguragu (SEQ ID NO: 42), CUGAguragu (SEQ ID NO: 43), GAGAguragu (SEQ ID NO: 44), GCGAguragu (SEQ ID NO: 45), GGGAguragu (SEQ ID NO: 46),

GUGAguragu (SEQ ID NO: 47), UAGAguragu (SEQ II ⁾ NO: 48), UCGAguragu (SEQ II ⁾ NO: 49), UGGAguragu (SEQ ID NO: 50) and UUGAguragu (SEQ ID NO: 51) at the RNA level, wherein r is adenine or guanine, and N is any nucleotide. In one or more aspects provided herein, N is adenine or guanine.

[0018] In a specific aspect, the intronic REMS referred to in a method or artificial gene construct described herein comprises, at the RNA level, a sequence presented in Table 1

(wherein r is adenine or guanine, and n or N is any nucleotide):

[0019] Table 1. Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0020] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0021] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0022] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0023] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0024] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0025] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

[0026] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0027] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0028] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0029] Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 1 (cont). Intronic REMS RNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

three or more RNA transcripts of a gene described herein, the method comprising contacting a ceil with a compound of Formula (I) or a form thereof. In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another aspect, provided herein are methods for modulating the amount of one, two, three or more R_NA. transcripts of a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 20 6/ 96386), wherein the precursor transcript transcribed from the gene compri ses an intronic REMS, the method compri sing contacting a cell with a compound of Formula (I) or a form thereof. In another aspect, provided herein are methods for modulating the amount of one, two, three or more RN A transcripts of a gene, disclosed in International Patent Application No. PCT/US201 7/063323 (International Publication No. WO/2018/098446), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a ceil with a compound of Formula (I) or a form thereof.

[0040] In one aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof.

[0041] In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, comprising contacting a ceil with a compound of Formula (I) or a form thereof. In certain aspects, the cell is contacted with the compound of Formula (I) or a form thereof in a ceil culture. In other aspects, the cell is contacted with the compound of Formula (I) or a form thereof in a subject (e.g., a non-human animal subject or a human subject).

[0042] In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor RNA transcript transcri bed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, the methods comprising administering to a human or non-human subject thereof a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutical ly acceptable carrier, excipient or diluent.

[0043] In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject thereof a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0044] In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0045] In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein. In some aspects, a compound of Formula (I) is a compound selected from a compound described herein.

[0046] In another aspect of any of the foregoing methods for modulating the amount of one, two, three or more RNA transcripts of a gene described herein, the minimally required functional intronic REMS elements comprise, in 5' to 3' order: an intronic REMS sequence, a branch point sequence and a 3' splice site sequence.

[0047] In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3 ' order: a first 5' splice site, a first branch point, a first 3' splice site, an iREMS, a second branch point and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound). In a specific aspect, the RNA transcript is a transcript of a gene described herein (e.g., in a table herein or the examples herein). In a specific aspect, the iREMS is non-endogenous.

[0048] In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3' order: a branch point, a 3' splice site, and an iREMS, wherein the iREMS comprises an RNA sequence GAgumgn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound). In a specific aspect, the RNA transcript is a transcript of a gene described herein (e.g., in a table herein or the examples herein). In a specific aspect, the iREMS is non-endogenous.

[0049] In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, and wherein the RNA nucleotide sequence comprises exonic and intronic elements illustrated in Figure 1 A, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound). In a specific aspect, the RNA transcript is a transcript of a gene described herein (e.g., in a table herein or the examples herein). In a specific aspect, the iREMS is non-endogenous.

[0050] In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, and wherein the RN A nucleotide sequence comprises exonic and intronic elements illustrated in Figure IB, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound). In a specific aspect, the RNA transcript is a transcript of a gene described herein (e.g., in a table herein or the examples herein). In a specific aspect, the iREMS is non-endogenous.

[0051] In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RN nucleotide sequence 1 - comprises three exons and two introns, and wherein the RNA nucleotide sequence comprises exonic and intronic elements illustrated in Figure 1C, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound). In a specific aspect, the RNA transcript is a transcript of a gene described herein (e.g., in a table or the examples herein). In a specific aspect, the iREMS is non-endogenous.

[0052] In a specific aspect, the RNA transcript is the RNA transcript of a gene described in a table in this disclosure.

[0053] In another aspect, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or a protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first Y splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucletodie sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0054] In another aspect, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5' to 3' order: a nucleotide sequence encoding a branch point, a nucleotide sequence encoding a 3' splice site, and a nucleotide sequence encoding an iREMS, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0055] In another aspect, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5' to 3' order: a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0056] In another aspect, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1 A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0057] In another aspect, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DN A nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure IB, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0058] In another aspect, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0059] In a specific aspect, the gene is a gene described in a table in this disclosure.

[0060] In another aspect, provided herein are methods for preventing and/or treating a disease associated with the aberrant expression of a product of a gene (e.g., an mRNA transcript or protein), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one aspect, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein) described herein, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition compri sing a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another aspect, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein) described herein, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another aspect, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein)described herein, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another aspect, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene described herein (e.g., an mRNA, RNA transcript or protein), comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a

pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein. In certain aspects, a compound of Formula (I) is a compound selected from a compound described herein ,

[0061] In another aspect, provided herein are methods for preventing and/or treating a disease in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition compri sing a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods compri sing administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0062] In another aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition compri sing a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0063] In another aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical

composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, one, two, three or more RNA isoforms encoded by a gene described herein are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein. In certain aspects, a compound of Formula (I) is a compound selected from a compound described herein.

[0064] In another aspect, provided herein are methods for preventing and/or treating a disease in which a change in the level of expression of one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0065] In one aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0066] In another aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor R A transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[0067] In another aspect, provided herein are methods for preventing and/or treating a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, one, two, three or more RNA isoforms encoded by a gene described herein are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein. In certain aspects, a compound of Formula (I) is a compound selected from a compound described herein.

[0068] In another aspect, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an iREMS, a

- 3 / - nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0069] In another aspect, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucieotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5' to 3' order: a nucieotide sequence encoding a branch point, a nucleotide sequence encoding a 3' splice site, and a nucleotide sequence encoding an iREMS, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0070] In another aspect, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1 A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0071] In another aspect, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure IB, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0072] In another aspect, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1 C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another small molecule splicing modulator compound) to the subject.

[0073] In a specific aspect, the gene is a gene described in a table in this disclosure.

[0074] In another aspect, provided herein are artificial gene constructs. In one aspect, provided herein is an artificial gene construct comprising endogenous DNA modified to introduce a non-endogenous nucleotide sequence encoding an intron comprising a 3' splice site(s) and a branch point(s) and an intronic REMS. In another aspect, provided herein is an artificial gene construct comprising DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS, functioning as a 5' splice site in the presence of a compound described herein, which may be upstream of an endogenous nucleotide sequence encoding a branch point and an endogenous nucleotide sequence encoding a 3' splice site, is modified to introduce a nucleotide sequence encoding a non-endogenous branch point and a non- endogenous 3' splice site further upstream from the endogenous intronic REMS. In another aspect, provided herein is an artificial gene construct comprising DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS 5' splice site, which may be downstream of an endogenous nucleotide sequence encoding a branch point and an endogenous nucleotide sequence encoding a 3' splice site, is modified to introduce a nucleotide sequence encoding a non-endogenous branch point and a non-endogenous 3' splice site further downstream from the endogenous intronic REMS. In another aspect, provided herein is an artificial gene construct comprising DNA encoding an intronic REMS, comprising nucleotides encoding an intronic REMS having one or more 5' splice site(s), 3' splice site(s) and branch point(s). In certain aspects, the artificial gene construct encodes a frameshift or premature stop codon or internal insertions or deletions within the open reading frame. In other aspects, the artificial gene construct encodes a mature mR ^' NA having a functional open reading frame, producing a novel protein which may or may not be functional. In some aspects, the artificial gene construct encodes a detectable reporter protein. RNA transcripts having an altered or truncated open reading frame due to the inclusion of a frame-maintaining sequence, frameshift, premature stop codon or internal insertions or deletions within the open reading frame can be substrates for nonsense-mediated decay and thus have low abundance. Any intronic REMS-mediated alternatively spliced RNA transcripts may also have modulated stability, intracellular transport, 3 ' end formation efficiency and/or translation efficiency when compared to the wild type RNA transcript.

[0075] In a specific aspect, the nucleotide sequence of the intronic REMS introduced into the nucleotide sequence of the artificial gene construct comprises the sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is adenine or guanine and n or N is any nucleotide. In a specific aspect in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1809), CNG Agtrngn (SEQ ID NO: 1810), GNGAgtrngn (SEQ ID NO: 1811), TNGAgtrngn (SEQ ID NO: 1812), NAGAgtrngn (SEQ ID NO: 1813), NCGAgtrngn (SEQ ID NO: 1814), NGGAgtrngn (SEQ ID NO: 1815), NTGAgtmgn (SEQ ID NO: 1816), AAGAgt ngn (SEQ ID NO: 1817), ACGAgt ngn (SEQ ID NO: 1818), AGGAgtrngn (SEQ ID NO: 1819), ATGAgtrngn (SEQ ID NO: 1820), CAGAgtrngn (SEQ ID NO: 1821), CCGAgtrngn (SEQ ID NO: 1822), CGGAgtmgn (SEQ ID NO: 1823), CTGAgtrngn (SEQ ID NO: 1824), GAGAgtrngn (SEQ ID NO: 1825), GCGAgtrngn (SEQ ID NO: 1826), GGGAgtrngn (SEQ ID NO: 1827), GTGAgtmgn (SEQ ID NO: 1828), TAGAgtmgn (SEQ ID NO: 1829), TCGAgtmgn (SEQ ID NO: 1830), TGGAgtrngn (SEQ ID NO: 1831) and TTGAgtrngn (SEQ ID NO: 1832), wherein r is adenine or guanine and n or N is any nucleotide.

[0076] In a further specific aspect in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtragt (SEQ ID NO: 1833), CNGAgtragt (SEQ ID NO: 1834), GNGAgtragt (SEQ ID NO: 1835), TNGAgtragt (SEQ ID NO: 1836), NAGAgtragt (SEQ II) NO: 1837), NCGAgtragt (SEQ ID NO: 1838), NGGAgtragt (SEQ ID NO: 1839), NTGAgtragt (SEQ ID NO: 1840), AAGAgtragt (SEQ ID NO: 1841), ACGAgtragt (SEQ ID NO: 1842), AGGAgtragt (SEQ ID NO: 1843), ATGAgtragt (SEQ ID NO: 1844), CAGAgtragt (SEQ ID NO: 1845), CCGAgtragt (SEQ ID NO: 1846), CCGAgtragt (SEQ ID NO: 1847), GTGAgtragt (SEQ ID NO: 1848), CAGAgtragt (SEQ ID NO: 1849), GCGAgtragt (SEQ ID NO: 1850), GGGAgtragt (SEQ ID NO: 1851),

GTGAgtragt (SEQ ID NO: 1852), TAGAgtragt (SEQ ID NO: 1853), TCGAgtragt (SEQ ID NO: 1854), TGGAgtragt (SEQ ID NO: 1855) and TTGAgtragt (SEQ ID NO: 1856), wherein r is adenine or guanine and N is any nucleotide. In one or more aspects provided herein, N is adenine or guanineA or G. In various specific aspects, the nucleotide sequence encoding the intronic REMS is a nucleotide sequence encoding a non-endogenous intronic REMS, i.e., a precursor RNA transcript comprising the non-endogenous intronic REMS not naturally found in the DNA sequence of the artificial construct.

[0077] In a specific aspect, the intronic REMS referred to in a method or artificial gene construct described herein comprises, at the DNA level, a sequence presented in Table 2

(wherein r is adenine or guanine, and n or N is any nucleotide):

[0078] Table 2. Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0079] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0080] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0081] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0082] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0083] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0084] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0085] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0086] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and or N is any nucleotide)

0090] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0091] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0092] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0093] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0094] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0095] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0096] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

0097] Table 2 (cont). Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide)

[0098] In certain aspects, provided herein is a vector comprising the artificial gene construct described herein. In some aspects, provided herein is a cell comprising an artificial gene construct described herein or a vector comprising an artificial gene construct described herein, [0099] In another aspect, provided herein is a method of modulating the amount and modifying the type of a protein produced by a cell containing an artificial gene construct described herein. In one aspect provided herein is a method of modulating the amount and modifying the type of a protein produced by a ceil containing an artificial gene construct described herein, the method comprising contacting the cell with a compound of Formula (I) or a form thereof. In certain aspects, the artificial gene constaict encodes a therapeutic protein. In certain aspects, the artificial gene constmct encodes a non-functional protein. In some aspects producing a therapeutic protein, the artificial gene construct may also encode a detectable reporter protein. In some aspects producing a non-functional protein, the artificial gene constmct may also encode a detectable reporter protein.

[00100] In another aspect, provided herein is a method of modulating the amount of a protein produced by a subject, wherein the subject is or was administered an artificial gene construct described herein. In one aspect, provided herein is method of regulating the amount of a protein produced by a subject, the method comprising: (a) administering an artificial gene construct or a vector comprising the artificial gene constmct described herein to the subject; and (b) administering a compound of Formula (I) or a form thereof to the subject. In another aspect, provided herein is a method of regulating the amount of a protein produced by a subject the method compri sing administering a compound of Formula (I) or a form thereof to a subject carrying a gene containing a nucleotide sequence encoding an intronic REMS. In another aspect, provided herein is a method of regulating the amount of a protein produced by a subject, the method comprising administering a compound of Formula (I) to the subject, wherein the subject was previously administered an artificial gene construct described herein. In certain aspects, the artificial gene construct may encode a therapeutic or a non-functional protein. In some aspects, the artificial gene construct encodes a detectable reporter protein. In certain aspects, the subject is a non-human. In specific aspects, the subject is a human ,

[00101] In one aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of an RNA transcript produced from precursor RNA comprising a RNA nucleotide sequence in 5' to 3 ' order: a branch point, a 3 ' splice site and an endogenous or non- endogenous intronic recognition element for splicing modifier (REMS), wherein the intronic REMS comprises an RNA sequence GAgumgn, wherein r is adenine or guanine (A or G, respectively) and n is any nucleotide, the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof wherein the compound of Formula (I) is:

0 ⁾

or a form thereof, wherein

W is i l l C I S or S;

X is CM?., CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C -iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1 , 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bi cyclic or tricyclic ring sy stem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri, wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R.2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, d^alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl~amino-Ci-4alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Cj-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyi~Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4a!ky!-carbony!-amino, heteroaiyl-Ci-4alkyl~amino-carbonyl-Ci-4aikyi, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino~C i-4al ky 1 , heterocyclyl , heterocyclyl -C 1 - ₄ al ky 1 , heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ; R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino, Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci- ₄ al ky], d-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bi cyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-d-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i- ₄ alky 1 ,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C 1 - ₄ alkyl, d^alkyl-carbonyl-amino, C alkyl-carbonyl-amino-C i- ₄ aikyi, hydroxyl-d-4alkyl, d^alkyl-carbonyl, Ci-ialkoxy, halo-d^alkoxy, amino-d-4alkoxy, hydroxyl -C _1-4 alkoxy , C _1-4 al kyl-C al koxy , C■ - ₄ al ky 1 -amino-C■ - ₄ al koxy ,

(Ci.4alkyl)2-amino-Ci-4alkoxy, C alkyl-carbonyl-amino-C^alkoxy, Ci-ialkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cyc!oalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-C 1 -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroar}'l-Ci-4alkyl-carbonyl-amino, heteroaryl-Ci-4al kyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl -C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydiOxyl-Ci.4alkyl-amino; and

R5 is hydrogen, d- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00102] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of an RNA transcript produced from precursor RNA comprising a RNA nucleotide sequence in 5' to 3' order: a branch point, a 3 ' splice site and an endogenous or non- endogenous intronic recognition element for splicing modifier (REMS), wherein the intronic REMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof, wherein the compound of Formula (I) is selected from a compound of Formula (la) and Formula (l :

(la) (lb)

or a form thereof, wherein

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally- substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein d-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-d- ₄ alkyl, amino, d-4alkyl-amino,

(d-4alkyl) ₂ -amino, amino-Ci- ₄ al kyl , d-4alkyl-amino-d-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d-4alkyl-amino-carbonyl,

Ci-4alkyl~ammo-carbonyl-Ci-4alkyl, d-4alkyl-carbonyl-amino, d-4alkyl-carbonyl-amino- d- ₄ alkyl, hydroxyl -d- ₄ alkyl, Ci- ₄ alkyl-carbonyl, d- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino- Ci-4alkoxy, hydroxyl-Cwalkoxy, d-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- Ci-4al koxy, d-4arkoxy~carbonyl, Ci-4alkoxy-carbonyl-an ino, Ci-4alkoxy-carboi yl- amino-Ci-4alkoxy, C2-4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalky]-Ci-4alkoxy, C3-7cycloalkei yl, heteroaryl, heteroaryl-Ci-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-d^alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl -d-4alkyl -amino-carbonyl -d-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-d-4alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl -Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R_ is halogen, hydroxyl, cyano, oxo, hydroxyl -imino, d-4alkyl, halo-d-4alkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-d-4alkyl, amino-carbonyl,

hydroxyl-Ci- ₄ alkyl, d-4alkoxy, Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-C ₁ - ₄ alkyl;

R ₃ is halogen, hydroxyl, nitro, oxo, hydroxyl -imino, Ci- ₄ alkyl, amino, Ci- ₄ alkyl-amino,

(d-4alkyl) ₂ -amino, amino-Ci-4al kyl , d-4alkyl-amino-d-4alkyl,

(d-4alkyl) ₂ -amino-d-4alkyl, amino-carbonyl, d^alkyl-amino-carbonyl,

C ₁ - ₄ alkyl-amino-carbonyl-C ₁ - ₄ alkyl, d-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~ Ci- ₄ alkyl, hydroxyl -d-4alkyl, d-4alkyl-carbonyl, Ci- ₄ alkoxy, halo-d- ₄ alkoxy, amino- Ci- ₄ alkoxy, hydroxyl -d-4alkoxy, d- ₄ alkyl-d-4alkoxy, d^alkyl-amino-d^alkoxy, (d-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, d-4alkoxy- C ! - ₄ alkoxy, C i - ₄ alkoxy-carbonyl, C i ^alkoxy-carbonyl-amino, C alkoxy-carbonyl- amino-d-4alkoxy, C ₂ -4al kenyl , C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C3-7cycloaikyl-Ci-4alkoxy, C ₃ -7cycioalkenyl, heteroaryl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-d^alkyl-carbonyl-amino, heteroaryl -d-4alkyl -amino-carbonyl -d-4alkyl, heteroaryl-Cwalky 1 -carbonyl -amino-C i - ₄ alky 1 , heterocyclyl , heterocyclyl -Ci-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

R'S is independently selected from halogen, Ci-4alkyl, hydroxyl-Ci-4alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

R.5 is hydrogen, Ci-4al kyl , or hydroxy 1-Ci - alky 1;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00103] In one aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of an RNA transcript produced from precursor RNA comprising a RNA nucleotide sequence in 5' to 3 ' order: a branch point, a 3 ' splice site and an endogenous or non- endogenous intronic recognition element for splicing modifier (REMS), wherein the intronic REMS comprises an RNA sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof wherein the compound of Formula (I) is:

(I)

or a form thereof, wherein

W is ( 1 1 C! f or S;

X is ( S k CH(Ci- ₄ aikyi), C(Ci-4alkyl) ₂ , ( 1 1 CM. O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R?., and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)?.-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4a!ky!)2-amino~Ci-4aikyi, amino-carbonyl, Cwalkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4aIkyI-earbonyI, Ci-4alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci-4alkoxy, hydroxy 1-C 1 - ₄ alkoxy , C i- ₄ alkyl-C 1 -4alkoxy , C 1 - ₄ alkyl-amino-C 1 - ₄ alkoxy ,

(Ci-4a!ky!)2-amino~Ci-4alkoxy, Ci-4a!ky!-carbonyl~amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -?cycloalkyl,

C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaiyl, heteroaryl-C i-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-C i- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroary4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Chalky), amino,

d^alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci-4a) kyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-Ci-4alkyl, wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-salkyl, halo-Cwalkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl) ₂ -amino, amino-d^alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d- ₄ alkyl-amino-carbonyl,

(d- ₄ dkyl) ₂ -amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (Ci-4alkyl) ₂ -amino- carbonyl-Ci-4alkyl, d^alkyl-carbonyl-amino, d-4alkyl-carbonyl-amino-d-4alkyl, hydroxyl-Ci-4alkyl, d-4alkyl-carbonyl, Ci-4alkoxy, halo-d-4alkoxy, amino-Ci-4al koxy, hydroxyl-Ci-4alkoxy, d-4alkyl-d-4alkoxy, Ci-4alkyl~amino-Ci-4alkoxy,

(d-4alkyl) ₂ -amino-d-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci-4alkoxy~ C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C2-4alkenyl-amino-carbonyl , Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4aikyi, phenyl, or phenyl-C alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00104] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of an RNA transcript produced from precursor RNA comprising a RNA nucleotide sequence in 5' to 3' order: a branch point, a 3 ' splice site and an endogenous or non- endogenous intronic recognition element for splicing modifier (REMS), wherein the intronic REMS comprises an RNA sequence NNGAguragn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof, wherein the compound of Formula (I) is selected from a compound of Formula la) and Formula (lb):

or a form thereof, wherein

X is CH ₂ , CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or Cg-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy], cyano, Ci-4alkyl, halo~Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)?.-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Cj -4alkyl)2-amino-Ci-4aikyi, amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~ Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Ci-4alkyl~carbonyi, Ci-4alkoxy, amino- Ci- ₄ al koxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4aikoxy, Ci-4alkyl-amino-Ci-4alkoxy, (Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, d^alkoxy-carbonyl, Ci.4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl, heteroaryl-C i -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroaryl-d^alkyl-carbonyl-amino, heteroaryl-d^alkyl-amino-carbonyl-Cwalkyl, heteroaryl-d^alkyl-carbonyl-amino-d^alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-d-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, d- ₄ alkyl, halo-d-4alkyl, amino,

Ci-4alkyl~amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-d-4alkyl, amino-carbonyl,

hydroxyl-Ci- ₄ alkyl, d-4alkoxy, d-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -?cycloalkyl, or heterocyclyl-Ci-4alkyl;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, amino, Ci- ₄ alkyl-amino,

(d-4alkyl) ₂ -amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Cj-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d^alkyl-amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, d-4alkyl-carbonyl-amino, d- ₄ alkyl-carbonyl-amino- Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino- Ci-4al koxy, hydroxyl -d-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, d-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl -amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloaIkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryl-C walkyl,

heteroaryl-Ci-4alkyl-amino,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-d- ₄ alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

R is independently selected from halogen, d- ₄ alkyl, hydroxyl-Ci-4alkyl, amino, d-4alkyl- amino, (Ci-4alkyl) ₂ -amino or hydroxyl-d-4alkyl-amino; and Rs is hydrogen, Cwalkyl, or hydroxyl-C - -4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantionier, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00105] In one aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3 ' order: a nucleotide sequence encoding a branch point, a nucleotide sequence encoding a 3' splice site and a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence GAgtmgn, wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein the com ound of Formula (I) is:

or a form thereof, wherein

W is Ci l C H or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2; B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-C i-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, C - -4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4al kyl, Ci-4alkyl-carbonyl, C ₁ - ₄ alkoxy, halo-C i- ₄ alkoxy, amino-Ci-4al koxy, hydroxyl-Ci-4alkoxy, C j -4alkyl-Ci-4a!koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C i -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl -amino-carbonyl, Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

C!- ₄ alkyl-amino, (Ci-4alkyl)2-amino, amino-Cj-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci- ₄ alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci- ₄ alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-'jcycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R ₃ is halogen, hydroxy!, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino~carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-C ₁ - ₄ alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Cwalkyl-carhonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci~4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4a!koxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci-4alkyl,

heteroary!-Ci-ialkyl-amino, heteroaryl-C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4aikyi, heteroar}'l-Ci alkyi~carbonyi~amino-Ci-4alkyi, heterocyclyl, heterocyc!yl~Ci-4alkyl, phenyl, or phenyl-C ₁ - ₄ alkoxy;

4 is independently selected from halogen, Cj.- ₄ alkyl, hydroxyl-Cj.- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino, and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00106] In one aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3' order: a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound of Formula (I) to the subject wherein the compound of Formula (I) is:

0)

or a form thereof, wherein

W is (Ί I CM or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, Rs, or a bond;

A is aryl, heteroaryl, heterocyclyl , or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tric clic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloalkyl is a saturated or partial ly unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxyl, cyano, d- ₄ alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl -amino,

(Ci-4alkyl)2-amino, amino-d-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci-4alkyl)2-amino- earbonyl-Ci-4alkyl, Ci-4aikyi~carbonyi~amino, Ci-4aikyi~carbonyi~amino-Ci-4aikyi, hydroxyl-d- ₄ alkyl, d- ₄ alkyl-carbonyl, Ci~4alkoxy, halo-Ci-4alkoxy, amino-d- ₄ alkoxy, hydroxyl-Ci- ₄ alkoxy, Ci-4alkyl-Ci-4alkoxy, d-4alkyl-amino-d-4alkoxy,

(Ci.4alkyl)2-amino-Ci-4alkoxy, d^alkyl-carbonyl-amino-d^alkoxy, d-4alkoxy- Ci-4alkoxy, d-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- aniino-Cwalkoxy, C2-4aikenyl, C2-4alkenyl~amino-carbonyl, Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl, heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaiy 1-C i-4al ky 1 -carbony 1 -amino-C ι - ₄ al ky 1 , heterocy cly 1 , heterocy cly 1 -C i- ₄ al ky 1 , heterocyclyl-d-4alkoxy, phenyl, or phenyl -d-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring sy stem having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R? is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-amino, (d-4alkyl) ₂ -amino, amino-C i-4alkyl, Ci- ₄ alkyl -amino-C i- ₄ alkyl, (Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, d-4alkoxy,

Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-d-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, d- ₄ alkyl, halo-d- ₄ alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-C i-4alkyl, C ₁ - ₄ alkyl -amino-C i-4alkyl , (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d- ₄ alkyl-amino-carbonyl,

(d- ₄ alkyl) ₂ -amino-carbonyl, d^alkyl-amino-carbonyl-d^alkyl, (d- ₄ alkyl) ₂ -amino- carbonyl-d- ₄ alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, d.- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-d.- ₄ alkoxy, amino-d- ₄ alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4al kyl-Ci-4al koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(d- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, d- ₄ alkyl-carbonyl-amino-d- ₄ alkoxy, d- ₄ alkoxy- Ci-4al koxy, Ci-4alkoxy-carbonyl, CMalkoxy-carbonyl-amino, d- ₄ alkoxy-carbonyl- amino-d-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C ! -lalkyl-amino, heteroaryl -C Malkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl-C^alkyl-amino-carbonyl-Cwalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl-C alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl~Ci-4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00107] In another aspect, provided herein is a method of modifying RNA. splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3' order: a nucleotide sequence encoding a branch point, a nucleotide sequence encoding a 3' splice site and a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence GAgtmgn, wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein the compound of Formula (I) is selected from a compound of Formula (la) and Formula lb):

(la) (lb)

or a form thereof, wherein

X is CI I2, CH(Ci- ₄ alkyl), C(Ci-4al kyl)2, i l l C S i. 0 NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or Cg-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri, wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with I , 2, 3, 4, or 5 substituents each selected from R?., and wherein d-iocyeloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R?.;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, d- ₄ alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl -amino,

(C ₁ -4alkyl) ₂ -amino, amino-d^alkyl, Ci-4alkyl-amino~Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

C ₁ - ₄ alkyl-amino-carbonyl-C ₁ - ₄ alkyl, d^alkyl-carbonyl-amino, d- ₄ alkyl-carbonyl-amino- Ci-4alkyl, hydroxyl-d- ₄ alkyl, d-4alkyl-carbonyl, d- ₄ alkoxy, halo-d-4alkoxy, amino- C ! - ₄ alkoxy, hydroxyl -C i- ₄ alkoxy, Ci- ₄ alkyl-C i - ₄ alkoxy, C i- ₄ alkyl-amino-C i- ₄ alkoxy, (Ci-4alkyl)2-amino-Ci-4alkoxy, d^alkyl-carbonyl-amino-d^alkoxy, C ₁ - ₄ alkoxy- d-4alkoxy, d- ₄ alkoxy-carbonyl, d-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -d- ₄ alkyl,

heteroaryl-d^alkyl-amino, heteroaryl-C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-d-4alkyl-amino-carbonyl-d-4alkyl, heteroaryl-d alkyl-carbonyl-amino-d-4alkyl, heterocyclyl, heterocyclyl-d-4alkyl, heterocyclyl-Ci- ₄ alkoxy, phenyl, or phenyl -d- ₄ alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of phenyl, heteroaryl or heterocyclyi is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxy] , cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci- ₄ alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, amino-carbonyl,

hydroxyl-Ci-4alkyl, Ci-4alkoxy, Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloal kyl , or heterocyclyl-Ci-4alkyl;

R3 is halogen, hydroxy!, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, amino, Ci- ₄ alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci.4a!ky!)2-amino~Ci-4aikyi, amino-carbonyl, Cwalkyl-amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Cwalkyl-carbonyl-amino- Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino- Ci-4al koxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (Cj.- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4a!koxy, d-ialkoxy-carbonyl, Ci-4a!koxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl -amino-carbonyl, C ₃ -7cycloalkyl,

C3-7cycloaIkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaiyl, heteroaryl-Ci.4alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-aniino-Ci-4arkyl, heterocyclyi, heterocyclyl-Ci-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

Rs is independently selected from halogen, Ci-4alkyl, hydroxyl-Ci-4alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl) ₂ -amino or hydroxyl-Ci-4alkyl-amino; and

R5 is hydrogen, Ci.4alkyl, or hydroxy!~Ci.4alkyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racernate, enantiomer, diastereorner, stereoisomer, polymorph and tautomer form thereof

[00108] In another aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3 ' order; a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein the compound of Formula (I) is selected from a compound of Formula (la) nd Formula (lb):

(la) (lb)

or a form thereof, wherein

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , Π I CI I. O, l ₅ , or a bond;

A is aryl, heteroaryl, heterocyclyl, or C -iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having I, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Gj-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxy!, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, Ci-4alkyl-arnino,

(Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino- Ci-4alkyl, hydroxyl -Cwalkyl, Ci- ₄ alkyl-carbonyl, d- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino- Ci- ₄ alkoxy, hydroxyl-Ci- ₄ alkoxy, Ci- ₄ alkyl-Ci- ₄ alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C i- ₄ alkoxy- Ci-4alkoxy, d-4alkoxy-earbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -d-4alkyl, heteroaryl-Cwalkyl-amino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl ,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroar}'l-Ci alkyl~carbonyl~amino-Ci-4alkyl, heterocyclyl, heterocyclyl-d-4alkyl, heterocyclyl-Ci- ₄ alkoxy, phenyl, or phenyl -d-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ,

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-d-4alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-d-4alkyl, amino-carbonyl,

hydroxyl-Ci-4alkyl, d- ₄ alkoxy, Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-C 1 - ₄ alkyl;

R.3 is halogen, hydroxyl, mtro, oxo, hydroxyl-imino, Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci- ₄ alkyl) ₂ -amino, amino-d-4alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amir!0-Ci-4alkyl, amino-carbonyl, d-4alkyl-amino-carbonyl,

C ! - ₄ alkyl-amino-carbonyl-C 1 - ₄ alkyl, d-4alkyl-carbonyl-amino,

Ci-4alkyl, hydroxyl -d-4alkyl, d-4alkyl-carbonyl, d- ₄ alkoxy, halo-d-4alkoxy, amino- Ci- ₄ alkoxy, hydroxyl-Cwalkoxy, Ci- ₄ alkyl-Ci- ₄ alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (Ci.4alkyl)2-amino-Ci-4alkoxy, d^alkyl-carbonyl-amino-d^alkoxy, d-4alkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, d-ialkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-d^alkyl, heteroaryl-C 1 -lalkyl-amino, heteroaryl -C Ma!ky!-amino-carbonyl,

heteroaryl-d^alkyl-carbonyl-amino, heteroaryl-d-4alkyl-amino-carbonyl-d-4alkyl, heteroaryl-Cwalky 1 -carbonyl -amino-C i - ₄ alky 1 , heterocyclyl , heterocyclyl -Ci-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

Rs is independently selected from halogen, Ci-4alkyl, hydroxyl-Ci-4alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

Rs is hydrogen, Ci-4al ky] , or hydroxy 1-Ci - alky! ;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00109] In one aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3 ' order; a nucleotide sequence encoding a branch point, a nucleotide sequence encoding a 3' splice site and a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein the compound of Formula (I) is:

(0

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is ary], heteroaryl, heterocyclyl, or Cg-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri, wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R.2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, d^alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl~amino-Ci-4alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Cj-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyi~Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4a!ky!-carbony!-amino, heteroaiyl-Ci-4alkyl~amino-carbonyl-Ci-4aikyi, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino~C i-4al ky 1 , heterocyclyl , heterocyclyl -C 1 - ₄ al ky 1 , heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ; R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino, Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci- ₄ al kyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bi cyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i- ₄ alky 1 ,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci-4alkyl)2-amir!0-carbonyl, Ci-4alkyl-amim>carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C 1 - ₄ alkyl, C i- ₄ aikyi-carbonyi-amino-C i- ₄ aikyi, hydroxyl-Ci~4alkyl, Ci-4alkyl~carbonyl, Ci-ialkoxy, halo-Ci- ₄ alkoxy,

hydroxyl -C _1-4 alkoxy , C _1-4 al kyl-C al koxy , C■ - ₄ al kyl -amino-C■ - ₄ al koxy ,

(Ci.4alkyl)2-amino-Ci-4alkoxy, Ci.4alkyl-carbonyl-amino-Ci-.4alkoxy, Ci- ₄ alkoxy~ Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-C 1 -lalkyl-amino, heteroaryl -C Ma!ky!-amino-carbonyl,

heteroar}'l-Ci-4alkyl-carbonyl-amino, heteroaryl-Ci-4al kyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl -C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydiOxyl-Ci.4alkyl-amino; and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00110] In one aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3' order: a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein the compound of Formula (I) is:

0 ⁾

or a form thereof, wherein

W is i l l CI S or S;

X is CM?., CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , (Ί I (Ί I, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1 , 2, 3, or 4 substituents each selected from Rs,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring sy tem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyi~amino-Ci-4alkyl, (Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl, (Ci- ₄ alkyl) ₂ -amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci- ₄ al ky] , Ci-4alkyl-carbonyl-amii o, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4al kyl-Ci-4alkoxy, Ci-4alkyl-an ii o-Ci-4alkoxy,

(C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C walkoxy- Cwaikoxy, Cwalkoxy-earbonyl, Ci-4alkoxy-carbonyl-arnino, C i-4alkoxy -carbonyi ~ amino-Cwalkoxy, C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkOxy, C ₃ -?cycloalkenyl, heteroaryl, heteroaryl-Ci-ialkyl, heteroaryl-Cwalkyl-amino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl ,

heteroaryl-Ci-ialkyl-carbonyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl-Ci^alkyl, heteroar^4-Ci-4alkyl-carbonyl-ainino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci- ₄ alkoxy, phenyl, or phenyl -Ci- ₄ alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R:<,

R2 is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4al kyl -amino, (Ci-4alkyl)2-amino, amino-Ci-4al ky] , C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl, (Cj.- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, hydroxyl-Ci-4alkyl, Ci-4aikoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-vcycloalkyl, or heterocyclyl -d^alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl -imi no, Ci-4alkyl, halo-Cwalkyl, amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci-4alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amir!0-Ci-4alkyl, amino-carbonyl , Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)?.-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino-Cj.- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl~amino-Ci-4alkOxy,

(Cj.- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, C i-4alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, C^alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl~Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl -amino, heteroaryl -Ci^alkyl-amino-carbonyl-d^alkyl, heteroaryl-Ci-4alkyl-carbonyl-aniino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

R is independently selected from halogen, Ci-4alkyl, hydroxyl-Ci-4alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl) ₂ -amino or hydroxyl-Ci-4alkyl-amino; and

R.5 is hydrogen, Ci-4alkyl, or hydroxyl~Ci-4alkyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00111] In another aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3 ' order; a nucleotide sequence encoding a branch point, a nucleotide sequence encoding a 3' splice site and a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises a DNA sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein the compound of Formula (I) is selected from a compound of Formula (la) and Formula (lb):

(la) (lb)

or a form thereof, wherein

X is ( ^' ! !.'.. CH(Ci- alkyl), C(Ci-4alkyl)2, CM (Ί L O, NR5, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1 , 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R?, and wherein C9-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B i s heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxy!, cyano, C ₁ - ₄ alkyl, halo-d- ₄ alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-d-4alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-armno-Ci-4alkyl, amino-carbonyl, d-ialkyl-amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, d- ₄ alkyl-carbonyl-amino, d-4alkyl-carbonyl-amino- Ci-4alkyl, hydroxyi-d-4alkyl, d-4alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino- Ci-4alkoxy, hydroxyl-d-4al koxy, d-4alkyl-d-4alkoxy, Ci-4al kyl-amino-Ci-4al koxy, (Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkoxy, d- ₄ alkoxy- Ci-4al koxy, d-4alkoxy-carbonyl, d-4alkoxy-carbonyl-amino, d-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloaikyi,

C ₃ -7cycloalkyl-d- ₄ alkoxy, C ₃ -?cycloalkenyl, heteroaryl, heteroary!-Ci-ialkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-d-4alkyl-amino-carbonyl, heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaiyl-Ci alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl -Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R.3 ,

.2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Chal ky) , amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, amino-carbonyl,

hydroxyl-Ci-4alkyl, Ci-4a) koxy, Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-C i - ₄ alkyl;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d^alkyl-amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, Chalkyl-carbonyl-amino, Chalkyl-carbonyl-amino- Ci- ₄ alkyl, hydroxyl -Cj.- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino- Ci-4alkoxy, hydroxyl -Ci- ₄ al koxy, Ci-4alkyl-Ci-4alkoxy, Ci- ₄ a) ky)-amino-Ci-4a) koxy, (Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkoxy, Ci-4alkoxy- Ci- ₄ a) koxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Chalkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cyc)oalkyl-Ci~4alkoxy, C ₃ -7C-ycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-Chalkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-Chalkyl-carbonyl-amino, heteroaryl -Chalkyl -amino-carbonyl -Cwalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4aikyi, phenyl, or phenyl -Cj.- ₄ alkoxy;

R ₄ is independently selected from halogen, Ci- ₄ alkyl, hydroxyl-€i- ₄ alkyi, amino, Ci-4alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Chalkyl-amino; and

R.5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4alkyl; wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00112] In another aspect, provided herein is a method of modifying RNA splicing in order to modulate the amount and type of a protein produced by a gene comprising a DNA nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the DNA nucleotide sequence comprises in 5' to 3 ' order: a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a Y splice site, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS compri ses a DNA sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising admini stering a compound of Formula (I) to the subject, wherein the compound of Formula (I) is selected from a com ound of Formula (la) and Formula (lb):

(la) (lb)

or a form thereof, wherein

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl , heterocyclyl , or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R: , and wherein Cg-iocycloalkyl is a saturated or partial ly unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R?.;

B is heterocyclyl, wherein heterocvclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, d- ₄ alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl -amino,

(Ci-4alkyl)2-amino, amino-d-4alkyl, Ci-4alkyl-aniino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

C ₁ - ₄ alkyl-amino-carbonyl-C ₁ - ₄ alkyl, d^alkyl-carbonyl-amino, d- ₄ alkyl-carbonyl-amino- Ci-4alkyl, hydroxyi-Cwalkyl, d-4alkyl-carbonyl, d- ₄ alkoxy, halo-d-4alkoxy, amino- Ci-4alkoxy, hydroxy! -d- ₄ alkoxy, d-4alkyl-Ci-4alkoxy, d-4alkyl-amino-d-4alkoxy, (Ci-4alkyl)2-amino-Ci-4alkoxy, d-4alkyl-carbonyl-amino-d-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci- ₄ alkoxy-carbonyl, d-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -d-4alkyl,

heteroaryl-d^alkyl-amino, heteroaryl-C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4aikyi, heteroar}'l-Ci aikyi~carbonyi~amino-Ci-4alkyi, heterocyclyl, heterocyclyl~Ci-4alkyl, heterocyclyl-d- ₄ alkoxy, phenyl, or phenyi-Ci-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ,

2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-d- ₄ alkyl, amino,

d- ₄ alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-d- ₄ alkyl, amino-carbonyl,

hydroxyl-d- ₄ alkyl, Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-C 1 - ₄ alkyl;

R.3 is halogen, hydroxyl, niiro, oxo, hydroxyl-imino, Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci- ₄ alkyl) ₂ -amino, amino-d- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amir!0-Ci-4alkyl, amino-carbonyl , Ci-4alkyl-amino-carbonyl,

Ci-4alkyl-amino-carbonyl-Ci-4alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino- d- ₄ alkyl, hydroxyl-d- ₄ alkyl, d-4alkyl-carbonyf, Ci-4alkoxy, halo-d-4alkoxy, amino- Ci-4alkoxy, hydroxyl-C j -4alkoxy, Ci - ₄ alkyl-d-4alkoxy, C j -4alkyl-amino-C j -4alkoxy, (Ci-4alkyl)2-amii o-Ci-4alk xy, Ci-4alkyl-carhony]-aniino-Ci-4al koxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C i -4alkoxy-carbonyl-aniino, C i-4alkoxy-earbonyl- an ii o-Ci-4alkoxy, C2-4al keny] , C2-4alkenyl-amii o-carbonyl, C ₃ -7cycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryl-C walkyl,

heteroaryl-d-ialkyl-amino, heteroaryl-C i- ₄ alkyl-amino-carbonyl,

heteroaryl-d^alkyl-carbonyl-amino, heteroaryl-d-4alkyl-amino-carbonyl-d- ₄ alkyl, heteroaryl-Ci.4alkyl-carbonyl-amino~Ci-4alkyl, heterocyclyl, heterocyclyl-d- ₄ alkyl, phenyl, or phenyl-d-4alkoxy;

R4 is independently selected from halogen, Ci- ₄ alkyl, hydroxyl-Ci- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (d-4alkyl) ₂ -amino or hydroxyl-d-4alkyl-amino; and

R5 is hydrogen, Ci- ₄ alkyl, or hydroxyl-d-4alkyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00113] In a specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCAl, ABCAl 0, ABCB7, ABCB8, ABCCl, ABCC3, ABHD10, ABL2, ABL1M3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, AD AMI 2,

ADAM 15, Λί)ΛΜ 1 7. ADAM23, ADAM33, ADAMTSl, ADAMTS 19, ADCY3, ADDl, ADGRG6, ADH6, AD FIFE 1 , AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC 1, AHRR, AJUBA, AK021888, AK 3 10472, AKAPl, AKAP3, AKAP8L, AKAP9, AKNA, AKT1, ALCAM, ALDH4A1, AMPD2, A K1, ANK2, ANK3, A KFY1, ANKHD1- EIF4EBP3, ANKRA2, ANKRD13C, A KRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA1 1 , A_NXA6, AP2B 1, AP4B1-AS1, APAF I, APIP, APLP2, APOA2, APP, APPL2, APTX, ARHGAPl , ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARMCX6, ARSJ, ASAPl, ASIC1, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C1 , ATXN1, ATXN3, AURKA, ΑΧΓΝΙ, B3GALT2, B3GNT6, B4GALT2, BACE1, BAG2, BASPI,

BC033281 , BCAR3, BCL2L15, BCYRNl, BECNl, BEND6, BHMT2, BICDI , BIN1 , BIN3, ΒΪΝ3-ΓΠ, BIRC3, BIRC6, BNC1, BNC2, BRCA1, BRCA2, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZWl, C1QTNF9B-AS1, Clorf27, Clorf86, C10orf54, CllorfiO, Cllorf70, Cllorf73, Cllorf76, Cllorf94, C12orf4, C12orf56, C14orfl32, C17orf76-ASl, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CAB, CA3, CAB39, CACNA2D2, CAC B1, CACNB4, CADMl, CADM2, CALU, CAMKK1, CAND2, CAPNSl, CASC3, CASP7, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CC F, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDHll, CDH13, CDH18, CDK11B, CDK16, CDKALl, CDKN1C, CECR7, CELSR1, CEMIP, CENPI, CEP 12, CEP162, CEP170, CEP192, CEP57, CEP68, CFH, CFLAR, CUD 8, CHEK1, CHRM2, CUT A, C!Z!, CLDN23, CLIC1, CL.K4, CLTA, CMAHP, CNGA4, CNOT1, CNRIP1, CN 11)1. CMSS1, CNOT7, CNRIP1, CNTN1, COGl, COLlAl, COLLI Al, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1, COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLSl, CRTAP, CRX, CRYBG3, CRYL1, CSDEL CS IAI, CSN 1E, CSNKIGI, CTDSP2, CTNND 1 , CTRC, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYPIB I, CYP51A1, DAAMl, DAB2, DACT1, DAGLB, DARS, DAXX, DCAFIO, DCAFll, DC AF 17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAHl, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGS1, DENND1 A, DE ND1B, DE ND4A, DENND5A, DEPTOR, DET1, DFNB59, DGCR2, DGKl, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLCl, DLG5, DLGAP4, DMD, DMXLl, DNAH8, DNAHl 1, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK!. DOCK 11, DPP8, DSEL, DST, DSTN, DYNC1I1, DYRK1 A, DZIP1L, EBF1, EEA1, EEF1A1, EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, E1F4G3, ELF2, ELM02, ELN, ELP4, EMX20S, EN AH, ENG, ENOX1, ENPP1, ENPP2, ENSA, EP300, EPNl, Ι ΡΊΊ. ERC1, ERC2, ERCCl, ERCC8, ERGIC3, ERLIN2, ERRFIl, ESM1, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADSl, FADS2, FAF1, FAIM, FAMlllA, FAM126A, FAM13A, FAM160A1,

FAM162A, F 4174A, FAM195B, FAM198B, FAM2QA, FAM208B, FAM219A, FAM219B, F.AM3C, FAM46B, F.AM49B, FAM65A, FAM65B, FAM69B, FAP, FARP1, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXOIO, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFTl, FDPS, FER, FEZ1, FGD4, FGD5-AS1, FGFR2, FGFRLl, FGL2, FH0D3, FLU, FLNB, FLT1, FNT, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FRAS1, FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNTl, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBP1, GCFC2, GLCE, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGBl, GORASPl, GPRI, GPR183, GPR50, GPRS 9 A, GPRC5A, GPRC5B, GPSM2, GREM1, GRK6, GRTP1, GSE1, GTF2H2B, GTSF1, GUCA1B, GULP1, GXYLT1, HAPLNl, HAPL.N2, HAS2, HAS3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, 11 OX, HECTD2-AS1, HEG1, HEPH, HEY1, III. -A. HLA-E, I II. F, HMGAl, HMGA2, HMGB1, HMGCR, HMGN3-AS1, !IMGCSI, HMGXB4, HOOK3, HOXB3, HMOXl, HNMT, HNRNPR, H RNPULl, HP1BP3, HPS1, HRHl, HSD17B12, HSD17B4, HSPAIL, HTATIP2, HTT, LARS, IDHl, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, I BKAP, IL16, IL6ST, IN A, ΙΝΉΒΑ, ΙΝΌ80, IPP4B, INPP5K, INSIGI, INTU, INVS, IQCE, IQCG, ITCH, ITGA11, ITGA8, ITGAV, ITGB5, ITGB8, ΠΊΗ1, ITM2C, ITPKA, ITSN1, ί VI) KANSL3, KAT6B, CNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1199, KIAA1456, KIAA1462, KIAA1522, KIAA1524,

KIAA1549, KIAA1715, KIAA1755, KIDINS220, KIF14, KIF2A, KIF21A, KIF3A, KIT, KLCI, KLC2, KLF17, KLF6, KLHL7, KLRG1, KMT2D, KRT7, .fi 8, KRT19, KRT34, TAPl · 1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB 1 , LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINCOOI I, LTNC00472, LINC00570, LINC00578, LTNC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINCOIOI 1, LINCOl 118, LINC01204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMODl, LOC400927, LONPl, LOX, LPHN1, LRBA, LRCH4, LRIG1, LRP4, LRP8, LRRC1, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPDl, LYRMl, LZTS2, MACR0D2, MADD, MAFB, MAGED4,

MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1, MANI A, MAP4K4, MAPK10, MAPK13, MARCH7, MARCH8, MASPl, MB, MB21D2, MBDl, MB0AT7, MC4R, MCMIO, MDM2, MDN1, MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl, MEPCE, MFGE8, MFN2, i AT. MICAL2, ΜΪΝΡΡ1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMPIO, MMP24, MMS19, MMS22L, MN1, MORF4L1, MOXD1, MPPE1, MP/].!, MRPL3, MRPL39, MRPL45, MRPL55, MRPS28, MRVI1, MSANTD3, MSC, MSH2, MSH4, MSH6, MSL3, MSMOl, MSRB3, MTAP,

MTERF3, MTERFD1, MTHFD1L, MTMR3, MTMR9, M I R . MUMl, MVD, \!\ ^' , M.XR A5, MYADM:, MYB, MYCBP2, MYLK, MY01D, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl, NEURLIB, NF2, NFASC, NFE2L1, NFXl, NGF, NGFR, NHLHl, NIDI , NID2, NIPA1 , NKX3-1 , NLGN1 , NLN, NOL10, NOM03, NOTCH3, NOTUM,

NOVA2, NOX4, NPEPPS, NRD1, NREP, NRGI, NRROS, NSUN4, NT5C2, NT5E, NTNGl, NUDT4, NUP153, NUP35, NUP50, NUPL1 , NUSAP1 , OCLN, ODF2, OLR1, OS9, OSBPL.3, OSBPL6, OSBPL10, OSMR, OXCT1, OXCT2, P4HA1, P4HB, PABPC1, PAIP2B, PAK4, PAPD4, P ARD3, PARN, PARP14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCBP4, PCCB, PCDH10, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE1C, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC 1, PDXDC2P, PEAR1, PELI1 , PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZOl, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNM1 , PITPNM3, PLAU, PLEC, PLEK2, PLE HA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNCl, PMS1, PNISR, PGDN, POLE3, POLN, POLRIA, POLR3D, POMT2, POSTN, POU2F 1, PPAPDC1A, PPARA, PPARG, PPFIBPl , PPHLN1, PPIP5K1, PPIP5K2, PPM IE, PPP1R12A, PPP1 R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKG l, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTCH1, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RADl, RAD9B, RAD23B, RAF 1 , RALB, RAP1 A, RAP1 GDS1, RAPGEF I , RARG, RARS, RARS2, RASIP1, RASSF8, RBBP8, RBCK1, RCOR3, RBFOX2, RBKS, RBM10, RCC1, RDX, RERE, RFTN1 , RFWD2, RFX3-AS1 , RGCC, RGLl, RGS10, RGS3, RIFl, RNF14, RNF19A, RNF130, RNFI44A, RNF213, RNF38, RNFTl, ROR1, ROR2, RPA1, RPF2, RPL10, RPS 10, RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF ^' 8, SCARNA9, SCD, SCLT1, SCOl, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC6I A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SF3B3, SGIP1, SGK3, SGMS 1 , SGOL2, SGPL1, SH2B3, SH3RF ^' l, SH3YL1, SHROOM3, SIGLEC10, SKA2, SKIL, SKP1, SLC 12A2, SLC24A3, SLC25AI6, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A1 1 , SLC41 A1, SLC44A2, SLC46A2, SLC6A15, SL.C7A6, SLC7A8,

SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNEiDl, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1, SORCS2, SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPINK5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBF l, SREKl, SRGAPl, SRRM1, SRSF3, SSBP1 , STAC2, STARD4, STAT1 , STAT3, STAT4, STAC K STC2,

STEAP2, STK32B, S TRAD 8, STRIP 1, STRN3, STRN4, STS, STX16, STXBP4, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC1, TAF2, TAGLN3, TANC2, TANG06, TARBP1, TARS, TASP1, TBC1D15, TBCA, TBLIXRI, TBI .2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1 , TENM2, TEP1 , ΊΈΤ1, ΤΈΤ3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1 , TGFBRAP1, TGM2, THADA, THAP4, THBS2, THRB, TIAM1, ΤΓΜΡ2, TJAPl, TJP2, TLE3, TLK1, TMC3, TMEM67, TMEM102, TMEM1 9, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, TMEM256-PL S CR3 , TMEM47, TIvIEMSOB, TMEM63A, TMX3, TNC, T FAIP3, TNFAIP8L3, TNFRSF 12 A, TNFRSF14, TNIPl , TNKS1BP1, TNP03, TNRC18P1, T RC6A, TNS1, TNS3, TNXB, TOE1, TQMM40, TOMM5, TOPORS, TP53AIP1, ΤΡ53ΓΝΡ1, TPRGI, TRAP 3, TRAK1, TRAPPC12, TRIB 1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65,

TRIM66, TRMT1L, I RPC4, FRPS l . TSC2, TSHZ1, TSHZ2, TSPANl l, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBE I, TXNIP, TXNL 1 , TXNL4B, TXNRD1, TYW5, U2SURP, ί. ΒΛΡ21., IJBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMKI, UHRFIBPIL, UNCI3B, UNC5B, URGCP, URGCP-MRPS24, USP 19, USP7, USP27X, UVRAG, VA.NGL1, VARS2, VA.V2, VCL, VDAC2, VIM-AS1, VIP ASS 9, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDRI9, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPF1 , WISP1 , WNK1, WNT5B, WNT10B, WSB l, WWTRl, XDH, XIAP, XRN2, YAPI, YDJC, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB 10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZFP82, Zl 1X3. ZMIZl, ZMIZ -AS l , ZMLZ2, ZMYM2, ZNF12, ZNFI38, ZNF 148, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, Z F350, ZNF37A, Z F37BP, ZNF395, Z F426, Z F431, ZNF583, Z F618, Z F621, ZNF652, ZNF655, ZNF660, Z F674, ZNF680, ZNF730, ZNF74, ZNF764, ZNF777, ZNF778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, Z F839, Z F91 and ZSCAN25.

[00114] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA1, ABCB7, ABCC1, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ADAM 12, ADAM 15, ADAM 17, ADAM33, AFF2, AGK, AGPAT3, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAPl, AKAP9, A NA, ALCAM, ALDH4A1 , AMPD2, ANK2, ANKFY1 , ANKHD 1 -EEF4EBP3 , ANKRD17, ANKS6, ANP32A, ANXA1 1, ANXA6, AP2B 1, APAFl, APLP2, APP, APPL2, APTX, ARHGAP22, ARID 1 A, ARID2, ARMCX3, ASAP1, ASL, ASNS, AS PI I, ATAD2B, ATF7IP, ATG9A, AT M IN, ATP2C1, ATXN3, AURKA, ΑΧΓΝ1, B4GALT2, BACE1, BAG2, BASPl, BC033281, BCAR3, BEND6, BICDl, ΒΓ 1, BNCl, BRD2, BRPFl, BSCL2, BTBDIO, BZW l, C l lorfiO, Cl lorf73, C17orf76-ASl, C4orf27, C5orf24, C6orf48, C9orf69, CAB39, CALU, CAMKKl, CAPNS1, CASC3, CASP8AP2, CAV1, CCARl, CCDC77, CCDC88A, CCDC92, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42B A, CDCA7, CDH1 1 , CDH13, CDK11B, CDK16, CDKALl, CEP68, CFLAR, CHD8, CIZl, CLIC1, CLK4, CNOT1, COGl, COL12A1 , COL1 A1, COL6A1 , COPS7B, CPEB2, CREB5, CRLS1, CRTAP, CSDE1 ,

CSNKIAI, CTDSP2, CTNND1, CUL2, CUL4A, CUXl, CYB5B, CYBRDl, CYP51A1, DAB2, DACT1, DARS, DAXX, DC F10, DCAF11, DCBLD2, DCUN1D4, DDAHl, DDAH2, DDHD2, DDR1, DDX39B, DDX42, DENND1 A, DENNDIB, DENND5A, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIS3L, DKFZp434M1735, DKK3, DLCl, DNM2, DOCKl, DPP 8, DSEL, DST, DSTN, EBFl, EEAl, EEFIAI, EFCAB14, EGRl, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ENG, ENPP2, ENSA, EPNl, EPT1, ERCl, ERGIC3, ETV5, EXOl, EXTL2, EYA3, FADS1 , FADS2, FAF1 , FAM1 1 1 A, FAM 198B, FAM219A, FAM219B, FAM3C, FAM65A, FBXOIO, FBX018, FBX031, FBX034, FBX09, FDFT1 , FDPS, FER, FEZ 1 , FGD5- AS 1 , FGFRL 1 , FHOD3, FLU, FLNB, FN1 , FNBPl ,

FOCAD, FOS, FOSB, FOSL1, FOXKl, FOXM1, FUS, FYN, GABPB1, GALC, GALNT1, GAS 7, GBA2, GCFC2, GGCT, GHDC, GIGYF2, GJC1, GMIP, GNA13, GNAS, GN1.3L, GOLGA2, GOLGA4, GOLGB l , GORASP1 , GPR1, GPRS 9 A, GPSM2, GREM1 , GRK6, GSE1, GTF2H2B, HAS2, HA I L HAUS3, HAUS6, HDAC7, HEG1, FILA-A, HLA-E, HLTF,

HMGA1 , HMGB 1 , HMGCR, HMGCS1, HMOX1, HNRNPR, HNRNPUL1, HP1BP3, HRH1, HSD17B12, HSD17B4, HTT, LARS, IDHl, IDH, IGF2BP2, IL6ST, INFfflA, FNSIGl, IQCE, ITGAV, ITGB5, ITM2C, ITSN1, KANSL3, KCNK2, KIAA1033, KIAA 1143, KIAA1 199, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIF 14, KIF2A, KIF3A, KLC1, KLC2, KLF6, KLHL7, KRT18, KRT19, KRT34, KRTAP2-3, LAMA2, LAMB1 , LARP4, L.ARP7, LATS2, LDLR, LEMD3, LGALS8, LIMS1, L1NC00341, LINC00657, LMAN2L, LM07, LONPl, LOX, LRCH4, LRIG1, LRP8, LRRC8A, LSS, LTBR, LUC7L2, LZTS2, MADD, MAGED4,

MAGED4B, MAN1A2, MAP4K4, MBDl, MBOAT7, MDM2, MEDl, MED AG, MEF2D, MEIS2, MEMOl, MEPCE, MFGE8, MICAL2, MINPP1 , MKL1 , MKLN1, MKNK2, MLLT4, MLST8, MMAB, MMS19, MMS22L, MPPE1, MPZL1, MRPL3, MSANTD3, MSG, MSH2, MSH6, MSL3, MSMOl, MSRB3, MTAP, MTERFDI , MTHFDIL, MTMR9, MTRR, MUMI , MVD, MVK, MY ADM, MYLK, MYOID, ΜΥΌ9Β, MYOF, NAA35, NADK, NASP, NAV 1 , NAV2, NCOA1, NCOA3, NCOA4, NC STN, NELFA, NEOl, NEURL1B, NF2, NFE2L1, NFX1, NIDI, NID2, PA1 , NKX3-1, NOL10, ΝΌΜ03, NPEPPS, NRD1, NREP, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, ODF2, OS9, OSBPL6, OSMR, P4HA1, P4HB, PABPC1 , PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCS 9, PDE4A, PDE7A, PDLIM7, PDXDC1 , PEPD, PEX5, PFKP, PHF19, PHF8, PHRF1 , PHTF2, PI4K2A, PIEZOL PIGU, PIK3C2B, PITPNA, PITPNB, PITPNM1, PLAU, PLEC, PLEKFJB2, PLSCR3, PLXNB2, PLXNC1, PMS1, POLE3, POLR3D, POSTN, POU2F1, PPAPDCl A, PPARA, PPHLNl, PPIP5K 1 , PPP1R12A, PPP6R1, PPP6R2, PRKACB, PRKDC, PRMT1, PRNP, PRSS23, PSMA4, PSMCl, PSMD6, PTK2B, PTPN14, PUF60, PUS7, PVR, PXN, QKI, RAB23, RAB2B, RAB34, RADl, RAD23B, RALB, RAPIA, RAPIGDS I , RARG, RASSF8, RBCK1, RBFOX2, RBM10, RCC1, RFTN1, RFWD2, RGS 10, RGS3, RIF1, RNF14, RNF19A, R.NF38, RNFT1 , RPLIO, RPS6KC1 , RRBPl , RWDD4, SAMD9, SAMD9L, SAR A, SART3, SCAF4, SCAF8, SCD, SCLTl, SCOl, SDCBP, SEC14LL SEC 22 A, SEC24B, SEC61A1 , SEPT9, SERPINE2, SF 1 , SGOL.2, SH3RF1, S IL, SLC25A17, SLC39A3,

SLC41A1, SLC4A4, SLC7A6, SLC7A8, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMGl, SMN2, SMPD4, SMYD3, SMYD5, SNAP23, SNUG 16, SNX14, SOCS2, SON, SOS2, SPATA20, SPATS2, SPG20, SPRED2, SQLE, SQRDL, SQSTM1, SRCA P, SREBF1, SREK1, SRSF3, STARD4, STATl, STAT3, STAUl, STC2, STEAP2, TRI P ! , STRN3, STX16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TACC1, TAF2, TANC2, TARBP1, TARS, TBC1D15, TBL2, TCF7L2, TENCL TEN I2, TEP1, TET3 , TFCP2, TGFBI, TGFBR1, TGFBRAP1, THADA, THAP4, TI IRB, TIMP2, TJP2, TLE3, TLKl , TM:EM154, TMEM47, TMEM63A, TNC, TNFAIP3, TNFRSF12A, TNIPl, TNKSIBPI, TNP03, TNS l, TNS3, TOEl, TOMM40, TOMM5, TOPORS, TP53INP1 , TRAF3, TRA 1, TRAPPC12, TRIB1 , TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRMT 1L, TRPS 1 , TSC2, TSHZl, TSPAN2, TTC7A, TUBB2C, TUBB3, TXNL1 , TXNRD1, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMKl, UHRFIBPIL, UNC5B, USP19, USP7, VANGL1, VARS2, VCL, VIPAS39, VPS 13 A, VPS29, VPS51, VWA8, WDR19, WDR37, WDR48, WlPF l , WNT5B, WSB1, WWTRl, XIAP, XRN2, YAPl, YESl, YPEL5, YTHDF3, Z24749, ZAK, ZBTB IO, ZBTB24, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC1 1, ZEB1, ZEB2, ZFAND1, ZFAND5, ZHX3, ZMIZ1, ZMYM2, ZNF12, ZNF148, ZNF219, ZNF227, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF37A, ZNF37BP, ZNF395, ZNF583, ZNF621, ZNF652, ZNF655, ZX 1-074. ZNF74, ZNF764, Z F778, ZNF780A, ZNF827, ZNF839 and ZNF91.

[00115] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ANKRD36, APLP2, ARHGAP12, ARMCX6, ASAP1, ATG5, AXINl, BIRC6, Clorf86, CDC42BPA, CLTA, DYRKIA, ERGIC3, FBXL6, FOXM1 , GGCT, KAT6B, KDM6A, KIF3A, KMT2D, LARP7, LYRM1 , MADD, MAN2C1, MRPL55, MYCBP2, MY09B, PNISR, RAPIA, RAPGEFl, SENP6, SH3YL1, SLC25A17, SMN2, SREK1, STR.N3, TAF2, TMEM134, VPS29, ZF AND I and ZNF431 ,

[00116] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ANKRD36, ARHGAP12, ARMCX6, ATG5, BIRC6, Cl orf86, CLTA, DYRKIA, FBXL6, KAT6B, KDM6A, KMT2D, LYRM1, MAN2C1, MRPL55, MYCBP2, PNISR, RAPGEFl, SENP6, SH3YL1, TMEM134 and

ZNF43 ,

[00117] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA10, ABCC1 , ACTA2, ADAL, ADAM 1.2, ADAMTS l, ADAMTS5, ADD1, ADGRG6, ADH6, ADHFEI, AFF2, AFF3, AGK, AGPS, AKAP3, ANKl, ANK2, A.NK3, ANKRD33B, ANXAl l, ANXA6, AP4B .1-AS1, ARHGEF16, ARID5B, ARL9, ARMCX3, ASAPl , ASIC1, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYR 1, BI 3-IT1, BIRC3, BTG2, C10orf54, Cl lorfVO, Cl .lorf73, C.l lorf94, C12orf56, C19orf47, C3, C4orf27, C7orf31 , C8orf34, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CCDC79, CCER2, CCNF, CDCA7, CDKAL1, CELSRI, CEMIP, CEP 170, CFH, CUT A, CLDN23, CMAHP, CNGA.4, CNTDl , COLl l A , COL12A1 , COL14A , COL15A1 , COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLFI, CRYLl, CUX1 , CYB5B, CYB5R2, CYGB, CYP1B1 , DCLK1 , DCN, DDIT4L, DDX42, DDX50, DEGS1, DENND1A, DENND5A, DEPTOR, DFNB59, DGKA, DHFR, DIAPH3, DIRAS3, DIS3L, DLG5, DNAH8, DNAJC27, DOC I, DOCK11, DYNC1I1, DZIP1L, EBF 1 , EFEMP1, EGR3, EIF2B3, ELN, ELP4, EMX20S, ENPP1, ERCC8, ESMl, EVC2, F2R, FAM160A1, FAM198B, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FB 2,

FBX09, FCHOl, FER, FGFR2, FGL2, FLTl, FRASl, FSCN2, GAL3ST4, GALC, GALNT15, GATA6, GBGT1, GCNTl, GDF6, GNAQ, GOLGBl, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GXYLT , HAPL l, HAPL 2, HAS3, HAVCR2, FID AC 5, HECTD2-AS1, HEPH, I!FYl. HLTF, HMGN3-AS1, HMOX1, HOOK3, HSD17B12, HSPA1L, HTATIP2, HIT, IGDCC4, IGF2R, IGFBP3, IL16, IN A, INTO, IQCG, ITGAll, ITGA8, ITGB8, ITIHl, ITPKA, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1524, KIAA1715, KIAA1755, KIT, KLF17, KLRG1, KRT7, KRTAPl-1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, LINC00472, LINC00570, LLNC00578, LINC00607, LINC00678,

L]:NC( ⁾ ()702, LINC00886, LINC00961, LINC01011, LINCOl 118, LINC01204, LMOD1, LRBA, LRP4, LRRC32, LRRC39, LSAMP, LUM, LYPD1, LYRMl, MAFB, MAMDC2, MAN1A2, MAN2A1, MAPK13, MASPl, MB, MC4R, MEDAG, MEGF6, MEMOl, MIAT, MIR612, MLLT10, MMP10, MMP24, MMS19, MN1, MOXDl, M YfK MSH4, MTERF3, MXRA5, MY01D, NA, NAALADL2, NAEl, NAGS, NDNF, NEURL1B, NGFR, NHL-Hl, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, NTNGl, OCLN, OLRl, OSBPL10, OXCT2, PAIP2B, PAPD4, PBLD, PCM1, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PDXDC1, PEAR , PEPD, PHACTR3, PI4K2B, PIK3R1, PIM2, ΡΓΓΡΝΒ, PITPNM3, PLAU, PLEK2, PLEKHA6, PLEKHH2, PLXNCl, PMSl, PGDN, POLK POLRIA, POSTN, PPMIE, PPP3CA, PRKCA, PRKDC, PRKG1, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RCC1, RDX, RFWD2, RFX3-AS1, RGCC, RNFT1, ROR1, ROR2, RWDD4, SCARNA9, SCOl, SEC22A, SHROOM3, SIGLEC10, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A 5, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SMYD3, SNEDl, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, SQRDL, STAC2, STAT1, STAT4, STEAP2, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNP02, SYNP02L, TAGLN3, TANG06, TARBP1, TEX21P, TGFA, TGFB2, TGFB3, TGM2, T ADA, THBS2, THRB, TMEM102, TMEM119, TMEM256- PLSCR3, TMEM50B, TNC, TNFAIP8L3, TNFRSF14, TNRC18P1, TNS3, TNXB, TP53AIP1, TPRG1, TRAF3, TRIM 66, TRPC4, TSHZ2, TSPAN11, IS PAN 18, TSPAN7, TSSK3, TXNIP, UNC5B, USP27X, UVRAG, VIM-ASl, VPS41, VSTM2L, VWA8, VWF, WDR91, WISPl, WNT10B, XRN2, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-AS1, Z F212, ZNF350,

ZNF660, ZNF79 and Z F837.

[00118] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCAlO, ACTA2, ADAL, ADAMTSl,

ADAMTS5, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AK.AP3, AN 1, ANK3, ANKRD33B, AP4B1-AS1, A il(i l ^; !6, ARID5B, A 1.9. ASICl, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYR 1, BIN3-IT1, BIRC3, BTG2, C10orf54, CllorfVO, Cllorf94, C12orf56, C19orf47, C3, C7orf31, C8orf34, CAB, CA3, CACNA2D2, CACNB1, CADMl, CAND2, CCDC79, CCER2, CCNF, CELSR1, CEMIP, CEP170, CFH, CIITA, CLDN23, CMAHP, CNGA4, CNTDI, COL11A1, COL14A1, COL15A1, COL5A1, COLS A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLF1, CRYL1, CYB5R2, CYGB, CYPIBI, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DNAH8, DNAJC27,

DOCK11, DYNCIH, DZIP1L, EFEMPl, EGR3, ELN, ELP4, EMX20S, E PP1, ERCC8, ESMl, EVC2, F2R, FAM160A1, FAM20A, FAM46B, FAM65B, FAP, FARPl, FBLN2, FBN2, FBX09, FCHOl, FGFR2, FGL2, FLT1, FRAS1, FSC 2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GNAQ, GPRI83, GPR50, GPRC5A, GPRC5B, GRTP1, GUCAIB, GXYLTl, HAPL 1, HAPL 2, HA S3, HAVCR2, HDAC5, HECTD2-AS1, HEPH, WHY I. 1IMG.\ -\SL HOOK3, HSPAIL, HTATIP2, IGDCC4, IGF2R, IGFBP3, IL16, INA, INTU, IQCG, ITGA11, ITGA8, ITGB8, ΠΊΗ1, ITPKA, KCNS1, K.CNS2, KDM6A, KDSR,

KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRGl, KRT7, KRTAPl-1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, 1.IXC00472, LINC00570, LINC00578,

LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LRBA, LRP4, LRRC32, LRRC39, LSAMP, LUM, LYPD1, MAFB, MAMDC2, MAN2A1, MAPK13, MASPI, MB, MC4R, MEGF6, MIAT, MIR612, MLLTIO, MMPIO, MMP24, MN1, MOXD1, MRVI1, MS! 14, MTERF3, MXRA5, NA, NAALADL2, NAE1, NAGS, NDNF, NGFR, Mil. Hi, LN, OTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PI4K2B, PIK3R1, PIM2, PITPNM3, PLEK.2, PLEKHA6,

PLEKHH2, PODN, POLN, POLRIA, PPMIE, PPP3CA, PRKCA, PRKGl, PRPH2, PRRG4, PR.UNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RDX, RF ^' X3-AS1, RGCC, ROR1, ROR2, SCARNA9, SHROOM3, SIGLEC10, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNEDL SORBS2, SORCS2, SOX7, SPDYA, SPEF2, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNP02, SYNP02L, TAGLN3, TANG06, TEX21P, TGFA, TGFB2, TGFB3, TGM2, THBS2,

TMEM102, TMEM119, TMEM 256-PL S C R3 , TMEM50B, TNFAIP8L3, TNFRSF14,

TNRC18P1, TNXB, TP53AIP1, TPRG1 , TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TXNIP, USP27X, UVRAG, VIM-ASi, VPS41, VSTM2L, VWF, WDR91, WISP1, WNTIOB, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-AS1, ZNF212, ZNF350, ZNF660, ZNF79 and ZNF837.

[00119] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ABCC3, ADAM 17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, ARHGAPl, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICDl, BTN3A1, Cllorf30, Cllorf73, C12orf4, C14orfl32, C8orf44, C8orf44-SGK3, C8orfB8, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEKl, CMAHP, CNRIPl, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNMBP, DOCK I. DYRKIA, EIF2B3, EN AH, ENOX1, EP30Q, ERC1, ERCCL ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, F AM 13 A, FAM162A, F AM 174 A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGBl, GPSM2, GULP1, GXYLTl, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPPSK, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, I t ( ^' 71.3, LYRM1, MADD, MB21D2, MCMIO, MED13L, MEDAG, MEMOl, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCTl, PAPD4, PC Ml. PDE7A, PDS5B, PDXDCl, PIGN, PIK3CD, PIK3R1, PIKFYW, PITPNB, PLEKHA1, PLSCRl, PMS1, POMT2, PPARG, PPHLNl, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAFl, RAPIA, RAPGEFl, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SARI A, SCO I, SEC24A, SEiNP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2,

SPATA18, SPATA5, SPIDR, SPRYD7, SRGAPl, SRRM1, STATI, STR.N3, STXBP6,

SUPT20H, TAF2, TASPl, TBC1D15, TCF12, TCF4, TLAM1, TJP2, TMC3, TMEM 189- UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP and ZNF680.

[00120] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ABCC3, ADCY3, AGPAT4, ANKRA2, APIP, ARHGAP1, ARL15, ATXN1, BECNl, BHMT2, BTN3A1, C12orf4, C 14orfl32,

C8orf44, C8orf44-SGK3, C8orf88, CASP7, CCDC122, CECR7, CENPI, CEP1 12, CEP192, CHEK1, CMAHP, CNRIP1, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK I GI, DAGLB, DC AF 17, DLGAP4, DNAJC13, DNMBP, DYRK1A, EN AH, EP300, ERCC1, ERLIN2, ERRFI1 , EVC, FAIM, FAM126A, F AM 13 A, FAM162A, F AM 174 A, FBN2, GGACT, GLCE, GULP1, GXYLTl, HDX, HMGA2, HNMT, HPS 1, IFT57, INPP5K, IVD, KDM6A, LETM2, LOC400927, LRRC42, LYRM1 , MB21 D2, MCM10, MED13L, MFN2, MRPL45, MRPS28, MTERF3, MYCBP2, NGF, OXCTl, PDS5B, PIGN, PIK3CD, PIK3R1, PIKFYVE, PLEKHAl, PLSCRl, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRUNE2, PXK, RAFl, RAPGEF l, RARS2, RBKS, RERE, .PA 1. RPSI O, RPS6KB2, SAMD4A, SEC24A, SENP6, SERGEF, SGK3, SH3YL1 , SKA2, SLC12A2, SLC44A2, SNX7, SPAT A 18, SPATA5, SPIDR, SPRYD7, SRGAPl , SRRMl, STXBP6, TASP1, TCF12, TCF4, TIAM1, TMC3, TMEM 189-UBE2V1 , TMEM214, TNRC6A, TTC7B, TUBE1, TYW5, URGCP, VAV2, WDR27, WDR91, WNK1, ZCCHC8, ZFP82, ZNF138, ZNF232 and ZNF680.

[00121] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABHD10, ADAL, AD AMI 7, ADAM23,

ADAMTS 19, AGPAT4, AGPS, AKAP8L, AKTl, ANKRD13C, ANXA11, APIP, APPL2, ARHGAPl , ARHGAP5, ARL15, ARL5B, ARSJ, ASAPl, ATF6, BECNl, BHMT2, BIND, BNC2, BTBD I O, C 1QTNF9B-AS1, C orf27, C l orf30, CI lorf73, CI lorf76, C 12orf4,

C2orf47, CACNB l, CACNB4, CADM2, CCNL2, CDH18, CENPI, CEP162, CEP170, CEP192, CEP57, CHEK1, CHRM2, CMAHP, CMSS1, CNOT7, CNRIP1, CNTN1, COPS7B,

CRISPLD2, CRYBG3, CUX1, DAAMl, DC AF 17, DCUN1D4, DDX42, DENND1A,

DENND4A, DENND5A, DETl , DG l, DHFR, DIAPH3, DL.G5, DMXLl, DNAJA4, DNMBP, DYRKIA, DZIPIL, ELM02, ENAH, ENOX1, EP300, ERC1, ERC2, EVC, EXOC3, EXOC6B, FAM162A, F AM 174 A, FAM195B, FAM208B, FAM49B, FAM69B, FBN2, FBXL16, FBX09, FGD4, FHOD3, GALC, GBP l , GLCE, GNG12, GOLGB1, GTSF1, GXYLTl, HDAC5, HDX, HMGXB4, HOXB3, HSD17B4, HTT, IFT57, IKBKAP, I NO80. IPP4B, I N VS. ITCH, IVD, KDM6A, KDSR, KIAA1524, KIAA1715, KIDINS220, KIF2IA, L3MBTL2, LGALS3, LlNCR-0002, LING02, LOC400927, I P! IM . LRRCl, L.RRC42, LYRM1, MACROD2, MA EA, MAPK10, MARCH7, MARCH8, MDN1, MEAF6, MEMG1, MFN2, MLLT10, MM SI 9, MORF4L1 , MRPL39, MRPL45, MRPS28, MTMR3, MYB, MYCBP2, MYLK, NEDD4, NFASC, NGF, NIPAl, NLGNl , NLN, NREP, NSUN4, NUPL I . 0SBPL3, PAPD4, PBX3, PCDH10, PDE3A, PDE7A, PDXDC1, PDXDC2P, PELtl , PIGN, PITPNB, PMS1, PNISR, P0MT2, PPARG, PPFIBPl, PRPF31, PSMA4, PX , RAB23, RAFT, RAPGEF1, RASIP1, RBBP8, RC0R3, RERE, RGL1, RNF 130, RNF144A, R.NF213, RPF2, RPSIO, SAMD4A, SCOl, SENP6, SF3B3, SGIP1 , SGMS1, SGPL1 , SH2B3, SKP1 , SLC12A2,

SLC25A16, SLC25A17, SMOX, SNAP23, SNX24, SNX7, SOCS6, SGGA2, SORCS1, SPIDR, SPRYD7, SREK1, SSBP1 , STRAD8, STXBP4, STXBP6, SUPT20H, TAF2, TARBP1 , TASP1, TBCA, TBLIXRI, TCF4, TEKT4P2, TET1, TIAM1, TJAP1, TJP2, TMEM214, TMX3, TNRC6A, TRAF3, TRIM65, TSPAN7, TXNL4B, UBE2D3, UBE2L3, UBN2, UNC13B, URGCP-MRPS24, UVRAG, VDAC2, WDR27, WDR90, WHSC2, WNK1, XRN2, ZFP82, ZMIZ2, ZNF138, ZNF208, ZNF212, ZNF280D, ZNF350, ZNF37BP, ZNF426, ZNF6I8, ZNF680, ZNF730, ZNF777, ZNF7804A, ZNF836 and ZSCAN25.

[00122] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: APOA2, ASAPI , BRCAl, BRCA2, CDKN IC, CRX, CTRC, DENND5A, DIAPH3, DMD, DNAH11, EIF2B3, GALC, HPSl, HTT, IKBKAP, KIAA1524, LMNA, MECP2, PAPD4, PAX6, PCCB, PITPNB, PTCH1, SLC34A3, SMN2, SPINK5, SREK1, TMEM67, VWF, XDH and XRN2.

[00123] In another specific aspect described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCAl, ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA 2, ADAL, AD AMI 5,

AD AM 17, ADAM23, ADAM33, ADAMTSl, ADAMTS19, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC 1, AHRR, AJUBA, AK 021888, AK310472, AKAP1, AKAP3, AKAP8L, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, ANK3, ANKFYT, ANKHD 1 -EIF4EBP3 , ANKRA2, ANKRD13C, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA6, AP2B1 , AP4B1-AS1, APAF1, APIP, APOA2, APP, APTX, ARHGAP1, ARHGA 12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARSJ, ASAP1, ASIC1, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG9A, ΑΤΜΓΝ, ATP2A3, ATP2C1, ATXN1, ATXN3, A.URKA, B3GALT2, B3GNT6, B4GALT2, BACE1 , BAG2, BASPL BC033281, BCAR3, BCL2L15, BCYRN1, BECNl, BEND6, BHMT2, BICDl, BIN1 , BIN3, BIN3-IT1, BIRC3, BIRC6, BNC1 , BNC2, BRCA1, BRCA2, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C 1QTNF9B-AS1, Cl orf27, Clorf 6, C10orf54, Cl lori-30, Cl lorfTO, C l lorf73, Cl lor†76, Cl lorf94, C12orf4, C12orf56, C14orfl 32, C17orf76- AS1, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44- SGK3, C8orf88, C9orf69, CA13, CA3, CAB 39, CACNA2D2, CACNBL CACNB4, CADMl, CADM2, CALU, CAMKK1 , CAND2, CAPNS1 , CASC3, CASP7, CASP8AP2, CAV1 , CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH1 1 , CDH13, CDH18, CDK l l B, CDK16, CDKALl, CDKNIC, CECR7, CELSR1, CEMIP, CENPI, CEP 112, CEP162, CEP 170, CEP 192, CEP68, CFH, CFLAR, CHD8, CHEK1, CHRM2, CIITA, CIZ 1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CN0T1, CNRIP1, CNTD1, CMSS1, CNOT7, CNRIP1, CNTNI, COGl, COLlAl, COLl l Al, COL12AL COL14A1, COLI SAL COL5A1 , COL5A3, COL6A1 , COL6A6, COL8A1, COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLFI, CRLSI, CRTAP, CRX, CRYBG3, CRYL1, CSDEL CSNKIAl, CSNK1 E, CSNKIGL CTDSP2, CTNND1 , CTRC, CUL2, CUL4A, CUX1 , CYB5B, CYB5R2, CYBRDl, CYGB, CYPIB I, CYP51A1, DAAMl, DAB2, DACTl, DAGLB, DARS, DAXX, DCAF10, DCAF11 , DCAF17, DCBLD2, DCLK1, DCN, DCUN1 D4, DDAH l, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGSI, DENNDIA, DENND1B, DENND4A, DEN D5A, DEPTOR, DET1, DFNB59, DGCR2, DGK L DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLCl, DLG5, DMD, DM XI 1 , DNAH8, DNAHLL DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK1 1 , DPP 8, DSEL, DST, DSTN, DYNClil , DYRK1 A, DZIP1L, EBF 1, EEA1, EEFlAl, EFCAB14, EFEMPl, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF 2, ELM02, ELN, ELP4, EMX20S, EN AH, ENG, ENOX1 , ENPP1, ENPP2, ENSA, EP300, EPT1, ERC1, ERC2, ERCC1, ERCC8, ERLIN2, ERRFIl, ESMI, ETV5, EVC, EVC2, EXOL EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADSL FADS 2, FAF 1 , FAIM:, FAMl l lA, FAM126A, FAM13A, FAM160A1, FAM162A, F AM 174 A, FAM 195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARPL FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXO10, FBX018, FBX031 , FBX034, FBX09, FCHOl, FDFT1 , FDPS, FER, FEZl , FGD4, FGD5-AS1, FGFR2, FGFRLL FGL2, FHOD3, FLU, FLNB, FLT1, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1 , FOXKl, FRAS1 , FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBP1, GCFC2, GLCE, GCNT1, GDF6, GGACT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, G L3L, GOLGA2, GOLGA4, GOLGBl, GORASPl, GPR1, GPR183, GPR50, GPRS 9 A, GPRC5A, GPRC5B, GPSM2, GREMl, GRK6, GRTPl, GSEl, GTF2H2B, GTSFl, GUCAIB, GULP1 , GXYLT1 , HAPLN1 , HAPLN2, HAS2, HAS3, HAT 1 , HAUS3, HAUS6, HA.VCR2, FID AC 5, HDAC7, HDX, HECTD2-AS1, HEGL HEPH, HEY1, HLA-A, HLA-E, HLTF, HMGA1 , HMGA2, HMGB1, HMGCR, HMGN3-AS 1 , HMGCS1, HMGXB4, HOOK3, HOXB3, HMOXl, HNMT, HNRNPR, HNRNPUL1, HP1BP3, HPS1, HRH1, HSD17B12, HSPA1L, HTATIP2, HTT, IARS, IDFIl, IDH, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, Π .16. IL6ST, IN A, INHBA, INO80, IPP4B, INPP5K, INSIGl, INTO, INVS, IQCE, IQCG, ITCH, ITGA1 1 , ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1, I MX KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1 143, KIAA1199, KIAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549, KIAA1715,

KIAA1755, KIDINS220, KIF14, KIF2A, KIF21 A, KIF3A, KIT, l .C i KLC2, KLF17, KLF6, KLHL7, KLRG1, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAP1-5,

KRTAP2-3, L3MBTL2, LAMA2, LAMB1 , LAMB2P1 , LARP4, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS 1, LINC00341, LINC00472,

LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC011 18, LINC01204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMOD l , LOC400927, LONPI, LOX, LPHNl, LRBA, LRCH4, LRIGI , LRP4, LRP8, LRRCl, LRRC32, LRRC39, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPDl, l .YRM I . LZTS2, MACROD2, MAFB, MAGED4, MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1 , MANEA, MAP4K4, MAPK10, MAPK13, MARCH?, MARCH8, MASP1, MB, MB21D2, MBD1, MBOAT7, MC4R, MCM10, MDM2, MDN1, MEAF6, MECP2, MED1 , MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl, MEPCE, MFGE8, MFN2, MI AT, MICAL2, MINPPl, MIR612, MKL1, MKLNl, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, M M . MORF4L1, MOXD1, MPPE1, MPZL1, MRPL3, MRPL45, MRPL55, MRPS28, MRVI1, MSANTD3, MSG, MSH2, MSH4, MSI 1 MSL3, MSMOl , MSRB3, MTAP, MTERF3, MTERFD1, MTHFD1 L, MTMR3, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MY ADM, MYB, MYCBP2, MYLK, MYOI D, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAEl, NAGS, NASP, NAVl, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl, NEURLIB, NF2, NFASC, NFE2L1, NFXI, NGF, NGFR, NHLHI, NID , NID2, NIPAl, NKX3-1, NLGNl , NLN, NOL10, NOM03, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRD1, NREP, NRG1, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1 , OCLN, ODF2, OLRl, OS9, OSBPL3, OSBPL6, OSBPL10, OSMR, OXCT1 , OXCT2, P4HA1, P4HB, PABPC l, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCCB, PCDH10, PCDHGB3, PCGF3, PCM1,

PCMTD2, PCNXL2, PCSK9, PDEIC, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDCl, PDXDC2P, PEAR1, PELI1, PEPD, PEX5, PFKP, PHACTR3, PHF 9, PHF8, PHRFl, PHTF2, PI4K2A, PIEZOl , PIGN, PIGU, PI 3C2B, PIK3CD, PI 3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNMl, PITPNM3, PLAU, PLEC, PI I K 2.

PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC l , PMS 1, PNISR, PGDN, POLE3, PGLN, POLRIA, POLR3D, POMT2, POSTN, POU2FL PPAPDC1 A, PPARA, PPARG, PPFIBP1, PPIP5K 1 , PPIP5K2, PPM1 E, PPP1R12A, PPP1 R26, PPP3CA, PPP6R1, PPP6R2, PRKCA, PR DC, PRKG1, PRMT1, PRNP, PRPF3 1, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMCI , PSMD6, PSMD6-AS2, PTCHI , PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF I, RALB, RAP1GDS1, RAPGEF1, RARG, RARS, RARS2, RASIP1, RASSF8, RBBP8, RBC 1, RCOR3, RBFOX2, RBKS, RBMIO, RDX, RERE, RFTNl, RFWD2, RFX3-AS 1, RGCC, RGL1, RGS10, RGS3, RIFl, RNF 14, RNFI9A, RNF130, RNF144A, RNF213, RNF38, RNFT1, ROR1, ROR2, RPA1, P! 2. RPL10, RPS10, RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SA¾iD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCOl, SDCBP, SEC14L1, SEC 22 A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SFL SF3B3, SGIP1, SGK3, SGMS 1 , SGOL2, SGPL1 , SH2B3, SH3RF1, SH3YL1, SHROOM3, SIGLECIO, SK.A2, SKIL, SKPl, SLC12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1 , SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A1 1, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNEDl, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SQCS6, SOGA2, SON, SORBS2, SORCS1, SORCS2, SOS2, SOX7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPIN 5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBF1, SRGAP1, SRRMl, SRSF3, SSBP1, STAC2, STARD4, STAT1, STAT3, STAT4, STAU1, STC2, STEAP2,

STK32B, STRAD8, STRIP 1 , STRN4, STS, STX16, STXBP4, STXBP6, SULF l , SUP 1 20! I, SVEP1, SYNEl, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC1, TAF2, TAGLN3, TANC2, TANG06, TARBP1, TARS, TASP1 , TBC1D15, TBCA, TBLI XRI , TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1, TENM2, TEPL TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAPl, TGM2, THADA, THAP4, THBS2, THRB, TIAM ^' l, TIMP2, TJAP1, TJP2, TLE3, TLK1, TMC3, TMEM67, TMEMI 02, TMEMI 19, TMEMI 34, TMEMI 54, TMEMI 89-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, TNFRSF14, TNIP1 , TNKS1BP1, TNP03, TNRC 18P1, TNSl, TNS3, TNXB, TOE1, TOMM40, TOMM5, TOPORS, TP53AIP1, ΤΡ53ΪΝ 1, TPRG1, TRAF3, TRAKl, TRAPPC12, TRIBl, TRIM2, TRTM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMTIL, TRPC4, TRPSl, TSC2, TSHZ1 , TSHZ2, TSPAN1 1 , TSPAN18, TSPAN2, TSPAN7, TSSK.3, TTC7A, TTC7B,

TUBB2C, TUBB3, TUBE1, TXNIP, TXNLl, TXNL4B, TXNRDl, TYW5, U2SURP,

UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMK1 , UHRF1BP1L, UNC13B, UNC5B, URGCP, URGCP-MRP S24, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VDAC2, VIM-ASl, VIPAS39, VPS 13 A, VPS 29, VPS41 , VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPFl, WISPl, WNKl, WNT5B, WNTIOB, WSBl, WWTRl, XDH, XIAP, XRN2, YAP1, YDJC, YES1, YPEL5, YTHDF3, Z24749, /.\ , ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHCl l, ZEBI, ZEB2, ZFAND1, ZFAND5, ZFP82, ZHX3, ZMIZ1 , ZMIZ1-AS1 , ZMIZ2, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF208, ZNF2I2, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281 , ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431 , ZNF583, ZNF618, ZN 1-62 1 , ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF730, ZNF74, ZNF764, ZNF777, Z F778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 and ZSCAN25.

[00124] In another specific aspect described herein, the gene, or the RNA transcript is transcribed from a gene that is not SMN2.

[00125] In another specific aspect described herein, the gene, or the RNA transcript is transcribed from a gene that is not selected from: ABHD I O, ADAM 12, AKT1, ANXA11, APLP2, APPL2, ARMCX6, ATG5, ΑΧΓΝ1, BAIAP2, CCNB IIPI, CCT7, CEP57, CSF1, DLGAP4, EPNl, ERGIC3, FOXMl , GGCT, GRAMD3, HSD17B4, LA P7, LRRC42, MADD, MANIBI, MRPL39, PCBP4, PPHLNl, PRKACB, RAB23, RAP 1 A, RCC l, SREKl, STRN3 and TNRC6A.

[00126] In another specific aspect described herein, the gene, or the RNA transcript is transcribed from a gene that is not selected from: ABHDIO, ADAM12, AKT1, ANXA l 1 , APLP2, APPL2, ARMCX6, ATG5, ΑΧΓΝ1, BAIAP2, CCNBIIPI, CCT7, CEP57, CSF 1, DLGAP4, EPNl, ERGIC3, FOXMl, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MANIBI, MRPL39, PCBP4, PPHLNl, PRKACB, RAB23, RAIM A, RCCl, SMN2, SREKl, STRN3 and TNRC6A.

[00127] In another specific aspect described herein, the gene, or the RNA transcript is transcribed from a gene that is SMN2.

[00128] In another specific aspect described herein, the gene, or the RN A transcript is transcribed from a gene that is selected from: ABHDIO, ADAM 12, AKT1, ANXAl 1, APLP2, APPL2, ARMCX6, ATG5, AX!X l . BAIAP2, CCNBIIPI, CCT7, CEP57, CSF1 , DL.GAP4, EPNl, ERGIC3, FOXMl, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MANIBI, MRPL39, PCBP4, PPHLNl, PRKACB, RAB23, RAP 1 A, RCCl, SREKl, STRN3 and

TNRC6A.

[00129] In another specific aspect described herein, the gene, or the RNA transcript is transcribed from a gene that is selected from: ABHD10, ADAM 12, AKT1, ANXA11, APLP2, APPL2, ARMCX6, ATG5, ΛΧΙΧ 1. BAIAP2, CCNBIIPI, CCT7, CEP57, CSF1 , DL.GAP4, EPNl, ERGIC3, FOXM1, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MANIBI, MRPL39, PCBP4, PPHLN1 , PR ACB, RAB23, RAP ! A, RCC1 , SMN2, SREK1 , STRN3 and TNRC6A.

[00130] In one aspect, provide herein is a method of modulating the amount and modifying the type of a protein produced by a cell containing the artificial gene construct as described above, the method comprising contacting the cell with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

(I)

or a form thereof, wherein

W is ( I I C! f or S;

X is ( ! ! :, CH(Ci- ₄ alkyl), C(Ci-4alkyl)2, ( ! l C S i. 0 NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or Cg-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2, and wherein CsMocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with I, 2, 3, 4, or 5 substituents each selected from R ₄ ; Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci-4alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl , Ci-4alkyl-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, Ci-4aikyi-aniino-carbonyl~Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci-4aikoxy, halo-C i-4alkoxy, amino-C ₁ - ₄ alkoxy, hydroxyi~Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci- ₄ alkoxy- Ci-4alkoxy, d-ialkoxy-carbonyl, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-C i ^alkyl, heteroaryl-d^alkyl-amino, heteroaryl-C i-4alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-C ^al ky 1 -carbony 1 -amino-C i-4al ky 1 , heterocy cly 1 , heterocy cly 1 -C i - ₄ al ky 1 , heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyciyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, halo-Ci- ₄ alkyl, amino,

Ci-4a!ky!~ammo, (C ₁ -4alkyl) ₂ -amino, amino-C i-4alkyl, C ₁ - ₄ alkyl -amino-C ₁ - ₄ alkyl ,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci-4alkyl, C --4alkoxy,

Cwalkoxy-carbonyl, C2-4alkenyl, C3-7cyeloaikyI, or heterocyclyi~Ci-4alkyl,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyciyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl , nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-C Malkyl, Ci-4alkyl-amino-Ci-4alkyl, (Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci- ₄ alkyl) ₂ -amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (C ₁ - ₄ alkyl) ₂ -amino- carbonyl-Ci- ₄ al ky] , C^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Cj.-4alkyl-carbonyl, Ci-4aikoxy, halo-Cj-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4al ky]-Ci~4al koxy, Ci-4alkyl-aniino-Ci-4alkoxy,

(C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C walkoxy- Cwalkoxy, Cwalkoxy-earbonyl, Ci-4alkoxy-carbonyl-arnino, C i-4alkoxy -carbonyi ~ amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -?cycloalkenyl, heteroaryl, heteroaryl-d^alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl ,

heteroaryl-Ci-ialkyl-carbonyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl-Ci^alkyl, heteroar}4-Ci-4alkyl-carbonyl-araino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, phenyl, or phenyl-Cj- ₄ alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyl-Ci-4alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-d^alkyl;

wherein a form of the compound is selected from the group consisting of a prodaig, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00131] In another aspect, provide herein is a method of modulating the amount and modifying the type of a protein produced by a cell containing the artificial gene construct as described above, the method comprising contacting the cell with a compound of Formula (I) or a form thereof, wherein Formula (I) is selected from a compound of Formula (la) and Formula (lb):

or a form thereof, wherein

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , (Ί I (Ί I, O, R

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

- I l l - wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryi is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocvclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring sy tem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyi~amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-earbonyl,

C ! - ₄ alkyl-amino-carbonyl-C 1 - ₄ alkyl,

Ci-4alkyl, hydroxyl -Cwalkyl, Ci-4alkyl-carbonyl, Ci-4alkoxy, halo-Ci-4alkoxy, amino- Ci-4alkoxy, hydroxyl -C j.- ₄ alkoxy, Ci -4alkyl~Ci-4alkoxy, C j.- ₄ alkyl-amino-C j.- ₄ alkoxy, (Ci-4alkyl)2-amir!0-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! - ₄ alkoxy, C i - ₄ alkoxy-carbonyl, C 1

amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl , C3-?cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryi, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaryi -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryi is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

.2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, 0- ₄ alkyl, halo-Chalky), amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci-4alkyl, amino-carbonyi,

hydroxyl-Ci-4alkyl, Ci.4alkoxy, Ci-4alkoxy~carbonyl, C ₂ - ₄ alkenyl, Cs-Tcycloalkyl, or heterocyclyl-Ci-4alkyl;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, amino, Ci- ₄ alkyl-amino,

(Ci- ₄ alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

Ci-4al kyl-amino-carbor!vl-Ci-4al kyl , Ci-4alkyl-carbonyl-amir!0, Ci-4alkyl-carbonyl-amirH> Ci- ₄ alkyl, hydroxyi-Cj-4alkyl, Ci-4alkyl-carbonyi, Ci-4alkoxy, halo-Ci-4alkoxy, amino- Ci-4alkoxy, hydroxyl -Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci.4alkyl-amino-Ci.4alkoxy, (C i-4alkyl)2-amino-C i-4alkoxy, C i-4alkyl-carbonyl-amino-C i-4alkoxy, C i-4alkoxy- Cwaikoxy, Cwalkoxy-carbonyl, Ci- ₄ alkoxy-carbonyl-amino, C i-4aikoxy-carbonyI- amino-Ci-4alkoxy, C ₂ -4alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryi~Cj- ₄ alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaiyl-C!-4alkyl~carbonyl~amino, heteroaryl-Ci-4alkyl-amino-carbonyl~Ci-4aikyi, heteroar}4-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyi-Cj-4alkoxy;

R ₄ is independently selected from halogen, Ci- ₄ alkyl, hydroxyl-Ci- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-d^alkyl;

wherein a form of the compound is selected from the group consisting of a prodaig, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00132] In a specific aspect, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1809), CNGAgtrngn (SEQ ID NO: 1810), GNGAgtrngn (SEQ ID NO: 1811), TNGAgtmgn (SEQ ID NO: 1812), NAGAgtmgn (SEQ ID NO: 1813), NCGAgtrngn (SEQ ID NO: 1814), NGGAgtrngn (SEQ ID NO: 1815), NTGAgtrngn (SEQ ID NO: 1816), AAGAgtrngn (SEQ ID NO; 181 7), ACGAgtrngn (SEQ ID NO: 1818), AGGAgtragn (SEQ ID NO: 1819), ATGAgtrngn (SEQ ID NO: 1820), CAGAgtrngn (SEQ ID NO: 1821), CCGAgtrngn (SEQ ID NO: 1822), CGGAgtrngn (SEQ ID NO: 1823), CTGAgtrngn (SEQ ID NO: 1824), GAGAgtrngn (SEQ ID NO: 1825), GCGAgtmgn (SEQ ID NO: 1826), GGGAgtrngn (SEQ ID NO: 1827), GTGAgtmgn (SEQ ID NO: 1828), TAGAgtrngn (SEQ ID NO: 1829), TCGAgtrngn (SEQ ID NO: 1830), TGGAgtrngn (SEQ ID NO: 1831) and TTGAgtrngn (SEQ ID NO: 1832), wherein r is adenine or guanine and n or N is any nucleotide. In a further specific aspect, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtragt (SEQ ID NO: 1833), GNGAgtragt (SEQ ID NO: 1834), GNGAgtragt (SEQ ID NO: 1835), TNGAgtragt (SEQ ID NO: 1836), NAGAgtragt (SEQ ID NO: 1837), NCGAgtragt (SEQ ID NO: 1838), NGGAgtragt (SEQ ID NO: 1839), NTGAgtragt (SEQ ID NO: 1840), AAGAgtragt (SEQ ID NO: 1841 ), ACGAgtragt (SEQ ID NO: 1842),

AGGAgtragt (SEQ ID NO: 1843), ATGAgtragt (SEQ ID NO: 1844), CAGAgtragt (SEQ ID NO: 1845), CCGAgtragt (SEQ ID NO: 1846), CGGAgtragt (SEQ ID NO: 1847), CTGAgtragt (SEQ ID NO: 1848), GAGAgtragt (SEQ ID NO: 1849), GCGAgtragt (SEQ ID NO: 1850),

GGGAgtragt (SEQ ID NO: 1851), GTGAgtragt (SEQ ID NO: 1852), TAGAgtragt (SEQ ID NO: 1853), TCGAgtragt (SEQ ID NO: 1854), TGGAgtragt (SEQ ID NO: 1855) and TTGAgtragt (SEQ ID NO: 1856), wherein r is adenine or guanine and N is any nucleotide. In one or more aspects provided herein, N is adenine or guanine. In various specific aspects, the nucleotide sequence encoding the intronic REMS is a nucleotide sequence encoding a non-endogenous intronic REMS, i.e., a precursor RNA transcript comprising the non-endogenous intronic REMS not naturally found in the DNA sequence of the artificial construct.

[00133] In one aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a pre- mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

0)

or a form thereof, wherein

W is (Ί I CM or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, Rs, or a bond;

A is aryl, heteroaryl , heterocvclyl , or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloalkyl is a saturated or partial ly unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxyl, cyano, d- ₄ alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl -amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci-4alkyl)2-amim>carbonyl, Ci-4alkyl-amim>carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- earbonyl-Ci-4alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci~4alkoxy, halo-Ci-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci- ₄ alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci.4alkyl)2-amino-Ci-4alkoxy, Ci.4alkyl-carbonyl-amino-Ci-.4alkoxy, Ci-ialkoxy- Ci-4alkoxy, d-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- aniino-Cwalkoxy, C2-4aikenyl, C2-4alkenyl~amino-carbonyl, Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl, heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaiy 1-C i-4al ky 1 -carbony 1 -amino-C ι - ₄ al ky 1 , heterocy cly 1 , heterocy cly 1 -C i- ₄ al ky 1 , heterocyclyl-d-4alkoxy, phenyl, or phenyl -d-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring sy stem having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R? is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-amino, (d-4alkyl) ₂ -amino, amino-C i-4alkyl, Ci- ₄ alkyl -amino-C i- ₄ alkyl, (Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, d-4alkoxy,

Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-d-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, d- ₄ alkyl, halo-d- ₄ alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-C i-4alkyl, C ₁ - ₄ alkyl -amino-C i-4alkyl , (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d- ₄ alkyl-amino-carbonyl,

(d- ₄ alkyl) ₂ -amino-carbonyl, d^alkyl-amino-carbonyl-d^alkyl, (d- ₄ alkyl) ₂ -amino- carbonyl-d- ₄ alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, d.- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-d.- ₄ alkoxy, amino-d- ₄ alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4al kyl-Ci-4al koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(d- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, d- ₄ alkyl-carbonyl-amino-d- ₄ alkoxy, d- ₄ alkoxy- Ci-4al koxy, Ci-4alkoxy-carbonyl, CMalkoxy-carbonyl-amino, d- ₄ alkoxy-carbonyl- amino-d-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C ! -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaiyl-C^alkyl-amino-carbonyl-Cwalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl-C alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl~Ci-4alkyl-amino; and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00134] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an intronic

recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

0)

or a form thereof, wherein

W is (Ί I CM or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, NR ₅ , or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri, wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with I , 2, 3, 4, or 5 substituents each selected from R?., and wherein d-iocyeloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R?.;

B is heterocyciyl,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, d- ₄ alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl -amino,

(C ₁ -4alkyl) ₂ -amino, amino-d^alkyl, Ci-4alkyl-amino~Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci.4alkyl)2-amino-carbonyl, d^alkyl-amino-carbonyl-d^alkyl, (C ₁ -4alkyl) ₂ -amino- carbonyl-Ci-4alkyl, d-4alkyl-carbonyl-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-d-4alkoxy, Ci-4al kyl-Ci-4alkoxy, d^alkyl-amino-d^alkoxy,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkoxy, d-4alkoxy- Ci-4al koxy, d- ₄ alkoxy-carbonyl, d^alkoxy-carbonyl-arnino, d-4alkoxy-carbonyl- amino-Ci- ₄ alkoxy, C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloalkyl, C3-7cycioalkyl-Ci-4alkOxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-d-4alkyl-amino-carbonyl,

heteroaryl-d-4alkyl-carbonyl-amino, heteroaryl-d-4alkyl-amino-carbonyl-d-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyciyl, heterocyclyl-C ₁ - ₄ alkyl, heterocyclyl-Ci- ₄ alkoxy, phenyl, or phenyl -Ci- ₄ alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxy!, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-d-4alkyl, amino,

Ci-4alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, d^alkyl-amino-d^alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-Tcycloalkyl, or heterocyclyl-Ci-4aikyi,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3 ;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci- ₄ alkyl, amino,

Ci-4al kyl -amino, (Ci-4alkyl)2-amino, amino-Ci-4al kyl , C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl,

(Cj -4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d^alkyl-amino-carbonyl,

(Ci-4a!ky!)2-amino~carbonyi, d-4alkyl-amino-carbonyl-d-4alkyl, (C ₁ - ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyi~Ci.4a!kyl, d-4alkyl-carbonyl, Ci-4alkoxy, ha!o-Ci.4alkoxy, amino-Cwalkoxy, hydroxyl-Ci- ₄ alkoxy, d-4alkyl-Ci-4alkoxy, d^alkyl-amino-d^alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.-4alkyl-carbonyl-amino-Cj.- ₄ alkoxy, Ci-4alkoxy- C ₁ - ₄ alkoxy, d-4alkoxy-carbonyl, C^alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4arkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -C ₁ - ₄ alkyl,

heteroaryl-Ci-4a!ky!-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroary!-Ci.4alkyl-carbonyl-amino, heteroaryl -d^alkyl-amino-carbonyl-d^alkyl, heteroaryl-Cwalkyl -carbonyl -amino-C 1 - ₄ alkyl , heterocyclyl , heterocyclyl -Ci-4aikyi, phenyl, or phenyl-Ci-4alkoxy;

R ₄ is independently selected from halogen, d- ₄ alkyl, hydroxyi-Ci-4alkyl, amino, Ci-4aikyi- amino, or hydroxyl-Ci- ₄ alkyl-amino; and

R.5 is hydrogen, d- ₄ alkyl, or hydroxy 1-C 1- alky 1;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantionier, diastereomer, stereoisomer, polymorph and tautomer form thereof. [00135] In a specific aspect of the foregoing aspect, the intron further comprises in 5' to 3' order: a 5' splice site, a branch point, and a 3' splice site upstream of the iREMS.

[00136] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises three exons and two introns, wherein three exons and two introns are in the following order 5' to 3' : a first ex on, a first intron, a second exon, a second intron and a third exon, wherein the first intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a first 5' splice site, a first branch point and a first 3' splice site, wherein the second intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a second 5' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3 ' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

or a form thereof, wherein

W is CH=CH or S;

X is (Ί ! :, CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2, and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₂ ; B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-C i-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, C - -4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci-4alkyl-carbonyl, C ₁ - ₄ alkoxy, halo-C i-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci-4alkoxy, C j -4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl -amino-carbonyl, Cs-Tcycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R ₂ is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

Ci-4alkyl~amino, (Ci-4alkyl)2-amino, amino-Cj-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci- ₄ alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci- ₄ alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-'jcycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

3 is halogen, hydroxy] , nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl~amino, (Ci- ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, d^alkyl-amino-d^alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d-4alkyl-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (Ci- ₄ alkyl) ₂ -amino- carbonyl-C ₁ - ₄ alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Cwalkyl-carhonyl, Ci-4aikoxy, halo-d-4alkoxy, amino-d-4alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4alkyl-Ci~4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, d-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-d^alkyl,

heteroaryl-d-4alkyl-amino, heteroaryl-C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-d-4alkyl-amino-carbonyl-d-4alkyl, heteroaryl-C alkyl-carbonyl-amino-d^alkyl, heterocyclyl, heterocyclyl-d-4alkyl, phenyl, or phenyl-d- ₄ alkoxy;

R4 is independently selected from halogen, Cj.- ₄ alkyl, hydroxyl-d- ₄ alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino, and

Rs is hydrogen, Ci-4alkyl, or

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00137] In some aspects, the iREMS is an endogenous iREMS. In other aspects, the iREMS is a non-endogenous iREMS,

[00138] In another aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a pre- mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from the genes listed in a table herein, and wherein Formula I) is:

(0

or a form thereof, wherein

W is CH C H or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from =.

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, amino, Ci-4aikyi-amino,

(Ci-4alky l) ₂ -amino, amino-Ci-4al kyl , Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi~amino-earbonyl,

(C ₁ -4alkyl) ₂ -amino-carbonyl, Ci-4alkyl-amino~carbonyi~Ci-4alkyl, (C ₁ - ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyl-Ci-4alkyl, Ci-4alkyl-carbonyl, Cualkoxy, haio-Ci-4aikoxy, amino-C i-4alkoxy , hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- Ci-4al koxy, Ci-4arkoxy~carbonyl, Ci-4alkoxy-carbonyl-an ino, Ci-4alkoxy-carboi yl- amino-Cwalkoxy, C?.-4alkenyl, C2-4alkenyl-amino-carbonyl, Cv'cyeloalkyl,

C3-7cycloalky]-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci-4alkyl, heteroaryl-Cwalkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl -C^alkyl -amino-carbonyl -CMalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-C ₁ - ₄ alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl -Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R_ is halogen, hydroxy!, cyano, oxo, hydroxyl-imino, d^alkyl, halo-Ci-4a!ky!, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-Cwalkyl, Ci-4alkyl-amino-Ci-4alkyl, (Cj-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, hydroxyl-Ci-4alkyl, Ci-4aikoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, (), and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R ₃ is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-Ci.4alkyl, C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl, (Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino-Cj.- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkOxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci- ₄ alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- aniino-Ci-4alkoxy, Ci alkenyl, C2-4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycIoalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaryl-Cwalky 1 -carbonyl -amino-C i - ₄ alky 1 , heterocyclyl , heterocyclyl -Ci-4alkyl, phenyl, or phenyl-Ci-salkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyl-d^alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2~amino or hydroxyl-C ₁ -4alkyl-amino; and

R.5 is hydrogen, Ci-4al ky] , or hydroxy 1-Ci - alky! ;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00139] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an intronic

recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the i REIMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from the genes listed in a table herein and wherein Formula (I) is:

CO

or a form thereof, wherein

W is CH=CH or S;

X is ( ! ! :, CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi, wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryi is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocvclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring sy tem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyi~amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi~amino-earbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyL (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl, Cwaikoxy, halo-Ci- ₄ alkoxy, amino-C ₁ - ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl- amino-Ci- ₄ alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycloalkyl, C3-7cycloalkyl~Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryi, heteroaryi -C ₁ - ₄ alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryi -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4arkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl -Cj.-4alkoxy,

wherein heteroaryi is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, wherein heterocvclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroary) or heterocvclyl is optional ly substituted with 1, or 2 substituents each selected from Rj;

.2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, d-4alkyl, halo-Chal ky) , amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-C i-4alkyl, d-4alkyl -amino-C i-4alkyl, (Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, d-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-Ci-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-d-4alkyl, amino,

C i-4alkyl~amino, (C ₁ -4alkyl) ₂ -amino, amino-C i-4alkyl, C i-4alkyl -amino-C i-4alkyl , (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci.4alkyl)2-amino-carbonyl, d^alkyl-amino-carbonyl-d^alkyl, (d-4alkyl) ₂ -amino- carbonyl-Ci-4alkyl, d-4alkyl-carbonyl-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, d-4alkyl-carbonyl, d-4aikoxy, halo-d-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4al kyl-Ci-4al koxy, Ci-4arkyl-amino-Ci-4al koxy,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkoxy, d-4alkoxy- Ci-4a) koxy, d-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, d- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, d-Tcycloaikyi,

C ₃ -7cycloalkyl-d-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci-ialkyl, heteroaiyl-Ci-4alkyl-amino, heteroaryl-d- ₄ alkyl-amino-carbonyl,

heteroaryl-d^alkyl-carbonyl-amino, heteroaryl-d-4alkyl -amino-carbonyl -d-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyelyl-Ci-4alkyl, phenyl, or phenyl-Cj- ₄ alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyl-d-4alkyl, amino, Ci-4alkyl- amino, (d-4alkyl) ₂ -amino or hydroxyl-d-4alkyl-amino; and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4alkyl; wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00140] In a specific aspect of the foregoing aspect, the intron further comprises in 5' to 3' order: a 5' splice site, a branch point, and a 3' splice site upstream of the iREMS.

[00141] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises three exons and two mtrons, wherein three exons and two introns are in the following order 5' to 3' : a first exon, a first intron, a second exon, a second intron and a third exon, wherein the first intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a first 5' splice site, a first branch point and a first 3' splice site, wherein the second intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a second 5' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from the genes listed in a table herein, and wherein Formula I) is:

(0

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or i¾-iocycioalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri, wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R.2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, d^alkyl-amino,

(Ci- ₄ alkyl) ₂ -amino, amino-Ci-4alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl , Ci-4alkyl-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyi~Ci-4alkoxy, d-4alkyl-d-4alkoxy, d-4alkyl~amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Cwalkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

C3-7cycloalkyl~Ci-4alkoxy, C3-7cycloaikenyl, heteroaryl, heteroaryi-C 1 ^alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4a!ky!-carbony!-amino, heteroaiyl-Ci-4alkyl~amino-carbonyl-Ci-4aikyi, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino~C i-4al ky 1 , heterocyclyl , heterocyclyl -C 1 - ₄ al ky 1 , heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ; R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino, Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci- ₄ al ky], d-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bi cyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-d-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i- ₄ alky 1 ,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C 1 - ₄ alkyl, d^alkyl-carbonyl-amino, C alkyl-carbonyl-amino-C i- ₄ aikyi, hydroxyl-d-4alkyl, d^alkyl-carbonyl, Ci-ialkoxy, halo-d^alkoxy, amino-d-4alkoxy, hydroxyl -C _1-4 alkoxy , C _1-4 al kyl-C al koxy , C■ - ₄ al ky 1 -amino-C■ - ₄ al koxy ,

(Ci.4alkyl)2-amino-Ci-4alkoxy, C alkyl-carbonyl-amino-C^alkoxy, Ci-ialkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cyc!oalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-C 1 -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroar}'l-Ci-4alkyl-carbonyl-amino, heteroaryl-Ci-4al kyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl -C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydiOxyl-Ci.4alkyl-amino; and

R5 is hydrogen, d- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00142] In another aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a pre- mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

(I)

or a form thereof, wherein

W is CH=CH or S;

X is ( ^' ! !.'.. CH(Ci- alkyl), C(Ci-4alkyi) ₂ , CM O L O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Gj-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with I, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl-amino,

(Ci-4alkyl)2-amino, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-arnmo-Ci-4alkyl, amino-carbonyl, d^alkyl-amino-carbonyl, (Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C i -4aikyi-carbonyi-amino, C i -4aikyi-carbonyi-amino-C i - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4alkoxy, ha)o-Ci~4alkoxy, annno~Ci-4alkoxy, hydroxy 1-C i - ₄ alkoxy , C i- ₄ alkyl-C i -4alkoxy , C i - ₄ alky 1-amino-C i - ₄ alkoxy ,

(Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -?cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -Chalkyl, heteroaryl-Chalkyl-amino, heteroaryl-C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaiyl-Ci alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-C ₁ -4alkyl, heterocyclyl-Ci-4alkoxy, phenyl,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Chal ky) , amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl, (Ci-4alkyl)2-amir!0-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci- ₄ a) ky), Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R? is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i-4alky 1 , (Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci-4alkyl)2-amir!0-carbonyl, Ci-4alkyl-amir!0-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci-4alkoxy, amino-C^alkoxy, hydroxyl-Ci- ₄ alkoxy, Cj-4alkyl-Ci-4alkoxy, Ci- ₄ alkyl-amino-Ci- ₄ alkoxy,

(Ci-4alkyl)2-amii o-Ci-4alk xy, Ci-4alkyl-carbony]-amino-Ci-4al koxy, Ci-4alkoxy~ C ! - ₄ alkoxy, C i - ₄ alkoxy-carbonyl, C i ^alkoxy-carbonyl-amino, C alkoxy-carbonyl- an ii o-Ci-4alkoxy, C ₂ -4al kenyl , C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl,

heteroaryl~Ci-4alkyl-amino~carbonyl,

heteroaryl-Ci^alkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, heteroaryl-Ci alkyl-carbonyl-amino~Ci-4alkyl, heterocyclyl, heterocyclyl-d^alkyl, phenyl, or phenyl-C alkoxy;

R4 is independently selected from halogen, Ci- ₄ alkyl, hydroxyl-Ci- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (Cwalkyl^-amino or hydroxyl-Ci- ₄ alkyl-amino; and

R5 is hydrogen, Ci- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereo

[00143] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an intronic

recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

(I)

or a form thereof, wherein

W is CH=CH or S;

X is CH2, CH(Ci-4alkyl), ( ^' ((Y iai kyi ).'.. H i O L O, NR5, or a bond; A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi,

wherein aryl is seiected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having I, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Cj-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C i-4alkyl, C i -4aikyi-carbonyi-amino, C i -4aikyi-carbonyi-amino-C i - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkyl-earboi yi, Ci-4alkoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxy 1-C i - ₄ alkoxy , C i- ₄ alkyl-C i -4alkoxy , C i - ₄ alkyl-amino-C i - ₄ alkoxy ,

(Ci-4alkyl)2-amino~Ci-4alkoxy, Ci-4alkyl-carbonyl~amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -?cycloalkyl,

C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl,

heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaiyl-C!-4alkyl~carbonyl~amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-Ci-4alkoxy, phenyl, wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl , heteroaryl or heterocyclyl i s optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R_ is halogen, hydroxy!, cyano, oxo, hydroxyl-imino, d- ₄ alkyl, halo-Ci-4a!ky!, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-Cwalkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino~Ci-4alkyl, amino-carbonyl, hydroxyl-Cwalkyl, Cwalkoxy,

Ci-4alkoxy-carbonyl , C ₂ - ₄ alkenyl, Cs-ycycloalkyl, or heterocyclyl-d-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R ₃ is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci- ₄ alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-Ci.4alkyl, C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d-4alkyl-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino-Cj.- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, d-4alkyl-amino-d-4alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, d^alkoxy-carbonyl, d^alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl -amino-carbonyl, C ₃ -7cycloaikyi, C3-7cycloalkyl~Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -C ₁ - ₄ alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

Rs is independently selected from halogen, Ci-4alkyl, hydroxyl-d- ₄ alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl) ₂ -amino and Rs is hydrogen, Cwalkyl, or hydroxyl-C - -4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantionier, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00144] In a specific aspect of the foregoing aspect, the intron further comprises in 5' to 3' order: a 5' splice site, a branch point, and a 3' splice site upstream of the iREMS.

[00145] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises three exons and two introns, wherein three exons and two introns are in the following order 5' to 3' : a first exon, a first intron, a second exon, a second intron and a third exon, wherein the first intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a first 5' splice site, a first branch point and a first 3' splice site, wherein the second intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a second 5' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

(0

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or Cg-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri, wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R.2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, d^alkyl-amino,

(Ci- ₄ alkyl) ₂ -amino, amino-Ci-4alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl , Ci-4alkyl-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyi~Ci-4alkoxy, d-4alkyl-d-4alkoxy, d-4alkyl~amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Cwalkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

C3-7cycloalkyl~Ci-4alkoxy, C3-7cycloaikenyl, heteroaryl, heteroaryi-C 1 ^alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4a!ky!-carbony!-amino, heteroaiyl-Ci-4alkyl~amino-carbonyl-Ci-4aikyi, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino~C i-4al ky 1 , heterocyclyl , heterocyclyl -C 1 - ₄ al ky 1 , heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ; R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino, Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-C i-4alkyl, d-4alkyl-amino-C!-4alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amii o-carbonyl, hydroxyl-Ci-4al kyl, d-4alkoxy,

Ci-4alkoxy-carbonyl, C2-4aikenyi, C ^' 3-7cycloalkyl, or heterocyclyl-Ci-4aikyi,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-salkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i- ₄ alky 1 ,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, d-4alkyl-amim>carbonyl-d-4alkyl, (Ci-4alkyl)2-amino- earbonyl-C ! -4alkyl, d-4aikyi~carbonyi~aniino, C i- ₄ aikyi-carbonyi-amino-C i- ₄ aikyi, hydroxyl-d- ₄ alkyl, Ci-4alkyl~carbonyl, Ci-ialkoxy, halo-Ci-4alkoxy, amino-Ci.4alkoxy, hydroxyl -C i-4alkoxy , C _1-4 al kyl-C i-4al koxy , C■ - ₄ al kyl -amino-C■ - ₄ al koxy ,

(Ci.4alkyl)2-amino-Ci-4alkoxy, Ci.4alkyl-carbonyl-amino-Ci-.4alkoxy, Ci-ialkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4aikenyi-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalker!vl, heteroaiyl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-C 1 -lalkyl-amino, heteroaryl-C i-4alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl-Ci-4al kyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl -C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydiOxyl-Ci.4alkyl-amino; and

R5 is hydrogen, d- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00146] In a specific aspect, the pre-mRNA transcript is in a cell or a lysate of the cell and the method comprises contacting the compound with the cell or cell lysate. In a specific aspect, the method modulates the amount and/or modifies the type of a protein produced from the mature mR A transcript and produced in the cell or lysate of the cell.

[00147] In a specific aspect, the method comprises administering the compound to a subject. In a specific aspect, the method modulates the amount and/or modifies the type of a protein produced from the mature mRNA transcript and produced in the subject. In one aspect, the subject is a non-human subject. In another aspect, the subject is a human subject.

[00148] In a specific aspect, the mature mRNA transcript encodes a detectable reporter protein.

[00149] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent or treat a disease or disorder in which a change in the level of expression of one, two, three or more RNA isofomis encoded by a gene is beneficial to the prevention or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from modifying RNA splicing of a pre-mR A transcript comprising two exons and an nitron, wherein a first exon is upstream of the intron and a second exon is downstream of the iiitron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgumgn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula I) is:

(I)

or a form thereof, wherein

W is CH=CH or S;

X is ( ! ! :, CH(Ci- ₄ alkyl), C(Ci-4alkyl)2, il l C S i. 0 NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or Cg-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri, wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R.2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, Ci-4alkyl-amii o,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl~amino-Ci-4alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Cj-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyL (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyi~Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4a!ky!-carbony!-amino, heteroaiyl-Ci-4alkyl~amino-carbonyl-Ci-4aikyi, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino~C i-ial ky 1 , heterocyclyl , heterocyclyl -C 1 - ₄ al ky 1 , heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ; R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino, Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci- ₄ al ky], d-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bi cyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-d-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i- ₄ alky 1 ,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C 1 - ₄ alkyl, d^alkyl-carbonyl-amino, C alkyl-carbonyl-amino-C i- ₄ aikyi, hydroxyl-d-4alkyl, Ci- ₄ alkyl~carbonyl, Ci-ialkoxy, halo-Ci- ₄ alkoxy, amino-d-4alkoxy, hydroxyl -C _1-4 alkoxy , C _1-4 al kyl-C al koxy , C■ - ₄ al ky 1 -amino-C■ - ₄ al koxy ,

(Ci.4alkyl)2-amino-Ci-4alkoxy, C alkyl-carbonyl-amino-C^alkoxy, Ci-ialkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cyc!oalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-C 1 -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroar}'l-Ci-4alkyl-carbonyl-amino, heteroaryl-Ci-4al kyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl -C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydiOxyl-Ci.4alkyl-amino; and

R5 is hydrogen, d- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00150] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent or treat a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript comprising two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3 ' order: an intronic recognition element for splicing modifier (iREMS), a branch point, and a 3 ' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or uanine and n is any nucleotide, and wherein Formula (I) is:

0 ⁾

or a form thereof, wherein

W is i l l C I S or S;

X is CM?., CH(Ci-4aikyi), C(Ci-4alkyl) ₂ , (Ί I (Ί I, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1 , 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bi cyclic or tricyclic ring sy stem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring sy tem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi~amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyi~amino-Ci-4alkyl, (Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl, (Ci- ₄ alkyl) ₂ -amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci- ₄ al ky] , Ci-4alkyl-carbonyl-amii o, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4al kyl-Ci-4alkoxy, Ci-4alkyl-an ii o-Ci-4alkoxy,

(C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C walkoxy- Cwaikoxy, Cwalkoxy-earbonyl, Ci-4alkoxy-carbonyl-arnino, C i-4alkoxy -carbonyi ~ amino-Cwalkoxy, C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci-4alkOxy, C ₃ -?cycloalkenyl, heteroaryl, heteroaryl-Ci-ialkyl, heteroaryl-Cwalkyl-amino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl ,

heteroaryl-Ci-ialkyl-carbonyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl-Ci^alkyl, heteroar^4-Ci-4alkyl-carbonyl-ainino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci- ₄ alkoxy, phenyl, or phenyl -Ci- ₄ alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R:<,

R2 is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4al kyl -amino, (Ci-4alkyl)2-amino, amino-Ci-4al ky] , C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl, (Cj.- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, hydroxyl-Ci-4alkyl, Ci-4aikoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-vcycloalkyl, or heterocyclyl -d^alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl -imi no, Ci-4alkyl, halo-Cwalkyl, amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci-4alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amir!0-Ci-4alkyl, amino-carbonyl , Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)?.-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-d-4alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino-Cj.- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, d-4alkyl-amino-d-4alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, d-4alkoxy-carbonyl, d-4alkoxy-carbonyl-amino, d-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-d-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-d-4alkyl-amino-carbonyl,

heteroaryl-d-4alkyl-carbonyl -amino, heteroaryl-d-4alkyl-amino-carbonyl-d-4alkyl, heteroaryl-d^alkyl-carbonyl-amino-d-ialkyl, heterocyclyl, heterocyclyl-d-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

R is independently selected from halogen, d- ₄ alkyl, hydroxyl-Ci-4alkyl, amino, d-4alkyl- amino, (Ci-4alkyl) ₂ -amino or hydroxyl-Ci-4alkyl-amino; and

R.5 is hydrogen, d-4alkyl, or hydroxyl-d-4alkyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof

[00151] In a specific aspect of the foregoing aspect, the intron further comprises in 5' to 3' order: a 5' splice site, a branch point, and a 3' splice site upstream of the iREMS.

[00152] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent or treat a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript comprising three exons and two introns, wherein three exons and two introns are in the following order 5' to 3' : a first exon, a first intron, a second exon, a second intron and a third exon, wherein the first intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a first 5' splice site, a first branch point and a first 3' splice site, wherein the second intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: a second 5' splice site, an intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula I) is:

0)

or a form thereof, wherein

W is (Ί I CM or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl , heterocvclyl , or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycvclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxy!, cyano, d- ₄ alkyl, halo-Ci- ₄ alkyl, amino, Ci- ₄ alkyl -amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci-4alkyl)2-amim>carbonyl, Ci-4alkyl-amim>carbonyl-Ci-4alkyl, (Ci-4aikyi)2-ammo~ earbonyl-Ci-4alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci~4alkoxy, ha!o-Ci-4a!koxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci- ₄ alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-arnmo-Ci-4alkoxy, Ci.4alkyl-carbonyl-amino-Ci-.4alkoxy, Ci-ialkoxy- Ci-4alkoxy, d-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- aniino-Cwalkoxy, C2-4aikenyl, C2-4alkenyl~amino-carbonyl, Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl, heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaiy 1-C i-4al ky 1 -carbony 1 -amino-C ι - ₄ al ky 1 , heterocy cly 1 , heterocy cly 1 -C i- ₄ al ky 1 , heterocyclyl-d-4alkoxy, phenyl, or phenyl -d-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring sy stem having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R? is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-amino, (d-4alkyl) ₂ -amino, amino-C i-4alkyl, Ci- ₄ alkyl -amino-C i- ₄ alkyl, (Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, d-4alkoxy,

Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-d-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, d- ₄ alkyl, halo-d- ₄ alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-C i-4alkyl, C ₁ - ₄ alkyl -amino-C i-4alkyl , (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d- ₄ alkyl-amino-carbonyl,

(d- ₄ alkyl) ₂ -amino-carbonyl, d^alkyl-amino-carbonyl-d^alkyl, (d- ₄ alkyl) ₂ -amino- carbonyl-d- ₄ alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, d.- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-d.- ₄ alkoxy, amino-d- ₄ alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4al kyl-Ci-4al koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(d- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, d- ₄ alkyl-carbonyl-amino-d- ₄ alkoxy, d- ₄ alkoxy- Ci-4al koxy, Ci-4alkoxy-carbonyl, CMalkoxy-carbonyl-amino, d- ₄ alkoxy-carbonyl- amino-d-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C ! -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl-C^alkyl-amino-carbonyl-Cwalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl-C alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-d-4alkyl-amino; and

R5 is hydrogen, d-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00153] In some aspects, the iREMS i s an endogenous iREMS, In other aspects, the iREMS is a non-endogenous iREMS.

[00154] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising exons and one or more introns, wherein at least one intron comprises an iREMS that is downstream of a branch point and a 3' splice site, and wherein the iREMS comprises the sequence GAgumgn, wherein r is adenine or guanine and n is any nucleotide.

[00155] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein a first exon i s upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an iREMS, a second branch point and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgumgn, wherein r is adenine or guanine and n is any nucleotide.

[00156] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3' order: an iREMS, a branch point and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgumgn, wherein r i s adenine or guanine and n is any nucleotide, [00157] In another aspect, provided herein is a cell comprising an artificial gene construct described herein. [00158] In a specific aspect, the iREMS comprises an RNA sequence GAguragu, wherein r is adenine or guanine.

[00159] In another specific aspect, the iREMS comprises an RNA sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide. In a specific aspect, the RNA sequence NNGAgurngn (SEQ ID NO: 1) is selected from the group consisting of ANGAgumgn (SEQ ID NO: 4), CNGAgurngn (SEQ ID NO: 5), GNGAgurngn (SEQ ID NO: 6), UNGAgurngn (SEQ ID NO: 7), NAGAgumgn (SEQ ID NO: 8), NCGAgurngn (SEQ ID NO: 9), NGGAgurngn (SEQ ID NO: 10), NUGAgurngn (SEQ ID NO: 11), AAGAgurngn (SEQ ID NO: 12), ACGAgumgn (SEQ ID NO: 13), AGGAgumgn (SEQ ID NO: 14), AUGAguragn (SEQ ID NO: 15), CAGAguragn (SEQ ID NO: 16), CCGAgurngn (SEQ ID NO: 17),

CGGAgumgn (SEQ ID NO: 18), CUGAgurngn (SEQ ID NO: 19), GAGAgurngn (SEQ ID NO: 20), GCGAgurngn (SEQ ID NO: 21), GGGAgurngn (SEQ ID NO: 22), GUGAguragn (SEQ ID NO: 23), UAGAgurngn (SEQ ID NO: 24), UCGAgumgn (SEQ ID NO: 25), UGGAgumgn (SEQ ID NO: 52) and UUGAgumgn (SEQ ID NO: 53), wherein r is adenine or guanine and n or N is any nucleotide.

[00160] In another specific aspect, the iREMS comprises an RNA sequence NNGAguragu (SEQ ID NO: 2), wherein r is adenine or guanine and N is any nucleotide. In a specific aspect, the RNA sequence NNGAguragu (SEQ ID NO: 2) is selected from the group consisting of ANGAguragu (SEQ ID NO: 28), CNGAguragu (SEQ ID NO: 29), GNGAguragu (SEQ ID NO: 30), UNGAguragu (SEQ ID NO: 31), NAGAguragu (SEQ ID NO: 32), NCGAguragu (SEQ ID NO: 33), NGGAguragu (SEQ ID NO: 34), NUGAguragu (SEQ ID NO: 35), AAGAguragu (SEQ ID NO: 36), ACGAguragu (SEQ ID NO: 37), AGGAguragu (SEQ ID NO: 38), AUGAguragu (SEQ ID NO: 39), GAGAguragu (SEQ ID NO: 40), CGGAguragu (SEQ ID NO: 41),

CGGAguragu (SEQ ID NO: 42), CUGAguragu (SEQ ID NO: 43), GAGAguragu (SEQ ID NO: 44), GCGAguragu (SEQ ID NO: 45), GGGAguragu (SEQ ID NO: 46), CUGAguragu (SEQ ID NO: 47), UAGAguragu (SEQ ID NO: 48), UCGAguragu (SEQ ID NO: 49), UGGAguragu (SEQ ID NO: 489) and UUGAguragu (SEQ ID NO: 508), wherein r is adenine or guanine, and N is any nucleotide.

[00161] In certain aspects, n is adenine or guanine.

[00162] In one aspect, provided herein is a method for modifying RNA splicing in order to produce a mature niRNA transcript having an iExon, the method comprising contacting a pre- mRNA transcript produced from a DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first Y splice site, a nucleotide sequence encoding an intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the i EMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is an nucleotide, and wherein Formula (I) is:

0)

or a form thereof, wherein

W is (Ί I CM or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R: , and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally- substituted with 1 , 2, 3, 4, or 5 substituents each selected from R?.; B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-C i-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, C --4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci-4alkyl-carbonyl, C ₁ - ₄ alkoxy, halo-C i-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci-4alkoxy, C j -4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl -amino-carbonyl, Cs-Tcycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Ci-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R ₂ is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

Ci-4alkyl~amino, (Ci-4alkyl)2-amino, amino-Cj-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci- ₄ alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci- ₄ alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-'jcycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R ₃ is halogen, hydroxy] , nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl~amino, (Ci- ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, d^alkyl-amino-d^alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-C ₁ - ₄ alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Cwalkyl-carhonyl, Ci-4aikoxy, halo-d-4alkoxy, amino-d-4alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4alkyl-Ci~4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, d-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-d^alkyl,

heteroaryl-d-4alkyl-amino, heteroaryl-d- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-d-4alkyl-amino-carbonyl-d-4alkyl, heteroaryl-d alkyl-carbonyl-amino-d-4alkyl, heterocyclyl, heterocyclyi~Ci-4alkyl, phenyl, or phenyl-C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, d- ₄ alkyl, hydroxyl-Cj.- ₄ alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino, and

Rs is hydrogen, Ci-4alkyl, or

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00163] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript that is produced by a DNA sequence, the method comprising contacting the pre-mRNA transcript produced from the DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding an intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtmgn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is: or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2, and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4a!kyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-d^alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4aikyi)2-amino~Ci-4alkyl, amino-carbonyl, Cwalkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (d- ₄ alkyl) ₂ -amino- carbonyl-C ₁ - ₄ alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci- ₄ alkoxy, halo-C i-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci- ₄ alkoxy, C j .- ₄ alkyl-Ci- ₄ alkoxy, Ci-4alkyl-aniino-Ci-4alkoxy,

(Ci-4alkyl)2-amir!0-Ci-4alk xy, Ci-4alkyl-carhony]-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! - ₄ alkoxy, C i - ₄ alkoxy-carbonyl, C i ^alkoxy-carbonyl-amino, C alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C alkyl -amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino-C i-4al ky 1 , heterocy cly 1 , heterocy cly 1 -C 1 - ₄ al ky 1 , heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyciyl is optionally substituted with 1, or 2 substituents each selected from R3;

R?. is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

Ci- ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-C j.- ₄ alkyl, Ci-4alkyl-amino-Ci-4alkyl, (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C -7cycloalkyl, or heterocyclyl-Ci-4aikyi,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyciyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-C walkyl, Ci-4alkyl-amino-Ci-4alkyl, (Cj -4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d^alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-Ci-4alkyl, Ci-4al kyl -carbony 1 , Ci-4alkoxy, halo-Ci-4al koxy, amino-Ci-4alkoxy, hydroxyl-Ci- alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C i- ₄ alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-earbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -C^alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroar}'l-Ci alkyl~carbonyl~amino-Ci-4alkyl, heterocyclyl, heterocyclyl~Ci-4alkyl, phenyl, or phenyl-C ₁ - ₄ alkoxy;

R ₄ is independently selected from halogen, Cwalkyl, hydroxyl-Cwalkyl, amino, Ci-salkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-C ₁ -4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00164] In a specific aspect of the foregoing aspect, the nucleotide sequence encoding the intron further comprises in 5' to 3' order: a nucleotide sequence encoding a 5' splice site, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site upstream of the nucleotide sequence encoding the iREMS.

[00165] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript that is produced by a DNA sequence, the method comprising contacting the pre-mRNA transcript produced from the DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes three exons and two introns, wherein the nucleotide sequences encoding the three exons and the two introns respectively are in the following order 5' to 3' : a nucleotide sequence encoding a first exon, a nucleotide sequence encoding a first intron, a nucleotide sequence encoding a second exon, a nucleotide sequence encoding a second intron and a nucleotide sequence encoding a third exon, wherein the nucleotide sequence encoding the first intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3' splice site, wherein the nucleotide sequence encoding the second intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding a second 5' splice site, a nucleotide sequence encoding an intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula I) is; or a form thereof, wherein

W is CH=CH or S;

X is (Ί ! :, CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo-Ci-4a!kyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-d^alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4aikyi)2-amino~Ci-4alkyl, amino-carbonyl, Cwalkyl-amino-carbonyl,

(Ci-4alkyl) ₂ -amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, (d- ₄ alkyl) ₂ -amino- carbonyl-C ₁ - ₄ alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci- ₄ alkoxy, halo-C i-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-Ci- ₄ alkoxy, C j .- ₄ alkyl-Ci- ₄ alkoxy, Ci-4alkyl-aniino-Ci-4alkoxy,

(Ci-4alkyl)2-amir!0-Ci-4alk xy, Ci-4alkyl-carhony]-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! - ₄ alkoxy, C i - ₄ alkoxy-carbonyl, C i ^alkoxy-carbonyl-amino, C alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C alkyl -amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl-Ci- ₄ alkyl, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino-C i-4al ky 1 , heterocy cly 1 , heterocy cly 1 -C 1 - ₄ al ky 1 , heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyciyl is optionally substituted with 1, or 2 substituents each selected from R3;

R?. is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

Ci- ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-C j.- ₄ alkyl, Ci-4alkyl-amino-Ci-4alkyl, (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C -7cycloalkyl, or heterocyclyl-Ci-4aikyi,

wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyciyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-C walkyl, Ci-4alkyl-amino-Ci-4alkyl, (Cj -4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d^alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-Ci-4alkyl, Ci-4al kyl -carbony 1 , Ci-4alkoxy, halo-Ci-4al koxy, amino-Ci-4alkoxy, hydroxyl-Ci- alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy, (C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C i- ₄ alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl--amino-carbonyl-Ci-4alkyl, heteroar}'l-Ci alkyl~carbonyl~amino-Ci-4alkyl, heterocyclyl, heterocyclyl~Ci-4alkyl, phenyl, or phenyl-C ₁ - ₄ alkoxy;

R ₄ is independently selected from halogen, Cwalkyl, hydroxyl-Cwalkyl, amino, Ci-salkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-C ₁ -4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00166] In some aspects, the nucleotide sequence encoding the iREMS is a nucleotide sequence encoding an endogenous iREMS, In other aspects, the nucleotide sequence encoding the iREMS is a nucleotide sequence encoding a non-endogenous iREMS.

[00167] In another aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mR A transcript having an iExon, the method comprising contacting a pre- mRNA transcript produced from a DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an endogenous intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, wherein the DNA sequence is the DNA sequence of a gene that is selected from the genes listed in a table herein, and wherein Formula (I) is:

0)

or a form thereof, wherein

W is (Ί I CM or S;

X is CH ₂ , CH(Ci-4aikyi), C(Ci-4alkyl)2, CH=CH, O, Rs, or a bond;

A is aryl, heteroaryl , heterocyclyl , or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tric clic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloaikyl is a saturated or partial ly unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from 4;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, haio-Ci-4alkyl, amino, Ci-4aikyi-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

(Ci-4alkyl)2-amim>carbonyl, Ci-4alkyl-amim>carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- earbonyl-Ci-4alkyl, Ci-4aikyi~carbonyi~amino, Ci-4aikyi~carbonyi~amino-Ci-4aikyi, hydroxyl-d- ₄ alkyl, d- ₄ alkyl-carbonyl, Ci~4alkoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, d-4alkyl-amino-d-4alkoxy,

(Ci.4alkyl)2-amino-Ci-4alkoxy, Ci.4alkyl-carbonyl-amino-Ci-.4alkoxy, Ci-ialkoxy- Ci-4alkoxy, d-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- aniino-Cwalkoxy, C2-4aikenyl, C2-4alkenyl~amino-carbonyl, Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl, heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaiy 1-C i-4al ky 1 -carbony 1 -amino-C ι - ₄ al ky 1 , heterocy cly 1 , heterocy cly 1 -C i- ₄ al ky 1 , heterocyclyl-d-4alkoxy, phenyl, or phenyl -d-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring sy stem having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R? is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-amino, (d-4alkyl) ₂ -amino, amino-C i-4alkyl, Ci- ₄ alkyl -amino-C i- ₄ alkyl, (Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, d-4alkoxy,

Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-d-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, d- ₄ alkyl, halo-d- ₄ alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-C i-4alkyl, C ₁ - ₄ alkyl -amino-C i-4alkyl , (Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d- ₄ alkyl-amino-carbonyl,

(d- ₄ alkyl) ₂ -amino-carbonyl, d^alkyl-amino-carbonyl-d^alkyl, (d- ₄ alkyl) ₂ -amino- carbonyl-d- ₄ alkyl, Ci-4aikyi-carbonyi-amino, Ci-4aikyi-carbonyi-amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, d.- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-d.- ₄ alkoxy, amino-d- ₄ alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4al kyl-Ci-4al koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(d- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, d- ₄ alkyl-carbonyl-amino-d- ₄ alkoxy, d- ₄ alkoxy- Ci-4al koxy, Ci-4alkoxy-carbonyl, CMalkoxy-carbonyl-amino, d- ₄ alkoxy-carbonyl- amino-d-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C ! -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl-C^alkyl-amino-carbonyl-Cwalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl-C alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl~Ci-4alkyl-ammo; and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00168] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript that is produced by a DNA sequence, the method comprising contacting the pre-mRNA transcript produced from the DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, wherein the DNA sequence is the DNA sequence of a gene that is selected from the genes listed in a table herein and wherein Formula (I) is:

(I)

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4alkyl), ( ^' ((Yiaikyi ).'.. H i O L O, NR5, or a bond; A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi,

wherein aryl is seiected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having I, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Cj -4alkyl)2-amino-Ci-4aikyi, amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C i-4alkyl, C i -4aikyi-carbonyi-amino, C i -4aikyi-carbonyi-amino-C i - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkyl-earboi yi, Ci-4alkoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxy 1-C i - ₄ alkoxy , C i- ₄ alkyl-C i -4alkoxy , C i - ₄ alkyl-amino-C i - ₄ alkoxy ,

(Ci-4alkyl)2-amino~Ci-4alkoxy, Ci-4alkyl-carbonyl~amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -?cycloalkyl, C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl,

heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaiyl-C!-4alkyl~carbonyl~amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl -Ci^alkoxy, wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl , heteroaryl or heterocyclyl i s optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R_ is halogen, hydroxy!, cyano, oxo, hydroxyl-imino, d- ₄ alkyl, halo-Ci-4a!ky!, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-Cwalkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino~Ci-4alkyl, amino-carbonyl, hydroxyl-Cwalkyl, Cwalkoxy,

Ci-4alkoxy-carbonyl , C ₂ - ₄ alkenyl, Cs-ycycloalkyl, or heterocyclyl-d-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

R ₃ is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci- ₄ alkyl, amino,

C ₁ - ₄ alkyl-amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-Ci.4alkyl, C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, d-4alkyl-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino-Cj.- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, d-4alkyl-amino-d-4alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, d^alkoxy-carbonyl, d^alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C ₂ -4alkenyl -amino-carbonyl, C ₃ -7cycloaikyi, C3-7cycloalkyl~Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -C ₁ - ₄ alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, phenyl, or phenyl -Ci- ₄ alkoxy;

Rs is independently selected from halogen, Ci-4alkyl, hydroxyl-d- ₄ alkyl, amino, Ci-4alkyl- amino, (Ci-4alkyl) ₂ -amino and Rs is hydrogen, Cwalkyl, or hydroxyl-C - -4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00169] In a specific aspect of the foregoing aspect, the nucleotide sequence encoding the intron further comprises in 5' to 3' order: a nucleotide sequence encoding a 5' splice site, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site upstream of the nucleotide sequence encoding the iREMS.

[00170] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript that is produced by a DNA sequence, the method comprising contacting the pre-mRNA transcript produced from the DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes three exons and two introns, wherein the nucleotide sequences encoding the three exons and the two introns respectively are in the following order 5' to Y : a nucleotide sequence encoding a first exon, a nucleotide sequence encoding a first intron, a nucleotide sequence encoding a second exon, a nucleotide sequence encoding a second intron and a nucleotide sequence encoding a third exon, wherein the nucleotide sequence encoding the first intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3' splice site, wherein the nucleotide sequence encoding the second intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding a second 5' splice site, a nucleotide sequence encoding an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence

GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, wherein the DNA sequence is the DNA sequence of a gene that is selected from the genes listed in a table herein, and wherein Formula (I) is:

CO

or a form thereof, wherein

W is CH=CH or S;

X is (Ί ! :, CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l ( I I, O, NRs, or a bond;

A is aryl , heteroaryl, heterocyclyl, or Cg-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalky] is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Cj -4alkyl) ₂ -amino-Ci-4aikyL amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C i-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkyl-carbonyl, Ci-salkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci-4alkoxy, hydroxyl-C i- ₄ alkoxy, C i-4alkyl-C■ -4alkoxy, C i- ₄ alkyl-amino-C i- ₄ alkoxy,

(Ci-4alkyl) ₂ -amino~Ci-4alkoxy, Ci-4alkyl-carbonyl~amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -?cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl, heteroaryl-C ! -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaiyl-C^alkyl-amino-carbonyl-Cwalkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl , heteroaryl or heterocyclyl i s optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxy!, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl~amino, (C ₁ - ₄ alkyl) ₂ -amino, amino-Cj-4alkyl, Ci-4a!ky!-amino-Ci-4a!ky!, (Ci-4a!ky!)2-amino~Ci-4alkyl, amino-carbonyl, hydroxyl-Cwalkyl, Cwalkoxy,

Ci- ₄ alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-Tcycloalkyl, or heterocyclyl-Ci-4aikyi,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-C halky!, amino,

Ci-4al kyl -amino, (Ci-4alkyl)2-amino, amino-Ci-4al kyl , C ₁ - ₄ alkyl-amino-C ₁ - ₄ alkyl, (Cj -4alkyl)2-amino-Ci-4aikyi, amino-carbonyl,

(Ci-4a!ky!)2-amino~carbonyi, Ci-4alkyl-amino~carbonyi~Ci-4alkyl, (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl-amino, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkyl, hydroxyl-Ci-4alkyl, Ci.4alkyl-carbonyl, Ci-4alkoxy, ha!o-Ci.4alkoxy, amino-Ci-4a!koxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, C !-4alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, C^alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4arkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl, heteroaryl-Ci-4alkyl-amino, heteroaryl-C i^alkyl-amino-carbonyl, heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl-Ci-salkoxy;

R4 is independently selected from halogen, Cj.- ₄ alkyl, hydroxyl-Cj.- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-C ₁ -4alkyl-amino; and

Rs is hydrogen, Cwalkyl, or hydroxyl-Ci-4alkyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00171] In another aspect, provided herein is a method for modifying RNA splicing in order to produce a mature m NA transcript having an iExon, the method comprising contacting a pre- mRNA transcript produced from a DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding a non-endogenous intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is:

CO

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi, wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryi is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocvclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring sy tem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyi~amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi~amino-earbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyL (Ci- ₄ alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl, Cwaikoxy, halo-Ci- ₄ alkoxy, amino-C ₁ - ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Cj.- ₄ alkyl) ₂ -amino-C ₁ - ₄ alkoxy, Cj.- ₄ alkyl-carbonyl-amino-Cj.-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl- amino-Ci- ₄ alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycloalkyl, C3-7cycloalkyl~Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryi, heteroaryi -C ₁ - ₄ alkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci^alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryi -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4arkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl -Cj.-4alkoxy,

wherein heteroaryi is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, wherein heterocvclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocvclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

.2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, d- ₄ alkyl, halo-Ci-4al kyl , amino,

Ci-4alkyl-amino, (Ci-4alkyl) ₂ -amino, amino-C i-4alkyl, Cwalkyl -amino-C walkyl,

(d-4alkyl) ₂ -amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, d-Tcycloalkyl, or heterocyclyl-Ci-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-d-4alkyl, amino,

C i-4alkyl~amino, (C ₁ -4alkyl) ₂ -amino, amino-C i-4alkyl, C i-4alkyl -amino-C i-4alkyl ,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(Ci.4alkyl)2-amino-carbonyl, d-4alkyl-amino-carbonyl-Ci-4alkyl, (d-4alkyl) ₂ -amino- carbonyl-Ci-4alkyl, Ci-4aikyi~carbonyi~amino, Ci-4aikyi~carbonyi~amino-Ci-4aikyi, hydroxyl-Ci- ₄ alkyl, Cj- ₄ alkyl-carbonyl, d-4aikoxy, halo-d-4alkoxy, amino-Ci- ₄ alkoxy, hydroxyl-d- ₄ alkoxy, Ci-4al kyl-Ci-4al koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkoxy, Ci- ₄ alkyl-carbonyl-amino-Ci- ₄ alkoxy, Ci-4alkoxy- Ci-4al koxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, d- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C3-?cycloaikyi,

C ₃ -7cycloalkyl-d- ₄ alkoxy, C ₃ -?cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-d- ₄ alkyl-amino-carbonyl,

heteroaryl-C alkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino~carbonyl~Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-d- ₄ alkyl, phenyl, or phenyl-Cj- ₄ alkoxy;

R ₄ is independently selected from halogen, Ci-4alkyl, hydroxyl-d-4alkyl, amino, Ci-4alkyl- amino, (d-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino: and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4alkyl;

wherein a form of the compound is selected from the group consisting of a prodaig, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00172] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript that is produced by a DNA sequence, the method comprising contacting the pre-mRNA transcript produced from the DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises a DNA nucleotide sequence comprising in 5' to 3 ' order: a nucleotide sequence encoding an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3 ' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula I) is:

(I)

or a form thereof, wherein

W is CM C! f or S;

X is i i k CH(Ci- ₄ aikyi), C(Ci-4alkyl) ₂ , C i i Ci i. O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R?., and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)?.-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4a!ky!)2-amino~Ci-4aikyi, amino-carbonyl, Cwalkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4aIkyI-earbonyI, Ci-4alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci-4alkoxy, hydroxy 1-C 1 - ₄ alkoxy , C i- ₄ alkyl-C 1 -4alkoxy , C 1 - ₄ alkyl-amino-C 1 - ₄ alkoxy ,

(Ci-4a!ky!)2-amino~Ci-4alkoxy, Ci-4alkyl~carbonyl~ammo-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -?cycloalkyl,

C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaiyl, heteroaryl-C i-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-C i- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroary4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Chalky), amino,

d^alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci-4a) kyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-Ci-4alkyl, wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-salkyl, halo-Ci-talkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)?.-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci-4alkyl~carbonyl, Ci-4alkoxy, halo-Ci-4alkoxy, amino-Ci-4al koxy, hydroxyl-Ci-4alkoxy, Cj-4alkyl-Ci-4alkoxy, Ci-4alkyl~amino-Ci-4alkoxy,

(Ci-4alkyl)2-amir!0-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-earbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl, Cs-Tcycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~ammo, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4aikyi, phenyl, or phenyl-Ci-4alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00173] In a specific aspect of the foregoing aspect, the nucleotide sequence encoding the intron further comprises in 5' to 3' order: a nucleotide sequence encoding a 5' splice site, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site upstream of the iREMS.

[00174] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript that is produced by a DNA sequence, the method comprising contacting the pre-mRNA transcript produced from the DNA sequence with a compound of Formula (I) or a form thereof, wherein the DNA sequence encodes three exons and two introns, wherein the nucleotide sequences encoding the three exons and the two introns respectively are in the following order 5' to 3' : a nucleotide sequence encoding a first exon, a nucleotide sequence encoding a first intron, a nucieotide sequence encoding a second exon, a nucieotide sequence encoding a second intron and a nucleotide sequence encoding a third exon, wherein the nucleotide sequence encoding the first intron comprises a DNA nucieotide sequence comprising in 5' to 3' order: a nucieotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3' splice site, wherein the nucleotide sequence encoding the second intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding a second 5' splice site, a nucleotide sequence encoding an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a nucieotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence

GAgtrngn, wherein r is adenine or guanine and n is an nucleotide, and wherein Formula (I) is:

(I)

or a form thereof, wherein

W is CH=CH or S;

X is ( ^' ! !.'.. CH(Ci-4alkyl), C(Ci-4alkyl)2, CM O L O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tric clic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R?, and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)?.-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4a!ky!)2-amino~Ci-4aikyi, amino-carbonyl, Cwalkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4aIkyI-earbonyI, Ci-4alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci-4alkoxy, hydroxy 1-C 1 - ₄ alkoxy , C i- ₄ alkyl-C 1 -4alkoxy , C 1 - ₄ alkyl-amino-C 1 - ₄ alkoxy ,

(Ci-4a!ky!)2-amino~Ci-4alkoxy, Ci-4alkyl~carbonyl~ammo-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -?cycloalkyl,

C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaiyl, heteroaryl-C i-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-C i- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroary4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Chalky), amino,

d^alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci-4a) kyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-Ci-4alkyl, wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R.3 is halogen, hydroxy!, nitro, oxo, hydroxy! -imi no, Ci-salkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci- ₄ alkyl -ammo-Chalky 1,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, d^alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci-4a!ky!~carbony!, Ci-4alkoxy, halo-Ci-4a!koxy, amino-Ci-4al koxy, hydroxyl-Ci-4alkoxy, Cj-4alkyl~Ci-4alkoxy, Ci-4alkyl~amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci-4al koxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C halkoxy-earbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl , C3-?cycioalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroary!-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4aikyi, phenyl, or phenyl-C alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

R5 is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00175] In a specific aspect, the pre-mRNA transcript is in a cell or a lysate of the cell and the method comprises contacting the compound with the cell or cell lysate. In a specific aspect, the method modulates the amount and/or modifies the type of a protein produced from the mature mRNA transcript and produced in the cell or lysate of the cell.

[00176] In a specific aspect, the method comprises administering the compound to a subject. In a specific aspect, the method modulates the amount and/or modifies the type of a protein produced from the mature mRNA transcript and produced in the subject. In one aspect, the subject is a non-human subject. In another aspect, the subject is a human subject.

[00177] In a specific aspect, the mature mRNA transcript encodes a detectable reporter protein.

[00178] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent or treat a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript that is produced from a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence

GAgtrngn, wherein r is adenine or guanine and n is an nucleotide, and wherein Formula (I) is:

or a form thereof, wherein

W is CH=CH or S;

X is ( ! ! :, CH(Ci- ₄ alkyl), C(Ci-4alkyl)2, ( ! l C S i. 0 NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or Cg-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri, wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R.2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poly cyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-Ci-4alkyl, amino, d^alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, Ci-4alkyl~amino-Ci-4alkyl,

(Ci-4alkyl)2-amim>Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Cj-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl~Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl -Ci- ₄ alkyl, Ci-4alkyl-carbonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyi~Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4aikoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4al kenyl-amino-carbonyl, C3-7cycloalkyl,

heteroaryl-Ci-4alkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4a!ky!-carbony!-amino, heteroaiyl-Ci-4alkyl~amino-carbonyl-Ci-4aikyi, heteroa.ryl-C1-.4al ky 1 -carbony 1 -amino~C i-4al ky 1 , heterocyclyl , heterocyclyl -C 1 - ₄ al ky 1 , heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Cwalkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1 , 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ; R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- ₄ alkyl, halo-Ci-4alkyl, amino, Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci- ₄ al ky], d-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bi cyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-d-4alkyl, amino,

Ci-4alkyl-ami no, (C ₁ -4alkyl) ₂ -amino, ami no-C i-4alkyl, C i- ₄ alky 1 -amino-C i- ₄ alky 1 ,

(Ci- ₄ alkyl) ₂ -amino-Ci- ₄ alkyl, amino-carbonyl, Ci- ₄ alkyl-amino-carbonyl,

(d-4alkyl) ₂ -amino-carbonyl, d-4alkyl-amino-carbonyl-d-4alkyl, (Ci-4alkyl)2-amino- carbonyl-C 1 - ₄ alkyl, d-4alkyl-carbonyl-amino, C alkyl-carbonyl-amino-C i- ₄ aikyi, hydroxyl-d-4alkyl, Ci- ₄ alkyl~carbonyl, Ci-ialkoxy, halo-Ci- ₄ alkoxy, amino-d-4alkoxy, hydroxyl -C _1-4 alkoxy , C _1-4 al kyl-C al koxy , C■ - ₄ al ky 1 -amino-C■ - ₄ al koxy ,

(Ci.4alkyl)2-amino-Ci-4alkoxy, C alkyl-carbonyl-amino-C^alkoxy, Ci-ialkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ - ₄ alkenyl-amino-carbonyl, C ₃ -7cycloalkyl, C3-7cyc!oalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci- ₄ alkyl,

heteroaryl-C 1 -lalkyl-amino, heteroaryl -C i-4alkyl-amino-carbonyl,

heteroar}'l-Ci-4alkyl-carbonyl-amino, heteroaryl-Ci-4al kyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, phenyl, or phenyl -C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, d- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydiOxyl-Ci.4alkyl-amino; and

R5 is hydrogen, d- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00179] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent or treat a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript that is produced from a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding an intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide, and wherein Formula I) is:

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , ( Ί I CI I. O, MU or a bond;

A is aryl, heteroaryl, heterocyclyl, or C -iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having I, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Oj-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ; B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R4;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-C i-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, C --4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci-4alkyl-carbonyl, C ₁ - ₄ alkoxy, halo-C i-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci-4alkoxy, C j -4alkyl-Ci-4alkoxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl -amino-carbonyl, Cs-Tcycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Ci-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R3;

R ₂ is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

Ci-4alkyl~amino, (Ci-4alkyl)2-amino, amino-Cj-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci- ₄ alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci- ₄ alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-'jcycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

3 is halogen, hydroxy] , nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-C ₁ - ₄ alkyl, amino,

Ci-4alkyl~amino, (Ci- ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino~carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-C ₁ - ₄ alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Cwalkyl-carhonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci- ₄ alkoxy, Ci-4alkyl-Ci~4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci-4alkoxy, Ci- ₄ alkoxy-carbonyl, C alkoxy-carbonyl-amino, Ci- ₄ alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci-4alkyl,

heteroaryl-C^alkyl-amino, heteroaryl-C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4aikyi, heteroar}'l-Ci alkyi~carbonyi~amino-Ci-4alkyi, heterocyclyl, heterocyclyi~Ci-4alkyl, phenyl, or phenyl-C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Cj.- ₄ alkyl, hydroxyl-Cj.- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino, and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00180] In a specific aspect of the foregoing aspect, the nucleotide sequence encoding the intron further comprises in 5' to 3' order: a nucleotide sequence encoding a 5' splice site, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site upstream of the nucleotide sequence encoding the iREMS.

[00181] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent or treat a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene i s beneficial to the prevention or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript that is produced from a DNA sequence encoding three exons and two introns, wherein the nucleotide sequences encoding the three exons and the two introns respectively are in the following order 5' to 3' : a nucleotide sequence encoding a first exon, a nucleotide sequence encoding a first intron, a nucleotide sequence encoding a second exon, a nucleotide sequence encoding a second intron and a nucleotide sequence encoding a third exon, wherein the nucleotide sequence encoding the first intron comprises a DNA nucleotide sequence comprising in 5' to 3 ' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first Y splice site, wherein the nucleotide sequence encoding the second intron comprises a DNA nucleotide sequence comprising in 5' to 3' order: a nucleotide sequence encoding a second 5' splice site, a nucleotide sequence encoding an intronic recognition element for splicing modifier (iREMS), a nucleotide sequence encoding a second branch point, and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence

GAgtrngn, wherein r is adenine or guanine and n is an nucleotide, and wherein Formula (I) is:

(I)

or a form thereof, wherein

W is CM C! f or S;

X is i i k CH(Ci- ₄ aikyi), C(Ci-4alkyl) ₂ , C i i Ci i. O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloalkyl,

wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1 , 2, 3, 4, or 5 substituents each selected from R ₂ , and wherein Cs-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or poiycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, (), or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ;

Ri is halogen, hydroxy!, cyano, Ci-4alkyl, halo~Ci-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)?.-amino, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4a!ky!)2-amino~Ci-4aikyi, amino-carbonyl, Cwalkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4alkyl-amino-carbonyl-Ci-4alkyl, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, C 1 - ₄ alkyl-carbonyl-amino, C 1 - ₄ alkyl-carbonyl-amino-C 1 - ₄ alkyl, hydroxyl-C ₁ - ₄ alkyl, Ci-4aIkyI-earbonyI, Ci-4alkoxy, halo-C ₁ - ₄ alkoxy, amino-Ci-4alkoxy, hydroxy 1-C 1 - ₄ alkoxy , C i- ₄ alkyl-C 1 -4alkoxy , C 1 - ₄ alkyl-amino-C 1 - ₄ alkoxy ,

(Ci-4a!ky!)2-amino~Ci-4alkoxy, Ci-4alkyl~carbonyl~ammo-Ci-4alkoxy, C ₁ - ₄ alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- C ₂ - ₄ alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -?cycloalkyl,

C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaiyl, heteroaryl-C i-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-C i- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroary4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci- ₄ alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having I, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R3;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci-4alkyl, halo-Chalky), amino,

d^alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl,

(Ci-4alkyl)2-amii o-Ci-4alkyl, amino-carbonyl, hydroxyl-Ci-4a) kyl, Ci-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C3-7cycloalkyl, or heterocyclyl-Ci-4alkyl, wherein heterocyciyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyciyl is optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R.3 is halogen, hydroxy!, nitro, oxo, hydroxyl-imino, Ci-salkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl-amino, (Ci- ₄ alkyl) ₂ -amino, amino-Ci-4alkyl, Ci- ₄ alkyl -ammo-Chalky 1,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4alkyl, Ci- ₄ alkyl-carbonyl, Ci-4alkoxy, halo-Ci-4alkoxy, amino-Ci-4al koxy, hydroxyl-Ci-4alkoxy, Cj-4alkyl-Ci-4alkoxy, Ci-4alkyl~amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C 1 -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl , Cs-Tcycloalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Cwalkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyciyl, heterocyclyl-Ci-4aikyi, phenyl, or phenyl-C alkoxy;

R4 is independently selected from halogen, Ci-4alkyl, hydroxyi-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Cwalkyl^-amino or hydroxyl-Ci- ₄ alkyl-amino; and

Rs is hydrogen, Ci- ₄ alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00182] In some aspects, the nucleotide sequence encoding the iREMS is an endogenous nucleotide sequence encoding the iREMS. In other aspects, the nucleotide sequence encoding the iREMS is a non-endogenous nucleotide sequence encoding the iREMS.

[00183] In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding exons and one or more introns, wherein the nucleotide sequence encoding at least one intron comprises a nucleotide sequence encoding an iREMS that is downstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site, and wherein the nucleotide sequence encoding the iREMS comprises the sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide.

[00184] In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide.

[00185] In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide.

[00186] In another aspect, provided herein is a cell comprising an artificial gene construct described herein.

[00187] In a specific aspect, the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtragu, wherein r is adenine or guanine.

[00188] In another specific aspect, the nucleotide sequence encoding the iREMS comprises a DNA sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is adenine or guanine and n or N is any nucleotide. In a specific aspect, the DNA sequence NNGAgtrngn (SEQ ID NO: 1 808) is selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1809), CNGAgtrngn (SEQ ID NO: 1810), GNGAgtrngn (SEQ ID NO: 181 1 ), TNGAgtrngn (SEQ ID NO: 1812), NAGAgtrngn (SEQ ID NO: 1813), NCGAgtmgn (SEQ ID NO: 1814), NGGAgtrngn (SEQ ID NO: 1815), TGAgtmgn (SEQ ID NO: 1816), AAGAgtmgn (SEQ ID NO: 1817), ACGAgtmgn (SEQ ID NO: 1818), AGGAgtrngn (SEQ ID NO: 1819), ATGAgtrngn (SEQ ID NO: 1820), CAGAgtrngn (SEQ ID NO: 1821 ), CCGAgtrngn (SEQ ID NO: 1822), CGGAgtrngn (SEQ ID NO: 1823), CTGAgtrngn (SEQ ID NO: 1824), GAGAgtrngn (SEQ ID NO: 1825), GCGAgtmgn (SEQ ID NO: 1826), GGGAgtrngn (SEQ ID NO: 1827), CTGAgtrngn (SEQ ID NO: 1828), TAGAgtrngn (SEQ ID NO: 1829), TCGAgtmgn (SEQ ID NO: 1830), TGGAgtrngn (SEQ ID NO: 1831) and TTGAgtrngn (SEQ ID NO: 1832), wherein r is adenine or guanine and n or N is any nucleotide, [00189] In another specific aspect, the nucleotide sequence encoding the iREMS comprises a DNA sequence NNGAgtragu (SEQ ID NO: 3609), wherein r is adenine or guanine and N is any nucleotide. In a specific aspect, the DNA sequence NNGAgtragu (SEQ ID NO: 3609) is selected from the group consisting of ANGAgtragu (SEQ ID NO: 3610), CNGAgtragu (SEQ ID NO: 3611), CNGAgtragu (SEQ ID NO: 3612), TNGAgtragu (SEQ ID NO: 3613), NAGAgtragu (SEQ ID NO: 3614), NCGAgtragu (SEQ ID NO: 3615), NGGAgtragu (SEQ ID NO: 3616), NTGAgtragu (SEQ ID NO: 3617), AAGAgtragu (SEQ ID NO: 3618), ACGAgtragu (SEQ ID NO: 3619), AGGAgtragu (SEQ ID NO: 3620), ATGAgtragu (SEQ ID NO: 3621), CAGAgtragu (SEQ ID NO: 3622), CCGAgtragu (SEQ ID NO: 3623), CGGAgtragu (SEQ ID NO: 3624), CTGAgtragu (SEQ ID NO: 3625), GAGAgtragu (SEQ ID NO: 3626), GCGAgtragu (SEQ ID NO: 3627), GGGAgtragu (SEQ ID NO: 3628), GTGAgtragu (SEQ ID NO: 3629), TAGAgtragu (SEQ ID NO: 3630), TCGAgtragu (SEQ ID NO: 3631), TGGAgtragu (SEQ ID NO: 3632) and TTGAgtragu (SEQ ID NO: 3633), wherein r is adenine or guanine, and N is any nucleotide.

[00190] In certain aspects, n is adenine or guanine,

[00191] In a specific aspect, the pre-mRNA transcript described herein is a pre-mRNA transcript of a gene that is not selected from: ABHDI O, AD AMI 2, AKT1, ANXAl 1, APLP2, APPL2, ARMCX6, ATG5, AXIN1, BAIAP2, CCNB1IP1, CCT7, CEP57, CSF1, DLGAP4, EPNl, ERGIC3, FOXMl , GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN IB 1 , MRPL39, PCBP4, PPHLN1, PRKACB, RAB23, RAP1A, RCC1, SMN2, SREK1, STRN3 and TNRC6A.

BRIEF DESCRIPTION OF THE DRAWINGS

[00192] Figures 1A-1C. Representative schematics of intronic exon splicing mediated by an intronic REMS, where 5'ss represents a 5' splice site; 3'ss represents a 3' splice site; BP represents a splicing branch point, Exon l e and Exon 2e represent eExons; and, iExon l a represents an intronic exon. Splicing events mediated by an intronic REMS in the absence of a compound described herein are illustrated by solid lines that connect exons, splicing events mediated by an intronic REMS in the presence of a compound described herein are illustrated by- dashed lines connecting exons and eExons or iExons.

[00193] Figures 2A, 2B, 3A, 3B, 4A, 4B, 5A, SB and 6A, The dose dependent production of iExons for certain genes in SH-SY5Y cells treated for 20 hours with a compound described herein are shown in Figures 2A, 2B, 3A, 3B, 4A, 4B. The dose dependent production of iExons for certain genes in GM04856 ceils treated for 20 hours with a compound described herein are shown in Figures 5A and 5B. The dose dependent production of iExons for the gene ELM02 in SH-SY5Y cells treated for 20 hours with a compound described herein is shown in Figure 6A, For each Figure, end-point RT-PCR from total RNA showed the resulting bands of interest for each gene, as indicated by open and closed arrowheads, where an open arrowhead represents an exon isoform where endogenous wild-type splicing occured; and, where a closed arrowhead represents an exon isoform having an iExon included in the mR A. In all cases, an increase in compound concentration resulted in the appearance of a slower migrating PGR product containing the intronic-derived exon, where the additional bands seen are intermediate spliced products. The asterisk (*) in some Figures represents an event where the targeted exon was skipped. Accordingly, the result for each gene demonstrates a statistically significant splicing event that represents various aspects of the operation of an intronic REMS in combination with splicing modifier compounds as described herein.

[00194] Figures 6B and 6C. Production of certain intronic exon isoform s for ELM02 in the presence of one or more compounds described herein are shown in these schematics, where the presence of each isoform demonstrates a statistically significant splicing event that represents various aspects of the interactions of an intronic REMS sequence, where one or more branch points and one or more 3' splice sites in the presence of compounds as described herein are shown.

INTRONIC RECOGNITION ELEMENTS FOR SPLICING MODIFIER (iREMS)

[00195] In one aspect, provided herein is an intronic recognition element for splicing modifier (otherwise referred to as "iREMS") having elements capable of being recognized by a small molecule splicing modifier, whereby the elements of the associated iREMS complex, in combination with the small molecule splicing modifier, affect interactions with the spliceosome as further described herein. In a specific aspect, the intronic REMS has the nucleotide sequence GAgurngn at the RNA level, wherein r is A or G {i.e., a purine nucleotide adenine or guanine) and 1 is any nucleotide. In another specific aspect, the intronic REMS has the nucleotide sequence GAguragu at the RNA level, wherein r is adenine or guanine. In one or more of such specific aspects provided herein, n is adenine or guanine. In a more specific aspect, the intronic REMS has the nucleotide sequence NNGAgurngn (SEQ ID NO: 1) at the RNA level, wherein r is A or G {i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide. In another more specific aspect, the intronic REMS has the nucleotide sequence NNGAguragu (SEQ ID NO: 2) at the RNA level, wherein r is adenine or guanine and N is any nucleotide. In one or more of such more specific aspects provided herein, N is adenine or guanine. In another specific aspect, the intronic REMS is downstream of an intronic branch point and a functional intromc 3' splice site, wherein the intronic REMS comprises a nucleotide sequence selected from the group consisting of ANGAgumgn (SEQ ID NO: 4), CNGAgurngn (SEQ ID NO: 5), GNGAgurngn (SEQ ID NO: 6), UNGAgurngn (SEQ ID NO: 7), NAGAgurngn (SEQ ID NO: 8), NCGAgurngn (SEQ ID NO: 9), NGGAgumgn (SEQ ID NO: 10), UGAgurngn (SEQ ID NO: 11),

AAGAgurngn (SEQ ID NO: 12), ACGAgumgn (SEQ ID NO: 13), AGGAgurngn (SEQ ID NO: 14), AUGAgumgn (SEQ ID NO: 15), CAGAgurngn (SEQ ID NO: 16), CCGAgurngn (SEQ ID NO: 17), CGGAgumgn (SEQ ID NO: 18), CUGAgurngn (SEQ ID NO: 19), GAGAgurngn (SEQ ID NO: 20), GCGAgurngn (SEQ ID NO: 21), GGGAgurngn (SEQ ID NO: 22), GUGAguragn (SEQ ID NO: 23), UAGAgumgn (SEQ ID NO: 24), UCGAgurngn (SEQ ID NO: 25),

UGGAgurngn (SEQ ID NO: 52) and UUGAgurngn (SEQ ID NO: 53) at the RNA level, wherein r is A or G {i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide, by which the intronic REMS, in the presence of a compound described herein, functions as an introni c 5' splice site, causing the NNGA nucleotides of the REMS and the intronic nucleotides between the intronic 3' splice site down to and including the NNGA nucleotides to be spliced into the mature RNA as an intronic exon to provide a non-wild-type, nonfunctional mRNA. In another specific aspect, the intronic REMS is upstream of an intronic branch point and a functional intronic 3' splice site, wherein the intronic REMS comprises a nucleotide sequence selected from the group consisting of ANGAgumgn (SEQ ID NO: 4), CNGAgurngn (SEQ ID NO: 5), GNGAgurngn (SEQ ID NO: 6), UNGAgurngn (SEQ ID NO: 7), NAGAgurngn (SEQ ID NO: 8), NCGAgurngn (SEQ ID NO: 9), NGGAgumgn (SEQ ID NO: 10), NUGAgurngn (SEQ ID NO: 11), AAGAgumgn (SEQ ID NO: 12), ACGAgurngn (SEQ ID NO: 13), AGGAgumgn (SEQ ID NO: 14), AUGAgurngn (SEQ ID NO: 15), CAGAgumgn (SEQ ID NO: 16), CCGAgumgn (SEQ ID NO: 17), CGGAgurngn (SEQ ID NO: 18), CUGAgurngn (SEQ ID NO: 19), GAGAgurngn (SEQ ID NO: 20), GCGAgurngn (SEQ ID NO: 21), GGGAgurngn (SEQ ID NO: 22), GUGAgurngn (SEQ ID NO: 23), UAGAgurngn (SEQ ID NO: 24), UCGAgurngn (SEQ ID NO: 25),

UGGAgurngn (SEQ ID NO: 52) and UUGAgurngn (SEQ ID NO: 53) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide, by which the intronic REMS, in the presence of a compound described herein, functions as an intronic 5' splice site, causing the NNGA nucleotides of the REMS and the intronic nucleotides between the intronic 3' splice site down to and including the NNGA nucleotides to be spliced into the mature RNA as an intronic exon to provide a non-wild-type, nonfunctional mRNA. In a preferred aspect, the REMS has a nucleotide sequence selected from the group consisting of ANGAguragu (SEQ ID NO: 28), CNGAguragu (SEQ ID NO: 29), GNGAguragu (SEQ ID NO: 30),

UNGAguragu (SEQ ID NO: 31), NAGAguragu (SEQ ID NO: 32), NCGAguragu (SEQ ID NO: 33), NGGAguragu (SEQ ID NO: 34), NUGAguragu (SEQ ID NO: 35), AAGAguragu (SEQ ID NO: 36), ACGAguragu (SEQ ID NO: 37), AGGAguragu (SEQ ID NO: 38), AUGAguragu (SEQ ID NO: 39), CAGAguragu (SEQ ID NO: 40), CCGAguragu (SEQ ID NO: 41 ), CGGAguragu (SEQ ID NO: 42), CUGAguragu (SEQ ID NO: 43), GAGAguragu (SEQ ID NO: 44),

GCGAguragu (SEQ ID NO: 45), GGGAguragu (SEQ ID NO: 46), GUGAguragu (SEQ ID NO: 47), UAGAguragu (SEQ ID NO: 48), UCGAguragu (SEQ ID NO: 49), UGGAguragu (SEQ ID NO: 489) and UUGAguragu (SEQ ID NO: 508) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and N is any nucleotide. In one or more aspects provided herein, N is adenine or guanine.

[00196] In the context of DNA, in a specific aspect, the nucleotide sequence encoding an intronic REMS has the sequence Gagtrngn, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n is any nucleotide. In another specific aspect, in the context of DN A, the nucleotide sequence encoding an intronic REMS has the sequence Gagtragt, wherein r is adenine or guanine. In a specific aspect, in the context of DNA, the nucleotide sequence encoding an intronic REMS has the sequence NNGAgtrngn (SEQ ID NO: 1808), wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide. In another specific aspect, in the context of DNA, the nucleotide sequence encoding an intronic REMS has the sequence NNGAgtragt (SEQ ID NO: 3634), wherein r is adenine or guanine and N is any nucleotide. In a specific aspect, in the context of DNA, the nucleotide sequence encoding an intronic REMS comprises a sequence selected from the group consisting of ANGAgtmgn (SEQ ID NO: 1809), CNGAgtrngn (SEQ ID NO: 1810), GNGAgtrngn (SEQ ID NO: 181 1), TNGAgtrngn (SEQ ID NO: 1812), NAGAgtrngn (SEQ ID NO: 1813), NCGAgtmgn (SEQ ID NO: 1814), NGGAgtrngn (SEQ ID NO: 1815), NTGAgtrngn (SEQ ID NO: 1816), AAGAgtrngn (SEQ ID NO: 1817), ACGAgtrngn (SEQ ID NO: 1818), AGGAgtrngn (SEQ ID NO: 1819), ATGAgtmgn (SEQ ID NO: 1820), CAGAgtrngn (SEQ ID NO: 1821), CCGAgtrngn (SEQ ID NO: 1822), CGGAgtrngn (SEQ ID NO: 1823), CTGAgtrngn (SEQ ID NO: 1824), GAGAgtrngn (SEQ ID NO: 1825), GCGAgtrngn (SEQ ID NO: 1826), GGGAgtrngn (SEQ ID NO: 1827), GTGAgtrngn (SEQ ID NO: 1828), TAGAgtmgn (SEQ ID NO: 1829), TCGAgtrngn (SEQ ID NO: 1830), TGGAgtrngn (SEQ ID NO: 1831 ) and TTGAgtrngn (SEQ ID NO: 1832), wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide. In a preferred aspect, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtragt (SEQ ID NO: 1833), CNGAgtragt (SEQ ID NO: 1834), GNGAgtragt (SEQ ID NO: 1835), TNGAgtragt (SEQ ID NO: 1836), NAGAgtragt (SEQ ID NO: 1837), NCGAgtragt (SEQ ID NO: 1838), NGGAgtragt (SEQ ID NO: 1839),

NTGAgtragt (SEQ ID NO: 1840), AAGAgtragt (SEQ ID NO: 1841), ACGAgtragt (SEQ ID NO: 1842), AGGAgtragt (SEQ ID NO: 1 843), ATGAgtragt (SEQ ID NO: 1844), CAGAgtragt (SEQ ID NO: 1845), CCGAgtragt (SEQ ID NO: 1846), CGGAgtragt (SEQ ID NO: 1847),

CTGAgtragt (SEQ ID NO: 1848), GAGAgtragt (SEQ ID NO: 1849), GCG Agtragt (SEQ ID NO: 1850), GGGAgtragt (SEQ ID NO: 1851), GTGAgtragt (SEQ ID NO: 1852), TAGAgtragt (SEQ ID NO: 1853), TCGAgtragt (SEQ ID NO: 1854), TGGAgtragt (SEQ ID NO: 1855) and

TTGAgtragt (SEQ ID NO: 1856), wherein r is adenine or guanine and N is any nucleotide. In one or more aspects provided herein, N is adenine or guanine.

[00197] An intronic REMS can be part of an endogenous RNA or can be introduced into an RNA sequence that does not naturally contain the intronic REMS sequence (in which case, the introduced intronic REMS is a non-endogenous intronic REMS, i.e., an intronic REMS not naturally present in the corresponding RNA. A nucleotide sequence encoding an intronic REMS can also be part of an endogenous DNA sequence, or a nucleotide sequence encoding the intronic REMS can be introduced into a DNA sequence that does not naturally contain the nucleotide sequence encoding an intronic REMS.

[00198] In a specific aspect, the REMS is located in an intron and is upstream of a branch point and a functional 3' splice site which, in the presence of a small molecule splicing modifier, enables the REMS to function as a 5' splice site. Without being bound by any theory or mechanism, the small molecule compounds described herein have been shown to increase the affinity of the interaction between the Ul snRNP, as well as other components of the pre-mRNA splicing machinery, and the nucleotides NNGA of the REMS whereby, in the presence of the compound, the intronic REMS functions as a Ul snRNP binding site, causing the intronic nucleotides to be spliced as an intronic exon.

COMPOUND USE

[00199] In one aspect provided herein are compounds of Formula (I) for use in the methods described herein:

or a form thereof, wherein

W is CH=CH or S;

X is CH ₂ , CH(Ci-4alkyl), C(Ci-4alkyl) ₂ , CH=CH, O, NR ₅ , or a bond;

A is aryl, heteroaryl, heterocyclyl, or C9-iocycloaikyi,

wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R?, and wherein Oj-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri; B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1 , 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, Ci-4al kyl , halo-C i-4alkyl, amino, Ci-4alkyl-amino,

(Ci-4alkyl)2-amino, amino-Ci-4alkyl, C - -4alkyl-amino-Ci-4alkyl,

(Ci.4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, Ci-ialkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino~Ci-4alkyl, hydroxyl-Ci-4al kyl, Ci-4alkyl-carbonyl, C ₁ - ₄ alkoxy, halo-C i- ₄ alkoxy, amino-Ci-4al koxy, hydroxyl-Ci-4alkoxy, C j -4alkyl-Ci-4a!koxy, Ci-4alkyl-amino-Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! -4alkoxy, C i -4alkoxy-carbonyl, C i -4alkoxy-carbonyl-amino, C i-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ - ₄ alkenyl, C2-4alkenyl -amino-carbonyl, Cs-Tcycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaiyl-Ci-4alkyl-amino-carbonyl-Ci-4alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, heterocyclyl-Ci-4alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 , or 2 substituents each selected from R ₃ ;

R2 is halogen, hydroxyl, cyano, oxo, hydroxyi-imino, Ci-4alkyl, halo-C i-4alkyl, amino,

C!- ₄ alkyl-amino, (Ci-4alkyl)2-amino, amino-Cj-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci- ₄ alkyl)2-amino-Ci-4alkyl, amino-carbonyl, hydroxyl-C ₁ - ₄ alkyl, Ci- ₄ alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, Cs-'jcycloalkyl, or heterocyclyl-Ci- ₄ alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

3 is halogen, hydroxy] , nitro, oxo, hydroxyl-imino, Ci-4alkyl, halo-Ci-4alkyl, amino,

Ci-4alkyl~amino, (Ci- ₄ alkyl) ₂ -amino, amino-Cj.-4alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4alkyl, amino-carbonyl, Ci-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-amino-carbonyl, Ci-4aikyi-amino-carbonyl-Ci-4aikyi, (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, d^alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-Ci-4alkyl, Cwalkyl-carhonyl, Ci-4aikoxy, halo-Ci-4alkoxy, amino-Ci-4alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci~4alkoxy, Ci-4alkyl-amino~Ci-4alkoxy,

(Ci-4alkyl)2-amino-Ci-4alkoxy, Ci-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- Ci-4alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, Ci-4alkoxy-carbonyl- amino-Ci-4alkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C ₃ -7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-Ci-4alkyl,

heteroaryl-Ci-ialkyl-amino, heteroaryl-Ci-4alkyi~amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl-Ci-4aikyi, heteroar}'l-Ci aikyi~carbonyi~amino-Ci-4alkyi, heterocyclyl, heterocyclyl~Ci-4alkyl, phenyl, or phenyl-C ₁ - ₄ alkoxy;

R4 is independently selected from halogen, Cj.- ₄ alkyl, hydroxyl-Cj.- ₄ alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino, and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-Ci-4aikyi;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00200] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Fonnula lb) for use in the methods described herein:

(la) (lb)

or a form thereof, wherein

X is (Ί ! :, CH(Ci-4alkyl), C(Ci.4alkyl) ₂ , C! l i l l, O, NRs, or a bond;

A is aryl, heteroaryl, heterocyclyl, or CViocycloaikyi, wherein aryl is selected from phenyl and naphthyi, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,

wherein heteroaryi is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,

wherein heterocvclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring sy tem having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and wherein Cg-iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₂ ;

B is heterocyclyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R ₄ ;

Ri is halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci- ₄ alkyl, amino, Ci-4aikyi-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyi~amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

C ! - ₄ alkyl-amino-carbonyl-C 1 - ₄ alkyl,

Ci-4alkyl, hydroxyl -Cwalkyl, Ci-4alkyl-carbonyl, Ci-4alkoxy, halo-Ci-4alkoxy, amino- Ci-4alkoxy, hydroxyl -C j.- ₄ alkoxy, Ci -4alkyl~Ci-4alkoxy, C j.- ₄ alkyl-amino-C j.- ₄ alkoxy, (Ci-4alkyl)2-amir!0-Ci-4alk xy, Ci-4alkyl-carbonyl-amino-Ci-4al koxy, Ci- ₄ alkoxy- C ! - ₄ alkoxy, C i - ₄ alkoxy-carbonyl, C 1

amino-Ci-4alkoxy, C2-4alkenyl, C2-4alkenyl-amino-carbonyl , C3-?cycloalkyl, C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryi, heteroaiyl-Ci-4alkyl,

heteroaryl-Ci-4alkyi~amino, heteroaryl-Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Ci-4alkyl-carbonyl-amino, heteroaryi -Ci- ₄ alkyl -amino-carbonyl -Ci- ₄ alkyl, heteroaryl-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci- ₄ alkyl, heterocyclyl-C ₁ - ₄ alkoxy, phenyl, or phenyl-Ci-4al koxy,

wherein heteroaryi is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from Rj;

.2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, 0- ₄ alkyl, halo-Chalky), amino,

Ci-4alkyl-amino, (Ci- alkyl) ₂ -amino, amino-Ci-4alkyl, amino-carbonyl,

hydroxyi~Ci-4alkyl, Ci.4alkoxy, Ci-4alkoxy~carbonyl, C ₂ - alkenyl, Cs-Tcycloalkyl, or heterocyclyl-Ci-4alkyl;

R.3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- ₄ alkyl, amino, Ci- ₄ alkyl-amino,

(Ci-4alkyl)2-amino, amino-C ₁ - ₄ alkyl, Ci-4alkyl-amino-Ci-4alkyl,

(Ci-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

Ci-4al kyl-amino-carbor!vl-Ci-4al kyl , Ci-4alkyl-carbonyl-amir!0, Ci-4alkyl-carbonyl-amir!0- Ci-4alkyl, hydroxyi-Cj-4alkyl, Ci-4alkyl-carbonyi, Ci-4alkoxy, halo-Ci-4alkoxy, amino- Ci-4alkoxy, hydroxyl -Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, Ci.4alkyl-amino-Ci.4alkoxy, (C i-4alkyl)2-amino-C i-4alkoxy, C i-4alkyl-carbonyl-amino-C i-4alkoxy, C i-4alkoxy- Cwaikoxy, Cwalkoxy-carbonyl, Ci-4alkoxy-carbonyl-amino, C i-4aikoxy-carbonyI- amino-Ci-4alkoxy, C ₂ -4alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycloaikyi, C3-7cycloalkyl-Ci-4alkoxy, C3-7cycloalkenyl, heteroaryl, heteroaryi~Cj-4alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl-Ci-4alkyl-amino-carbonyl,

heteroaiyl-C!-4alkyl~carbonyl~amino, heteroaryl-Ci-4alkyl-amino-carbonyl~Ci-4aikyi, heteroar}4-Ci-4alkyl-carbonyl-amino-Ci-4alkyl, heterocyclyl, heterocyclyl-Ci-4alkyl, phenyl, or phenyi-Cj-4alkoxy;

R ₄ is independently selected from halogen, Cwalkyl, hydroxyl-Ci-4alkyl, amino, Ci- ₄ alkyl- amino, (Ci-4alkyl)2-amino or hydroxyl-Ci-4alkyl-amino; and

Rs is hydrogen, Ci-4alkyl, or hydroxyl-d^alkyl;

wherein a form of the compound is selected from the group consisting of a prodaig, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof. [00201] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula lb) for use in the methods described herein:

(la)

or a form thereof, wherein

X is O, NH, NiC! b ) or a bond;

A is ary], heteroaryl or heterocyclyl,

wherein aryl is selected from the group consistin

l a2 a3 wherein heteroar l is selected from the group consistin

al2 al3 al4 al5

- 196 - wherein heteroc clyl is selected from the group consisting of

a45 a46, and a47

B is heteroc clyl selected from the group consisting of

b25 b26. and

, Rib and Ric are each, where allowed by available valences, one or more substituents each selected from halogen, hydroxyl, cyano, Ci-4alkyl, halo-Ci-salkyl, amino,

Ci-4alkyl-amino, (Ci-4alkyl)2-amino, amino-Ci-4alkyl, d-4alkyl-aiTiino-C!-4alkyl, (d-4alkyl) ₂ -amino-d-4alkyl, amino-carbony] , d-4alkyl-amino-carbonyl,

(Ci-4alkyl)2-aniino-carbonyl, Ci-4aikyi-aniino-carbonyl~Ci-4aikyL (Ci-4alkyl)2-amino- carbonyl-Ci-4alkyl, d^alkyl-carbonyl-amino, d-4alkyl-carbonyl-amino-d-4alkyl, hydroxyl-Ci-4alkyl, Ci-4alkyl-carbonyl, d- ₄ alkoxy, halo-C i-4alkoxy, amino-d-4alkoxy, hydroxyi~Ci-4alkoxy, Ci-4alkyl~Ci-4alkoxy, d-4alkyl~amino~Ci-4alkoxy, (C i-4alkyl)2-amino-C i-4aikoxy, C ^alkyl-carbonyl-amino-C i-4alkoxy, C walkoxy- d-4alkoxy, Ci-4alkoxy-carbonyl, d-4alkoxy-earbonyl-amino, Ci-4alkoxy-carbonyl- amino-CMalkoxy, C ₂ -4alkenyl, C ₂ -4alkenyl-amino-carbonyl, C ₃ -7cycloalkyl,

C3-7cycloalkyl-Ci- ₄ alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl -d-4alkyl,

heteroaryl-Cwalkyl-arnino, heteroaryl -C ₁ - ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroaryl-d^alkyl-amino-carbonyl-d^alkyl, heteroaryl-d-4alkyl-carbonyl-amino-d-4alkyl, heterocyclyl, heterocyclyl-d-4alkyl, heterocyclyl-Ci- ₄ alkoxy, phenyl, or phenyl -d-4alkoxy,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ,

R2a, Rib and R _2c are each, where allowed by available valences, one or more substituents each selected from halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Cwalkyl, haio-Cwalkyl, amino, d-4alkyl-amino, (d-4alkyl)2-amino, amino-Ci- ₄ alkyl, Ci- ₄ alkyl-amino-Ci- ₄ alkyl, (Cj-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, hydroxyl-Ci-4alkyl, d-4alkoxy,

Ci-4alkoxy-carbonyl, C ₂ - ₄ alkenyl, C ₃ -7cycloalkyl, or heterocyclyl-Ci-4alkyl,

wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and

wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R ₃ ;

R ₃ is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci-4alkyl, amino, d^alkyl-amino,

(d-4alkyl) ₂ -amino, amino-C ₁ - ₄ alkyl, d^alkyl-amino-d^alkyl,

(d-4alkyl)2-amino-Ci-4aikyi, amino-carbonyl, Ci-4aikyi-amino-carbonyl,

(Cj.- ₄ alkyl) ₂ -amino-carbonyl, d-4aikyi-amino-carbonyl~d-4aikyi, (Ci- ₄ alkyl) ₂ -amino- carbonyl-d-4alkyl, Ci-4alkyl-carbonyl-amino, Ci-4alkyl-carbonyl-amino-Ci-4alkyl, hydroxyl-d- ₄ alkyl, Ci- ₄ alkyl-carbonyl, Ci- ₄ alkoxy, halo-Ci- ₄ alkoxy, amino-Cj.- ₄ alkoxy, hydroxyl-Ci-4alkoxy, Ci-4alkyl-Ci-4alkoxy, d-4alk.yl-amino-d-4alk.oxy,

(Ci.-4alkyl)2-amino-Cf.-4aikoxy, d-4alkyl-carbonyl-amino-Ci-4alkoxy, Ci-4alkoxy- Ci- ₄ alkoxy, Ci-4alkoxy-carbonyl, Ci-4alkoxy-earbonyl-amino, Ci-4alkoxy-carbonyl- aniino-Ci-4alkoxy, Ci alkenyl, C2-4alkenyl-amino-carbonyl, C3-7cycioalkyl,

C3-7cycloalkyl-Ci-4alkoxy, C ₃ -7cycloalkenyl, heteroaryl, heteroaryl-C ₁ - ₄ alkyl,

heteroaryl-Cwalkyl-amino, heteroaryl -Ci- ₄ alkyl-amino-carbonyl,

heteroaryl-Cwalkyl-carbonyl-amino, heteroar^4-Ci-4alkyl-amino-carbony]-Ci-4alkyl, heteroaryl-Cwalkyl -carbonyl -amino-C ι - ₄ alkyl , heterocyclyl , heterocyclyl -Ci-4alkyl, phenyl, or phenyl-C^alkoxy; and

R _4a , 4 , R4c, R4d, 4e, R4f and R ₄ g are independently selected from halogen, Ci-4alkyl,

hydroxyl-d-4alkyl, amino, Ci-4alkyl-amino, (Ci-4alkyl)2~ammo or

hydroxyl-Ci-4alkyl-amir!o;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantionier, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00202] In another aspect provided herein are compounds of Formula (I) for use in the methods described herein, wherein the compound of Formula (I) is selected from a compound of

Formula (lai l Formula (Ial5), Formula (la 18) or Formula (lb I ) :

(Ial8), (Ibl)

or a form thereof, wherein (when present),

X is selected from O, NRs, or a bond;

A is selected from phenyl, thiophenyl, indazolyl, pyridinyl, pyrimidinyl or phenoxy,

wherein phenyl and phenoxy are each optionally substituted with I , 2 or 3 substituents each

selected from R _la , wherein thiophenyl, indazolyl, pyridinyl, pyrimidinyl are each optionally substituted with 1 or 2 substituents each selected from R ,

B is selected from 1 H-pyrazolyl, piperidinyl, 1 ,2,3,6-tetrahydropyridinyl, (\R,5S)-S- azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, 2,6-diazaspiro[3.4]octyl or 2,7- diazaspiro[3.5]nonyl, each optionally substituted with 1 or 2 substituents each selected from R _4a ;

Ria is selected from halogen, hydroxy!, Ci-4alkyl, halo-Ci-ialkyl, amino, C ₁ - ₄ alkoxy, or

heteroaryl,

wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S optionally substituted with 1 or 2 substituents each selected from R _3a ;

R _3a is selected from nitro or Ci- alkyl, and,

R4a is Ci- ₄ alkyl;

-5a is hydrogen, Ci-ialkyl, or hydroxyi~Ci-4alkyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

Another aspect of the present description relates to a compound of Formula (I) selected from a compound of Formula (lal 1 ), Formula (Ial 5), Formula (Ial 8) or Formula (Ibl):

or a form thereof, wherein (when present),

Ria is selected from fluoro, chloro, hydroxyl, methyl, difluoromethyi, amino, methoxy or I H- pyrazolyl or lH-imidazol-l-yl,

wherein 1 H-pyrazolyl is optionally substituted with 1 or 2 substituents each selected from R■■.·: lha is selected from nitro or methyl or amino; and,

R¾a is methyl or ethyl;

R.¾ is hydrogen or methyl;

wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00203] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of

- 2ul - Formula (Ial ) or a form thereof, wherein substituents R _la , Rib, and X, when present, are indicated in the table below with multiple substituents separated by a comma; and, "-" indicates that one or more Ria, Rib, and X substituents are not present:

( Ial)

[00204] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia2) or a form thereof, wherein substituents Ria, Rib, and R4a, when present, are indicated in the table below with multiple substituents separated by a comma; and, "-" indicates that one or more Ria, Rib, and R _4a substituents are not present:

(Ia2)

[00205] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia3) or a form thereof, wherein substituents Ria, Rib and X, when present, are indicated in the table below with multiple substituents separated by a comma, and, "— " indicates that one or more R _la , Rib and X substituents are not present:

(Ia3)

f >] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia4) or a form thereof, wherein substituents X, R _la , Rib and R _4a , when present, are indicated in the table below: and, indicates that one or more A. ja Rib and R _4a substituents are not present:

ia4)

- LO - [00207] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia5) or a form thereof, wherein substituents R _la and Rr ₀ , when present, are indicated in the table below with multiple substituents separated by a comma; and, "— " indicates that one or more Ria and Rr ₀ substituents are not present:

(Ia5)

)8] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia6) or a form thereof, wherein substituents Ria, when present, are indicated in the table below; and, "— " indicates that one or more Ria substituents are not present:

[00209] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia7) or a form thereof, wherein substituents Ria, when present, are indicated in the table below; and, "— " indicates that one or more R _la substituents are not present:

- 2u 7 - [00210] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia8) or a form thereof, wherein substituents Ria and B, when present, are indicated in the table below; and, "— " indicates that one or more Ria and B substituents are not present:

[00211] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ia9) or a form thereof, wherein substituents Ria and B, when present, are indicated in the table below; and, "— " indicates that one or more Ria and B substituents are not present:

ia9)

[00212] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (la 10 ) or a form thereof, wherein substituents Ri _a and B, when present, are indicated in the table below; and, "— " indicates that one or more R _la and B substituents are not present:

(lalO)

[00213] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula { lal 1) or a form thereof, wherein substituents A, X and R.4a, when present, are indicated in the tab! e below; and, "— " indicates that one or more A, X and R _4a substituents are not present:

(M l)

Cpd A X

21 quinolin-3-yl N(CH ₃ ) H

22 phthalazin-6-yl N(CH ₃ ) H

23 benzo[c][l,2,5]oxadiazol-5-yl NH H

24 b enzo [djthi azol - 5 -y 1 NH H

25 2-CH ₃ -benzo[d]oxazol-6-yl NH H

30 2-(4-CN-phenol) N(CH ₃ ) H

32 2-(4-CF ₃ -phenol) N(CH ₃ ) H

33 6-(2-F-phenol) N(CH ₃ ) H

34 2-[3,5-(OCH3)2-phenol] N(CH ₃ ) H

35 2-[4,5-(OCH ₃ )2-phenol] N(CH ₃ ) H

37 2-(4,5-F ₂ -phenol) \(C! 1 :} H

41 b enzo [bjthi ophen-2-y 1 NH CH ₃

53 2-[4-(lH-pyrazol- 1 -yl)-phenol] \(C! 1 :} H

115 2-[3-OH-5-(lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

116 2-[3-OCH ₃ -5-(lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

117 2-[5-(lH-pyrazol-4-yl)-3-OCF ₃ -phenol] NH H

118 2-[5-(l-C¾-lH-pyrazol-4-yl)-3-OCF ₃ -phenol] N(CH ₃ ) H

119 2-[5-(lH-pyrazol-4-yl)-3-OCF ₃ -phenol] N(CH ₃ ) H

120 2-[5-(l-CH ₃ -pyridin-2(lH)-one)-3-OCF ₃ -phenol] N(CH ₃ ) H

121 2-[3-OCH ₃ -5-(l-CH ₃ -lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

2-[3-OCH ₃ -5-(5,6,7,8-tetrahydroimidazo-[l,2-

122 a]pyridin-3-yl)-phenol] N(CH ₃ ) H

123 2-[3-OCFJj-5-(pyridin-3-yl)-phenol] \(C! 1 :} H

2-[3-OCH ₃ -5-(l-cyclopentyl-lH-pyrazol-4-yl)-

124 phenol] N(CH ₃ ) H

125 2-[5-(3-OCH ₃ -phenyl)-3-OCH ₃ -phenol] N(CH ₃ ) H

126 2-[3-benzyloxy-5-(5-CH ₃ -oxazol-2-yl)-phenol] N(CH ₃ ) H

127 2-[3-OCH ₂ CH ₃ -5-(5-CH ₃ -oxazol-2-yl)-phenol] N(CH ₃ ) H

2-[3-(OCH2-cyclopropyl)-5-(5-CH ₃ -oxazol-2-yl)-

128 phenol] XiC! ] :} H

129 5-(2-CH ₃ -lH-benzo[d]imidazol-6-ol) N(CH ₃ ) H

134 2-[4-(lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

2-[4-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyridin-3-

135 yl)-phenol] N(CH ₃ ) H Cpd A X B a

2-[4-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-

136 yl)-phenol] N(CH ₃ ) H

137 2-[4-(l H-indol-2-yl)-phenol] ON H

138 2- [4-(cy cl open t- 1 -en - 1 -y 1 )-phenol ] N(CH ₃ ) H

139 2-[4-(l H-pyrazol-3-yl)-phenol] N(CH ₃ ) H

140 2-[4-(2-OH-pyridin-4-yl)-phenol] \(C! 1 :} H

141 2[4-(l-CH ₃ -pyridin-2(lH)-one)-phenol] 0 H

142 2-[4-(2-OH-pyridin-4-yl)-phenol] 0 H

144 2-[4-Cl-5-(lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

145 2-[4-F-5-(lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

146 2-[5-F-4-(lH-imidazol-4-yl)-phenol] N(CH ₃ ) H

147 2-[5-F-4-(lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

148 2- [5 -F-( 1 H-pyrazol-5 -yl)-phenol] N(CH ₃ ) H

149 6-OH- 1 -oxo-2, 3 -dihy dro- 1 H-inden-5 -yl N(CH ₃ ) H

150 6-(l,4-dihydroindeno[l,2-c]-lH-pyrazol-7-ol) (CH ₃ ) H

151 6-OH-l-OH-imino-2,3-dihydro-lH-inden-5-yl N(CH ₃ ) H

152 6-OH-l-OH-2,3-dihydro-lH-inden-5-yl N(CH ₃ ) H

153 6-(2-NH2-8H-indeno[ 1 ,2-d]thiazol -5-ol) N(CH ₃ ) H

154 9-(5,6-dihydroimidazo[5,l-a]isoquinolin-8-ol) N(CH ₃ ) H

2-{4-[C(0)NHCH2-(l-CH ₃ -lH-pyrazol-4-yl)]-

155 phenol } N(CH ₃ ) H

156 2-[4-(4-CH20H- lH-pyrazol- 1 -yl)-phenol] N(CH ₃ ) H

158 3 -(OCH2-phenyl)~i soquinolin-6-y 1 N(CH ₃ ) H

160 2-[3-F-5-(2-OCH3-pyridin-4-yl)-phenol] N(CH ₃ ) H

161 4-[l-(4-pyridin-2(lH)-one)-3-F-5-OH-phenyl] (CH ₃ ) H

4-{ l-[4-(l-CH ₃ -pyridin-2(lH)-one)]-3-F-5-OH-

162 phenyl } MO! h) H

4-{ l-[5-(l -CH3-pyridin-2(lH)-one)]-3-F-5-OH-

163 phenyl} N(CH ₃ ) H

164 2-[3-F-5-(lH-pyrazol-4-yl)-phenol] 0 H

165 2-(5-Cl-3-F-phenol) N(CH ₃ ) H

166 2-[3-F-5-(lH-pyrazol-4-yl)-phenol] (CH ₃ ) H

167 2-[3-F-5-(l-CH ₃ -lH-pyrazol-4-yl)-phenol] N(CH ₃ ) H

219 8-(quinolin-7-ol) N(CH ₃ ) H

230 6-(7-OH-quinolin-2(l H)-one) N(CH ₃ ) H Cpd A X R4a

231 6-(7-OH-l-CH3-quinolin-2(lH)-one) N(CH ₃ ) H

245 7-(6-OH-l-CH ₃ -quinolin-4(lH)-one) NiCHs) H

257 6-(7-OH-quinazolin-4(lH)-one) (CH3) H

259 6-(7-OH-l-CH ₃ -3,4-dihydroquinolin-2(l H)-one) N(CH ₃ ) H

7-OH-l,3-(CH3)2-quinazolin-6-yl-2,4(lH,3H)-

277 dione N(CH ₃ ) H

278 6-OH-benzo[d]oxazol-5-yl-2(3H)-one N(CI h ) H

279 2-CH3-6-OH-2H-indazol-5-yl N(CH ₃ ) H

280 I-CH3-6-OH- 1 H-indazol .-5-yl N(CI h ) H

281 7-(6-OH-2-CH3-isoquinolin- 1 (2H)-one) N(CH ₃ ) H

282 7-(6-OH-2-CH2CH3-isoquinolin- 1 (2H)-one) 0 H

[00214] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lal 1 ) or a form thereof, wherein substituents A, X and . =:·,, when present, are indicated in the table below: and, indicates that one or more A, X and R _4a substituents are not present:

Cpd A X

445 2-CH ₃ -pyrazolo[l,5-a]pyridin-3-yl N(CH ₃ )

446 imidazo[ 1 ,2-a]pyridin-6-yl 0

447 2-OCH3-4-(lH-pyrazol - 1 -yl)phenyl 0

448 5-(lH-pyrazol-4-yl)thiophen-2-yl 0

449 5-(l-CH ₃ -lH-pyrazol-4-yl)thiophen-2-yl 0

450 4-(lH-pyrazol-4-yl)thiophen-2-yl 0

451 2-OH-4-[3,5-(CH3)2-lH-pyrazol-4-yl]phenyl 0

452 2-F-4-( 1 H-pyrazol -4-yl)phenyl N(CH ₃ )

453 2-OCH ₃ -4-OH-phenyl 0

454 2-()α-Ϊ3-4-(4-Νθ2- 1 H-pyrazol- 1 -yl)pheny 1 0

455 2,4-(OH) ₂ -phenyl 0

456 2-Cl-4-(lH-pyrazol-4-yl)phenyl N(CH ₃ )

457 5-amino-2-(lH-pyrazol-4-yl)pyrimidin-4-yl 0

458 2,6-F ₂ -4-(lH-pyrazol-4-yl)phenyl 0

464 2-(CHF ₂ )-4-(lH-pyrazol-4-yl)phenyl 0

465 2-(CHF ₂ )-4-(lH-pyrazol-4-yl)phenyl N(CH ₃ )

[00215] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lal 1 ) or a form thereof, wherein substituents A, X and . =:·,, when present, are indicated in the table below: and, indicates that one or more A, X and R _4a substituents are not present:

(M l)

Cpd A X

438 4-(l-CH ₃ -lH-pyrazol- -yl)thiophen-2-yl 0

440 2-F-4-OH-phenyl N(CH ₃ )

442 2-CH3-2H-indazol-5-yl (CH ₃ )

443 2-CH ₃ -2H-indazol-5-yl 0

4-Cl-2-OCH ₃ -phenyl 0

445 2-CH ₃ -pyrazolo[l,5-a]pyridin-3-yl N(CH ₃ )

446 imi dazo[ 1 ,2-a]pyri din-6-y 1 O

447 2-OCH ₃ ~4-( l H-pyrazol- l~yl)phenyl 0

448 5 -( 1 H-pyrazol -4-yl)thi ophen-2-yl 0

449 5-(l -CH3-I H-pyrazol-4-yl )thiophen-2-yl 0

450 4~( 1 H-pyrazol -4-yl)thi ophen-2-yl 0

451 2-OH-4-[3,5-(CH3)2-lH-pyrazol-4-yl]phenyl 0

452 2-F-4-( J H-pyrazol -4-yl)phenyl N(CH ₃ )

453 2-OCH ₃ -4-OH-phenyl 0

454 2-OCH ₃ -4-(4-N02-lH-pyrazol-l-yl)phenyl 0

455 2,4-(OH)2-phenyl 0

456 2-Cl-4-(lH-pyrazol-4-yl)phenyl N(CH ₃ )

457 5-amino-2-(lH-pyrazol-4-yl)pyrimidin-4-yl 0

458 2, 6-F ₂ -4-(l H-pyrazol -4-yl)phenyl 0

464 2-(CHF ₂ )-4-(lH-pyrazol-4-yl)phenyl 0

465 2-(CHF ₂ )-4-(l H-pyrazol -4-yl)phenyl N(CH ₃ )

[00216] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (la 12) or a form thereof, wherein substituents X, R _la and B, when present, are indicated in the table below; and, "— " indicates that one or more X, Ria and B substituents are not present:

[00217] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ial3) or a form thereof, wherein substituents X, R _la and R _a , when present, are indicated in the table below: and, indicates that one or more X. ja and R4a substituents are not present:

[00218] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (la 14) or a form thereof, wherein substituents X and B, when present, are indicated in the table below; and, "— " indicates that one or more X and B substituents are not present:

Ial4) Cpd X B

71 — 4-CH ₂ CH ₂ QH-piperazin- 1 -y 1

72 2,7-diazaspiro[3.5]non-7-yl

73 — 2,7-diazaspiro[3.5]non-7-yl

74 3-CH ₂ OH-piperazin-l -yl

75 ~ l,7-diazaspiro[4.4]non-7-yl

76 __ 4- H2-4-CH3-piperidin- 1 -yl

77 — 3 - N(CH ₃ ) ₂ -piperi din- 1 -yl

79 — 3,3-(CH ₃ ) ₂ -piperazin-l -yl

80 — 7-CH2CH20H-2,7-diazaspiro[4.4]-nonan-2-yl

83 — l,2,3,6-tetrahydropyridin-4-yl

84 _. piperidin-4-yl

102 0 (6S)-6-[(S)-CH(OH)CH3]-2,2-(CH3)2-piperidin-4-yl

133 0 2,2-(CH ₃ ) ₂ -piperidin-4-yl

[00219] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ial5) or a form thereof, wherein substituents X, R _la and R _a , when present, are indicated in the table below: and, indicates that one or more X. ja and R4a substituents are not present:

(Ial5)

in Cpd X Rla

43 N(CH ₃ ) IH-pyrazol-l-yl H

44 N(CH ₃ ) 5-CH ₃ -oxazol-2-yl H

45 N(CH ₃ ) 4 -Π K)H - lH-pyrazole- 1 -yl H

46 N(CH ₃ ) lH-imidazole-l -yl H

47 N(CH ₃ ) 4 -M h- 1 H-pyrazol - 1 -y 1 H

48 N(CH ₃ ) lH-pyrazol-4-yl H

49 N(CH ₃ ) 3 -ΝΉ.2- 1 H-pyrazol - 1 -yl H l-(CH ₂ C¾-morpholin-4-yl)-lH-

50 N(CI-I ₃ ) pyrazol-4-yl H

51 (CH ₃ ) l-CH ₃ -lH-pyrazol-4-yl H

52 N(CH ₃ ) 5 -NH ₂ - 1 H-pyrazol - 1 -y 1 H

54 N(CH ₂ CH ₂ OH) 1 H-pyrazol- 1-yl H

62 0 IH-pyrazol-l-yl CH ₃

63 0 1 H-pyrazol -1 -yl H

64 0 I H-pyrazol-4-yl H

78 H 1 H-pyrazol -1 -yl CH ₃

100 CH ₂ 1 H-pyrazol- 1-yl H

130 (CH ₃ ) CI H

131 NH 1 H-pyrazol- 1-yl H

132 NH CN H

143 N(CH ₃ ) l H-indazol-7-yl H

157 CH2 1 H-pyrazol -4-yl H

168 N(CH ₃ ) 5-OCH ₃ -pyridin-3-yl H

169 N(CH ₃ ) 5-pyridin-2-ol H

170 N(CH ₃ ) 4-pyridin-2-ol H

171 N(CH ₃ ) 6-OCH ₃ -pyridin-3-yl H

172 N(CH ₃ ) 5-(3-CF ₃ -pyridin-2-ol) H

173 N(CH ₃ ) 5-(l-CH ₃ -pyridin-2(lH)-one) H

174 N(CH ₃ ) 4-(l-CH3-pyridin-2(lH)-one) H

175 N(CH ₃ ) 2-OCH ₃ -pyridin-4-yl H

176 0 4-pyridin-2-ol H

177 N(CH ₃ ) 6-N(CH ₃ ) ₂ -pyridin-3-yl H

178 0 4-(l-CH3-pyridin-2(lH)-one) H

179 N(CH ₃ ) pyrimidin-5-yl H Cpd X Rla

180 N(CH ₃ ) 5-pyridin-3-ol H

4-(l-cyclopropyl-pyridin-2(lH)-

181 (CH ₃ ) one) H

182 !\ (Q-fe) 1,2,3, 6-tetrahydropyridin-4-yl H

183 IN ^' (Cft) cyclope t- -en- 1 -y 1 H

184 JS (CH ₃ ) 3,6-dihydro-2H-pyran-4-yl H

185 IS XCl ) imidazo[ 1 , 5-a]pyridin-7-yl H

186 JS (CH ₃ ) imidazo[ 1 ,2-a]pyridin-7-yl H

187 IS XClh) 2-CH ₃ -pyridin-4-yl H

188 i (CH ₃ ) lH-imidazol-2~yl H

189 IS TCH ₃ ) lH-imidazol-4-yl H

190 i (CH ₃ ) imidazo[l,2-a]pyrazin-3-yl H

5,6,7,8-tetrahydroimidazo[l,2-

191 !\ (CH ₃ ) a]pyrazin-3-yl H

192 IS XCB3) 4-CH ₃ - 1 H-imidazol-2-yl H

193 N (CH ₃ ) 1 -CH ₃ - 1 H-i m i dazol-4-yl H

194 IS XClh) l -CH ₃ -l H-imidazol-5-yl H

195 JS (CH ₃ ) 4-NO2- lH-imidazol-2-yl H

196 IS XClh) 2-CH ₃ -l H-imidazol-4-yl H

197 JS (CH ₃ ) 1 ,2-(CH ₃ )2- 1 H-imidazol-4-yl H

198 TS TCH ₃ ) 4-C(0) H2- lH-pyrazol- 1 -yl H

206 is (CH ₃ ) H H

[00220] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ial5) or a form thereof, wherein substituents X, R _la and Ria, when present, are indicated in the table below: and, indicates that one or more A. ja and R4a substituents are not present:

[00221] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lal 6) or a form thereof, wherein substituents Ri _a and R.4a, when present, are indicated in the table below; and, "— " indicates that one or more R _la and R4a substituents are not present:

[00222] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lal 7) or a form thereof, wherein substituent Ria, when present, is indicated in the table below; and, "— " indicates that one or more R _la substituents are not present:

lal 7) [00223] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ial8) or a form thereof, wherein substituents X and B, when present, are indicated in the table below; and, "— " indicates that one or more X and B substituents are not present:

[00224] In another aspect provided herein are compounds of Formula (la) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ial 8) or a form thereof, wherein substituents X, R _la and B, when present, are indicated in the table below: and, "— " indicates that one or more A. ja and B substituents are not present:

(Ial8)

[00225] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ibl) or a form thereof wherein substituent A is indicated in the table below:

(Ib l) Cpd A

302 6-(naphthalen-2-ol)

320 6-(naphthalen-2,7-diol)

331 7-OCH ₃ -quinolin-6-yl

332 7-OH-quinolin-6-yl

337 2-CN-7-OCH ₃ -quinolin-6-yl

355 3 -F-5 -( lH-pyrazol-4-yl)-pyridin-2-y i

364 2-(6-OCH ₃ -3,4-dihydroisoquinolin-l (2H)-one)

392 6-OH-l.-oxo-2,3-dihydro-lH-inden-5-yl

401 3 -(4-OCH3- 1 -CH3-quinoli n-2( 1 H)-one)

402 3-(4-OH-l-CH ₃ -quinolin-2(lH)-one)

403 3-(quinolin-2(lH)-one)

404 3-(l-OCH ₃ -quinolin-2(lH)-one)

408 5-CN-benzo[b]thiophen-2-yl

409 3-Cl-benzo[b]thiophen-2-yl

[00226] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ibl) or a form thereof, wherein substituent A is indicated in the table below

[00227] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ib ) or a form thereof, wherein substituent A is indicated in the table below:

(Ibl)

Cpd A

462 3 -( 1 H-pyrazol-4-y 1 )phenoxy

463 4-(lH-pyrazol-4-yl)phenoxy

124 [00228] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lb 2) or a form thereof, wherein substituent A is indicated in the table below;

)2)

[00229] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lb 3) or a form thereof wherein substituents Ria, Rib and B, when present, are indicated in the table below; and, indicates that one or more R _la , Rib and B substituents are not present:

[00230] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ib4) or a form thereof, wherein substituents R _la , Rib, Ric, Rid (each representative of the scope of Ri) and X, when present, are indicated in the table below; and, "— " indicates that one or more R _la , Rib, Ric, Rid and X substituents are not present;

(Ib4)

[00231] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (lb 5) or a form thereof, wherein substituents R _la , Rib, Ric, Rid (each representative of the scope of Ri) and R4a, when present, are indicated in the table below; and, "— " indicates that one or more Ri _a , Rib, Ric, Rid and R _4a substituents are not present:

)5 )

Cpd Rla Rib id Ria

380 lH-pyrazol-4-yl CI H H CH ₃

384 lH-pyrazol-4-yl F H H CH ₃

396 l H-pyrazol-4-yl F H OH __

405 lH-pyrazol-4-yl CI H H __

[00232] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ib6) or a form thereof, wherein substituents R _la , Rib, Ric and Rid (each representative of the scope of Ri), when present, are indicated in the table below; and, "— " indicates that one or more Ria, Rib, Ric and Rid substituents are not present:

(Ib6)

133] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula ( b 7) or a form thereof, wherein substituent Rib, when present, is indicated in the table below:

(0)7)

[00234] In another aspect provided herein are compounds of Formula (lb) or a form thereof for use in the methods described herein, wherein the compound is selected from a compound of Formula (Ib8) or a form thereof, wherein substituent Rib, when present, is indicated in the table below:

Qb8)

PREPARATION OF COMPOUNDS

[00235] Compounds provided herein can be prepared by those skilled in the art, such as, by the synthetic methods set forth in International Application Number PCT/US2013/054687 filed August 13, 2013 and published as International Publication Number WO2014/028459 on February 20, 2014; International Application Number PCTJUS2014/012774 filed January 23, 2014 and published as International Publication Number WO2014/1 16845 Al on July 31, 2014; International Application Number PCT/US2014/048984 filed July 30, 2014 and published as International Publication Number WO201 5/01.7589 on February 5, 2015; and, International Application Number PCT/US2016/066042 filed December 1 1, 2016 and published as

International Publication Number WO2017/100726 on June 15, 2017, each of which are incorporated by reference in their entirety as if fully set forth herein.

[00236] In one aspect, the compound of Formula (I) used in a method disclosed herein is a compo

- 234 -

- 235 -

- 245 -

179 180

- 248 -

-256 -

-260 -

- 265 -

-266 - 

- Δ ! 4 -

[00237] wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racernate, enantiomer, diastereorner, stereoisomer, polymorph and tautomer form thereof.

[00238] In another aspect, the compound of Formula (I) used in a method disclosed herein is a compound selected from the group consisting of:

465

[00239] wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00240] In another aspect, the compound of Formula (Γ) or a form thereof used in a method disclosed herein is a compound of Formula (I) or a form thereof (wherein compound number indicates that the salt form was isolated) selected from the group consisting of;

Cpd Name

1 6-(naphthalen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyr idazin-3-amine

6-(benzo[b]thiophen-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpip eridin-4-yl)pyridazin-3-

2 amine

3 2-(6-(2,2,6,6-tetramethylpiperidin-4-yl-amino)-pyridazin-3-y l)phenol

2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyrida zin-3-yl)benzo[b]-

4 thiophene-5-carbonitrile

5 6-(quinolin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrid azin-3-amine

6 3-(benzo[b]-thiophen-2-yl)-6-(2,2,6,6-tetramethylpiperidin-4 -yl-oxy)pyridazine

7 2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino)-pyrid azin-3-yl)phenol

8 6-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino)-pyrid azin-3-yl)naphthalen-2-ol

9 6-(benzo[b]-thiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4 -yl)pyridazin-3-amine

10 7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl) isoquinoline

11 6-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl) isoquinoline

12 N~methyl-6-(quinolin-7-yl)~N-(2,2,6,6 etramethylpiperidin~4-yl)py

13 N-methyl-6-(quinolin-6-yl)- -(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine

14 6-(isoquinolin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidi n-4-yl)pyridazin-3-amine

15 6-(isoquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidi n-4-yl)pyridazin-3-amine

6-(imidazo[l,2-a]pyridin-6-yl-pyridazin-3-yl)-methyl-(2,2 ,6,6-tetramethylpiperidin-4-

16 yi)-amine

N-methyl-6-(6-phenylpyridin-3-yl)-N-(2,2,6,6-tetramethylpipe ridin-4-yl)pyridazin-3-

17 amine 6-(6-(lH-pyrrol-l-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetra methylpiperidin-4- yl)pyridazin-3 -amine

6-(6-(lH-pyrazol-l-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetr amethylpiperidin-4- yi)pyridazi n-3 -amine

methyl-(6-quinoxalin-2-yl-pyridazin-3-yl)-(2,2,6,6-tetram ethylpiperidin-4-yl)-amine methyl-(6-quinolin-3-yl-pyridazin-3-yl)-(2,2,6,6-tetramethyl piperidin-4-yl)-amine N-methyl-6-(phthalazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin -4-yl)pyridazin-3-amine

6-(benzo[c][l,2,5]oxa-diazol-5-yl)-N-(2,2,6,6-tetramethyl piperidin-4-yl)pyridazin-3- amine

6-(benzo[d]thiazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin- 4-yl)pyridazin-3-amine

6-(2-methylbenzo-[d]oxazol-6-yl)-N-(2,2,6,6-tetramethylpi peridin-4-yl)pyridazin-3- amine

3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyri dazin-3-yl)naphthalen-2-ol 5-chloro-2-(6-(methyl(l ,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyridazin-3-yl)phen ol 3-(6-(2,2,6,6-tetramethylpiperidin-4-yl-amino)pyridazin-3-yl )naphthalen-2-ol

5-chloro-2-(6-(l ,2,2,6,6-pentaniethylpiperidin-4-ylamino)pyridazin-3-yl)phen ol

4-hydroxy-3-(6-(methyl(2,2,6,6-tetraniethylpiperidin-4-yl )amino)pyridazin-3- yi)benzonitrile

3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3- yl)naphthalen-2-ol

2- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)-4- (trifl uoromethyl)phenol

2-fluoro-6-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl) -amino)-pyridazin-3-yl)phenol

3,5-dimethoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3- yl)phenol

4,5-dirneihoxy-2-(6~(methyl(2,2,6,6~tetramethylpiperi

yl)phenol

5-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)pyridazin-3-yl)phenol

4,5-difluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3- yl)phenol

5-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)a mino)pyridazin-3-yl)phenol

3- hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3- yi)benzonitrile

l-dlyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3- yl)naphthalen-2-ol

6-(benzo[b]thiophen-2-yl)-N-(l,2,2,6,6-pentamethylpiperid in-4-yl)pyridazin-3-amine

N-allyl-3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperid in-4-yl)amino)pyridazin-3- yl)benzamide 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(lH-pyrazol-l- yi)phenol

5-(5-methyl-oxazol-2-yl)-2-(6-(methyl-(2,2,6,6-tetramethylpi peridin-4-yl)-amino)- pyridazin-3-yl)phenol

5-(4-hydroxymethyl)-lH-pyrazole-l-yl)-2-(6-(methyl(2,2,6,6-t etramethylpiperidin-4- yl)amino)pyridazin-3-yl)phenol

5-(lH midazol-l-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl )amino)pyridazin- 3-yl)phenol

5-(4-aniino-lH-pyrazole-l -yl)-2-(6-(niethyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(l.H-pyrazol-4- yi)phenol

5-(3-amino-lH-pyrazol-l -yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(l-(2- morpholi no-ethyl)- lH-pyrazol-4-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(l-methyl-lH- pyrazol-4-yl)phenol

5-(5-amino-lH-pyrazol-l-yl)-2-(6-(methyl-(2,2,6,6-tetramethy lpiperidin-4- yl)amino)pyridazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-4-(lH-pyrazol-l- yl)phenol

2-((6-((2-hydroxy-ethyl)-(2,2,6,6-tetramethylpiperidin-4-yl) -amino)-pyridazin-3-yl)-5- pyrazol-l-yl)phenol

2-(6-(piperidin-4-yloxy)pyridazin-3-yl)-5-(lH-pyrazol-l-y l)phenol

2-(6-(((2S,4R,6R)-2,6-dimethylpiperidin-4-yl)oxy)pyridazin-3 -yl)-5-(l H-pyrazol-l- yl)phenol

2-(6-((-2,6-dimethylpiperidin-4-yl)oxy)pyridazin-3-yl)-5- (l H-pyrazol-l-yl)phenol 5-(lH-pyrazol-l-yl)-2-(6-(pyrrolidin-3-yl-oxy)pyridazin-3-yl )phenol

2-(6-(((2S,4S)-2-methylpiperidin-4-yl)oxy)pyridazin-3-yl) -5-(l H-pyrazol-l-yl)phenol (5-(lH-pyrazol-l-yl)-2-(6-(pyrrolidin-3-ylmethoxy)pyridazin- 3-yl)phenol

2-(6-((3-fluoropiperidin-4-yl)oxy)pyridazin-3-yl)-5-(lH-p yrazol-l -yl)phenol

2-(6-(l,2,2,6,6-pentamethyl-piperidin-4-yl-oxy)-pyridazin-3- yl)-5-(lH-pyrazol-l- yl)phenol

5-lH-pyrazol-l-yl-2-(6-(2,2,6,6-tetramethylpiperidin-4-yl -oxy)-pyridazin-3-yl)phenol 5-(l H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy )pyridazin-3-yl)phenol 2-(6-piperazin-l-yl-pyridazin-3-yl)-5-(lH-pyrazol-l -yl)phenol

3-(6-(azetidin-3-ylamino)-pyridazin-3-yl)naphthalen-2-ol 2-(6-(azetidin-3-ylamino)pyridazin-3-yl)-5-(lH-pyrazol-l-yl) phenol 2-(6-(3,5-dimethylpiperazin-l -yl)pyridazin-3-yl)-5-(l H-pyrazol-l-yl)phenol

2-(6-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)pyridazin-3-yl) -5-(lH-pyrazol-l- yl)phenol

2-(6-( 1 ,4-diazepan- 1 -yl)pyridazin-3-yl)-5-(lH-pyrazol- 1 -yl)phenol

2-(6-(4-(2-hydroxyethyl)piperazin-l-yl)pyridazin-3-yl)-5-(l H-pyrazol-l-yl)phenol 2-(6-(3,6-diazabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)-5-(l H-pyrazol-l-yl)phenol 2-(6-(2,7-diazaspiro[3.5]nonan-7-yl)pyridazin-3-yl)-5-(lH-py razol-l-yl)phenol

2-(6-(3-(hydroxymethyl)piperazin-l-yl)pyridazin-3-yl)-5-(lH- pyrazol-l-yl)phenol 2-(6-(l,7-diazaspiro[4.4]nonan-7-yl)pyridazin-3-yl)-5-(lH-py razol-l-yl)phenol

2-(6-(4-amino-4-methylpiperidin-l -yl)pyridazin-3-yl)-5-(lH-pyrazol-l-yl)phenol 2-(6-(3-(dimethylamino)piperidin-l-yl)pyridazin-3-yl)-5-(lH- pyrazol-l-yl)phenol

2- (6-(l,2,2,6,6-pentamethylpiperidin-4-ylamino)-pyridazin-3-yl )-5-lH-pyrazol-l-yl- phenol

2-(6-(3,3-dimethylpiperazin-l-yl)pyridazin-3-yl)-5-(lH-pyraz ol-l-yl)phenol

2~(6-(7-(2~hydroxyethyl)-2,7-diazaspiro[4 ]~no

l-yl)phenol

2 6-((3aR,6aS)-hexahydropyirolo[3,4-c]py

pyrazol-l-yl)phenol

s 3-(6-(piperazin-l-yl)pyridazin-3-yl)naphthalene-2,7-diol

5-(lH-pyrazol-l-yl)-2-(6-(l,2,3,6-tetrahydropyridin-4-yl)pyr idazin-3-yl)phenol

2-(6-piperidin-4-yl-pyridazin-3-yl)-5-lH-pyrazol-l-yl -phenol

3-(6-(l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthal en-2-ol

1 3-(6-(l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthal ene-2,7-diol

3- (6-(2,2,6,6-tetramethyl-l,2,3,6-tetrahydropyridin-4-yl)pyrid azin-3-yl)naphthalene-2,7- diol

* 3-(6-(l -methyl- l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalene-2, 7-diol ¹ 3-(6-(piperidin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol

3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl) naphthalene-2,7-diol

3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyri dazin-3-yl)naphthalene-2,7- diol

3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-y l)naphthalene-2,7-diol tert-butyl (3-((7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3-yl)naphthalen-2-yl)oxy)propyl)carbamate

7-(3-amino-propoxy)-3-(6-(methyl-(2,2,6,6-tetramethylpiperid in-4-yl)-amino)- pyridazin-3-yl)naphthalen-2-ol N-(3-((7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3-

95 yl)naphthalen-2-yl)oxy)propyl)acetamide

7-(3-hydroxypropoxy)-3-(6-(methyl(2,2,6,6-tetramethylpiperid in-4-yl)amino)pyridazin-

96 3-yl)naphthalen-2-ol

7-(3-methoxypropoxy)-3-(6-(methyl(2,2,6,6-tetramethylpiperid in-4-yl)amino)pyridazin-

97 3-yl)naphthaien-2-oI

7-(2-morpholinoethoxy)-3-(6-((2,2,6,6-tetramethylpiperidin-4 -yl)oxy)pyridazin-3-

98 yl)naphthalen-2-ol

99 3-(6-(piperidin-4-ylmethyl)pyridazin-3-yl)naphthalen-2-ol

5-(lH-pyrazol-l-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl )methyl)pyridazin-3-

100 yl)phenol

3-methoxy-2-(6-(methyl(2,2,6-trimethylpiperidin-4-yl)amino)p yridazin-3-yl)-5-(5-

101 methyloxazol-2-yl)phenol

2- (6-((6S)-6-((S)-l-hydroxyethyl)-2,2-dimethylpiperidin-4-ylox y)pyridazin-3-yl)-5-

102 (lH-pyrazol-l-yl)phenol

7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)-2-

103 naphthonitrile

3- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)-7-

104 (piperidinylmethyl)naphthalen-2-ol

3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-7-

105 (pyrrolidinylmethyl)naphthalen-2-ol

l-bromo-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

106 yl)naphthalene-2,7-diol

l-chloro-6-(6-(niethyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

107 yl)naphthalene-2,7-diol

7-methoxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

108 yl)naphthalene-2-ol

7-methoxy-3-(6-(methyl(l,2,2,6,6-pentamethylpiperidin-4-yl)a mino)pyridazin-3-

109 yl)naphthalen-2-ol

7-(3,6-dihydro-2H-pyran-4-yl)-3-(6-(methyl(2,2,6,6-tetrameth ylpiperidin-4-

110 yl)amino)pyridazin-3-yl)naphthalen-2-ol

3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-7-(tetrahydro-2H-

111 pyran-4-yl)naphthalene-2-ol

7-(difluoromethyl)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin -4-yl)amino)pyridazin-3-

112 yl)naphthalen-2-ol

7-((4-hydroxy-2-methylbutan-2-yl)oxy)-3-(6-(methyl(2,2,6,6-t etramethylpiperidin-4-

113 yl)amino)pyridazin-3-yl)naphthalen-2-ol

7-(3-hydroxy-3-methylbutoxy)-3-(6-(methyl(2,2,6,6-tetramethy lpiperidin-4-

114 yl)amino)pyridazin-3-yl)naphthalen-2-ol 2- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)-5-(lH-pyrazol-4-

115 yl)benzene-l,3-diol

3- methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-yl)-5-

116 (lH-pyrazol-4-yl)phenol

5-(lH~pyrazol-4~yl)~2-(6-((2,2,6,6 etramethylpiperidin~4-yI)amino)pyri

117 (trifluoromethoxy)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(l -methyl- 1H-

118 pyrazol-4-yl)-3-(trifluoromethoxy)phenol

2- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)-5-(l H-pyrazol-4-

119 yl)-3 -(trifluoromethoxy)phenol

4- (3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)pyridazin-3-yl)-5-

120 (trifluoromethoxy)phenyl)- 1 -methylpyridin-2( lH)-one

3- methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-yl)-5-(l -

121 methyl- lH-pyrazol-4-yl)phenol

3-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)-5-

122 (5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-3-yl)phenol

3-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)-5-

123 (pyridine-3-yl)phenol

5- (l-cyclopentyl-lH-pyrazol-4-yl)-3-methoxy-2-(6-(methyl(2,2,6 ,6-

124 tetram ethylpiperi din-4-yl)amino)pyri dazin-3 -yl)phenol

3',5-dimethoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-y l)amino)pyridazin-3-yl)-

125 (l,l '-biphenyl)-3-ol

3-(benzyloxy)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl )amino)pyridazin-3-yl)-5-

126 (5-methyloxazol-2-yl)phenol

3-ethoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-5-(5-

127 methyloxazol-2-yl)phenol

3-(cyclopropylmethoxy)-2-(6-(methyl(2,2,6,6-tetramethylpiper idin-4-yl)amino)-

128 pyridazin-3-yl)-5-(5-methyloxazol-2-yl)phenol

2-methyl-5-(6-(methyl(2,2,6,6-tetram ethylpiperi din-4-yl)amino)pyridazin-3-yl)-lH-

129 benzo[d]imidazol-6-ol

130 5~chloro-2-(6-(methyl(2,2,6,6-tetrarnethylpiperidin-4-yl)arm no)pyTi

5-(lH-pyrazol-l-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl )amino)pyridazin-3-

131 yl)phenol

132 3-hydroxy-4-(6-((2,2,6,6-tetramethylpiperidin-4-yl)amino)pyr idazin-3-yl)benzonitrile

133 2-(6-((2,2-dimethylpiperidin-4-yl)oxy)pyridazin-3-yl)-5-(lH- pyrazol-l -yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyri dazin-3-yl)-4-(lH-pyrazol-4-

134 yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridin -3-yl)-4-(4,5,6,7-

135 tetrahydropyrazol o[ 1 , 5-a]pyri din-3 -y 1 )phenol Cpd Name

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-4-(4,5,6,7-

136 tetrahydropyrazolo[l,5-a]pyrazin-3-yl)phenol

4-(lH-indol-2-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin- 4-yl)amino)pyridazin-3-

137 yi)phenol

4-(cyclopent-l -en-l-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-

138 yl)amino)pyridazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-4-(lH-pyrazol-3-

139 yi)phenol

4-(4-hydroxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)pyridazin-3-

140 yl)phenyl)pyridin-2-ol

4-(4-hydroxy-3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)py ridazin-3-yl)phenyl)-l -

141 methylpyridin-2( 1 H)~one

4- (4-hydroxy-3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyri dazin-3-

142 yl)phenyl)pyridin-2-ol

5- (lH-indazol-7-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin- 4-yl)amino)pyridazin-3-

143 yl)phenol

4-chloro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-5-(lH-

144 pyrazol-4-yl)phenol

4- fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)-5-(lH-

145 pyrazol-4-yl)phenol

5- fluoro-4-(lH-imidazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethyl piperidin-4-

146 yl)amino)pyridazin-3-yl)phenol

5-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-4-(lH-

147 pyrazol-4-yl)phenol

5- fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)-4-(lH-

148 pyrazol-5-yl)phenol

6- hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-yl)-2,3-

149 dihydro-lH-inden-l -one

6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-l ,4-

150 dihydroindeno[l,2-c]-lH-pyrazol-7-ol

6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)-2,3- 151 ¹ dihydro-lH-inden-l-one oxime

5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-2,3-dihydro-lH^ 152 indene-l,6-diol

2-amino-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-yl)-8H- 153 ^! indeno[l,2-d]thiazol-5-ol

9-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5,6- 154 ¹ dihydroimidazo[5, 1 -a]isoquinolin-8-ol 4-hydroxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)-N-((l-

155 methyl-lH-pyrazol-4-yl)methyl)benzamide

4- (4-(hydroxymethyl)- lH-pyrazol-l-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -

156 yl)amino)pyridazin-3-yl)phenol

5- (lH-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)m

157 yl)phenol

6- (3-(benzyloxy)isoquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramet hylpiperidin-4-

158 yl)pyridazin-3 -amine

6-(l -(benzyl oxy)isoquinolin-7-yl)-N-methyl-N-(2,2,6,6-tetr am ethylpiperi din-4-

159 yl)pyridazin-3 -amine

3- f!uoro-5-(2-methoxypyridin-4-yl)-2-(6-(methyl(2,2,6,6-tetram ethylpiperidin-4- 160 ¹ yl)amino)pyridazin-3-yl)phenol

4- (3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetram ethylpiperi din-4-yl)amino)pyridazin- 161 ^! 3-yl)phenyl)pyridin-2(l H)-one

4- (3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidi n-4-yl)amino)pyridazin- 162 ¹ 3 -y 1 jphenyl)- 1 -methylpyri din-2( 1 H)-one

5- (3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetram ethylpiperi din -4-yl)amino)pyridazin- 163 ^! 3 -yl)phenyl)- 1 -methylpyri din-2( 1 H)-one

3-fluoro-5-(lH-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiper idin-4-yl)oxy)pyridazin-3- 164 ¹ yl)phenol

5-chloro-3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin- 4-yl)amino)pyridazin-3- 165 ¹ yl)phenol

3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-5-(lH- Ί 66 ¹ pyrazol-4-yl)phenol

3- fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)-5-(l- 167 ¹ methyl- lH-pyrazol-4-yl)phenol

5~(5-methoxypyridin-3-yl)-2-(6-(methyl(2,2,6,6~tetramethylpi

168 y i )amino)pyridazin-3 -yl)phenol

5-(3-hydroxy-4-(6-methyl(2,2,6,6-tetramethylpiperidin-4-yl)a mino)pyridazin-3-

169 yl)phenyl)pyridin-2-ol

4- (3-hydroxy-4-(6-methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

170 yl)phenyl)pyridin-2-ol

5- (6-methoxypyridin-3-yl)-2-(6-(methyl(2,2,6,6-tetramethylpipe ridin-4-

171 yl)amino)pyridazin-3-yl)phenol

5-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)pyridazin-3-

172 yl)phenyl)-3-(trifluoromethyl)pyridin-2-ol

5-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetram ethylpiperi din-4-yl)amino)pyri dazin-3-

173 yl)phenyl)-l -methylpyri din-2(lH)-one Cpd Name

4- (3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)pyridazin-3-

174 yi )phenyl)-l -methylpyridin-2(l H)-one

5- (2-methoxypyridin-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpipe ridin-4-

175 yl)amino)pyridazin-3-yl)phenol

4- (3-hydroxy-4-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyri dazin-3-

176 yf)phenyl)pyridin-2-ol

5- (6-(dimethylamino)pyridin-3-yl)-2-(6-(methyl(2,2,6,6-tetrame thylpiperidin-4-

177 yl)amino)pyridazin-3-yl)phenol

4- (3-hydroxy-4-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyri dazin-3-yl)phenyl)-l-

178 methylpyridin-2(lH)-one

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-( yrimi

179 yl)phenol

5- (3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)pyridazin-3-

180 yl)phenyl)pyridin-3-ol

1- cyclopropyl-4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpip eridin-4-

181 yl)amino)pyridazin-3-yl)phenyl)pyridin-2(lH)-one

2- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)-5-(l, 2,3,6-

182 tetrahydropyridin-4-yl)phenol

5-(cyclopent- 1 -en- 1 -yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-

183 yl)amino)pyridazin-3-yl)phenol

5-(3,6-dihydro-2H-pyran-4-yl)-2-(6-(methyl(2,2,6,6-tetrameth ylpiperidin-4-

184 yl)amino)pyridazin-3-yl)phenol

5-(imidazo[l,5-a]pyridin-7-yl)-2-(6-(methyl(2,2,6,6-tetramet hylpiperidin-4-

185 yl)amino)pyridazin-3-yl)phenol

5-(imidazo[l,2-a]pyridin-7-yl)-2-(6-(methyl(2,2,6,6-tetramet hylpiperidin-4-

186 yl)amino)pyridazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(2-

187 methylpyridin-4-yl)phenol

5-(lH midazol-2-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl )amino)pyridazin-

188 3-yl)phenol

5-(lH-imidazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperid in-4-yl)amino)pyridazin-

189 3-yl)phenol

5-(imidazo[l,2-a]pyrazin-3-yl)-2-(6-(methyl(2,2,6,6-tetramet hylpiperidin-4-

190 yl)amino)pyridazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(5, 6,7,8-

191 tetrahydroimidazo[l,2-a]pyrazin-3-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(4-methyl-l H-

192 imidazoi -2-y 1 jphenol 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(l-methyl-lH-

193 imidazol-4-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(l -methyl- 1H-

194 imidazol-5-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(4-nitro-lH-

195 imidazol-2-yl)phenol

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5-(2-methyl-lH-

196 imidazol-4-yl)phenol

5- (l,2-dimethyl-l H-imidazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -

197 yl)amino)pyridazin-3-yl)phenol

1- (3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)pyridazin-3-

198 yi)phenyl)- lH-pyrazole-4-carboxamide

2- (6-((3aR,6aS)-5-(2-hydroxyethyl)hexahydropyrrolo[3,4-c]pyrro l-2(lH)-yl)pyridazin-

199 3-yl)-5-(lH-pyrazol-4-yl)phenol

2-(6-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyrid azin-3-yl)-5-(lH-

200 pyrazol-4-yl)phenol

2-(6-((3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)pyridazin-3-yl)-5-

201 (lH-pyrazol-4-yl)phenol

4-(3-hydroxy-4-(6-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(l H)-yl)pyridazin-3-

202 yl)phenyl)- 1 -methyl pyridin-2( 1 H)-one

4-(3-hydroxy-4-(6-((3aR,6aR)-l-methylhexahydropyrrolo[3,4-b] pyrrol-5(lH)-

203 yl)pyridazin-3-yl)phenyl)-l-methylpyridin-2(l H)-one

204 2-(6-(2,7-diazaspiro[4.5]decan-2-yl)pyridazin-3-yl)-5-(lH-py razol-4-yl)phenol

4-(4-(6-(2,7-diazaspiro[4.5]decan-2-yl)pyridazin-3-yl)-3-hyd roxyphenyl)-l -

205 methylpyridin-2(lH)-one

206 2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)-amino)-pyri dazin-3-yl)phenol

207 6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinolin-7-ol

208 6-(6-(methyl(l ,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyridazin-3-yl)quin olin-7-ol

6- (6-((3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl )pyridazin-3-

209 yl)quinolin-7-ol

2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)quinolin-

210 7-ol

211 7-(6-(methyl(l,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyrid azin-3-yl)isoquinolin-6-ol

212 7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)isoquinolin-6-ol

213 7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl) isoquinoline-6-ol

7- (6-((3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl )pyridazin-3-

214 yl)isoquinolin-6-ol

l-cyclopropyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl )amino)pyridazin-3-

215 yl)isoquinolin-6-ol 7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)isoquinoline-l,6-

216 did

6- hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

217 yl)isoquinoline-l-carbonitrile

218 6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)isoquinolin-7-ol

219 8-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinolin-7-ol

220 6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinolin-6-ol

2- methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)quinolin

221 6-ol

3- chloro-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)quinolin-

222 7-ol

3-bromo-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-yl)quinolin-

223 7-ol

7- hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

224 yl)quinoline-3-carbonitrile

6- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)-3-(l-methyl-lH-

225 imidazol-4-yl)quinolin-7-ol

3-(lH-imidazol-l-yl)-6-(6-(methyl(2,2,6,6-tetramethylpiperid in-4-yl)amino)pyridazin- 226 ¹ 3-yl)quinolin-7-ol

227 6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinoline-3,7-diol

3-ethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)pyridazin-3-yl)quinolin-

228 7-ol ^"

3- isopropyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

229 yl)quinolin-7-ol

7- hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

230 yl)quinolin-2(lH)-one

7-hydroxy-l -methyl -6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyrida zin-3- 231 ¹ yl)quinolin-2(l H)-one

4- methoxy-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3-

232 yl)quinolin-7-ol

2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-4-

233 (pyrroli din- 1 -yl)quinolin-7-ol

2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-4-

234 morpholinoquinolin-7-ol

4-(dimethylamino)-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylp iperidin-4-

235 yl)amino)pyridazin-3-yl)quinolin-7-ol

4-ethoxy-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin- 4-yl)amino)pyridazin-3-

236 yl)quinolin-7-ol 2- methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)-4-(l- 237 methyl- lH-pyrazol-4-yl)quinolin-7-ol

4- methoxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3- 238 ¹ yl)quinolin-6-ol

239 ^! 7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinoxalin-6-ol

6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyri dazin-3-yl)-3-(tetrahydro-2H-

240 pyran-4-yl)quinolin-7-ol

3- chloro-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)quinolin-

241 6-ol

3-bromo-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-yl)quinolin-

242 6-ol

3-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)quinolin-

243 6-ol

5- bromo-3-methyl-7-(6-(memyl(2,2,6,6-tetramethylpiperidin-4-yl )amino)pyridazin-3-

244 yl)quinolin-6-ol

6- hydroxy-l-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3-

245 yl)quinolin-4(lH)-one

2,3-dimethyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)pyridazin-3-

246 yl)quinolin-6-ol

2- methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-

247 yl)quinoxalin-6-ol

3- methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-

248 yl)quinoxalin-6-ol

4- methoxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

249 yl)quinolin-7-ol

4-(azetidin-l-yl)-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylp iperidin-4-

250 yl)amino)pyridazin-3-yl)quinolin-7-ol

7- hydroxy-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3-

251 yl)quinolone-4-carbonitrile

4-cyclopropyl-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiper idin-4-

252 yl)amino)pyridazin-3-yl)-quinolin-7-ol

4-(3,6-dihydro-2H-pyran-4-yl)-2-methyl-6-(6-(methyl(2,2,6,6- tetramethylpiperidin-4-

253 yl)amino)pyridazin-3-yl)quinolin-7-ol

2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-4- 254 ¹ (tetrahydro-2H-pyran-4-yl)quinolin-7-ol

2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-4- 255 (oxetan-3-yl)quinolin-7-ol

4-(dimethylamino)-6-(6-(methyl(2,2,6,6-tetramethylpiperidin- 4-yl)amino)pyridazin-3- 256 ¹ yl)-quinolin-7-ol 7-hydroxy-6-(6-(methyl(2,2,6,6-tetraniethylpiperidin-4-yl)am ino)pyridazin-3-

257 yl)quinazolin-4(lH)-one

258 6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinazolin-7-ol

7-hydroxy-l -methyl -6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyrida zin-3-

259 yl)-3,4-dihydroquinolin-2(lH)-one

2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-

260 yi)quinazolin-7~ol

7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

261 yl)i soquin oline- 1 -carbonitri 1 e

7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

262 yl )quinoline-2-carbomtri le

6-hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

263 yl)quinolin-2-carbonitrile

6- hydroxy-7-(6-(methyl(2,2,6,6-tetraniethylpiperidin-4-yl)amin o)pyridazin-3-

264 yl)isoquinoline- 1 -carboxamide

7- hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

265 yl)quinolin-2-carboxamide

6- hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

266 yl)quinoline-2-carboxamide

methyl 6-hydroxy-7-(6~(methyl(2,2,6,6 etramethylpiperidin-4-yl)amino)pyri

267 yl)quinoline-2-carboxylate

268 6-hydroxy-7-(6-(piperazin- 1 ~yl)pyridazin-3 -yl)quinoline-2-carbonitrile

269 7-hydroxy-6-(6-(piperazin-l-yl)pyridazin-3-yl)quinoline-2-ca rbonitrile

270 7-(6-(piperazin- l-yl)pyridazin-3-yl)isoquinolin-6-ol

271 7-(6-(l ,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)quinolin-6-ol

l-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-

272 yl)isoquinolin-7-ol

1 -methyl -7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyrida zin-3-

273 yl)isoquinolin-6-ol

l,3-dimethyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)pyridazin-3-

274 yl)isoquinolin-6-ol

7- hydroxy-3-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3-

275 yl)isoquinoline- 1 -carbonitrile

l-amino-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )pyridazin-3-

276 yl)isoquinolin-6-ol

7-hydroxy-l , 3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-

277 yl)amino)pyridazin-3-yl)quinazoline-2,4(lH,3H)-dione

6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-

278 yl)benzo[d]oxazol-2(3H)-one 2-methyl-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-2H-

279 indazol-6-ol

1- methyl-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)-lH-

280 indazol-6-ol

6- hydroxy-2-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4 -yl)amino)pyridazin-3- 281 ¹ yl)isoquinolin-l(2H)-one

2- ethyl-6-hydroxy-7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy )pyridazin-3-

282 yl)isoquinolin- 1 (2H)-one

l-ethoxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-

283 yl)isoquinolin-6-ol

284 7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl) isoquinoline-l,6-diol

7- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-pyridazi n-3-yl)-3-

285 phenylisoquinolin-6-ol

3- methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-

286 yl)isoquinolin-6-ol

3-cyclopropyl-7-(6-(methyl(2,2,6,64etramethylpiperidin-4-yl) amino)pyridazi

287 yl)isoquinolin-6-ol

3-isopropyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)a mino)pyridazin-3-

288 yl)isoquinolin-6-ol

289 3-propyl-7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)-pyrid azin-3-yl)isoquinolin-6-ol

3-isopropyl-7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy) -pyridazin-3-yl)isoquinolin-6-

290 ol

291 3-methyl-7-(6-(piperazin-l-yl)pyridazin-3-yl)isoquinolin-6-o l

6-(3-(benzyloxy)isoquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetram ethylpiperidin-4-

292 yl)pyridazin-3 -amine

3-chloro-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)quinolin-

293 7-ol

3-isopropyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)a mino)pyridazin-3-

294 yl)quinolin-7-ol

3- methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-

295 yl)quinoxalin-6-ol

4- chloro-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3-

296 yl)quinolin-7-ol

4- chloro-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)quinolin-

297 6-ol

300 7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinolin-6-ol

5- (2~methoxy-4~(lH-pyrazol-l -yl)phenyl)~N-rnethyl~N-(2,2,6,6 e

301 yl)-l,3,4-thiadiazol-2-amine 6-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4- thiadiazol-2-yl)naphthalen-

302 2-ol

5-(2-methoxyquinolin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpi peridin-4-yl)-l,3,4-

303 thiadiazol-2-amine

5-(3-me1hoxy-naphthalen-2-yl)-N-methyI-N-(2,2,6,6-tetramethy lpiperi

304 thiadiazol-2-amine

5-(2-methoxy-4-(lH-pyrazol-lyl)phenyl)-N-(l ,2,2,6,6-pentamethylpiperidin-4-yl)-

305 l,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(l -methyl-lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-

306 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6- tetramethylpiperidin-4-

307 yi)- 1 ,3 ,4-thiadi azol-2-amine

4- (3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpi^^

308 yl)phenyl)-l-methylpyridin-2(lH)-one

5- (3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)-l,3,4-thiadiazol-2-

309 yl)phenyl)pyridin-2-ol

5-(3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)-l ,3,4-thiadiazol-2-

310 yl)phenyl)-l-methylpyridin-2(lH)-one

N-methyl-5-(2-methyl-4-(l -methyl- lH-pyrazol-4-yl)phenyl)-N-(2,2,6,6-

311 tetramethylpiperidin-4-yl)-l ,3,4-thiadiazol-2-amine

1- methyl-4-(4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)-l,3,4-thiadiazol-2-

312 yl)-3-(trifluoromethoxy)phenyl)pyridin-2(l H)-one

5-(4-(3,5-dimethyl-lH-pyrazol-4-yl)-2-methoxyphenyl)-N-methy l-N-(2,2,6,6-

313 tetramethylpiperidin-4-yl)-l ,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(l-methyl-lH-pyrazol-4-yl)phenyl)-N-methyl-N- (2,2,6,6-

314 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

2- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4,-t hiadiozol-2-yl-5-(l-

315 methyl- lH-pyrazol-4-yl)phenol

2- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4,-t hiadiozol-2-yl-5-(lH-

316 pyrazol-l-yl)phenol

5-(3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)-l ,3,4-thiadiazol-2-

317 yl)phenyl)-l-methylpyridin-2(lH)-one

4- (3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)-l,3,4-thiadiazol-2-

318 yl)phenyl)-l-methylpyridin-2(lH)-one

5- (3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)-l ,3,4-thiadiazol-2-

319 yl)phenyl)pyridin-2-ol

3- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l ,3,4-thiadiazol-2-

320 yl)naphthalene-2, 7-di ol 3-(5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)-l,3, 4-thiadiazol-2- 321 yl)naphthalene-2,7-diol

3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)- l,3,4-thiadiazol-2-yl)naphthalen- 322 ¹ 2-ol

3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4- thiadiazol-2-yl)quinolin-2-

323 ol

2- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4-th iadiazol-2-yl)-4-(lH-

324 pyrazol-l-yl)phenol

5-(2-chloro-4-(l -methyl-l H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-

325 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

3- chloro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) -l,3,4-thiadiazol-2-yl)-

326 5-(l-methyl-lH-pyrazol-4-yl)phenol

5-(2-chloro-4-(l -methyl-l H-pyrazol-4-yl)phenyl)-N-(2,2,6,6-tetraniethylpiperidin-4-yl )-

327 l,3,4-thiadiazol-2-amine

3-methoxy-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)-l,3,4-thiadiazol-2-

328 yl)-5 -methyl oxazol-2-yl)phenol

2- (2-methoxy-4-(lH-pyrazol-l-yl)phenyl)-5-(l, 2,3, 6-tetrahydropyridin-4-yl)- 1,3,4-

329 thiadiazole

330 2-(5-(piperazin-l-yl)-l,3,4-thiadiazol-2-yl)-5-(lH-pyrazol-l -yl)phenol

5- (7-methoxyquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpipe ridin-4-yl)-l,3,4-

331 thiadiazole-2-amine

6- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4-th iadiazol-2-yl)quinolin-7-

332 ol

3- methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )-l,3,4-thiadiazol-2-

333 yl)benzonitrile

3- fluoro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) -l ,3,4-thiadiazol-2-

334 yl)benzonitrile

methyl-3-fluoro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)-l,3,4-thiadiazol-

335 2-yl)benzoate

5-(2-methoxy-4-(3-(methylamino)-lH-pyrazol-l -yl)phenyl)-N-methyl-N-(2,2,6,6-

336 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

7- methoxy-6-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )-l,3,4-thiadiazol-2-

337 yl)quinoline-2-carbonitrile

4- (3-methoxy-4-(5-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)-l,3 ,4-thiadiazol-2-

338 yl)phenyl)-l-methylpyridin-2(lH)-one

4- (3-chloro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)-l,3,4-thiadiazol-2-

339 yl)phenyl)- 1 -methyl pyridin-2( 1 H)-one

5- (2-chloro-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tet ramethylpiperidin-4-

340 yl)-l,3,4-thiadiazol-2-amine Cpd Name

5-(2-chloro-4-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyridin-3-yl )phenyl)-N-methyl-N- 341 (2,2,6,6-tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

N-methyl-5-(5-(l -methyl- lH-pyrazol -4-yl)pyridin-2-yl)-N-(2,2,6,6- 342 ¹ tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

2-(2-chloro-4-(l -methyl- lH-pyrazol-4-yl)phenyl)-5-((2,2,6,6-tetramethylpiperidin-4-

343 y i )oxy- 1 ,3 ,4-thiadiazole

5-(2-chloro-4-(6-methoxypyridin-3-yl)phenyl)-N-methyl-N-(2,2 ,6,6-

344 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(4-(6-aminopyridin-3-yl)-2-fluorophenyl)-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-

345 4-yl)- 1,3 ,4-thiadiazol-2-amine

5-(2-fluoro-4-(3-methyl-lH-pyrazol-5-yl)phenyl)-N-methyl-N-( 2,2,6,6-

346 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(2-fluoro-4-(lH-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6-t etramethylpiperidin-4-

347 yl)-l,3,4-thiadiazol-2-amine

5-(2,3-difluoro-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-

348 4-yl)- 1 ,3,4-thiadiazol-2-amine

5-(2,3-difluoro-4-(lH-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-

349 4-yl)- 1 ,3 ,4-thi adiazol -2-amine

5-(2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-

350 4-yl)-l ,3,4-thiadiazol-2-amine

5-(2,5-difluoro-4-(lH-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-

351 4-yl)-l,3,4-thiadiazol-2-amine

5-(2,6-difluoro-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-

352 4-yl)-l ,3,4-thiadiazol-2-amine

2-(2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-hexa hydropyrrolo[3,4-

353 c]pyrrol-2( 1 H)-yl)- 1 , 3 ,4-thi adiazol e

5-(2-chloro-5-fluoro-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-( 2,2,6,6-

354 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol -2-amine

5-(3-fluoro-5-(lH-pyrazol-4-yl)pyridin-2-yl)-N-methyl-N-(2,2 ,6,6-tetramethylpiperidin-

355 4-yl)- 1 , 3 ,4-thi adiazol -2-amine

5-(4-(2-aminopyrimidin-4-yl)-2-chlorophenyl)-N-methyl-N-(2,2 ,6,6-

356 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(5-(2-aminopyrimidin-4-yl)-2-chlorophenyl)-N-methyl-N-(2,2 ,6,6-

357 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(4-(2,4-dimethylthiazol-5-yl)-2,5-dif!uorophenyl)-N-methyl -N-(2,2,6,6-

358 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(4-(2,4-dimethylthiazol-5-yl)-2,3-difluorophenyl)-N-methyl -N-(2,2,6,6-

359 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol -2-amine 4- (3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)am ino)-l,3,4-thiadiazol-2-

360 yl)-5-(trifluoromethoxy)phenyl)-l -methylpyridin-2(l H -one

5- (2-fluoro-6-methoxy-4-(lH-pyrazol-4-yl)phenyl)-N-methyl-N-(2 ,2,6,6-

361 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

2-(2-fluoro-6-methoxy-4-(lH-pyrazol-4-yl)phenyl)-5-((3aR,6aS )-5-

362 methylhexahydropyrrol o[3 ,4-c]pyrrol-2( lH)-yl)- 1,3 ,4-thiadiazole

5- (2,3-difluoro-6-methoxy~4 lH~pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-

363 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

6- methoxy-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino )-l ,3,4-thiadiazol-2-

364 yl)-3,4-dihydroisoquinolin-l-(2H)-one

5-(2-chloro-4-(lH-pyrazol-l -yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-

365 yl)- 1 ,3 ,4-thiadi azol-2-amine

5-(2-chloro-4-(l H-l ,2,3-triazol-l-yl)phenyl)- -methyl- -(2,2,6,6-tetramethylpiperidi

366 4~yl)~ 1 ,3 ,4-thi adiazol -2-amine

5-(2-chloro-4-(2H-l,2,3-triazol-2-yl)phenyl)-N-methyl-N-(2,2 ,6,6-tetramethylpiperidin-

367 4-yl)- 1 ,3,4-thiadiazol-2-amine

5-(2-chloro-4-(lH-l,2,4-triazol-l-yl)phenyl)-N-methyl-N-(2,2 ,6,6-tetramethylpiperidin-

368 4-yl)- 1 ,3 ,4-thi adiazol -2-amine

5-(4-(3-amino-lH-pyrazol-l-yl)-2-chlorophenyl)-N-methyl-N-(2 ,2,6,6-

369 tetramethylpiperidin-4-yl)-l ,3,4-thiadiazol-2-amine

2-(2-chloro-4-(lH-imidazol-l-yl)phenyl)-5-((3aR,6aS)-5-

370 methy lhexahydropyrrolo[3 ,4c]pyrrol-2( 1 H)-yl)- 1 ,3 ,4-thi adiazol e

5-(2-chloro-4-(lH-imidazol-l-yl)phenyl)-N-methyl-N-(2,2,6,6- tetramethylpiperidin-4-

371 yl)-l ,3,4-thiadiazol-2-amine

5-(2-fluoro-4-(lH-imidazol-l-yl)phenyl)-N-methyl-N-(2,2,6,6- tetramethylpiperidin-4-

372 yl)-l,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(lH-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6- tetramethylpiperidin-4-

373 yl)-l,3,4-thiadiazol-2-amine

5-(4-(2,4-dimethyIthiazoI-5-yl)-2-methoxyphenyl)-N-me1hyl-N- (2,2,6,6-

374 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(pyridin-3-yl)phenyl)-N-methyl-N-(2,2,6,6-tet ramethylpiperidin-4-yl)-

375 l,3,4-thiadiazol-2-amine

5-(2-fluoro-4-(l H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperi din-4-

376 yl)- 1 ,3 ,4-thiadi azol -2-amine

5-(2-methoxy-4-(2-methoxypyridin-4-yl)phenyl)-N-methyl-N-(2, 2,6,6-

377 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(6-methoxypyridin-3-yl)phenyl)-N-methyl-N-(2, 2,6,6-

378 tetramethylpiperidin-4-yl)-l,3,4-thiadiazol -2-amine 2-(2-chloro-4-(l-methyl-lH-pyrazol-4-yl)phenyl)-5-((3aR,6aS) -5-

379 methylhexahydropyrrol o[3 ,4-c]pyrrol-2( lH)-yl)- 1,3 ,4-thiadiazole

2-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-5-methyl hexahydropyrrolo[3,4-

380 c]py rrol-2( 1 H)-y 1)- 1 , 3 ,4-thi adiazol e

2-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-5-((3aR,6aR)-l-methyl hexahydropyrrolo[3,4-

381 b]pyrrol-5(lH)-yl)-l,3,4-thiadiazole

1- (4-(5-(2-chloΓo-4-(lH-pyrazol-4-yl)phenyl)-l ,3,4-thiadiazol-2-yl)mo holin-2-yl)-

382 N,N-dimethylmethanamine

2- (2-chloro-4-(l H-pyrazol-4-yl)phenyl)-5-(2-methyl-2,7-diazaspiro[4.5]decan- 7-yl)-

383 1,3,4-thiadiazole

2-(2-fluoro-4-(l H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-5-niethylhexahydropyrrol o[3,4-

384 c]pyrrol-2(lH)-yl)-l,3,4-thiadiazole

2-(2-methoxy-4-(l -methyl-lH-pyrazol-4-yl)phenyl)-5-(2,6-diazaspiro[3.5]nonan- 2-yl)-

385 1,3,4-thiadiazole

2-(2-methoxy-4-(l-methyl-lH-pyrazol-4-yl)phenyl)-5-(2,7-diaz aspiro[3.5]nonan-2-yl)-

386 1,3,4-thiadiazole

2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4- thiadiazol-2-yl)-5-(lH-

387 pyrazol-l-yl)phenol

5- (3-chloro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)-l,3,4-thiadiazol-2-

388 yl)phenyl)pyridin-2(l H)-one

2- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4-th iadiazol-2-yl)-5-(3-

389 (methylamino)-lH-pyrazol-l -yl)phenol

3- fluoro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) -l,3,4-thiadiazol-2-yl)-5-

390 ( 1 H-pyrazol-4-yl)phenol

3,4-difluoro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl) amino)-l,3,4-thiadiazol-2-

391 yl)-5-(lH-pyrazol-4-yl)phenol

6- hydroxy-5-(5-(methyl(2,2,6,6-tetramethylpiperi^

392 yl)-2,3-dihydro-lH-inden-l-one

2-(5~(methyl(2,2,6,6 etramethyIpiperidin-4-yl)amino)-l,3,4-tWadi

393 pyrazol-4-yl)phenol

2-(5-(2,6-diazaspiro[3.5]nonan-2-yl)-l ,3,4-thiadiazol-2-yl)-5-(l -methyl- lH-pyrazol-4-

394 yi)phenol

2- (5-(2,7-diazaspiro[3.5]nonan-2-yl)-l,3,4-thiadiazol-2-yl)-5- (l-methyl-l H-pyrazol-4-

395 yi)phenol

3- fluoro-2-(5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(l H)-yl)-l,3,4-thiadiazol-2- 96 ^! yl)-5-(lH-pyrazol-4-yl)phenol

3-chloro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)-l,3,4-thiadiazol-2-yl)- 397 5-(lH-pyrazol-4-yl)phenol Cpd Name

2-(2-methoxy-4-(lH-pyrazol-l-yl)phenyl)-5-((2,2,6,6-tetramet hylpiperidin-4-

398 yi jmeths ! )- 1 ,3 ,4-thiadi azole

2-(2,3-difluoro-4-(lH-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro [3.5]nonan-2-yl)- 1,3,4-

399 thiadiazole

2- (5-(2,7-diazaspiro[3.5]nonan-2-yl)-l ,3,4-thiadiazol-2-yl)-3-fluoro-5-(lH-pyrazol-4-

400 yl)phenol

4-methoxy-l -methyl -3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)- 1,3,4-

401 thiadiazol-2-yl)quinolin-2(lH)-one

4- hydroxy-l -methyl -3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l, 3,4-

402 thiadiazol-2-yl)quinolin-2(lH)-one

3- (5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l ,3,4-thiadiazol-2-yl)quinolin-

403 2(lH)-one

1- methyl-3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) -l,3,4-thiadiazol-2-

404 yl)quinolin-2(lH)-one

2- (2-cMoro-4-(lH-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-hexahydropy rrolo[3,4-c]pyrrol-

405 ^s 2(li-I)-yl)-l,3,4~thiadiazole

2-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro[4.5 ]decan-2-yl)-l,3,4- 406 ^! thiadiazole

(R)-(4-(5-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-l,3,4-thiadia zol-2-yl)piperazin-2- 407 ¹ yl)methanol

2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-l,3,4- thiadiazol-2-

408 yl)benzo[b]thiophene-5-carbonitrile

5- (3-chlorobenzo[b]thiophen-2-yl)-N-methyl-N-(2,2,6,6-tetramet hylpiperidin-4-yl)-

409 1 ,3,4-thiadiazol-2-amine

5-(2-methoxy-4-(lH-pyrazol-4-yi)phenyl)-N-methyl-N-(2,2,6,6- tetramethylpiperidi

410 yl)-l,3,4-thiadiazol-2-amine

2-{6-[(lR,5S)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyrid azin-3-yl}-5-(lH- 411 ¹ pyrazol-4-yl)phenol

2-[6-((lR,5S)-8-azabicyclo[3.2. l]oct-3-ylamino)pyridazin-3-yl]-5-(lH-pyrazol-4- 412 ¹ yl)phenol

5-(lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl )amino]pyridazin-3- 413 ¹ yl} phenol

5-(l -methyl-lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin -4-yl)oxy]pyridazin-3- 414 yl} phenol

2-[6-((l /?,55)-8-azabicyclo[3 J ]oct-3-yloxy)pyridazin-3-yl]-5

415 ^! yl)phenol

5-(5-methyl-l H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4- 416 yl)amino]pyridazin-3-yl}phenol Cpd Name

5-(lH-imidazol-l-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-y l)oxy]pyridazin-3-

417 yi}phenoi

5- (5-methyl-lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperid in-4-yl)oxy]pyridazin-3-

418 yi} phenol

2-{6-[methyl(2,2,6,6-tetramethylpipeiidin-4-yl)amino]pyridaz in-3-yl}-5-(4-nitro-lH- 419 ¹ pyrazol-l-yl)phenol

6- [2-methoxy-4-(4-nitro-lH-pyrazol-l-yl)phenyl]-N-methyl-N-(2, 2,6,6-

420 tetramethylpiperidin-4-yl)pyridazin-3 -amine

5-(4-amino-lH-pyrazol-l -yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin- 3-

421 yi} phenol

2- [6-(l -methyl -l ,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(lH-pyrazol -4- 422 ¹ yi)phenol

5- (4-nitro-lH-pyrazol-l-yl)-2-{6-[(2,2,6,6-tetramethylpiperidi n-4-yl)oxy]pyridazin-3- 423 yl} phenol

424 ¹ 5-(l H-pyrazol-4-yl)-2-[6-(l,2,3,6-tetrahydropyridin-4-yl)pyridaz in-3-yl]phenol 425 ¹ 2-[6-(l-ethyl-l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl] -5-(lH-pyrazol-4-yl)phenol 426 ¹ 2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(l H-pyrazol-4-yl)phenol

427 ¹ 2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(lH-pyrazol-4-yl )phenol

6- [2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6 -tetramethylpiperidin- 428 ¹ 4-yl)pyridazin-3 -amine

429 ¹ 2-[6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(l H-pyrazol-4-yl)phenol

6-[2,3-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin- 430 ¹ 4-yl)pyridazin-3 -amine

3- [2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetrame thylpiperidin-4- 431 ¹ yi)oxy]pyridazine

432 2- [6-(pi peridin-4-y 1 oxy )pyridazin-3 -y 1 ] - 5 -( I H-pyrazol -4-y Ijphenol

2- {6-[(lR,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl} -5-(lH-pyrazol-4- 433 ¹ yl)phenol

6-[2-methoxy-6-(l H-pyrazol -4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6- 434 ¹ tetramethylpiperidin-4-yl)pyridazin-3-amine

435 3-[4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperid in-4-yl)oxy]pyridazine 436 ¹ 2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(l H-pyrazol -4-yl)phenol

3- [2-fluoro-4-(l H-pyrazol -4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4- 437 ¹ yl)oxy]pyridazine

3-[4-(l -methyl- lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperi din-4- 438 yl)oxy]pyridazine

439 ¹ 2-[6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(lH-pyra zol-4-yl)phenol

440 3-iluoro~4-{6-[rnethyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no] 441 2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(lH- pyrazol-l-yl)phenol -methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylp iperidin-4-yl)pyridazin-

442 3 -amine

443 2-methyl-5-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrida zin-3-yl}-2H-indazole

444 3-(4-chloro-2-methoxyphenyl)-6-[(2,2,6,6-tetramethylpiperidi n-4-yl)oxy]pyridazine -methyl-6-(2-methylpyrazolo[l,5-a]pyridin-3-yl)-N-(2,2,6,6-t etramethylpiperidin-4-

445 yl)pyridazin-3 -amine

446 6-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl }imidazo[l ,2-a]pyridine

3-[2-methoxy-4-(lH-pyrazol-l-yl)phenyl]-6-[(2,2,6,6-tetra methylpiperidin-4-

447 yi)oxy]pyridazine

3-[5-(lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethyl piperidin-4- 448 ¹ yl)oxy]pyridazine

3-[5-(l -methyl- lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperi din-4-

449 yi)oxy]pyridazine

3-[4-(lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethyl piperidin-4- 4S0 ¹ yl)oxy]pyridazine

5- (3,5-dimethyl-l H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-

451 yl)oxy]pyridazin-3-yl}phenol

6- [2-fluoro-4-(l H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperi din-4-

452 yl)pyridazin-3 -amine

453 3-methoxy-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrid azin-3-yl }phenol

3-[2-methoxy-4-(4-nitro-lH-pyrazol-l-yl)phenyl]-6-[(2,2,6,6- tetramethylpiperidin-4-

454 yi)oxy]pyridazine

455 4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl} benzene-l,3-diol

6-[2-chloro-4-(l H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperi din-4- 456 ^! yl)pyridazin-3-amine

2- (lH-pyrazol-4-yl)-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)o xy]pyridazin-3- 457 yi }pyrimidin-5-amine

3- [2,6-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetrame thylpiperidin-4- 458 ¹ yl)oxy]pyridazine

459 2-[6-(2,6-diazaspiro[3.4]oct-2-yl)pyridazin-3-yl]-5-(lH-pyra zol-4-yl)phenol

3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridaz in-3-yl }-6-(lH-pyrazol-4- 460 ¹ yl)pyridin-2-ol

6-(lH-pyrazol-4-yl)-3-{6-[(2,2,6,6-tetramethylpiperidin-4-yl )oxy]pyridazin-3- 461 yl}pyridin-2-ol

N, 2,2, 6,6-pentam ethyl-N- { 5 - [3 -( 1 H-pyrazol -4-y 1 )phenoxy ] - 1 , 3 ,4-thi adi azol -2- 462 ¹ yl }piperidin-4-amine

N,2,2,6,6-pentamethyl-N-{5-[4-(l H-pyrazol-4-yl)phenoxy]-l ,3,4-thiadiazol-2- 463 ^! yl}piperidin-4-amine 3-[2-(difluoromethyl)-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6 -tetramethylpiperidin-4- 464 ¹ yi)oxy]pyridazine and

6-[2-(difluoromethyl)-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N- (2,2,6,6- 465 ¹ tetramethylpiperidin-4-yl)pyridazin-3-amine

[00241] wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00242] In another aspect, the compound of Formula (I) or a form thereof used in a method disclosed herein is a compound selected from the group consisting of:

Cpd Name

2-{6-[(lR,5S)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyrid azin-3-yl}-5-(lH- 411 ¹ py razol -4-y l)ph en ol

2-[6-((lR,5S)-8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-y l]-5-(lH-pyrazol-4- 412 ¹ yl)phenol

5-(lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl )amino]pyridazin-3- 413 ¹ yUphenoi

5-(l-methyl-lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiper idin-4-yl)oxy]pyridazin-3- 414 yl}phenol

2-[6-((lR,5S)-8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl] -5-(lH-pyrazol-4- 415 ¹ yi)phenol

5~(5-methyl-lH-pyrazol-4-yl)-2-{6~[methyl(2,2,6,6 eto

416 yl)amino]pyridazin-3-yl}phenol

5-(lH-imidazol-l-yl)-2-{6-[(2,2,6,6-tetramethylpipOT

417 yi) phenol

5- (5-methyl-l H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy ]pyridazin-3-

418 yi} phenol

2-{6-[methyl(2,2,6,6-tetramethylpiperi

419 ¹ pyrazol-l-yl)phenol

6- [2-methoxy-4-(4-nitro-lH-pyrazol-l-yl)phenyl]-N-methyl-N-(2, 2,6,6-

420 tetramethylpiperidin-4-yl)pyridazin-3-amine

5-(4-amino-lH-pyrazol-l-yl)-2-{6-[(2,2,6,6-tetramethylpiperi din-4-yl)oxy]pyridazin-3-

421 yljphenol

2-[6-(l -methyl- l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(lH-pyrazol -4- 422 ¹ yl)phenol

5-(4-nitro-lH-pyrazol-l-yl)-2-{6-[(2,2,6,6-tetramethylpiperi din-4-yl)oxy]pyridazin-3-

423 yl jphenol

424 ¹ 5-(lH-pyrazol-4-yl)-2-[6-(l,2,3,6-tetrahydropyridin-4-yl)pyr idazin-3-yl]phenol Cpd Name

425 ¹ 2-[6-(l-ethyl-l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl] -5-(lH-pyrazol-4-yl)phenol

426 ¹ 2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(lH-pyra zol-4-yl)phenol

427 ¹ 2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(lH-pyrazol-4-yl )phenol

6-[2,5-difluoro-4-(l H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperi din- 428 ¹ 4-yl)pyridazin-3 -amine

429 ¹ 2-[6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(l. H-pyrazol-4-yl)phenol

6-[2,3-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin- 430 ¹ 4-yl)pyridazin-3 -amine

3-[2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetra methylpiperidin-4- 431. ¹ yi)oxy]pyridazine

432 2-[6-(piperidin-4-yloxy)pyridazin-3-yl]-5-(lH-pyrazol-4-yl)p henol

2- {6-[(lR,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl } -5-(l H-pyrazol-4- 433 ^! yl)phenol

6-[2-methoxy-6-(lH-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2, 2,6,6- 434 ¹ tetramethylpiperidin-4-yl)pyridazin-3-amine

435 3-[4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperid in-4-yl)oxy]pyridazine 436 ^! 2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(lH- pyrazol-4-yl)phenol

3- [2-fluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethyl piperidin-4- 437 ^! yl)oxy]pyridazine

3-[4-(l -methyl- lH-pyrazol -4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4- 438 yl)oxy]pyridazine

439 ¹ 2-[6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(lH-pyra zol-4-yl)phenol

440 3-fluoro-4-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o]pyridazin-3-yl }phenol

441 2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(lH- pyrazol-l-yl)phenol

N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethyl piperidin-4-yl)pyridazin-

442 3 -amine

443 2-methyl-5-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrida zin-3-yl}-2H-indazole

444 3-(4-chloro-2-methoxyphenyl)-6-[(2,2,6,6-tetramethylpiperidi n-4-yl)oxy]pyridazine

N-methyl-6-(2-methylpyrazolo[l,5-a]pyridin-3-yl)-N-(2,2,6 ,6-tetramethylpiperidin-4-

445 yl)pyridazin-3 -amine

446 6-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl} imidazo[l,2-a]pyridine

3-[2-methoxy-4-(lH-pyrazol-l -yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-

447 yl)oxy]pyridazine

3-[5-(lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethyl piperidin-4- 448 ¹ yl)oxy]pyridazine

3-[5-(l-methyl-lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-te tramethylpiperidin-4- 449 yl)oxy]pyridazine Cpd Name

3-[4-(lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethyl piperidin-4-

450 ¹ yf)oxy]pyridazine

5- (3,5-dimethyl-lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpip eridin-4-

451 yl)oxy jpyri dazi n-3 -yl } phenol

6- [2-fluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tet ramethylpiperidin-4-

452 yl)pyridazin-3 -amine

453 3-methoxy-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrid azin-3-yl}phenol

3-[2-methoxy-4-(4-nitro-lH-pyrazol-l-yl)phenyl]-6-[(2,2,6,6- tetramethylpiperidin-4-

454 yl)oxy]pyridazine

455 4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl} benzene-l,3-diol

6-[2-c-hloro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6- tetramethylpiperidin-4- 456 ¹ yl)pyridazin-3 -amine

2- (lH-pyrazol-4-yl)-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)o xy]pyridazin-3- 457 yl}pyrimidin-5-amine

3- [2,6-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetrame thylpiperidin-4-

458 ¹ yi)oxy]pyridazine

459 2-[6-(2,6-diazaspiro[3.4]oct-2-yl)pyridazin-3-yl]-5-(lH-pyra zol-4-yl)phenol

3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridaz in-3-yl}-6-(lH-pyrazol-4- 460 ¹ yl)pyridin-2-ol

6-(lH-pyrazol-4-yl)-3-{6-[(2,2,6,6-tetramethylpiperidin-4-yl )oxy]pyridazin-3- 461 yl}pyridin-2-ol

N,2,2,6,6-pentamethyl-N-{5-[3-(lH-pyrazol-4-yl)phenoxy]-l,3, 4-thiadiazol-2- 462 ¹ yl}piperidin-4-amine

N,2,2,6,6-pentamethyl-N-{5-[4-(lH-pyrazol-4-yl)phenoxy]-l,3, 4-thiadiazol-2- 463 ¹ yl }piperidin-4-amine

3-[2-(difluoromethyl)-4-(l H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4- 464 ¹ yi)oxy]pyridazine and

6-[2-(difluoromethyl)-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N- (2,2,6,6- 465 ¹ tetramethylpiperidin-4-yl)pyridazin-3 -amine

[00243] wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof. [00244] In another aspect, the compound of Formula (I) or a form thereof used in a method disclosed herein is a compound salt selected from the group consisting of:

Cpd Name

2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-4-

32 (trifluoromethyl)phenol hydrochloride

2-(6-(methyl(2,2,6,6-tetramethylpiperi

53 yl)phenol hydrochloride

65 2-(6-piperazin-l-yl-pyridazin-3-yl)-5- l H-pyrazol-l-yl-phenol hydrochloride

82 3-(6-(piperazin-l-yl)pyridazin-3-yl)naphthalene-2,7-diol trifluoroacetate

86 3 -( 6-( 1 ,2,3 ,6-tetrahydropyridi n-4-yl)pyridazin-3 -yl)naphthal ene-2,7-diol trifluoroacetate

3 -(6-(l -methyl- 1 ,2,3 ,6-tetrahydropyridin-4-yl)pyridazin-3 -yi)naphthalene-2, 7-dioi

88 trifluoroacetate

89 3-(6-(piperidin-4-yl)pyridazin-3-yi)naphthalene-2,7-dioi trifluoroacetate

6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)-2,3- 151 dihydro-lH-inden-l-one oxime hydrochloride

2- amino-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)p yridazin-3-y

153 indeno[l ,2-d]thiazol-5-ol hydrochloride

9-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)-5,6-

154 dihydroimidazo[5, l-a]isoquinolin-8-ol hydrochloride

3- fluoro-5-(2-methoxypyridin-4-yl)-2-(6-(methyl(2,2,6,6-tetram ethylpiperidin-4-

160 yl)amino)pyridazin-3-yl)phenol hydrochloride

4- (3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidi n-4-yl)arnino)pyridazin-3-

161 yl)phenyl)pyridin-2(l H)-one hydrochloride

4- (3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidi n-4-yl)amino)pyridazin-3-

162 yl)phenyl)- l -methylpyridin-2(I H)-one hydrochloride

5- (3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidi n-4-yl)amino)pyridazin-3-

163 yl)phenyl)- 1 -methylpyridin-2(lH)-one hydrochloride

3-fluoro-5-(lH-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiper idin-4-yl)oxy)pyridazin-3-

164 yl)phenol hydrochloride

5- chloro-3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3-

165 yl)phenol hydrochloride

3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amin o)pyridazin-3-yl)-5-(lH-

166 pyrazol-4-yl)phenol hydrochloride

3-fluoro-2-(6-(methyl(2,2,6,6 etrarnethylpiperidin-4-yl)arnino)py

167 methyl- lH-pyrazol-4-yl)phenol hydrochloride

3-( l H~imidazol~l-yI)-6-(6-(methyI^

226 yl)quinolin-7-ol hydrochloride

6- (6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin -3-yl)quinoline-3

227 formate 7-hydroxy-l-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin -4-yl)amino)pyridazin-3- 231 yl)quinolin-2(lH)-one hydrochloride

4-methoxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)ami no)pyridazin-3-yl)quinolin-

238 6~ol formate

7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridaz in-3-yl)quinoxalin-6-ol

239 hydrochloride

2- methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino) pyridazin-3-yl)-4- 254 (tetrahydro-2H-pyran-4-yl)quinolin-7-ol formate

4- (dimethylamino)-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4- yl)amino)pyridazin-3-y 256 quinolin-7-ol formate

6-hydroxy-2-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin -4-yl)aniino)pyridazin-3- 281 yl)isoquinolin-l(2H)-one hydrochloride

3- (5-(methyl(2,2,6,6-tetrame1hylpiperidin-4-yl)amino)-l,3,4-th iadiazol-2-yl)naph

322 2-ol hydrobromide

N-methyl-5-(5-(l-methyl-lH-pyrazol-4-yl)pyridin-2-yl)-N-(2,2 ,6,6-tetramethylpiperidin- 342 4-yl)-l,3,4-thiadiazol-2-amine hydrochloride

3-fluoro-2-(5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(lH) -yl)-l,3,4-thiadiazol-2-yl)- 396 5-(lH-pyrazol-4-yl)phenol dihydrochloride

2-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-hexahydr opyrrolo[3,4-c]pyrrol-

405 2(lH)-yl)-l,3,4-thiadiazole hydrochloride

2-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro[4.5 ]decan-2-yl)- l,3,4-

406 thiadiazole hydrochloride

(R)-(4-(5-(2-chloro-4-(lH-pyrazol-4-yl)phenyl)-l,3,4-thiadia zol-2-yl)piperazin-2-

407 yl)methanol hydrochloride

2-{6-[8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-y l}-5-(lH-pyrazol-4-

411 yl)phenol hydrochloride

2-[6-(8-azabicyclo[3 ,2.1 ]oct-3-ylamino)pyridazin-3-yl]-5-(l H-pyrazol-4-yl)phenol

412 hydrochloride

5- (lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)a mino]pyridazin-3-

413 yl }phenol hydrochloride

2-[6-(8-azabicyclo[3.2.1 ]oct-3-yloxy)pyridazin-3-yl]-5-(lH-pyrazol-4-yl)phenol

415 hydrochloride

2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridaz in-3-yl} -5-(4-nitro- l H- 419 pyrazol-l-yl)phenol dihydrochloride

2-[6-(l-methyl-l ,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(lH-pyrazol- 4-yl)phenol 422 trihydrochloride

5-(l H-pyrazol-4-yl)-2-[6-(l ,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol

424 trihydrochloride 2-[6-(l-ethyl-l,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl] -5-(lH-pyrazol-4-yl)phenol

425 trihydrochloride

2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl }-5-(l H-pyrazol-4-yl)phenol

426 tetrahydrochloride

427 2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(lH-pyrazol-4-yl )phenol tetrahydrochloride

6-[2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2, 2,6,6-tetramethylpiperidin-4-

428 yl)pyridazin-3 -amine tetrahydrochloride

2- [6-(8-azabicyclo[3.2.1 ]oct-2-en-3-yl)pyridazin-3-yl]-5-(lH-pyrazol-4-yl)phenol

429 hydrochloride

6-[2,3-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-4-

430 yl)pyridazin-3-amine hydrochloride

3- [2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetrame thylpiperidin-4-

431 yl)oxy]pyridazine tri hydrochloride

2-{6-[(lR,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-y l}-5-(lH-pyrazol-4-

433 yl)phenol hydrochloride

6-[2-methoxy-6-(lH-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2, 2,6,6-

434 tetramethylpiperidin-4-yl)pyridazin-3 -amine hydrochloride

2- {6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl }-5-(l H-pyrazol-4-yl)phenol

436 trihydrochloride

3- [2-fluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethyl piperidin-4-

437 yl)oxy]pyridazine hydrochloride

2- [6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(l H-pyrazol-4-yl)phenol

439 tetrahydrochloride

3- [5-(l H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperid in-4- 448 yl)oxy]pyridazine hydrochloride

3-[4-(lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethyl piperidin-4- 450 yl)oxy]pyridazine hydrochloride

6-[2-chloro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-t etramethylpiperidin-4- 456 yl)pyridazin-3 -amine trihydrochloride

3-[2,6-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetra methylpiperidin-4- 458 yl)oxy]pyridazine trihydrochloride

3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridaz in-3-yl}-6-(lH-pyrazol-4- 460 yl)pyridin-2-ol hydrochloride

N,2,2,6,6-pentamethyl-N- {5-[3-(lH-pyrazol-4-yl)phenoxy]-l,3,4-thiadiazol-2-

462 yl }piperidin-4-amine hydrochloride

N,2,2,6,6-pentamethyl-N-{5-[4-(lH-pyrazol-4-yl)phenoxy]- l,3,4-thiadiazol-2-

463 yl}piperidin-4-amine hydrochloride

3-[2-(difluoromethyl)-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6 -tetramethylpiperidin-4-

464 yl)oxy]pyridazine hydrochloride and 6-[2-(difluoromet yl)-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6- 465 tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride

[00245] wherein a form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00246] In another aspect, the compound of Formula (I) used in a method disclosed herein is a compound salt selected from the group consisting of:

Cpd Name

2-{6-[8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-y l}-5-(lH-pyrazol-4-

411 yl)phenol hydrochloride

2-[6-(8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(lH -pyrazol-4-yl)phenol

412 hydrochloride

5-(lH-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl )amino]pyridazin-3-

413 yl} phenol hydrochloride

2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(lH-p yrazol-4-yl)phenol

415 hydrochloride

2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridaz in-3-yl}-5-(4-nitro-lH- 419 pyrazol-l-yl)phenol dihydrochioride

2-[6-(l -methyl- 1, 2,3, 6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(lH-pyrazol-4-yl) phenol 422 trihydrochloride

5- (lH-pyrazol-4-yl)-2-[6-(l,2,3,6-tetrahydropyridin-4-yl)pyrid azin-3-yl]phenol

424 trihydrochloride

2-[6-(l -ethyl- 1, 2,3, 6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(lH-pyrazol-4-yl) phenol

425 trihydrochloride

2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(lH-pyra zol-4-yl)phenol

426 tetrahydrochloride

427 2-[6-( iperidin-4-ylamino)pyridazin-3-yl]-5-(l H-pyrazol-4-yl)phenol tetrahydrochloride

6- [2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6 -tetramethylpiperidin-4-

428 yl)pyridazin-3-amine tetrahydrochloride

2- [6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(lH-p yrazol-4-yl)phenol

429 hydrochloride

6-[2,3-difluoro-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6 ,6-tetramethylpiperidin-4-

430 yl)pyridazin-3 -amine hydrochloride

3- [2,5-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetrame thylpiperidin-4-

431 yl)oxy]pyridazine trihydrochloride

2-{6-[(lR,5S)-8-azabicyclo[3.2.1 ]oct-3-ylamino]pyridazin-3-yl}-5-(lH-pyrazol-4- 433 yl)phenol hydrochloride Cpd Name

6-[2-methoxy-6-(lH-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2, 2,6,6- 434 tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride

2- {6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(lH-py razol-4-yl)phenol

436 trihydrochloride

3- [2-fluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethyl piperidin-4-

437 yl)oxy]pyridazine hydrochloride

2- [6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(lH-pyrazo l-4-yl)phenol

439 tetrahydrochloride

3- [5-(lH-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpi peridin-4- 448 yl)oxy]pyridazine hydrochloride

3-[4-(l H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperid in-4- 450 yl)oxy]pyridazine hydrochloride

6-[2-chloro-4-(l H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperi din-4- 456 yl)pyridazin-3 -amine trihydrochloride

3-[2,6-difluoro-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetra methylpiperidin-4- 458 yl)oxy]pyridazine trihydrochloride

3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridaz in-3-yl }-6-(lH-pyrazol-4- 460 yl)pyridin-2-ol hydrochloride

N,2,2,6,6-pentamethyl-N-{5-[3-(lH-pyrazol-4-yl)phenoxy]-l,3, 4-thiadiazol-2-

462 yl}piperidin-4-amine hydrochloride

N,2,2,6,6-pentamethyl-N-{5-[4-(lH-pyrazol-4-yl)phenoxy]-l,3, 4-thiadiazol-2-

463 yl }piperidin-4-amine hydrochloride

3-[2-(difluoromethyl)-4-(lH-pyrazol-4-yl)phenyl]-6-[(2,2,6,6 -tetramethylpiperidin-4-

464 yl)oxy]pyridazine hydrochloride and

6-[2-(difluoromethyl)-4-(lH-pyrazol-4-yl)phenyl]-N-methyl-N- (2,2,6,6-

465 tetramethylpiperidin-4-yl)pyridazin-3 -amine hydrochloride

[00247 ] wherein a form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

TERMINOLOGY

[00248] As used herein, the term "Cwalkyl" generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration, including, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and the like. In some aspects, Ci-salkyl includes Ci-salkyl, Ci-2alkyl, and the like. A Ci-4alkyl radical may be optionally substituted where allowed by available valences. [00249] As used herein, the term "Cz-ealkenyl" generally refers to partially unsaturated hydrocarbon radicals having from two to five carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, without limitation, ethenyl, aliyl, propenyl and the like. In some aspects, Ci-eaikenyi includes

C ₂ - ₄ alkenyl, C ₂ - ₃ alkenyl, and the like. A C ₂ -6alkenyl radical may be optionally substituted where allowed by available valences.

[00250] As used herein, the term "Cwalkoxy" generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration of the formula: -O-Ci-saikyi, including, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like. In some aspects, Ct-4alkoxy includes Ci-salkoxy, Ci-aalkoxy and the like. A Cwalkoxy radical may be optionally substituted where allowed by available valences.

[00251] As used herein, the term "C ₃ -j.4cycloalkyl" generally refers to a saturated monocyclic, bicyclic or polycvclic hydrocarbon radical, including, without limitation, cyclopropyl, cyclobutyl, cyclopentyi, cyclohexyl, cycioheptyl, cyclooctyl, lH-indanyl, indenyl,

tetrahydro-naphthalenyi and the like. In some aspects, C ₃ - ₁₄ cycloalkyl includes C ₃ - ₁₀ cycloalkyl, C ₃ -8cycloalkyl, C ₃ -7cycloalkyl, Cs-scycloalkyl, C9-iocycloalkyl and the like. A C ₃ -i ₄ cycloalkyl radical may be optionally substituted where allowed by available valences.

[00252] As used herein, the term "C ₃ - ₁₄ cycloalkenyl" generally refers to a partially unsaturated monocyclic, bicyclic or polycvclic hydrocarbon radical having one or more chemically stable carbon-carbon double bonds therein, including, without limitation, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenvl, cyclooctenyl and the like. In some aspects, C3- Hcycloalkenyl includes C ₃ -7cycloalkenyl, Cs-scycloalkenyl, Cs-scycloalkenyl, C ₃ - ₁₀ cycloalkenyl and the like. A C ₃ - ₁₄ cycloalkenyl radical may be optionally substituted where allowed by available valences,

[00253] As used herein, the term "aryl" generally refers to a monocyclic, bicyclic or polycvclic aromatic carbon atom ring structure radical, including, without limitation, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like. An aryl radical may be optionally substituted where allowed by available valences.

[00254] As used herein, the term "heteroaryl" generally refers to a monocyclic, bicyclic or polycvclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, without limitation, furanyl, thienyl (also referred to as thiophenyl), pyrrolyl, pyrazolyl, imidazolyl, isoxazoly], isothiazolyl, oxazoly], thiazolyl, triazolyl, oxadiazoiyl, thiadiazolyi, tetrazolyl, pyranyi, thiopyranyl, pyridinyl, pyrimidiny], pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, benzofuranyl, benzothienyi, benzimidazolyl, benzothiazolyl, benzooxazolyl, 9H-purinyl, quinoxalinyl, isoindolyl, quinolinyl, isoquinolinyl, quinazolinyl, acridinyl, phthalazinyi, imidazo[l ,2- ajpyridinyl, imidazo[l ,5-a]pyridinyl, imidazo[5, l-a]isoquinolinyl, l,4-dihydroindeno[l,2-c]-lH- pyrazolyl, 2,3-dihydro-lH-inden-l-one, 2,3-dihydro-lH-indenyl, 3,4-dihydroquinolin-2(lH)- one, 5,6-dihydroimidazo[5, 1 -ajisoquinolinyl , 8H-indeno[l ,2-d]thiazolyl,

benzo[c][l,2,5]oxadiazolyi, benzo[d]oxazol-2(3H)-one, quinolin-2(lH)-one, quinazolin-4(lH)- one, quinazoline-2,4(l H,3H)-dione, benzo-[d]oxazolyl, pyrazolo[l ,5-a]pyridinyl, and the like, A heteroaryl radical may be optionally substituted on a carbon or nitrogen atom ring member where allowed by available valences.

[00255] As used herein, the term "heterocyclyl" generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, without limitation, oxiranyi, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, pyrrolinyl, pyrroiidinyl, dihydropyrazoiyl, pyrazolinyl, pyrazolidinyl, dihydroimidazolyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyi, thiazolinyl, thiazolidinyl, triazolinyl, triazoiidinyl, oxadiazoiinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, dihydro-2H-pyranyl,

dihydro-pyridinyl, tetrahydro-pyridinyi, 1,2,3, 6-tetrahydropyridinyl, hexahydro-pyridinyl, dihydro-pyrimidinyl, tetrahydro-pyrimidinyl, 1,4,5,6-tetrahydropyrimidinyl, dihydro-pyrazinyl, tetrahydro-pyrazinyl, dihydro-pyridazinyl, tetrahydro-pyridazinyl, piperazinyl, piperidinyl, morphoiinyl, thiomorpholinyl, dihydro-triazinyl, tetrahydro-triazinyl, hexahydro-triazinyi, 1,4-diazepanyl, dihydro-indolyl, indolinyl, tetrahydro-indolyl, dihydro-indazolyl,

tetrahydro-indazolyl, dihydro-isoindolyi, dihydro-benzofuranyl, tetrahydro-benzofuranyl, dihydro-benzothienyl, tetrahy dro-benzothienyl, di hydro-benzimidazolyl,

tetrahydro-benzimidazolyi, dihydro-benzooxazolyl, 2,3-dihydrobenzo[d]oxazolyl, tetrahydro-benzooxazolyl, dihydro-benzooxazinyl, 3,4-dihydro-2H-benzo[b][l,4]oxazinyl, tetrahydro-benzooxazinyl, benzo[ 1 ,3]dioxolyl, benzo[ 1 ,4]dioxanyl, dihydro-purinyl,

tetrahydro-purinyl, dihydro-quinolinyl, tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydroquinolinyl, dihydro-isoquinolinyl, 3,4-dihydroisoquinolin-(lH)-yl, tetrahydro-isoquinolinyl, 1,2,3,4- tetrahydroisoquinolinyl, dihydro-quinazolinyl, tetrahydro-quinazolinyl, dihydro-quinoxalinyl, tetrahydro-quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,3-dioxolanyl, 2,5-dihydro-lH- pyrrolyl, 4,5-dihydro-lH-imidazolyl, tetrahydro-2H-pyranyl, hexahydropyrrolo[3,4- b][l,4]oxazin-(2H)-yl, (4aR,7aS)-hexahydropyrrolo[3,4-b][l ,4]oxazin-(4aH)-yl, 3,4-dihydro-2H- pyrido[3,2-b][l ,4]oxazinyl, (cis)-octahydrocyclopenta[c]pyrrolyl, hexahydropyrrolo[3,4- b]pyrrol-(l H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(l H)-yl, (3aR,6aS)~

hexahydropyrrolo[3,4-c]pyrrol-(lH)-yl, 5H-pyrrolo[3,4-b]pyridin-(7H)-yl, 5,7-dihydro-6H- pyrrolo[3,4-b]pyridinyl, tetrahydro-l.H-pyrrolo[3,4-b]pyridin-(2H,7H,7aH)-yl, hexahydro-lH- pyrrolo[3,4-b]pyridin-(2H)-yl, (4aR,7aR)-hexahydro-lH-pyrrolo[3,4-b]pyridin-(2H)-yl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, 2,3,4,9-tetrahydro-lH-carbazolyl, 1,2,3,4- tetrahydropyrazino[l ,2-a]indolyl, 2,3-dihydro-lH-pyrrolo[l,2-a]indolyl, (3aR,6aR)- hexahydrocyclopenta[c]pyrrol-(lH)-yl, (3aR,4R,6aS)-hexahydrocycIopenta[c]pyrrol-(lH)-yl, (3aR,4S,6aS)-hexahydrocyclopenta[c]pyrrol-(lH)-yl, (3aR,5r,6aS)- hexahydrocyclopenta[c]pyrrol-(lH)-yl, l,3-dihydro-2H-isoindolyl, octahydro-2H-isoindolyl, (3aS)-l ,3,3a,4,5,6-hexahydro-2H-isoindolyl, (3aR,4R,7aS)-I H-isoindol- (3H,3aH,4H,5H,6H,7H,7aH)-yl, (3aR,7aS)-octahydro-2H-isoindolyl, (3aR,4R,7aS)-octahydro- 2H-isoindolyl, (3aR,4S,7aS)-octahydro-2H-isoindolyl, 2,5-diazabicyclo[2.2.1 jheptanyl, 2- azabicyclo[2.2. Ijheptenyl, 3-azabicyclo[3.1.OJhexanyl, 3,6-diazabicyclo[3.1.OJhexanyl, (1R,5S)- 3-azabicyclo[3.1.OJhexanyl, ( 1 S,5R)-3 -azabicy clo[3.2. Ojheptanyl , 5-azaspiro[2.4]heptanyl, 2,6- diazaspiro[3.3]heptanyl, 2,5-diazaspiro[3.4]octanyl, 2,6-diazaspiro[3.4]octanyl, 2,7- diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2-azaspiro[4.5]decanyl, 2,8- diazaspiro[4.5]decanyl, 3,6-diazabicyclo[3.2.1 ]octyl, l,4-dihydroindeno[l,2-c]pyrazolyl, dihydropyranyl, dihydropyridinyl, dihydroquinolinyl, 8H-indeno[ 1 ,2-d]thiazolyl,

tetrahydroimidazo[ 1 ,2-a]pyridinyl, pyridin-2(lH)-one, (1R,5 S)-8-azabicycl o[3.2.1 joctyl, 8-azabicyclo[3.2.1]oct-2-enyl and the like. A heterocyclyl radical may be optionally substituted on a carbon or nitrogen atom ring member where allowed by available valences. 156] As used herein, the term "C2- ₄ alkenyl-amino-carbonyl" refers to a radical of the formula: -C(=0)- H-C ₂ - ₄ alkenyl.

[00257] As used herein, the term "Ci-4alkoxy-C i-4alkOxy" refers to a radical of the formula: -0-Ci-4alkyl-0-Ci- ₄ alkyl.

[00258] As used herein, the term "Ci-4alkoxy-earbonyi" refers to a radical of the

formula: -C(=0)-0-C ₁ -4alkyl .

[00259] As used herein, the term "Cwalkoxy-carbonyl-amino" refers to a radical of the formula: -TMH-C(=0)-0-C i-4alkyl .

[00260] As used herein, the term "C alkoxy-carbonyl-amino-Cwalkoxy" refers to a radical of the formula: -0-C ₁ -4alkyl-NH-C(=0)-0-C ₁ - ₄ alkyl .

[00261] As used herein, the term "Cj -4alkyl-Ci-4alkoxy" refers to a radical of the

formul a: -0-Ci- ₄ al ky] -Ci-4alkyl.

[00262] As used herein, the term "Ci- ₄ alkyl-amino" refers to a radical of the

formula: -NH-C i-4alkyl .

[00263] As used herein, the term "(Ci- ₄ alkyl) ₂ -amino" refers to a radical of the

formul a : -N(C i - ₄ al ky 1)2.

[00264] As used herein, the term "Ci-4alkyl-amino-Ci-4alkoxy" refers to a radical of the formula: -O-C i -4alkyl-NH-C Malkyl .

[00265] As used herein, the term "(Ci-4alkyl)2-amino-Ci-4alkOxy" refers to a radical of the formula: -0-Ci-4alkyl- (Ci-4alkyl)2.

[00266] As used herein, the term "Ci-4alkyl-amino-Ci-4alkyl" refers to a radical of the formula: -C^alkyl- H-C i -4aikyi .

[00267] As used herein, the term "(Ci-4alkyl)2~amino-Ci-4alkyi" refers to a radical of the formula: -C i-4al ky 1 -N(C i -4alky 1 ) ₂ .

[00268] As used herein, the term "Cwalkyl-amino-carbonyl" refers to a radical of the formula: -C(=0)-NH-Ci-4alkyl.

[00269] As used herein, the term ' Ci-4alkyl) ₂ -amino-carbonyl" refers to a radical of the formula: C( ( ))-X(C i- ial kyl) ₂ .

[00270] As used herein, the term "Cj.-4alkyl-amino-carbonyl-Cj.-4alkyr' refers to a radical of the formula: -C ₁ -4alkyl-C(=0)-NH-C ₁ -4alkyl. [00271] As used herein, the term "(Ci-4alkyl)2-amino-carhonyl-Ci-4alkyl" refers to a radical of the formula: -Cj.- ₄ alkyl-C(=0)-N(C ₁ - ₄ alkyl) ₂ .

[00272] As used herein, the term "C ^alkyl-carbonyl" refers to a radical of the

formula:

[00273] As used herein, the term "Ci-4alkyl-carhonyl -amino" refers to a radical of the formula: -NH-C(=0)-Ci-4alkyl.

[00274] As used herein, the term "Ci-4alkyl~carbonyl~amino-Ci-4alkoxy" refers to a radical of the formula: -0-CMalkyl-NH-C(=0)-Ci-4alkyl.

[00275] As used herein, the term "Ci-4alkyl-carbonyl-amino-Ci-4alkyl" refers to a radical of the formula: -C ₁ - ₄ alkyl-NH-C(=0)-C ₁ - ₄ al kyl .

[00276] As u sed herein, the term "amino" refers to a radical of the formula: - H ₂ .

[00277] As used herein, the term "amino-C^alkoxy" refers to a radical of the

formula: -O-C i - ialkvl-N I h.

[00278] As used herein, the term "amino-C^alkyl" refers to a radical of the

formula: -Ci- ₄ alkyl-NH2.

[00279] As used herein, the term "amino-carbonyl" refers to a radical of the

formula: -C(=0)-NH2.

[00280] As used herein, the term "cyano" refers to a radical of the formula: -CN.

[00281] As used herein, the term "C3-7cycl oalky l-Ci-tal koxy" refers to a radical of the formula: -0-Ci-4alkyl-C3-?cycioalkyl.

[00282] As used herein, the term "halo-C ₁ - ₄ alkoxy" refers to a radical of the

formula: -0-Ci- ₄ alkyl-halo, wherein Ci- ₄ alkyl may be partially or completely substituted where allowed by available valences with one or more halogen atoms. In some aspects,

halo-C i-4alkoxy includes halo-Ci-ealkoxy, halo-0- ₄ alkoxy and the like.

[00283] As used herein, the term "halo-C ₁ - ₄ alkyl" refers to a radical of the

formula: -Ci-4alkyl-halo, wherein Ci-4aikyi may be partially or completely substituted where allowed by available valences with one or more halogen atoms. In some aspects, halo-C i-4alkyl includes halo-Ci-eal kyl , halo-Ci-4alkyl and the li ke.

[00284] As u sed herein, the term "heteroaryi-Ci-4alkyl" refers to a radical of the

formula: -C ₁ - ₄ alkyl-heteroaryl , [00285] As used herein, the term "heteroaryi~Ci-4alkyl-ammo" refers to a radical of the formula: - H-C J -4alkyl-heteroaryl .

[00286] As used herein, the term "heteroaryl-Ci-4al ky]-amino-carbor!yl" refers to a radical of the formula: -C(=0)-NH-C ₁ - ₄ alkyl-heteroaryl.

[00287] As used herein, the term "heteroaryl-C ₁ -4alkyl-amino-carbonyl-C ₁ -4alkyl" refers to a radical of the formula: -C ₁ -4alkyl-C(=0)-NH-C ₁ - ₄ alk} ^r l-heteroaryl.

[00288] As used herein, the term "heteroaryl-Cwalkyl-carbonyl-amino" refers to a radical of the formula: -NH-C(=0)-C ₁ - ₄ alkyl-heteroaryl.

[00289] As used herein, the term "heteroaryl-Ci^alkyl-carbonyl-amino-d^alkyl" refers to a radical of the formula: -C ₁ - ₄ alkyl-NH-C(=0)-C ₁ -4alkyl-heteroaryl.

[00290] As used herein, the term "heterocyclyl-Cj.- ₄ alkoxy" refers to a radical of the formul a: -C ₁ - ₄ alkoxy-heterocyclyl .

[00291] As used herein, the term "heterocyclyl-Ci- ₄ alkyl" refers to a radical of the

formula: -C ₁ - ₄ alkyl-heterocyclyl .

[00292] As used herein, the term "hydroxyl" refers to a radical of the formula: -OH.

[00293] As used herein, the term "hydroxyl-d^alkoxy" refers to a radical of the

formula: wherein Ci-4alkyl may be partially or completely substituted where allowed by available valences with one or more hydroxy radicals.

[00294] As used herein, the term "hydroxyl-Cwalkyl" refers to a radical of the

formula: -Ci- ₄ alkyl-OH, wherein Ci-4alkyl may be partially or completely substituted where allowed by available valences with one or more hydroxy radicals,

[00295] As used herein, the term refers to a radical of the formula: may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.

[00296] As u sed herein, the term "hydroxy 1-imino" refers to the =NOH radical of the formula: C(=NOH).

[00297] As used herein, the term "oxo" refers to the radical of the formula: C=0.

[00298] As used herein, the term "phenyl -Ci-4alkoxy" refers to a radical of the

formula: -Ci- ₄ alkoxy-phenyl.

[00299] As used herein, the term "substituent" means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A person of ordinary skill in the art should note that any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown. In certain instances one or more substituents having a double bond (e.g., "oxo" or "=0") as the point of attachment may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I). A person of ordinary skill in the art would understand that, while only a single bond is shown, a double bond is intended for those substituents.

[00300] As used herein, the term "and the like," with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional staictural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by- available valences which result in a stable compound.

[00301] For the purposes of this description, where one or more substituent variables for a compound of Formula (I) or a form thereof encompass functionalities incorporated into a compound of Formula (I), each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.

[00302] As used herein, the terms "independently selected," or "each selected" refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence. Further, the use of a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthaienyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein.

[00303] As used herein, the terms "each instance of or "in each instance, when present," when used preceding a phrase such as " . . . C3-Mcycioalkyl, C3-i4cycloaikyl-Ci-4alkyl, aryl, heteroaryl, heteroaryl-C 1 -4alkyl, heterocyclyl and heterocyciyl-Cwaikyi," are intended to refer to the C ₃ - ₁₄ cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent.

[00304] As used herein, the term "optionally substituted" means optional substitution with the specified substituent variables, groups, radicals or moieties.

COMPOUND FORMS

[00305] As used herein, the term "form" means a compound of Formula (I) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

[00306] In certain aspects described herein, the form of the compound of Formula (I) is a free acid, free base or salt thereof.

[00307] In certain aspects described herein, the form of the compound of Formula (I) is a salt thereof.

[00308] In certain aspects described herein, the form of the compound of Formula (I) is an isotopologue thereof.

[00309] In certain aspects described herein, the form of the compound of Formula (I) is a stereoisomer, racemate, enantiomer or diastereomer thereof.

[00310] In certain aspects described herein, the form of the compound of Formula (I) is a tautomer thereof

[00311] In certain aspects described herein, the form of the compound of Formula (I) is a pharmaceutically acceptable form.

[00312] In certain aspects described herein, the compound of Formula (I) or a form thereof is isolated for use.

[00313] As used herein, the term "isolated" means the physical state of a compound of Formula (I) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterized by- standard analytical techniques described herein or well known to the skilled artisan . [00314] As used herein, the term "protected" means that a functional group in a compound of Formula (I) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T.W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York. Such functional groups include hydroxy, phenol, amino and carboxylic acid.

Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsiiyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyl oxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include aikyi, aryl or arylalkyl esters. In certain instances, the protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl- chloride resin. Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art, although such protected derivatives of compounds described herein may not possess pharmacological activity as such, they may be administered to a subject and thereafter metabolized in the body to form compounds described herein which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds described herein are included within the scope of the use described herein.

[00315] As used herein, the term "prodrug" means a form of an instant compound {e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or a form thereof. The transformation may occur by various mechanisms {e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S.

Symposium Series, and in Bioreversibie Carriers in Drug Design, ed. Edward B. Roche,

American Pharmaceutical Association and Pergamon Press, 1987.

[00316] In one example, when a compound of Formula (I) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like. In another example, when a compound of Formula (I) or a form thereof contains a hydroxy! functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxy! with another functional group such as a!ky!, alkyl carbonyl or a phosphonate ester and the like. In another example, when a compound of Formula (I) or a form thereof contains an amine functional group, a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of compounds of Formula (I) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As descri bed herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or a form thereof as a prodrug.

[00317] One or more compounds described herein may exist in unsolvated as well as soivated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both soivated and unsolvated forms.

[00318] As used herein, the term "solvate" means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, "solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.

[00319] As used herein, the term "hydrate" means a solvate wherein the solvent molecule is water.

[00320] The compounds of Formula (I) can form salts, which are intended to be included within the scope of this description. Reference to a compound of Formula (I) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) or a form thereof contains both a basic moiety, such as, without limitation an amine moiety, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "sait(s)" as used herein.

[00321] The term "pharmaceutically acceptable salt(s)", as used herein, means those salts of compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals and that possess biological activity, although other salts are also useful. Salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound of Formula (I) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[00322] Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. In certain aspects, acid addition salts may include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bi sulfate, bi tartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesuifonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthaienesuifonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate salts and the like. Certain aspects of acid addition salts may further include chloride, dichioride, trichloride, bromide, acetate, formate or trifluoroacetate salts,

[00323] Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahi et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley- VCH; S. Berge el al, Journal of Pharmaceutical Sciences (1977) 66( 1) 1-19; P. Gould, InternationalJ. of Pharmaceutics (1986) 33, 201-217; Anderson et al, I he Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

[00324] Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts.

[00325] All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. In addition, all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of this description.

[00326] Compounds of Formula (I) and forms thereof, may further exist in a tautomeric form. Ail such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or a form thereof as described herein.

[00327] The compounds of Formula (I) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. The present description is intended to include all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures.

[00328] The compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R'S) or as substantialiy pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present). In one aspect, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer. In another aspect, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantialiy comprising only the (R) isomer. As one of skill in the art will recognize, when more than one chiral center is present, the compounds described herein may also exist as a (R,R), (RS), (S,R) or (S,S) isomer, as defined by RIP AC Nomenclature

Recommendations.

[00329] As used herein, the term "substantially pure" refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer.

[00330] In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%>, or in an amount equal to 100%.

[00331] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein: [00332] In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.

[00333] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

[00334] As used herein, a "racemate" is any mixture of isometric forms that are not

"enantiomericaliy pure", including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20,

[00335] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

[00336] In addition, the present description embraces all geometric and positional isomers. For example, if a compound of Formula (I) or a form thereof incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the description. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art, Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher' s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure

enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this description.

[00337 ] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

[00338] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra,

[00339] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

[00340] The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the instant compounds,

[00341] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

[00342] The term "isotopologue" refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ² H, ¾ ¹³ C, ¹⁴ C, ¹⁵ N, ^l8 0, ¹⁷ G, ³¹ P, ³² P, ³⁵ S, ^l8 F, ³⁵ C1 and ⁶ C1, respectively, each of which are also within the scope of this description,

[00343] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

[00344] Certain isotopically-enriched compounds described herein (e.g., those labeled with ³ H and ¹⁴ C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ³ H) and carbon- 14 (i.e., ¹⁴ C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ² H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.

[00345] In another aspect provided herein are compounds of Formula (I) selected from a compound of Formula (la) and Formula (lb) for use in the methods described herein:

polymorphic crystalline and amorphous forms of the compounds of Formula (I) and of the salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) are further intended to be included in the present description.

[00346] Compound names provided herein were obtained using ACD Labs Index Name software provided by ACD Labs and/or ChemDraw Ultra software provided by CambridgeSoft ¹ ®. When the compound name disclosed herein conflicts with the structure depicted, the structure shown will supercede the use of the name to define the compound intended. Nomenclature for substituent radicals defined herein may differ slightly from the chemical name from which they are derived; one skilled in the art will recognize that the definition of the substituent radical is intended to include the radical as found in the chemical name.

[00347] As used herein the term "aberrant" refers to a deviation from the norm of, e.g., the average healthy subject or a cell(s) or tissue sample from a healthy subject. The term "aberrant expression," as used herein, refers to abnormal expression (up-regulated or down -regulated resulting in an excessive or deficient amount thereof) of a gene product (e.g., RNA transcript or protein) by a cell, tissue sample, or subject relative to a corresponding normal, healthy cell, tissue sample or subject. In a specific aspect, the "aberrant expression" refers to an altered level of a gene product (e.g., RNA transcript or protein) in a cell, tissue sample, or subject relative to a corresponding normal, healthy cell, tissue sample or subject. The term "aberrant amount" as used herein refers to an altered level of a gene product (e.g., RNA, protein, polypeptide, or peptide) in a cell, ti ssue sample, or subject relative to a corresponding normal, healthy cell, ti ssue sample or subject. In specific aspects, the amount of a gene product (e.g., RNA, protein, polypeptide, or peptide) in a cell, tissue sample, or subject relative to a corresponding cell or tissue sample from a healthy subject or a healthy subject, is considered aberrant if it is 1, 1.5, 2, 2,5, 3, 3.5, 4, 4.5, 5, 5.5, 6-fold or more above or below the amount of the gene product in the corresponding cell or tissue sample from a healthy subject or healthy subject.

[00348] The term "intronic REMS" refers to a REMS sequence present in an intron that functions as a 5' splice site in the presence of a compound described herein. The intronic REMS, when downstream of a first branch point (BP) sequence and a first 3' splice site (3' ss) sequence and upstream of a second branch point (BP) sequence and a second 3 ' splice site (3 ' ss) sequence) (as shown in Figure I A) and in the presence of a compound described herein, functions as a 5' splice site. The intronic REMS may also function as a 5' splice site when upstream of a branch point and a 3 ' splice site in the presence of a compound described herein (see Figure B or 1C) and the minimally required elements are present. Any one, two, three, or more or ail of the following may be present endogenously or non-endogenously in the affected intron: the intronic REMS, the first BP, the second BP, the first 3' ss, and the second 3'ss. The minimally required additional elements necessary for an intronic REMS to function as a 5' splice site comprises a downstream branch point (BP) sequence and a downstream 3' splice site (3' ss) sequence. Either or both the BP and 3'ss may be present endogenously or non-endogenously in the affected intron.

[00349] As used herein, a "non-endogenous" nucleotide sequence (such as a non-endogenous 5' splice site, a non-endogenous branch point or a non-endogenous Y splice site) is a nucleotide sequence not naturally found to be part of a pre-RNA or a DNA sequence encoding a pre-RNA sequence. In other words, the hand of man is required to synthesize or manipulate the RNA or DNA sequence to introduce the nucleotide sequence.

[00350] As used herein, the term "non-endogenous intronic REMS" refers to a REMS sequence not naturally found to be part of an RNA sequence or naturally encoded by a DNA sequence. In other words, the hand of man is required to synthesize or manipulate the RNA or DNA sequence to introduce the intronic REMS or the nucleotide sequence encoding the intronic REMS.

[00351] As used herein, the terms "intron-derived exon," "intronic exon," "iExon" and "intronic exon" (collectively iExon) refer to an exon that is produced from an intronic RNA sequence when an intronic REMS sequence, a branch point, a 3' splice site and a splicing modifier compound are present. In particular, when RNA splicing of an RNA transcript comprising two exons and an intron occurs in the presence of a compound described herein, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, and wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an xREMS, a second branch point, and a second 3' splice site, a resulting iExon comprises the following RNA sequence: the RNA sequence between the first 3' splice site and the iREMS (corresponding to iExon la as shown in Figure 1 A). One or more of the intronic REMS sequence, branch point and 3' splice site may be naturally present in an intronic RNA sequence or may be introduced into the intronic RNA sequence. When all such elements are present or introduced, in the presence of a compound described herein, the elements define an exonic boundary that enables the splicing machinery to generate an iExon in RNA, a result that would not naturally occur without the addition of a splicing modifier compound.

[00352] As used herein, the term "pseudoexon" refers to known endogenous intronic sequences naturally present in intron coding DNA that may match those of a branch point, a 3 ' splice site and a 5' splice site, yet is neither active in the splicing process, spliced nor present in the mature mR A. Some pseudoexons contain an intronic REMS at their 5' splice site. An intronic REMS-containing pseudoexon is not known to be endogenously recognized by the splicing machinery for producing an iExon but in the presence of a splicing modifier compound as described herein, the splicing machinery produces an iExon, Accordingly, production of an iExon from a pseudoexon is intended to be included wi thin the scope of various aspects of the collective term "iExon."

[00353] As used herein, the term "unannotated exon" refers to endogenous sequences that are naturally present as exons in mature mRNA product according to experiemtnal evidence but are not annotated in NCBFs RefSeq database (https://wvvw.ncbi. nlm.nih.gov/refseq/). Some unannotated exons contain an intronic REMS at the 5' splice site. A REMS-containing unannotated exon is not known to be endogenously recognized by the splicing machinery for producing an iExon, but in the presence of a splicing modifier compound as described herein, the splicing machinery produces an iExon. Accordingly, production of an iExon from an

unannotated exon is intended to be included within the scope of various aspects of the collective term "iExon."

[00354] As used herein, the terms "extended exon" (i.e., eExon) refer to an exon that includes an exon and a portion of an adjacent intronic sequence when an intronic REMS sequence, a branch point, a Y splice site and a splicing modifier compound are present in, e.g., the order shown in Figure IB. In particular, when RNA splicing of an RNA transcript comprising two exons and an intron occurs in the presence of a compound described herein, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, and wherein the intron comprises in 5' to 3' order: a 5' splice site, an iREMS, a branch point, and a 3' splice site, and wherein there is no intervening branch point and no intervening 3' splice site between the iREMS sequence and the 5' splice site, a resulting eExon comprises the first exon and the RNA sequence between the 5' splice site and the intronic REMS (corresponding to Exon l e as shown in Figure IB, and Exon 2e as shown in Figure IC). [00355] As used herein, the term "substantial change" in the context of the amount of one or more NA transcripts (e.g., rRNA, tRNA, miRNA, siRNA, piRNA, incRNA, pre-mRNA or mRNA transcripts), an alternative splice variant thereof or an isoform thereof, or one or more proteins thereof, each expressed as the product of one or more of genes, means that the amount of such products changes by a statistically significant amount such as, in a nonlimiting example, a p value less than a value selected from 0.1, 0.01, 0.001, or 0.0001.

[00356] As used herein, the terms "subject" and "patient" are used interchangeably to refer to an animal or any living organism having sensation and the power of voluntary movement, and which requires for its existence oxygen and organic food. Non-limiting examples include members of the human, equine, porcine, bovine, rattus, murine, canine and feline species. In some aspects, the subject is a mammal or a warm-blooded vertebrate animal. In certain aspects, the subject is a non-human animal. In specific aspects, the subject is a human ,

[00357] As used herein, the term "functional protein" refers to a form of a protein that retains a certain biological function or the functions of a full-length protein or protein isoform encoded by a gene.

[00358] As used herein, the term "non-functional protein" refers to a form of a protein that does not retain any biological function compared to full length protein or a protein isoform encoded by a gene in the absence of a splicing modifier compound as described herein.

[00359] As used herein, in the context of a functional protein produced from an artificial construct, the term "produce substantially less" means that the amount of functional protein produced in the presence of a compound described herein is at least substantially 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% less than the amount of functional protein produced in the absence of the compound.

[00360] In another aspect, provided herein are methods for determining whether the splicing of the precursor RNA of a gene is likely to be modified by a compound of Formula (I) or a form thereof, compri sing searching for the presence of an intronic REMS (i.e., a sequence functioning as a 5 ' splice site responsive to the presence of compound) in a gene intronic sequence, wherein the presence of the intronic REMS, 3 ' splice site and an intronic branch point in the gene sequence indicates that the splicing of the precursor RNA of the gene is likely to be modified by the compound of Formula (I) or a form thereof, and the absence of the intronic REMS and an intronic 3' splice site and an intronic branch point in the gene sequence indicates that the splicing of the precursor RNA of the gene is unlikely to be modified by the compound of Formula (I) or a form thereof. In specific aspects, the methods further comprise searching for the presence of the combination of an intronic REMS, an intronic 3' splice site and an intronic branch point in the gene sequence.

[00361] In another aspect, provided herein are methods for determining whether the amount of a product (e.g., an mRNA transcript or protein) of a gene is likely to be moduiated by a compound of Formula (I) or a form thereof, comprising searching for the presence of an intronic REMS in the gene sequence, wherein the presence of the combination of an intronic REMS, an intronic 3' splice site and an intronic branch point in the gene sequence indicates that the amount of a product (e.g., an mRNA transcript or protein) of the gene is likely to be modulated by the compound of Formula (I) or a form thereof, and the absence of the combination of an intronic REMS, an intronic 3' splice site and an intronic branch point in the gene sequence indicates that the amount of a product (e.g., an mRNA transcript or protein) of the gene is unlikely to be modulated by the compound of Formula (I) or a form thereof. In specific aspects, the methods further comprise searching for the presence of any of an intronic REMS, an intronic 3' splice site, and an intronic branch point in the gene sequence. In specific aspects, the methods further comprise searching for the presence of the combination of an intronic REMS, a downstream branch point and a downstream 3' splice site in the gene sequence.

[00362] The step of searching for the presence of the minimally required combination of an intronic REMS, a downstream 3' splice site, and a downstream branch point in the gene sequence described herein can be performed by a computer system comprising a memory storing instructions for searching for the presence of the combination in the gene sequence, or such a search can be performed manually.

[00363] In certain aspects, the splicing of a precursor RNA containing an intronic REMS is assessed by contacting a compound described herein with the precursor RNA in cell culture. In some aspects, the splicing of a precursor RNA containing an intronic REMS is assessed by contacting a compound described herein with the precursor RNA in a cell-free extract. In a specific aspect, the compound is one known to modulate the splicing of a precursor RNA containing an intronic REMS. See, e.g., the section below relating to methods for determining whether a compound modulates the expression of certain genes, and the example below for techniques that could be used in these assessments.

METHODS FOR DETERMINING WHICH COMPOUNDS MODULATE OR MODIFY EXPRESSION OF CERTAIN GENES

[00364] Provided herein are methods for determining whether a compound of Formula (I) or a form thereof modulates the amount of one, two, three or more RNA transcripts (e.g., pre-mRNA or mKNA transcripts or isoforms thereof) of one, two, three or more genes. In some aspects, the gene is any one of the genes described herein.

[00365] In one aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript, comprising: (a) contacting a ceil(s) with a compound of Formula (I) or a form thereof, and (b) determining the amount of the RNA transcript produced by the cell(s), wherein modulation in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first cell(s) with a compound of Formula (I) or a form thereof, (b) contacting a second cell(s) with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of the RN A transcript produced by the first ceil(s) and the second cell(s); and (d) comparing the amount of the RNA transcript produced by the first cell(s) to the amount of the RNA transcript expressed by the second ceil(s), wherein modulation in the amount of the RNA transcript produced by the first cell(s) relative to the amount of the RNA transcript produced by the second cell(s) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In certain aspects, the contacting of the cell(s) with the compound occurs in cell culture. In other aspects, the contacting of the ceil(s) with the compound occurs in a subject, such as a non-human animal subject.

[00366] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) culturing a cell(s) in the presence of a compound of Formula (I) or a form thereof; and (b) determining the amount of the two or more RNA transcript splice variants produced by the cell(s), wherein modulation in the amount of the two or more RNA transcript in the presence of the compound relative to the amount of the two or more RNA transcript splice variants in the absence of the compound or the presence of a negative controi (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modifies the splicing of the RNA transcript.

[00367] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) culturing a cell(s) in the presence of a compound of Formula (I) or a form thereof; (b) isolating two or more RNA transcript splice variants from the cell(s) after a certain period of time; and (c) determining the amount of the two or more RNA transcript splice variants produced by the cell(s), wherein modulation in the amount of the two or more RNA transcript in the presence of the compound relative to the amount of the two or more RNA transcript splice variants in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modifies the splicing of the RN A transcript. In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RNA transcript (e.g., an mRNA transcript), comprising (a) culturing a first ceil(s) in the presence of a compound of Formula (I) or a form thereof; (b) culturing a second cell(s) in the presence of a negative control (e.g., a vehicle control, such as PBS or DMSO); (c) isolating two or more RNA transcript splice variants produced by the first cell(s) and isolating two or more RNA transcript splice variants produced by the second cell(s); (d) determining the amount of the two or more RNA transcript splice variants produced by the first cell(s) and the second ceil(s); and (e) comparing the amount of the two or more RNA transcript splice variants produced by the first cell(s) to the amount of the two or more RNA transcript splice variants produced by the second celi( s), wherein modulation in the amount of the two or more RNA transcript splice variants produced by the first cell(s) relative to the amount of the two or more RNA transcript splice variants produced by the second eel li s) indicates that the compound of Formula (I) or a form thereof modulates the aplicing of the RNA transcript.

[00368] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a cell-free system with a compound of Formula (I) or a form thereof, and (b) determining the amount of the RNA transcript produced by the ceil-free system, wherein modulation in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first cell-free system with a compound of Formula (I) or a form thereof, (b) contacting a second cell-free system with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of the RNA transcript produced by the first cell-free system and the second cell-free system; and (d) comparing the amount of the RNA transcript produced by the first cell-free system to the amount of the RNA transcript expressed by the second cell-free system, wherein modulation in the amount of the RN A transcript produced by the first ceil-free system relative to the amount of the RNA transcript produced by the second cell-free system indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In certain aspects, the cell-free system comprises purely synthetic RNA, synthetic or recombinant (purified) enzymes, and protein factors. In other aspects, the cell-free system comprises RNA transcribed from a synthetic DNA template, synthetic or recombinant (purified) enzymes, and protein factors. In other aspects, the cell-free system comprises purely synthetic RNA and nuclear extract. In other aspects, the cell-free system comprises RNA transcribed from a synthetic DNA template and nuclear extract. In other aspects, the cell-free system comprises purely synthetic RNA and whole cell extract. In other aspects, the cell-free system comprises RNA transcribed from a synthetic DNA template and whole cell extract. In certain aspects, the cell-free system additionally comprises regulatory RNAs (e.g., microRNAs).

[00369] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RN A transcript (e.g., an mRNA. transcript), comprising: (a) contacting a cell-free system with a compound of Formula (I) or a form thereof; and (b) determining the amount of two or more RNA transcript splice variants produced by the cell -free system, wherein modulation in the amount of the two or more RNA transcript splice variants in the presence of the compound relative to the amount of the two or more RNA transcript splice variants in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DM SO) indicates that the compound of Formula (I) or a form thereof modifies the splicing of the RNA transcript. In another aspect provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first cell-free system with a compound of Formula (I) or a form thereof; (b) contacting a second cell -free system with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of two or more RN A transcript splice variants produced by the first cell -free system and the second cell -free system; and (d) comparing the amount of the two or more RNA transcript splice variants produced by the first cell-free system to the amount of the RNA transcript expressed by the second cell -free system, wherein modulation in the amount of the two or more RNA transcript splice variants produced by the first cell-free system relative to the amount of the two or more RN A transcript splice variants produced by the second cell-free system indicates that the compound of Formula (I) or a form thereof modifies the splicing of the RNA transcript. In certain aspects, the cell-free system comprises purely synthetic RNA, synthetic or recombinant (purified) enzymes, and protein factors. In other aspects, the cell-free system comprises RNA transcribed from a synthetic DNA template, synthetic or recombinant (purified) enzymes, and protein factors. In other aspects, the ceil-free system comprises purely synthetic RNA and nuclear extract. In other aspects, the ceil- free system comprises RNA transcribed from a synthetic DNA template and nuclear extract. In other aspects, the cell-free system comprises purely synthetic RNA and whole cell extract. In other aspects, the cell-free system comprises RNA transcribed from a synthetic DNA template and whole ceil extract. In certain aspects, the ceil-free system additionally comprises regulatory RNAs (e.g., microRNAs).

[00370] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), compri sing: (a) culturing a cel l(s) in the presence of a compound of Formula (I) or a form thereof, (b) isolating the RNA transcript from the cell(s) after a certain period of time; and (c) determining the amount of the RNA transcript produced by the cell(s), wherein modulation in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an niRNA transcript), comprising (a) culturing a first cell(s) in the presence of a compound of Formula (I) or a form thereof, (b ) culturing a second cell(s) in the presence of a negative control (e.g., a vehicle control, such as PBS or DMSO), (c) isolating the RNA transcript produced by the first cell(s) and isolating the RNA transcript produced by the second cell(s); (d) determining the amount of the RNA transcript produced by the fi rst cell(s) and the second cel l(s); and (e) comparing the amount of the RNA transcript produced by the first ceil(s) to the amount of the RNA transcript produced by the second cell(s), wherein modulation in the amount of the RNA transcript produced by the first cell(s) relative to the amount of the RNA transcript produced by the second celi(s) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript.

[00371] In certain aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject. In some aspects, the cell(s) contacted or cultured with a compound of Formula (Γ) or a form thereof is a primary cell(s) from a subject with a disease. In specific aspects, the ceil(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject with a disease associated with an aberrant amount of an RNA transcript(s) for a particular gene(s). In some specific aspects, the celi(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject with a disease associated with an aberrant amount of an isoform(s) of a particular gene(s). In some aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a fibroblast (e.g., GM03813 or PNN 1-46 fibroblasts), an immune cell (e.g., a T cell, B cell, natural killer cell, macrophage), or a muscle cell. In certain aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a cancer cell.

[00372] In certain aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is from a cell line. In some aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a ceil line derived from a subject with a disease. In certain aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is from a cell line known to have aberrant RN A transcript levels for a particular gene(s). In specific aspects, the celi(s) contacted or cultured with a compound of Formula (I) or a form thereof is from a cell line derived from a subject with a disease known to have aberrant RNA transcript levels for a particular genefs). In certain aspects, the cellfs) contacted or cultured with a compound of Formula (I) or a form thereof is a cancer cell line.

[00373] In some specific aspects, the cellfs) contacted or culured with the compound of Formula (I) or a form thereof is from a ceil line derived from a subject with a disease known to have an aberrant amount of an RNA isoform(s) and/or protein isoform(s) of a particular gene(s). Non-limiting examples of cell lines include 3T3, 4T1 , 721, 9L, A2780, A 172, A20, A253, A431, A-549, ALC, B 16, B35, BCP-1, BEAS-2B, bEnd.3, BHK, BR 293, BT20, BT483, BxPC3, C2C 12, C3H-10T1/2, C6/36, C6, Cal-27, CHO, COR-L23, COS, COV-434, CML Tl, CMT, CRL7030, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6, FM3, H1299, H69, HB54, HB55, HCA2, HD-1994, HDF (human dermal fibroblasts), HEK-293, HeLa, Hepal cl c?, HL-60, HMEC, Hs578T, HsS78Bst, HT-29, HTB2, HUVEC, Jurkat, J558L, JY, K562, Ku812, KCL22, KG1, ΚΥΌ 1 , LNCap, Ma-Mel, MC-38, MCF-7, MCF-IOA, MDA-MB-23 1 , MDA-MB- 468, MDA-MB-435, MDCK, MG63, MOR/G.2R, MONO-MAC 6, MRC5, MTD-1A, NCI-H69, NIH-3T3, NALM- 1, NSO, \ W- 145, OPCN, OPCT, PNT- 1 A, PNT-2, Raji, RBL, RenCa, RTN- 5F, RMA, Saos-2, Sf21, Sf9, SH-SY5Y, SiHa, SKBR3, SKOV-3, T2, T-47D, T84, THP1 , U373, U87, U937, VCaP, Vero, WRY, W138, WM39, WT-49, X63, YAC-1, and YAR ceils. In one aspect, the cells are from a patient. In another aspect, the patient cells are GM03813 cells. In another aspect, the patient cells are GM04856, GM04857, GM09197, GM04281, GM04022, GM07492 cells,

[00374] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a tissue sample with a compound of Formula (I) or a form thereof; and (b) determining the amount of the RNA transcript produced by the tissue sample, wherein modulation in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first tissue sample with a compound of Formula (I) or a form thereof, (b) contacting a second tissue sample with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of the RNA transcript produced by the first tissue sample and the second tissue sample; and (d) comparing the amount of the RNA transcript produced by the first tissue sample to the amount of the RNA transcript produced by the second tissue sample, wherein modulation in the amount of the RNA transcript produced by the first tissue sample relative to the amount of the RNA transcript produced by the second tissue sample indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. Any tissue sample containing cells may be used in the accordance with these methods. In certain aspects, the tissue sample is a blood sample, a skin sample, a muscle sample, or a tumor sample. Techniques known to one skilled in the art may be used to obtain a tissue sample from a subject.

[00375] In some aspects, a dose-response assay is performed. In one aspect, the dose response assay comprises: (a) contacting a cell(s) with a concentration of a compound of Formula (I) or a form thereof; (b) determining the amount of the RN A transcript produced by the cell(s), wherein modulation in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript; (c) repeating steps (a) and (b), wherein the only experimental variable changed is the concentration of the compound or a form thereof; and (d) comparing the amount of the RNA transcript produced at the different concentrations of the compound or a form thereof. In another aspect, the dose response assay- comprises: (a) cuituring a cell(s) in the presence of a compound of Formula (I) or a form thereof; (b) isolating the RNA transcript from the cell(s) after a certain period; (c) determining the amount of the RNA transcript produced by the cell(s), wherein modulation in the amount of the RN A transcript in the presence of the compound relative to the amount of the RN A transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript, (d) repeating steps (a), (b), and (c), wherein the only experimental variable changed is the concentration of the compound or a form thereof; and (e) comparing the amount of the RN A transcript produced at the different concentrations of the compound or a form thereof. In another aspect, the dose-response assay comprises: (a) contacting each well of a microtiter plate containing cells with a different concentration of a compound of Formula (Γ) or a form thereof; (b) determining the amount of an RNA transcript produced by cells in each well; and (c) assessing the change of the amount of the RNA transcript at the different concentrations of the compound or form thereof.

[00376] In one aspect, the dose response assay comprises: (a) contacting a cell(s) with a concentration of a compound of Formula (Γ) or a form thereof, wherein the ceils are within the wells of a cell culture container (e.g., a 96-well plate) at about the same density within each well, and wherein the ceils are contacted with different concentrations of compound in different wells; (b) isolating the RNA from said cells in each well, (c) determining the amount of the RN A transcript produced by the cell(s) in each well ; and (d) assessing change in the amount of the RNA transcript in the presence of one or more concentrations of compound relative to the amount of the RNA transcript in the presence of a different concentration of the compound or the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO).

[00377] In certain aspects, the contacting of the ceil(s) with the compound occurs in cell culture. In other aspects, the contacting of the cell(s) with the compound occurs in a subject, such as a non-human animal subject.

[00378] In certain aspects described herein, the cell(s) is contacted or cultured with a compound of Formula (I) or a form thereof, or a ti ssue sample is contacted with a compound of Formula (I) or a form thereof, or a negative control for a period of 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 1 8 hours, 24 hours, 48 hours, 72 hours or longer. In other aspects described herein, the celi(s) is contacted or cultured with a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a compound of Formula (I) or a form thereof, or a negative control for a period of 15 minutes to 1 hour, I to 2 hours, 2 to 4 hours, 6 to 12 hours, 12 to 8 hours, 12 to 24 hours, 28 to 24 hours, 24 to 48 hours, 48 to 72 hours.

[00379] In certain aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample i s contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 0.0001 μΜ, 0.0003 μΜ, 0.001 μΜ, 0.003 μΜ, 0.01 μΜ, 0.05 μ,Μ, 1 μ,Μ, 2 μ,Μ, 5 μΜ, 10 μΜ, 15 μΜ, 20 μΜ, 25 μΜ, 50 μΜ, 75 μΜ, 100 μΜ, or 150 μ \ ί . In other aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 0,0001 μΜ, 0.0003 μΜ, 0.0005 μΜ, 0.001 μΜ, 0.003 μΜ, 0.005 μΜ, 0.01 μΜ, 0.03 μΜ, 0.05 μΜ, 0.1 μΜ, 0.3 μΜ, 0.5 μ,Μ or 1 μΜ. In other aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 175 μΜ, 200 μΜ, 250 μΜ, 275 μΜ, 300 μΜ, 350 μΜ, 400 μΜ, 450 μΜ, 500 μΜ, 550 μΜ 600 μΜ, 650 μΜ, 700 μΜ, 750 μΜ, 800 μΜ, 850 μΜ, 900 μΜ, 950 μΜ or 1 rnM. In some aspects described herein, the eel li s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 450 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, or 950 nM. In certain aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is between 0,0001 μΜ to 0,001 μΜ, 0,0001 μΜ to 0,01 μΜ, 0.0003 μΜ to 0.001 μ,Μ, 0.0003 μΜ to 0.01 μΜ, 0.001 μ\ί to 0.01 μΜ, 0.003 μΜ ίο 0.01 μΜ, 0.01 μ\ί !ο 0.1 μΜ, 0.1 μ\ ! ίο 1 μΜ, 1 μ\ί !ο 50 μΜ, 50 μΜ to 100 μΜ, 100 μΜ to 500 μΜ, 500 μ,Μ to 1 nM, 1 nM to 10 nM, 10 nM to 50 nM, 50 nM to 100 nM, 100 nM to 500 nM, 500 nM to 1000 nM.

[00380] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a subject (in certain aspects, a non-human animal); and (b) determining the amount of the RNA transcript in a sample obtained from the subject, wherein modulation in the amount of the RNA transcript measured in the sample from the subject administered the compound or form thereof relative to the amount of the RNA transcript in a sample from the subject prior to administration of the compound or form thereof or a sample from a different subject from the same species not administered the compound or form thereof indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a first subject (in certain aspects, a non-human animal); (b) administering an inactive control (e.g., a pharmaceutical carrier) to a second subject (in certain aspects, a non-human animal) of the same species as the first subject; and (c) determining the amount of the RNA transcript in a first tissue sample from the first subject and the amount of the RN transcript in the second tissue sample from the second subject; and (d) comparing the amount of the RNA transcript in the first tissue sample to the amount of the RNA transcript in the second tissue sample, wherein modulation in the amount of the RNA transcript in the first tissue sample relative to the amount of the RNA transcript in the second tissue sample indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In certain aspects, a compound of Formula (I) or form thereof is administered to a subject at a dose of about 0,001 mg/kg/day to about 500 mg/kg/day. In some aspects, a single dose of a compound of Formula (I) or a form thereof is administered to a subject in accordance with the methods described herein. In other aspects, 2, 3, 4, 5 or more doses of a compound of Formula ( !) is administered to a subject in accordance with the methods described herein. In specific aspects, the compound of Formula (I) or a form thereof is administered in a subject in a pharmaceutically acceptable carrier, excipient or diluent.

[00381] In another aspect, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a subject (in certain aspects, a non-human animal); and (b) determining the amount of two or more RN transcript splice variants in a sample obtained from the subject, wherein modulation in the amount of the two or more RNA transcript splice variants measured in the sample from the subject administered the compound or form thereof relative to the amount of the two or more RNA transcript splice variants in a sample from the subject prior to administration of the compound or form thereof or a sample from a different subject from the same species not administered the compound or form thereof indicates that the compound of Formula (I) or a form thereof modifies the splicing of the RNA transcript. In another aspects, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modifies the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a first subject (in certain aspects, a non-human animal), (b) administering a negative control (e.g., a pharmaceutical carrier) to a second subject (in certain aspects, a non-human animal) of the same species as the first subject; (c) determining the amount of two or more RNA transcript splice variants in a first tissue sample from the first subject and the amount of two or more RNA transcript splice variants in the second tissue sample from the second subject; and (d) comparing the amount of the two or more RNA transcript splice variants in the first tissue sample to the amount of the two or more RNA transcript splice variants in the second tissue sample, wherein modulation in the amount of the two or more RNA transcript splice variants in the first tissue sample relative to the amount of the two or more RNA transcript splice variants in the second tissue sample indicates that the compound of Formula (I) or a form thereof modifies the splicing of the RNA transcript. In certain aspects, a compound of Formula (I) or form thereof is administered to a subject at a dose of about 0.001 mg/kg/day to about 500 mg/kg/day. In some aspects, a single dose of a compound of Formula (I) or a form thereof is administered to a subject in accordance with the methods described herein. In other aspects, 2, 3, 4, 5 or more doses of a compound of Formula (I) is administered to a subject in accordance with the methods described herein. In specific aspects, the compound of Formula (I) or a form thereof is administered in a subject in a pharmaceutically acceptable carrier, excipient or diluent,

[00382] In some aspects, the compound of Formula (I) or a form thereof that is contacted or cultured with a cell(s) or a tissue sample, or administered to a subject is a compound described herein.

[00383] Techniques known to one skilled in the art may be used to determine the amount of an RNA transcript(s). In some aspects, the amount of one, two, three or more RNA transcripts is measured using deep sequencing, such as ILLUMINA ¹ * RNASeq, ILLUMIN A*' next generation sequencing (NGS), ION TORRENT™ RNA next generation sequencing, 454 ^iM pyrosequencing, or Sequencing by Oligo Ligation Detection (SOLID™), Single Molecule, Real-Time (SMRT) sequencing, Nanopore sequencing. In other aspects, the amount of multiple RNA transcripts is measured using an exon array, such as the GENECHIP ^® human exon array. In certain aspects, the amount of one, two, three or more RN A transcripts is determined by RT-PCR, In other aspects, the amount of one, two, three or more RNA transcripts is measured by RT-qPCR or digital color-coded barcode technology. Techniques for conducting these assays are known to one skilled in the art.

[00384] In some aspects, analysis is performed on data derived from the assay to measure the magnitude of splicing to determine the amount of exons spliced into an mRNA transcript that is produced in the presence of the compound relative to the amount in the absence of the compound or presence of a negative control. In a preferred aspect, the method utilized is calculation of change in Percent Spliced In (APSI). The method utilizes read data from RNAseq (or any other method that can distinguish mRNA splice isoforms) to calculate the ratio (percentage) between reads that either demonstrate inclusion (junctions between the upstream exon and the exon of interest) or exclusion (junction between the upstream and downstream exons, excluding the exon of interest), to demonstrate whether the presence of the compound affects the amount of exon inclusion relative to the amount of inclusion in the absence of the compound or the presence of a negative control .

[00385] The APSI value is derived from the formula:

[00386] APSI (%) = C - U xlOO

[00387] Where "U" represents the value for probability of iExon inclusion

(a+b)/2/[(a+b)/2+c] in the absence of the compound, and, where "C" represents the value for probability of iExon inclusion (a+b)/2/[(a+b)/2 + c] in the presence of the compound. The values for "a" and "b" represent the number of reads supporting inclusion of an iExon in an RNA transcript. In other words, the "a" value is derived from the amount of reads for a first intronic nucleotide sequence comprising, in 5' to 3' order: a first exon 5' splice site operably linked and upstream from a first intronic nucleotide sequence comprising a first branch point further operably linked and upstream from a first intronic 3' splice site (upstream of the nascent iExon). The "b" value is derived from the amount of reads for a second intronic nucleotide sequence comprising, in 5' to 3' order: a REMS sequence operably linked and upstream from a second intronic nucleotide sequence comprising a second branch point further operably linked and upstream from a second intronic 3' splice site of a second exon. The value for "c" represents the number of reads supporting exclusion of an iExon. Accordingly, when a compound enables the splicing machinery to recognize a nascent iExon, the value for "C" in the presence of the splicing modulates compound will differ from the value for "U" in the absence of the compound. The statistically significant value for the likelihood of iExon inclusion may be obtained according to statistical analysis methods or other probability analysis methods known to those of ordinary skill in the art.

[00388] In some aspects, a statistical analysis or other probability analysis is performed on data from the assay utilized to measure an RNA transcript. In certain aspects, for example, a Fisher's Exact Test statistical analysis is performed by comparing the total number of read for the inclusion and exclusion of an iExon (or region) based on data from one or more assays used to measure whether the amount of an RNA transcript is modulated in the presence of the compound relative to the amount in the absence of the compound or presence of a negative control. In specific aspects, the statistical analysis results in a confidence value for those modulated RNA transcripts of 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1 %, 0.01%, 0.001% or 0.0001%. In some specific aspects, the confidence value is a p value for those modulated RNA transcripts of 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1 %, 0,01%, 0.001% or 0.0001%, In certain specific aspects, an exact test, student t-test or p value for those modulated RNA transcripts is 10%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1% and 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001% or 0.0001%, respectively.

[00389] In certain aspects, a further analysis is performed to determine how the compound of Formula (I) or a form thereof is changing the amount of an RNA transcript(s). In specific aspects, a further analysis is performed to determine if modulation in the amount of an RNA transcript(s) in the presence of a compound of Formula (I) or a form thereof relative the amount of the RNA transcript(s) in the absence of the compound or a form thereof, or the presence of a negative control is due to changes in transcription, splicing, and/or stability of the RNA transcript(s). Techniques known to one skilled in the art may be used to determine whether a compound of Formula (I) or a form thereof changes, e.g., the transcription, splicing and/or stability of an RNA transcript(s).

[00390] In certain aspects, the stability of one or more RN A transcripts is determined by serial analysis of gene expression (SAGE), differential display analysis (DD), RNA arbitrary primer (RAP)-PCR, restriction endonuciease-iytic analysis of differentially expressed sequences (READS), amplified restriction fragment-length polymorphism (ALFP), total gene expression analysis (TOGA), RT-PCR, RT-RPA (recombinase polymerase amplification), RT-qPCR, RNA- Seq, digital color-coded barcode technology, high-density cDNA filter hybridization analysis (HDFCA), suppression subtractive hybridization (SSH), differential screening (DS), cDNA arrays, oligonucleotide chips, or tissue microarrays. In other aspects, the stability of one or more RNA transcripts is determined by Northern blot, RNase protection, or slot blot.

[00391] In some aspects, the tra scription in a cell(s) or tissue sample is inhibited before (e.g., 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 72 hours before) or after (e.g., 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 72 hours after) the cell or the tissue sample is contacted or cultured with an inhibitor of transcription, such as a-amanitin, DRB, flavopiridol, triptolide, or actinomycin-D. In other aspects, the transcription in a cell(s) or tissue sample is inhibited with an inhibitor of

transcription, such as a-amanitin, DRB, flavopiridol, triptolide, or actinomycin-D, while the ceilfs) or tissue sample is contacted or cultured with a compound of Formula (I) or a form thereof,

[00392] In certain aspects, the level of transcription of one or more RNA transcripts is determined by nuclear run-on assay or an in vitro transcription initiation and elongation assay. In some aspects, the detection of transcription is based on measuring radioactivity or

fluorescence. In some aspects, a PCR-based amplification step is used,

[00393] In specific aspects, the amount of alternatively spliced forms of the RNA transcripts of a particular gene are measured to see if there is modulation in the amount of one, two or more alternatively spliced forms of the RNA transcripts of the gene. In some aspects, the amount of an isoform(s) encoded by a particular gene is measured to see if there is modulation in the amount of the isoform(s). In certain aspects, the levels of spliced forms of RNA are quantified by RT-PCR, RT-qPCR, RNA-Seq, digital color-coded barcode technology, or Northern blot. In other aspects, sequence-specific techniques may be used to detect the levels of an individual spliceoform. In certain aspects, splicing is measured in vitro using nuclear extracts. In some aspects, detection is based on measuring radioactivity or fluorescence. Techniques known to one skilled in the art may be used to measure modulation in the amount of alternatively spliced forms of an RNA transcript of a gene and modulation in the amount of an isoforni encoded by a gene.

PHARMACEUTICAL COMPOSITIONS AND MODES OF ADMINISTRATION

[00394] When administered to a patient, a compound of Formula (I) or a form thereof is preferably administered as a component of a composition that optionally comprises a pharmaceutically acceptable carrier, excipient or diluent. The composition can be administered orally, or by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa) and may be administered together with another biologically active agent.

Administration can be systemic or local. Various delivery systems are known, e.g.,

encapsulation in liposomes, microparticles, microcapsules, capsules, and can be used to administer the compound.

[00395] Methods of administration include, but are not limited to, parenteral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intraocular, intratumoral, intracerebral, intravaginal, transdermal, ocularly, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of a compound into the bloodstream, tissue or ceil(s). In a specific aspect, a compound is administered orally.

[00396] The amount of a compound of Formula (I) or a form thereof that will be effective in the treatment of a disease resulting from an aberrant amount of mRNA transcripts depends, e.g., on the route of administration, the disease being treated, the general health of the subject, ethnicity, age, weight, and gender of the subject, diet, time, and the severity- of disease progress, and should be decided according to the judgment of the practitioner and each patient's or subject's circumstances.

[00397] In specific aspects, an "effective amount" in the context of the administration of a compound of Formula (I) or a form thereof, or composition or medicament thereof refers to an amount of a compound of Formula (I) or a form thereof to a patient which has a therapeutic effect and/or beneficial effect. In certain specific aspects, an "effective amount" in the context of the administration of a compound of Formula (I) or a form thereof or composition or

medicament thereof to a patient results in one, two or more of the following effects: (i) reduces or ameliorates the severity of a disease; (ii) delays onset of a disease; (iii) inhibits the progression of a disease; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life of a subject; (viii) reduces the number of symptoms associated with a disease; (ix) reduces or ameliorates the severity of a symptom(s) associated with a disease; (x) reduces the duration of a symptom associated with a disease associated; (xi) prevents the recurrence of a symptom associated with a disease; (xii) inhibits the development or onset of a symptom of a disease; and/or (xiii) inhibits of the progression of a symptom associated with a disease. In certain aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to restore the amount of a RNA transcript of a gene to the amount of the RNA transcript detectable in healthy patients or cells from healthy patients. In other aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to restore the amount an RNA isoform and/or protein isoform of gene to the amount of the RNA isoform and/or protein isoform detectable in healthy patients or cells from healthy patients,

[00398] In certain aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to decrease the aberrant amount of an RNA transcript of a gene which associated with a di sease. In certain aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to decrease the amount of the aberrant expression of an isoform of a gene. In some aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to result in a substantial change in the amount of an RNA transcript (e.g., mRNA. transcript), alternative splice variant or isoform.

[00399 ] In certain aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to increase or decrease the amount of an RNA transcript (e.g., an mRNA transcript) of gene which is beneficial for the prevention and/or treatment of a disease. In certain aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to increase or decrease the amount of an alternative splice variant of an RNA transcript of gene which is beneficial for the prevention and/or treatment of a disease. In certain aspects, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to increase or decrease the amount of an isoform of gene which is beneficial for the prevention and/or treatment of a disease. Non-limiting examples of effective amounts of a compound of Formula (I) or a form thereof are described herein.

[00400] For example, the effective amount may be the amount required to prevent and/or treat a disease associated with the aberrant amount of an mRNA transcript of gene in a human subject.

[00401] In general, the effective amount will be in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day for a patient having a weight in a range of between about 1 kg to about 200 kg. The typical adult subject is expected to have a median weight in a range of between about 70 and about 100 kg.

[00402] Within the scope of the present description, the "effective amount" of a compound of Formula (I) or a form thereof for use in the manufacture of a medicament, the preparation of a pharmaceutical kit or in a method for preventing and/or treating a disease in a human subject in need thereof, is intended to include an amount in a range of from about 0.001 mg to about 35,000 mg.

[00403] The compositions described herein are formulated for administration to the subject via any drug delivery route known in the art. Non-limiting examples include oral, ocular, rectal, buccal, topical , nasal , ophthalmic, subcutaneous, intramuscular, intravenous (bolus and infusion), intracerebral, transdermal, and pulmonary routes of administration.

[00404] Aspects described herein include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition. In a specific aspect, described herein is the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for preventing and/or treating a disease in a human subject in need thereof comprising administering an effective amount of a compound of Formula (I) or a form thereof in admixture with a

pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the human subject is a patient with a disease associated with the aberrant amount of an mRNA transcript(s).

[00405] A compound of Formula (I) or a form thereof may optionally be in the form of a composition comprising the compound or a form thereof and an optional carrier, excipient or diluent. Other aspects provided herein include pharmaceutical compositions comprising an effective amount of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient, or diluent. In a specific aspect, the pharmaceutical compositions are suitable for veterinary and/or human administration. The pharmaceutical compositions provided herein can be in any form that allows for the composition to be administered to a subject.

[00406] In a specific aspect and in this context, the term "pharmaceutically acceptable carrier, excipient or diluent" means a carrier, excipient or diluent approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant (e.g., Freund' s adjuvant (complete and incomplete)), excipient, or vehicle with which a therapeutic agent is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oi l, sesame oil and the li ke. Water i s a specific carrier for intravenously administered pharmaceutical compositions. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.

[00407] Typical compositions and dosage forms comprise one or more excipients. Suitable excipients are well-known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanoi and the like. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient and the specific active ingredients in the dosage form. Further provided herein are anhydrous pharmaceutical compositions and dosage forms comprising one or more compounds of Formula (I) or a form thereof as described herein. The compositions and single unit dosage forms can take the form of solutions or syaips (optionally with a flavoring agent), suspensions (optionally with a flavoring agent), emulsions, tablets (e.g., chewable tablets), pills, capsules, granules, powder (optional ly for reconstitution), taste-masked or sustained-release formulations and the like.

[00408] Pharmaceutical compositions provided herein that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets, caplets, capsules, granules, powder, and liquids. Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art.

[00409] Examples of excipients that can be used in oral dosage forms provided herein include, but are not limited to, binders, fillers, disintegrants, and lubricants.

[00410] In one aspect, described herein are methods for modifying RNA splicing in order to modulate the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, and the methods utilize a compound described herein. In certain aspects, the gene is any one of the genes described herein. In certain aspects, the gene contains a nucleotide sequence encoding a non-endogenous intronic REMS. In one aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, the method comprising contacting a ceil with a compound of Formula (I) or a form thereof.

[00411] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or a protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting a ceil with a compound described herein (for example, a compound of Formula (I) or a form thereof).

[00412] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein ), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5' to 3' order: a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting a ceil with a compound described herein (for example, a compound of Formula (I) or a form thereof). [00413] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1 A, the method comprising contacting a cell with a compound described herein.

[00414] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure IB, the method comprising contacting a cell with a compound described herein.

[00415] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein ), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure IC, the method comprising contacting a ceil with a compound described herein.

[00416] In a specific aspect, the gene is a gene described in a table in this disclosure.

[00417] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a ceil with a compound of Formula (I) or a form thereof. In a specific aspect, the precursor transcript contains in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00418] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a ceil with a compound of Formula (I) or a form thereof. In a specific aspect, the precursor transcript contains in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3 ' splice site.

[00419] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, comprising contacting a cell with a compound of Formula (I) or a form thereof. See the example section for additional information regarding the genes described herein. In certain aspects, the ceil is contacted with the compound of Formula (I) or a form thereof in a cell culture. In other aspects, the cell is contacted with the compound of Formula (I) or a form thereof in a subject (e.g., a non-human animal subject or a human subject).

[00420] In one aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon from a pre-mRNA tra script, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non- endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide.

[00421] In one aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a pre- mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA. transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide.

[00422] In another aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a ceil or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide. In some aspects, the pre-mRNA transcript is encoded by a gene disclosed herein (e.g., in a table herein).

[00423] In a particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre- mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3 ' splice site, an endogenous or non- endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second Y splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre- mRNA transcript of a gene that is selected from ABCB8, ABCC3, AD AMI 7, ADCY3,

AGPAT4, ANKRA2, ANXAl l, APIP, APPL2, ARHGAP1, ARL15, ASAP , ASPH, ATAD2B, ATXN1, BECNl, BHMT2, BICDl, BTN3A1, Cl lorBO, Cl lorf73, C 12orf4, C 14orfl32, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, C CDC 122, CDH13, CECR7, CENPI, CEP 112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSN 1E, CSNK1G1 , DCAF 17, DCUN1 D4, DDX42, DENND1A, DENND5A, DG A, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRKIA, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAFl , FAIM, FAM126A, FAM13A, F AMI 62 A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB , GPSM2, GULP! , GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B 12, HSD17B4, HTT, IFT57, IVD, KDM6A, IAA1524, KIAA1 715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1,

MB21D2, MCM1Q, MED13L, MED AG, MEMQ1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, WWW NSUN4, NT5C2, OSMR, OXCT1 , PAPD4, PCMl, PDE7A, PDS5B, PDXDCl, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHAl, PLSCR1 , PMS1 , POMT2, PPARG, ΡΡΪΡ5Κ2, PPP1R26, PRPF31 , PRSS23, SMA4, PXK, RAF 1 , RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1 , RPS10, SAMD4A, SAR ! A, SCOl, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, S HG16, SNX7, SGS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STATl, STXBP6, SUPT20H, TAF2, TASP1, TBC1 D15, TCP 12, TCF4, TLAMl, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91 , WNK1 , XRN2, ZCCHC8, ZFP82, ZNF I 38, ZNF232 and

ZNF37BP.

[00424] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM 17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXNl, BECNl, BHMT2, BICDl, BTN3A1, Cl lorBO, Cl lorf73, C12orf4, C 14orfl 32, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP1 12, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1 G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOXl, EP300, ERC1, ERLIN2, ERRFIl , EVC, FAFl, FAIM, FAM126A, FAM13 A, F AM 162 A, FAM174A, FBN2, PER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGBl, GPSM2, GULPl, GXYLTl, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMOl, MFN2, MM SI 9, MRPL.45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCTl, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD,

PIK3R1, PI FYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POM 1 2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PX , RAF , RAPGEF l , RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SARI A, SCOl, SEC24A, SENP6, SERGEF, SGK3, SLC 12A2, SLC25AI7, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1 , STAT1 , STXBP6, SUPT20H, TAF2, TASP1 , TBC1D15, TCF 12, TCF4, TIAMl, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 and ZNF37BP.

[00425] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA1, ABCAIO, ABCB7, ABCB8, ABCC1, ABCC3, ABHDIO, ABL2, ABLIM3, ACACA,

ACADVL, ACAT2, ACTA2, ADAL, ADAM 12, AD AMI 5, AD AMI 7, ADAM23, ADAM33, ADAMTS1 , ADAMTS19, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGP AT 3, AGPAT4, AGPS, AHCYL2, AHDCl, AHRR, AJUBA, AK021888, AK310472, AKAP1 , A AP3, AKAP8L, A AP9, AKNA, AKT1 , ALCAM, ALDH4A1, AMPD2, ANK.1 , ANK2, ANK3, ANKFY1, ANKHD1-EIF4EBP3, ANKRA2, ANKRD13C, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, AP4B 1-AS1, APAF1, APIP, APLP2, APOA2, APP, APPL2, APTX, ARHGAPl, ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARMCX6, ARSJ, ASAP1, ASICl, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG5, ATG9A, ΑΤΜΓΝ, ATP2A3, ATP2C I, ATXN1, ATXN3, AURKA, ΑΧΓΝ1, B3GALT2, B3GNT6, B4GALT2, BACEl, BAG2, BASP1 , BC033281 , BCAR3, BCL2L15, BCYRN1, BECNL BEND6, BHMT2, BICDl, BINl, ΒΓΝ3, ΒΓΝ3-ΠΊ, BIRC3, BIRC6, BNC l, BNC2, BRCA1 , BRCA2, BRD2, BRPF1 , BSCL2, BTBD10, BTG2, BTN3A1 , BZW1 , C1QTNF9B- AS1, Clorf27, Clorf86, C10orf54, Cl lorGO, Cl lorf70, C l lorf73, Cl lorf76, Cl lorf94, C12orf4, C12orf56, C14orfl32, C17orf76-ASl, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orfiS8, C9orf69, CAB, CA3, CAB39, CACNA2D2, CACNB!, CACNB4, CADM1, CADM2, CALU, CAMK 1, CAND2, CAPNS1, CASC3, CASP7, CASP8AP2, CAV1, CCARl, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, ( 1)1111, CD! 11 . CDH18, CDK lB, CDK16, CDKALl, CDKN1C, CECR7, CELSR1, CEMIP, CENPI, CEP 112, CEP 162, CEP 170, CEP 192, CEP57, CEP68, CFH, CFLAR, CHD8, CHEK1, CHRM2, CIITA, CXZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CNOT1, CNRIP1, CNTD1, CMSS1, CNOT7, CNRIP1, CNTN1, COGl, COL1A1, COLLI Al,

COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1,

COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1, CRTAP, CRX, CRYBG3, CRYLl, CSDE1, CSNK1A1, CS K1E, CSNK1G1,

CTDSP2, CTNNDl, CTRC, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYPIBI, CYP51A1, DAAMl, DAB2, DACTl, DAGLB, BARS, DAXX, DCAFIO, DCAFll, DC AF 17, DCBLD2, DCLK1, DON, DCUN1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDRl, DDX39B, DDX42, DDX50, DEGSl, DENND1A, DENND1B, DENND4A, DENND5A, DEPTOR, DET1, DFNB59, DGCR2, DGK1, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLCl, DLG5, DLGAP4, DMD, DMXL1, DNAH8, DNAH11, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCKl, DOCKll, DPP 8, DSEL, DST, DSTN, DYNCHl, DYRKIA, DZIP1L, EBF1, EEA1, EEF1 Al, EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, ENAH, ENG, ENOXl, ENPPl, ENPP2, ENSA, EP300, EPN1, EPT1, ERC1, ERC2, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADS I, FADS2, FAFl, FAIM, FAMlllA, F AM 126 A, FAM13A, FAM160A1, F AMI 62 A, FAM174A, FAM195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARPl, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXO10, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFT1, FDPS, FER, FEZ1, FGD4, FGD5- AS1, FGFR2, FGFRLl, FGL2, FHOD3, FLU, FLNB, FLT1, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FRAS1, FSCN2, FUS, FYN, GAB B1, GAL3ST4, GALC, GALNTl, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBPl, GCFC2, GLCE, GCNTl, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, G L3L, GOLGA2, GOLGA4, GOLGB l, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREMl , GR 6, GRTP1 , GSE1 , GTF2H2B, GTSF1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS2, HAS 3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1 , HEG1 , HEPH, HEY1 , HLA-A, HLA-E, HLTF, HMGAl, HMGA2, HMGB l, HMGCR, HMGN3-AS1, HMGCSl, HMGXB4, HOQK3, HOXB3, HMOX1, HNMT, HNRNPR, HNRNPULl, HP1BP3, HPS1, HRH1, HSD17B12, HSD17B4, HSPA1L, HTATIP2, HI T, LARS, IDH1, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, IL16, IL6ST, IN A, INHBA, INO80, ΪΡΡ4Β, ΪΝΡΡ5Κ, INStGI, INTU, INVS, IQCE, IQCG, ITCH, ITGA1 1, ITGA8, ITGAV, ITGB5, ITGB8, ΓΠΗ1, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAAl 199, KLAA1456, KIAA1462, KIAA1522, KIAA1524, KLAA1549,

KIAA1715, KIAA1755, KIDINS220, KIF14, KIF2A, KIF21A, KIF3A, KIT, KLCl, KLC2, KLF17, KLF6, KLHL7, KLRGI, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAPl-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB l, LAMB2 1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS 1, LINC00341 , Li:NC00472, LINC00570, LINC00578, Li:NC00607, LINC00657, LINC00678, LINC00702, LTNC00886, LINC00961, LINC01011, LTNC011 18, LINC0I204, LINCR-0002, LING02, LM:AN2L, LMNA, LM:07, LMOD I , LOC400927, LONPl , LOX, LPHN1, LRBA, L.RCH4, LRIGl, LRP4, LRP8, LRRC1, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPDl , LYRMl , LZTS2, MACROD2, MADD, MAFB, MAGED4,

MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1, MANEA, MAP4K4, MAPK10, MAPK13, MARCH7, MARCH8, MASPl, MB, MB21D2, MBDl, MBOAT7, MC4R, MCM I O, MDM2, MDNl, MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl, MEPCE, MFGE8, MFN2, MI AT, MICAL2, MINPPI, MIR612, MKL 1 , MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MM:S19, MM:S22L, MNl, MORF4L1, MOXDI, MPPE1, MPZL1, MRPL3, MRPL39, MRPL45, MRPL55, MRPS28, MR VII , MSANTD3, MSG, MSI 12, MSH4, MSH6, MSL3, MSMOl, MSRB3, MTAP,

MTERF3, MTERFDl, MTHFDIL, MTMR3, MTMR9, MTRR, MUMl, MVT), MVK, MXRA5, MY.ADM, MYB, MYCBP2, MYL , MY01 D, MY09B, MYOF, NA, N.AA35, NAALADL2, NADK, NAEl, NAGS, NASP, NAV1 , NAV2, NCOA1 , NCOA3, NCOA4, NCSTN, NDNF, EDD4, NELFA, NEOl, NEURL1B, NF2, NFASC, NFE2L1, NFXl, NGF, NGFR, NHLH1, NIDI, NID2, PA1, NKX3-1, NLGN1, NLN, NOL10, NOM03, NOTCH3, NOTUM,

NOVA2, NOX4, NPEPPS, NRDl, NREP, NRGI , NRROS, NSUN4, NT5C2, NT5E, NTNGI , NUDT4, NUP153, MJP35, NUP50, NUPLl, NUSAPl, OCLN, ODF2, OLRl, OS9, OSBPL3, OSBPL6, OSBPL10, OSMR, OXCT1 , OXCT2, P4HA1 , P4HB, PABPC1, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARI ⁵ 4, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCBP4, PCCB, PCDHIO, PCDHGB3, PCGF3, PCMl, PCMTD2, PCNXL2, PCSK9, PDEIC, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1, PDXDC2P, PEAR1, PELLl, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, ΡΪΕΖ01 , PIGN, PIGU, PIK3C2B, PI 3CD, PI 3R1 , PIKFYVE, PIM2, PITPNA, PITPNB, PITPNM1, PITPNM3, PLAU, PLEC, PLEK2, PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PI . SCR h PLSCR3, PLXNB2, PLXNC1 , PMS1, PNISR, PGDN, POLE3, POLN, POLR1 A, POLR3D, POMT2, POSTN, POU2F 1, PPAPDCIA, PPARA, PPARG, PPFIBP1, PPHLN1, PPIP5K1, PPIP5K2, PPM IE, PPP1R12 A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PR G1 , PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTCLL1, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PX , PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD 1 , RAD9B, R.AD23B, RAF l, RALB, RAP1A, RAP1GDS1, RAPGEF 1, RARG, RARS, RARS2, RASIPl , RASSF8, RBBP8, RBCK1 , RCOR3, RBFOX2, RBKS, RBM10, RCC1 , RDX, RERE, RFTN1, RFWD2, RFX3-AS 1, RGCC, RGLl, RGS10, RGS3, RIFl, RNF14, RNF19A, RNF130, RNF144A, RNF213, RNF38, RNFT1 , ROR1, ROR2, RPA1 , RPF2, RPLI O, RPS10, RPS6 B2, RPS6KC1, RRBPl, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCOl, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF l , SF3B3, SGIP1, SGK3, SGMS1, SGOL2, SGPL1, SH2B3, SH3RF1, SH3YL1, SHROOM3, SIGLECI O, SKA2, SKIL, SKPl, SLC12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A1 1, SLC41A1, SLC44A2, SLC 6A2, SLC6A15, SLC7A6, SLC7A8,

SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, S X14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1, SORCS2, SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPIN 5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRGAP1, SRRMl, SRSF3, SSBP1, STAC2, STARD4, STAT1, STATS, STAT4, STAU1, STC2,

STEAP2, STK32B, STRAD8, STRIP!, STRN3, STRN4, STS, STX16, STXBP4, STXBP6, SI SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC1 , TAF2, TAGLN3, TANC2, TANG06, TARBP1, TARS, TASP1 , TBC1D15, TBCA, TBL1XR1, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENCl, TENM2, TEPl , TETl, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBRl , TGFBRAPl, TGM2, THADA, THAP4, THBS2, THRB, TIAMl, ΊΊΜΡ2, TJAP1, TJP2, TLE3, TLKl, TMC3, TMEM67, TMEM102, TMEM119, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAIP8L3, TNFRSF 12A, TNFRSF14, TNIPl, TNKSIBPI, TNP03, TNRC 18P1, TNRC6A, TNSl, TNS3, TNXB, TOEl, TOMM40, TOMM5, TOPORS, TP53AIP1 , TP53INP1, TPRG1 , TRAF3, TRAKl, TRAPPC12, TRIB 1, TRTM2, TRIM23, TRFM26, TRIM28, TRIM65,

TRIM66, TRMTIL, TRPC4, TRPS1, TSC2, TSHZl, TSHZ2, TSPAN11, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBEl , TXNIP, TXNLl, TXNL4B, TXNRD1, TYW5, U2SURP, UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMKl , UHRFIBPIL, UNC13B, UNC5B, URGCP, URGCP-MRPS24, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VDAC2, VTM-ASl, VIPAS39, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPF1, WISP1, WXK I . WNT5B, WNT10B, WSBl, WWTRl, XDH, XIAP, XRN2, YAPI , YDJC, YESl , YPEL5, YTHDF3, Z24749, ZAK, ZBTB 10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC 11, ZEB1, ZEB2, ZFANDI, ZFAND5, ZFP82, / 1 1 3, ZMIZ1, ZMIZ1-AS1, ZMIZ2, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431, ZNF583, ZNF618, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF730, ZNF74, ZNF764, ZNF777, ZNF778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 and ZSCAN25.

[00426] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from APOA2, ASAP1, BRCA1, BRCA2, CDKN1C, CRX, CTRC, DE ND5A, DIAPH3, DMD, DNAH1 1 , EIF2B3, GALC, HPS !, HTT, IKBKAP, KIAA1524, LMNA, MECP2, PAPD4, PAX6, PCCB, ΡΓΓΡΝΒ, PTCH1 , SLC34A3, SMN2, SPINK 5, SREK1 , TMEM67, VWF, XDH and XRN2.

[00427] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a ceil or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA1, ABCA10, ABCB7, ABCB8, ABCC1 , ABCC3, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, AD AMI 5, AD AM 17, ADAM23, ADAM33, ADAMTSl, ADAMTS19, ADCY3, ADD!, ADGRG6, ADH6, ADHFE1, AFP2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1, AHRR, AJIJBA, AK021888, AK310472, AKAP1, AKAP3, AKAP8L, AKAP9, AKNA, ALCAM, ALDH4A1 , AMPD2, ANK1 , ANK2, ANK3, ANKFY1, ANKHD1- EIF4EBP3, ANKRA2, ANKRD13C, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA6, AP2B 1, AP4B 1-AS1, APAF l, APIP, APOA2, APP, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARSJ, ASAP1, ASIC 1, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG9A, A TM IN. ATP2A3, ATP2C1, ATXN! , ATXN3, AURKA, B3GALT2, B3GNT6, B4GALT2, BACEl, BAG2, BASPI, BC033281 , BCAR3, BCL2L15, BCYRNl, BECNl, BEND6, BHMT2, BICDl, ΒΓΝ1, BIN ^' , BIN3-IT1, BIRC3, BIRC6, BNC1, BNC2, BRCA1, BRCA2, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1QTNF9B-AS1, Clorf27, ClorfB6, C10orf54, CI lorfiO, Cllorf70, Cllorf73, Cllorf76, Cllorf94, C12orf4, C12orf56, C14orfl32, C17orf76-ASl, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34,

C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CAB, CA3, CAB39, CACNA2D2, CACNB1, CACNB4, CADMl, CADM2, CALU, CAMKK1, CAND2, CAPNSl, CASC3, CASP7,

CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDH18, CDKllB, CDK16, CDKALl, CDKNIC, CECR7, CELSRl, CEMIP, CENPI, CEP112, CEP162, CEP170, CEP192, CEP68, CFH, CFLAR, CUD 8, CHEK1, CHRM2, CIITA, CIZl, CLDN23, CLICl, CLK4, CLTA, CMAHP, CNGA4, CNOTl, CNRIPl, CNTDL CMSSl. CNOT7, CNRIPl, CNTN1, COG1, COL1A1, COL11A1, COL12AL COL14A1, COL15AL CGL5AL COL5A3, COL6A1, COL6A6, COL8A1, CGLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLFL CRLS1, CRTAP, CRX, CRYBG3, CRYLl, CSDE1, CSNK1A1, CSNK1E, CSNK1G1, CTDSP2, CTNND1, CTRC, CUL2, CUL4A, CUXl, CYB5B, CYB5R2, CYBRDl, CYGB, CYPIBI, CYP51A1, DAAML DAB 2, DACT , DAGLB, DARS, DAXX, DCAF10, DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDRl, DDX39B, DDX42, DDX50, DEGSL DENND1A, DENND1B, DENND4A, DENND5A, DEPTOR, DET1, DFNB59, DGCR2, DGK1, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DMD, DMXL1, DNAH8, DNAH11, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP 8, DSEL, DST, DSTN, DYNCIII, DYRKIA, DZIPIL, EBFl, EEAl, EEFlAl, EFCAB14, EFEMPl, EGRL EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, EN AH, ENG, ENOXl, ENPPl, ENPP2, ENSA, EP300, EPT1, ERCl, ERC2, ERCCl, ERCC8,

ERLIN2, ERRFIl, ESM1, ETV5, EVC, EVC2, EXO l , EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADSl, FADS2, FAFl, FAIM, FAM111 A, FAM126A, FAM13A, FAM160A1,

F AM 162 A, FAM174A, FAM195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARP1, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXO10, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFTL FDPS, PER, FEZ1, FGD4, FGD5-AS1, FGFR2, FGFRL1, FGL2, FHOD3, FLU, FLNB, FLT1, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOX 1, I ^' ASK FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNTL GALNT15, GAS7, GATA6, GBA2, GBGTl, GBPL GCFC2, GLCE, GCNT1, GDF6, GGACT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, G L3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPRI, GPRI 83, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM1, GR 6, GRTP1, GSE1, GTF2H2B, GTSF1, GUCA1B, GULP1, GXYLTl, HAPLN1, HAPLN2, HAS2, HAS3, HAT1, HAUS3, HAUS6, HAVCR2, FID AC 5, FID AC 7, HDX, HECTD2-AS1, F1EG1, HEPH, HEYl, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB1, HMGCR, HMGN3-AS1, HMGCS1, HMGXB4, HOOK3, HOXB3, HMOX1, HNMT, UNRNPR, HNRNPULl, HP1BP3, HPS1, FIRFI1,

HSD17B12, HSPA1L, HTATIP2, HTT, IARS, IDH1, IDI1, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, DBKAP, IL16, IL6ST, INA, FNFfflA, INO80, IPP4B, INPP5K, INSIGl, FNTU, INVS, IQCE, IQCG, ITCH, ITGAll, ITGA8, ITGAV, ITGB5, ITGB8, ITIHl, ITM2C, ΓΓΡΚΑ, ITSN1, rVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA 199, KIAAI456, KIAA1462, KIAA1522, KIAA1524, KIAA1549,

KLAA1715, KIAA1755, KIDINS220, KIF14, KIF2A, KIF21A, KIF3A, KIT, KLC1, KLC2, i.! ^; 17, KLF6, KLHL7, KLRG1, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB 1 , LAMB2P1, LARP4, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMSl, LINC00341, LFNC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINCOlOll, LINC01118, LINC01204, LINCR-0002, LING02, LMAN2L, LMNA, 1.M07. LMODI, LOC400927, LONPl, LOX, LPHNl, LRBA, LRCH4, LRIGI, LRP4, LRP8, LRRCl, LRRC32, LRRC39, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRMl, LZTS2, MACROD2, MAFB, MAGED4, MAGED4B, MAMDC2, MAN1 A2,

MAN2A1, MAN2C1, MANEA, MAP4K4, MAPK10, MAPK13, MARCH7, MARCH 8, MASPl, MB, MB21D2, MBD1, MBOAT7, MC4R, MCM IO, MDM2, MDN , MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl, MEPCE, MFGE8, MFN2, MIAT, MICAL2, ΜΓΝΡΡ1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLTIO, MLST8, M:MAB, MMPIO, MMP24, MMS19, MMS22L, MN1, MORF4L1, MOXD1, MPPE1, MPZL1, MRPL3, MRPL45, MRPL55, MRPS28, MRVI1, MSANTD3, MSG, MSH2, MSH4, MSI 1 MSL3, MSMOl, MSRB3, MTAP, MT:E¾F3, M:TERFD1, MTHFDIL, MTMR3, MTMR9, MTRR, MUM1, MVD, MVK, MXIL45, MYADM, MYB, MYCBP2, MYLK, MYOID, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOAI, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl, NEURLIB, NF2, NFASC, NFE2L1 , NFX1 , NGF, GFR, NHLH1 , NIDI, NID2, NIPA1, NKX3-1, NLGN1 , NLN, NOL10, NOM03, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRDl, NREP, NRGl, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, M PI . I , NUSAP1, OCLN, ODF2, OLR1, OS9, OSBPL3, OSBPL6, OSBPL10, OSMR, OXCTl , OXCT2, P4HA1, P4HB, PABPC l, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCCB, PCDH10, PCDHGB3, PCGF3, PCMl,

PCMTD2, PCNXL2, PCSK9, PDEIC, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1 , PDXDC2P, PEAR1, PELI1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRFl, PHTF2, PI4K2A, PIEZOL PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, ΡΪΜ2, PITPNA, PITPNB, ΡΓΓΡΝΜ1, ΡΓΓΡΝΜ3, PLAU, PLEC, PLEK2,

PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCRl, PLSCR3, PLXNB2, PLXNCl, PMS 1, PNISR, PGDN, POLE3, POLN, POLRIA, POLR3D, POMT2, POSTN, POU2F1, PPAPDC1 A, PPARA, PPARG, PPFIBP1, PPIP5K1, PPIP5K2, PPM1E, PPP1R12A, PPP1R26, PPP3CA, PPP6R1 , PPP6R2, PRKCA, PRKDC, PRKG1, PRMT1 , PRNP, PRPF3 1, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTCHl , PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1 , RAD9B, RAD23B, RAF1, RALB, RAP1GDS1, RAPGEF1, RARG, RARS, RARS2, RASIP1, RASSF8, RBBP8, RBCK1, RCOR3, RBFOX2, RBKS, RBM10, RDX, RERE, RFTN1 , RFWD2, RFX3-AS 1 , RGCC, RGL1 , RGS10, RGS3, RIF1, RNF14, RNF19A, RNFI30, RNF144A, RNF2I3, RNF38, RNFT1, RORI, ROR2, RPA1, RPF2, RPLIO, RPSIO, RPS6KB2, RPS6KC1, RRBPl, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCOl, SDCBP, SEC14L1, SEC22A, SEC 24 A, SEC24B, SEC6I A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SF3B3, SGIP1, SGK3, SGMS1, SGOL2, SGPLl , SH2B3, SH3RF1, SH3YL1, SHROOM3, SIGLEC10, SKA2, SKIL, SKP1, SLCI2A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3,

SLC39A10, SLC4A4, SLC4A11, SLC41A1 , SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A1 I, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHDI, SMG1, SMG1P3, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1, SORCS2, SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPINK5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBF l, SRGAP1, SRRMl, SRSF3, SSBP1, STAC2, STARD4, ST ATI , STAT3, STAT4, STAU1, STC2, STEAP2,

STK32B, S TRIADS, STRIP!, STRN4, STS, STX16, STXBP4, STXBP6, SULFl, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SY PO, SYNP02, SYNP02L, SYT15, SYTL2, TACC1 , TAF2, TAGLN3, TANC2, TANG06, TARBPl, TARS, TASPl , TBC1D I 5, TBCA, TBL1XR1, TBL2, TCP 12, TCF4, TCF7L2, TEKT4P2, TENC1, TENM2, TEPI, TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBRl, TGFBRAPl, TGM2, TH DA, ΤΉΑΡ4, THBS2, THRB, TIAM1, TIMP2, TJAP1 , TJP2, TLE3, TLKl, TMC3, TMEM67, TMEM102, TMEM1 19, TMEM134, TMEM154, TMEM! 89-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TMX3, TNC, T FAIP3, T FAIP8L3, TNFRSF 12A, TNFRSF14, TNIPl , TNKS1BP1, TNP03, TNRC 18P1, TNS1, TNS3, TNXB, TOEl, TOMM40, TOMM5, TOPORS, TP53AIP1, ΤΡ53ΓΝΡ1, TPRG1, TRAF3, TRA 1, TRAPPC12, TRIB 1, TRIM2, TRIM 23, TRIM26, TRIM28, TRIM65, TRIM66, TRMTIL, TRPC4, TRPSl, TSC2, TSHZl , TSHZ2, TSPAN11, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B,

TUBB2C, TUBB3, TUBE!., TXNIP, TXNLl, TXNL4B, TXNRD1, TYW5, U2SURP,

UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC13B, UNC5B, URGCP, URGCP-MRP S24, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VDAC2, VIM-ASl, VIPAS39, VPS 13 A, V S 29, VPS41, VPS5 I, VSTM2L, VWA8, WF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPF1 , WISP1, WNK1, WNT5B, WNT10B, WSB1, WWTR1 , XDH, XLAP, XRN2, YAPl, YDJC, YESl, YPEL5, YTHDF3, Z24749, ZAK, ZBTB IO, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHCl l, ZEB1, ZEB2, ZFAND1, ZFAND5, ZFP82, ZHX3, ZMIZ! , ZMIZ 1-AS1, ZMIZ2, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431 , ZNF583, Z F618, Z F621, ZNF652, Z F655, Z F660, ZNF674, ZNF680, ZNF730, Z F74, ZNF764, ZNF777, Z F778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 and ZSCAN25.

[00428] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a ceil or cell lysate containing a pre-mR A transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is not SMN2.

[00429] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a ceil or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is not selected from ABHDIO, ADAM 12, AKT1 , ANXA1 1 , APLP2, APPL2, ARMCX6, ATG5, AXIN1, BAIAP2, CCNBIIPI, CCT7, CEP 57, CSF1, DLGAP4, EPN1, ERGIC3, FOXMl, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN IB I , MRPL39, PCBP4, PPHLN1 , PRKACB, RAB23,

RAP1A, RCC1, SREK1, STRN3 and TNRC6A.

[00430] In another particular aspect, provided herein is a method for modifying RNA splicing in order to produce a mature mRNA transcript having an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3 ' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mR A transcript of a gene that is not selected from ABHDIO, ADAM 12, AKT1, ANXAI i, APLP2, APPL2, ARMCX6, ATG5, AXIN1, BAIAP2, CC B1IP1, CCT7, CEP57, CSFl, DLGAP4, EPN1, ERGIC3, FOXM1, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN1BI, MRPL39, PCBP4, PPHLN1, PRKACB, RAB23,

RAP1A, RCC1 , SMN2, SREK1 , STRN3 and TNRC6A,

[00431] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non- endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide.

[00432] In one aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide.

[00433] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide. In some aspects, the intron further comprises in 5' to 3' order: a 5' splice site, a branch point, and a 3' splice site upstream of the iREMS. In some aspects, the pre-mRNA transcript is encoded by a gene disclosed herein (e.g., in a table herein).

[00434] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre- mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS !, ADCY3, ADD1, ADGRG6, API 16, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1 , ARHGAP12, ARFIGEF 16, ARID5B, ARL15, ARL9, ARMCX6, ASIC l , ATG5, ATP2A3, ATXN1,

B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECNl, BHMT2, ΒΙΝ3-ΓΠ, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, Cl lorf70, Cl lorf94, C12orf4, C12orf56, C14orfl32, C 19orf47, Clorf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNBl, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP1 12, CLP 1 70, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL1 1A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNKIE, CSNKIGI, CYB5R2, CYGB, CYPIBI , DAGLB, DCAF17, DCLKl , DCN, DDIT4L, DDX50, DEGSl, DEPTGR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNCIII, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX20S, ENAH, ENPPl, EP300, ERCCl, ERCC8, ERGIC3, ERLIN2, ERRFIl, ESMl, EVC, EVC2, F2R, FAIM, FAM126A, F AM 13 A, F M 160 A 1 , F AM 162 A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHG1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GAL NT 1.5, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRIP I , GUCAIB, GULPl, GXYLT l , HAPLN1, HAPLN2, HA S3, HAVCR2, HDAC5, HDX, HECTD2-AS1 , HEPH, HEY1,

HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, 11. 1 , IN A, ΓΝΡΡ5Κ, INTU, IQCG, ITGA11, ITGA8, ITGB8, ΓΠΗ1, ITP A, LVD, KAT6B, KCNSL KCNS2, KDM6A, KDSR, KIAAI456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAPl-1 , KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LG12, LGR4, LHX9, LL C00472, LLNC0Q570, LINC00578, LINC00607, LLNC00678,

LINC00702, LINC00886, LINC00961, LINCOlOl 1 , LINCOl 118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD l , LYRM1, MAFB, MAMDC2, MAN2A1 , MAN2C1, MAPK13, MASPl, MB, MB21D2, MC4R, MCMI O, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1 , MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA,

NAALADL2, NAE1 , NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDEIC, PDE5A, PDGFD, PDGFRB, PDS5B, PEARl , PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCRl , PNISR, PGDN, POLN, POLRIA, POMT2, PPARG, PPIP5K2, PPMIE, PPP1R26, PPP3CA, PRKCA, PRKGl, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAFl, RAPGEF 1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1 , RGCC, ROR1 , ROR2, RPA 1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC IO, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A1 1 , SLC6A15, SLC7A1 1 , SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPAT A 18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAPl, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNP02, SYNP02L, TAGLN3,

TANG06, TASPl, TCF 12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAMl, TMC3, TMEM102, TMEMl 19, TMEM134, TMEM 189-UBE2V1 , TMEM214, TMEM256 -PL S CR3 , TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TR1M66, TRPC4, TSHZ2, TSPAN1 1 , TSPAN18, TSPAN7, TSSK.3, TTC7B, TUBE1, TXNTP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1 , WNK1 , WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZl- AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, and ZNF837. [00435] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exoi is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgumgn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFEl, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS 1 , APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, ΒΓΝ3-ΓΠ, BIRC3, BIRC6, BTG2, BTN3A1 , C 10orf54, Cl lorfJO, Cl lorf94, C12orf4,

C12orf56, C14orfl32, C 19orf47, Clorf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CAB, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122,

CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP 112, CEP 170, CEP192, CFH, CHEK 1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1 , COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLFl, CRYBG3, CRYLl, CSNK1 E, CSNKI GI, CYB5R2, CYGB, CYP1B 1, DAGLB, DCAF 17, DCLK1, DCN, DDIT4L, DDX50, DEGSl, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK! 1, DYXC ! l l . DYRK 1 A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX20S, EN AH, ENPPl, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, F AM 126 A, FAM13A, FAM160A1, FAM162A, F AM 174 A, 1 ^; A.\!20,\. FAM46B, FAM:65B, FAP, FARPl, FBLN2, FBN2, FBXL6, FCHOl, FGFR2, FGL2, FLT1, FRAS 1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1 , GCNTl, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTPl, GUCAIB, GULP1, GXYLT1, HAPLNl, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HEiCTD2-ASl, HEPH, HEY 1 , HMGA2, HMGN3-AS 1 , H MT, HOOK.3, HPS1, HSPAIL, ΗΤΑΊΊΡ2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, ΓΝΡΡ5 , INTO, IQCG, ITGA11, ITGA8, ITGB8, ΪΤΪΗ1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF 17, KLRGl, KMT2D, KRT7, KRTAPl- 1 , KRTAPl -5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LLNC00578, LINC00607, LTNC00678, LLNC00702, LINC00886, LTNC00961, LINCOlOl l, LINCOl 118, LINC01204, I . MOD I LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, I . SAMP, LUM, LYPDl, i .YRM i , MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCMIO, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1 , MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAEl , NAGS, NDNF, NGF, NGFR, M il . I I I . NLN, NOTCH3, NOTUM, NOVA2, NOX4, RROS, OCLN, 01. R i OSBPL10, 0XCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEARl, PHACTR3, PIGN, PIK3CD, PIK3R1 , PIKFYVE, ΡΪΜ2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PGDN, POLN, POLR1A, POMT2, PPARG,

PPIP5K2, PPMIE, PPP1R26, PPP3CA, PRKCA, PRKGl, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEFl, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, RORl, ROR2, RPAl , RPSI O, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHRGOM3, SIGLEC IO, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A1 1 , SLC6A15, SLC7A1 1 , SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1 , SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF 1 , SVEP1 , SYNGR2, SYNPO, SYNP02, SYNP02L, TAGLN3, TANGG6, TASP 1 , TCF 12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAMl, TMC3, TMEM102, TMEM1 19, TMEM134, TMEM189-UBE2V1 , TMEM:214, TMEM256-PL S CR3 , TMEM50B, TNFAIP8L3, TNFRSF 14, TNRC18P1, TNRC6A, TNXB, TP53 AIP1, TPRGl, TRIM66, TRPC4, TSHZ2, TSPANl l, T SPAN 18, TSPAN7, TSSK3, TTC7B, TUBEl, TXMP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-ASI, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNTIOB, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1 -AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, and ZNF837. In some aspects, the intron further comprises a first 5' splice site, a second branch point, and a second 3' splice site upstream of the iREMS. [00436] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature n RNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exoi is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgumgn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA1 ,

ABCAIO, ABCB7, ABCB8, ABCC1, ABCC3, ABHDIO, ABL2, ABLF 3, ACACA,

ACADVL, ACAT2, ACTA2, ADAL, AD AMI 2, ADAM 15, AD AMI 7, ADAM23, ADAM33, ADAMTS 1, ADAMTS19, ADCY3, ADD1, ADGRG6, ADH6, ADHFEl, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AKQ21888, A 310472, A AP1, A AP3, AKAP8L, AKAP9, AKNA, AKT1, ALCAM, ALDH4A1, AMPD2, ANK1, AN 2, ANK3, AN FY1 , ANKUD 1 -EIF4EBP3 , ANKRA2, ANKRD13C, ANKRD17,

ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXAl l , ANXA6, AP2B1, AP4B1-AS1, APAFI, APIP, APLP2, APOA2, APP, APPL2, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARMCX6, ARSJ, ASAP1, ASIC 1, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C 1 , ATXN 1, ATXN3, AURKA, AXIN1, B3GALT2, B3GNT6, B4GALT2, BACEl, BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYRN1, BECN1 , BEND6, BHMT2, BICDl, BIN1, BIN3, BIN3-IT1, BIRC3, BIRC6, BNC !, BNC2, BRCA1, BRCA2, BRD2, BRPF1, BSCL2, BTBD I O, BTG2, BTN3A1, BZW1, C1QTNF9B- AS 1, Clorf27, Clorf86, C 10orf54, Cl lorfiO, Cl lorf70, C l lorf73, CI lorf76, Cl lorf94, C12orf4, C12orf56, C 14orfl32, C17orf76-ASl, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orfi4, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CAI3, CA3, CAB 39, CACNA2D2, CACNB1, CACNB4, CADM , CADM2, CALU, CAM K1 , CAND2, CAPNS1, CASC3, CASP7, CASP8AP2, CAVI, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDHl l, CDH13, CD! 1 18. CDKl lB, CDK 16, CDKALl , CDKNI C, CECR7, CELSRl, CEMIP, CENPI, CEP 112, CEP 162, CEP 1 70, CEP 192, CEP57, CEP68, CFH, CFLAR, CHD8, CHEKl, CHRM2, CUT A, CIZL CLDN23, CLICL CLK4, CLTA, CMAHP, CNGA4, CNOTl, CNRIP1, CNTDL CMSSL CNOT7, CNRIP1, CNTN1, COGl , COL1 A1, (Oi l 1A1 ,

CGL12A1, COL14A1, CGL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1,

COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLSl , CRTAP, CRX, CRYBG3, CRYL1 , CSDEl , CSNKIAI, CSNK1E, CSNK1G1 ,

CTDSP2, CTNND1, CTRC, CUL2, CUL4A, CUXl , CYB5B, CYB5R2, CYBRDl, CYGB, CYP1B1, CYPS lAl, DAAMl, DAB2, DACTl, DAGLB, DARS, DAXX, DCAFI O, DCAFl l, DCAF 17, DCBLD2, DCLKI, DCN, DCUN1D4, DDAHl, DDAH2, DDHD2, DDIT4L, DDR 1. DDX39B, DDX42, DDX50, DEGS1, DENND1 A, DENND1.B, DENND4A, DENND5A, DEPTOR, DETI, DFNB59, DGCR2, DGKl, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1 , DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1 , DLG5, DLGAP4, DMD, DMXLL DNAH8, DNAH11, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK1 1, DPP 8, DSEL, DST, DSTN, DYNC1I1, DYRK1 A, DZIP IL, EBF1, EEAL EEF1A1, EFCAB14, EFEMP1 , EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF 2, ELM02, ELN, ELP4, EMX20S, EN AH, ENG, ENOX1, ENPP1, ENPP2, ENSA, EP300, EPNl, EPTl , ERCl, ERC2, ERCCl, ERCC8, ERGIC3, ERLIN2, ERRFIl, ESMl, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYAS, F2R, FADS1, FADS2, FAF1, FAIM, FAM1 1 1 A, F AM 126 A, F AM 13 A, FAM 160A1, F AM 162 A, F AM 74 A, FAM195B, FAM198B, FAM2QA, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FAR l, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXO10, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFTl, FDPS, FER, FEZl, FGD4, FGD5- AS1, FGFR2, FGFRLl , FGL2, FHOD3, FLU, FLNB, FLT1, FNl, FNBPl, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXMl , FRAS1, FSCN2, FUS, FYN, GABPB I , GAL3ST4, GALC, GALNT1 , GALNT15, GAS7, GATA6, GBA2, GBGT1, GBP1 , GCFC2, GLCE, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC l, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGB l, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM 1, GRK6, GRTP1, GSE1, GTF2H2B, GTSF1 , GUCAIB, GULP1, GXYLTl, HAPLNl, HAPLN2, HAS2, HAS3, HATI, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEY1, HLA-A, HLA-E, HLTF, l !MGA L HMGA2, HMGB l , HMGCR, HMGN3-AS1, HMGCS l , HMGXB4, HOOK3, HOXB3, HMOX1, HNMT, HNR PR, HNRNPUL1, HP 1 BPS, HPS1 , HRH1, HSD 1 7B12, HSD17B4, HSPAIL, HTATIP2, HTT, LARS, IDHl, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, IL16, IL6ST, IN A, INHBA, INO80, IPP4B, ΪΝΡΡ5Κ, INSIG1 , INTU, INVS, IQCE, IQCG, ITCH, ITGA11, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, CNS1, KCNS2, KDM6A, KDSR, IAA 1033, KIAAl 143, KIAA1199, KIAA1456, IAA1462, KIAA1522, KIAA1524, KIAA1549,

KIAAI715, KIAA1755, KIDINS220, IF14, KIF2A, KIF21 A, KIF3A, KIT, KLC1, KLC2, KLF17, KLF6, KLHL7, KLRG1 , KMT2D, KRT7, KRT 18, KRT I 9, KRT34, KRTAPl-1 , KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB l, LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS1, LI C00341, LINC00472, LLNC00570, LLNC00578, LINC00607, LLNC00657, LLNC00678, LINC00702, LINC00886, LINC00961, LINCOlOl l, LINC011 18, UNCO 1204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMOD1, LOC400927, LONP1, LOX, LPHN1, LRBA, LRCH4, LRIGl , LRP4, LRP8, LRRC1, LRRC32, LRRC39, LRRC42, LRRC8 A, LS AMP, LSS, LTBR, LUC7L2, LUM, LYPDl, LYRM1, LZTS2, MACROD2, MADD, MAFB, MAGED4,

MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1, MANEA, MAP4K4, MAPK O, MAPK13, MARCH7, MARCH 8, MASP1, MB, MB21D2, MBD1, MBOAT7, MC4R, MCMIO, MDM2, MDN1, MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMO 1 , MEPCE, MFGE8, MFN2, M i AT. MICAL2, MINPP1 , MIR612, MKL1, MK.LN1 , MKNK2, MLLT4, MILT 10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MNI, MORF4L1, MOXD1 , MPPE1, MPZL1, MRPL3, MRPL39, MRPL.45, MRPL55, MRPS28, MRVTl, MSANTD3, MSG, MSH2, MSH4, MSH6, MSL3, MSMOI, MSRB3, MTAP,

MTERF3, MTERFDl, MTHFDIL, MTMR3, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MY ADM, MYB, MYCBP2, MYLK, MY01D, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAY ! , NAV2, NCOAl, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl, NEURL1B, NF2, NFASC, NFE2L1, NFX1 , NGF, NGFR, NHLH1, NIDI, NID2, NIPAl, N X - L NLGN1, NLN, NOL10, NOM03, NOTCH3, NOTUM,

NOVA2, NOX4, NPEPPS, NRD1 , NREP, NRG1, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPLI, NUSAPl, OCLN, ODF2, OLRl, OS9, OSBPL3, OSBPL.6, OSBPL10, OSMR, OXCT1, OXCT2, P4HA1, P4HB, PABPC1 , PAIP2B, PA 4, PAPD4, PARD3, PARN, PARP14, PARP4, PA \ P, PAX6, PBLD, PBX3, PCBP2, PCBP4, PCCB, PCDHI O, PCDHGB3, PCGF3, PCMl , PCMTD2, PCNXL2, PCSK9, PDEIC, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC 1, PDXDC2P, PEAR1 , PELI1, PEPD, PEX5, PF P, PHACTR3, PHF19, PHF8, PHRF1 , PHTF2, PI4K2A, PIEZ01, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITP A, PITPNB, PiTPNMl, ΡΓΓΡΝΜ3, PLAU, PLEC, PLEK2, PLEKHA1 , PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1, PMSl , PNISR, PGDN, POLE3, POLN, POLR1A, POLR3D, POMT2, POSTN, POU2F1, PPAPDC1A, PPARA, PPARG, PPFIBPL PPHLN1, ΡΡΓΡ5Κ1 , PPIP5K2, PPM IE, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKGl , PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMCl, PSMD6, PSMD6-AS2, PTCH1, PTGIS, PTK.2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF1, RALB, RAP1A, RAPIGDSI , RAPGEFl, RARG, RARS, RARS2, RASIPl, RASSF8, RBBP8, RBCKl, RCOR3, RBFOX2, RBKS, RBMIO, RCCl, RDX, RERE, RFTNl, RFWD2, RFX3-AS1, RGCC, RGLl, RGSIO, RGS3, RIF1 , RNF14, RNF 19A, RNF 130, RNF144A, RNF213, RNF38, RNFT1, RORl, ROR2, RPA1, RPF2, RPL10, RPS10, RPS6KB2, RPS6KC1, RRBP1 , RWDD4, SAMD4 A, SAMD9, SAMD9L, SARI A, SART3, SC AF4, SCAF8, SCARNA9, SCD, SCLT , SCOl, SDCBP, SEC14L1 , SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SF3B3, SGIP1, SGK3, SGMSl, SGOL2, SGPL1, SH2B3, SH3RF1 , SH3YL1, SHROOM3, SIGLECIO, SKA2, SKIL, SKPl , SLC 12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A1 , SLC41A1 , SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8,

SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHDl, SMGl, SMG1P3, SMN2, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1, SORCS2, SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPINK5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBFl, SREKl , SRGAPl, SRRM1, SRSF3, SSBP1, STAC2, STARD4, STAT1, STAT3, STAT4, STAL L STC2,

STEAP2, ST 32B, S TRAD 8, STRIPl , STRN3, STRN4, STS, STX16, STXBP4, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SY ^' NP02, SYNP02L, SYT15, SYTL2, TACC 1, TAF2, TAGLN3, TANC2, TANG06, TARBP1 , TARS, TASP1, TBC1D15, TBCA, TBL1XR1, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1 , TENM2, TEP1, TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAP1, TGM2, THADA, THAP4, THBS2, THRB, TIAMl, 1ΊΜΡ2, TJAP1, TJP2, TLE3, TLK1, TMC3, TMEM67, TMEM102, TMEM119, TMEM134, TMEM154, TMEM 189-UBE2V1 , TMEM214, TME 256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, I ^' M RSI 14. I ^' M Pi T S1BP1, TNP03, TNRC18P1, TNRC6A, TNS1, TNS3, TNXB, TQEl, TOMM40, TOMM5, TQPQRS, TP53AIP1, ΤΡ53ΓΝΡ1, TPRG1, TRAF3, IRAKI, TRAPPC12, Ί RIB 1 , TRIM2, TRIM23, TRIM26, TRIM28, TRIM65,

TRIM66, TRMT1L, TRPC4, TRPSl, TSC2, TSHZ1, TSHZ2, TSPAN11, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBEl, TX IP, TXNL1, TXNL4B, TXNRD 1 , TYW5, U2SURP, UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC13B, UNC5B, URGCP, URGCP-MRPS24, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VDAC2, VIM-AS1, VIPAS39, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPF1, WISP1, WNK1, WNT5B, WNT10B, WSBl, WWTRl, XDH, XIAP, XRN2, YAPl, YDJC, YESl, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEBl, ZEB2, ZFANDl, ZFAND5, ZFP82, ZHX3, ZMLZ1, ZMIZ1-AS1, ZMIZ2, ZMYM2, ZNF12, ZNF138, ZNF148, Z F208, ZNF212, ZNF219, Z F227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, Z F281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431, ZNF583, Z F618, ZNF621, ZNF652, Z F655, ZNF660, Z F674, Z F680, ZNF730, ZNF74, ZNF764, ZNF777, ZNF778, ZNF780A, ZNF7804A, ZNF79, ZNF827, Z F836, Z F837, ZNF839, Z F91 and ZSCAN25.

[00437] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from APOA2, ASAP , BRCA1, BRCA2, CDKN1C, CRX, CTRC, DENND5A, DIAPH3, DMD, DNAH1 1, EIF2B3, GALC, HPS1, ! i l l ^' . I BKAP, KIAA1524, LMNA, MECP2, PAPD4, PAX6, PCCB, ΡΓΓ ΝΒ, PTCH1, SLC34A3, SMN2, SPINK5, SREK1, TMEM67, VWF, XDH and XRN2.

[00438] In a particular aspect, provided herein is a method for modifying UNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method compri sing contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the ititron and a second ex on is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgumgn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA1 ,

ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM 15, ADAM 17, ADAM23, ADAM33, ADAMTS 1, ADAMTS19, ADCY3, ADDl, ADGRG6, ADH6, ADHFEl, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC 1, AHRR, AJUBA, AK021888, AK310472, AKAPl, AKAP3, AKAP8L, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, AN 1, ANK2, AN 3, ANKFYI , ANKHD1- EIF4EBP3, ANKRA2, ANKRD13C, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA6, AP2B 1, AP4B 1 -AS1 , APAF1, APIP, APOA2, APP, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF 16, ARID 1 A, ARID2, ARID5B, ARL9, ARE 15, ARL5B, ARMCX3, ARSJ, ASAP1, ASIC 1, ASL, ASNS, ASP! I, ATAD2B, ATF6, ATF7IP, ATG9A, ΑΤΜΓΝ, ATP2A3, ATP2C1, ATXNl, ATXN3, AURKA, B3GALT2, B3GNT6, B4GALT2, BACEl, BAG2, BASPl, BC033281 , BCAR3, BCL2L15, BCYRNl, BECNl, BEND6, BHMT2, BICDl, BIN1, BIN3, ΒΓΝ3 ΊΠ , BIRC3, BIRC6, BNC l, BNC2, BRCA1, BRCA2, BRD2, BRPFl, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1QTNF9B-AS1, Clorf27, Clorf86, Cl()orf54, Cl lorGO, C 1 1 orf70, CI l orf73, CI l orf76, CI l orf94, C12orf4, C12orf56, C14orfl32, C17orf76-AS l, C 19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34,

C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CA13, CA3, CAB 39, CACNA2D2, CACNB 1 , CACNB4, CADMl, CADM2, CALU, CAMKK1 , CAND2, CAPNS1, CASC3, CASP7, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2,

CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH1 1, CDH13, CDH18, CDK1 IB, CDK16, CD AL1 , CDKN1C, CECR7, CELSR1, CEMIP, CE PI, CEP 112, CEP162, CEP170, CEP192, CEP68, CFH, CFLAR, CHD8, CHEK1, CHRM2, CIITA, CIZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, ( NO I I , C RIP1 , CNTD1 , CMSS1 , CNOT7, CNRIP1 , CNTN1, COG1, COL1A1, COL 1A1, COL12A1, COL14A1, COL15A1, COL5A1 , COLS A3, COL6A1, COL6A6, COL8A1, COLEC12, COM P. COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF 1 , CRLS1, CRTAP, CRX, CRYBG3, CRYL1 , CSDE1, CSNKlAl, CSNK1E, CSNK1G1, CTDSP2, CTNND1, CTRC, CUL2, CUL4A, CUX1 , CYB5B, CYB5R2, CYBRDl, CYGB, CYP1 B1, CYP51 Al, DA AMI , DAB2, DACT1, DAGLB, DARS, DAXX, DCAF10, DC AF 11, DCAF17, DCBLD2, DCLK1, DCN, DCUN 1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGS1 , DENNDIA, DE ND1B, DE ND4A, DENND5A, DEPTOR, DET1, DFNB59, DGCR2, DGK1, DGKA, DHCR24, DHCR7, DHFR, DHX9, 1)1 API I I . DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DMD, DMXL1 , DNAH8, DNAHl l, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK ! 1, DPP 8, DSEL, DST, DSTN, DYNC IH, DYRK1A, DZIP1L, EBF , EEA1, EEF1A1, EFCAB14, EFEMP1, EGR1 , EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, ENAH, ENG, ENOX1, ENPP1, ENPP2, ENS A, EP300, EPT1, ERC1 , ERC2, ERCC1 , ERCC8,

ERLIN2, ERRFI1, ESM1, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADS1 , FADS2, FAF1, I A IM FAM111A, F AM 126 A, FAM13A, FAM160A1 ,

FAM162A, FAM174A, FAM195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARP1, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXOIO, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFT1, 1 DPS _; PER, FEZl, FGD4, FGD5-AS1, FGFR2, FGFRL1, FGL2, FHOD3, FLU, FLNB, FLT1, FNI, FNBPl, FOCAD, FOS, FOSB, FOSLI, FOXK1, FRASl , FSCN2, FUS, FYN, GABPB l, GAL3ST4, GALC, GALNTl, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBP1, GCFC2, GLCE, GCNTl , GDF6, GGACT, GHDC, GIGYF2, GJC1 , GLCE, GMIP, GNA 13, GNAQ, GNAS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGB l, GORASPl, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM l, GRK6, GRTPl, GSEl, GTF2H2B, GTSF1, GUCA1B, GULP1, GXYLT1, HAPLNl, HAPLN2, HAS2, HA S3, HAT1 , HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEY1, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB1, HMGCR, HMGN3-ASI, HMGCS1, HMGXB4, HOOK3, HOXB3, HMOX1, HNMT, HNRNPR, HNRNPUL1, H 1BP3, HPS1, HRHl,

HSD17B12, HSPAIL, HTATIP2, HTT, LARS, IDHl, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, 31.16. IL6ST, IN A, INHBA, INO80, IPP4B, INPP5K, INSIG1, INTU, INVS, IQCE, IQCG, ITCH, ITGAl l, ITGA8, ITGAV, ITGB5, ITGB8, ΪΊΊΗ1, ITM2C, ITPKA,

ITSN1, I YD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, IAA1199, KLAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549,

KIAA1715, KIAA1755, KIDINS220, KIF14, IF2A, KIF21A, KIF3A, KIT, KLCl, KLC2, KLF17, KLF6, KLHL.7, KLRG1, KMT2D, KRT7, KRT18, RT19, KRT34, KRTAPl-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMBl, LAMB2P1, LARP4, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, L.GR4, LHX9, LIMS1, LINC00341, LINC00472, LINC0057Q, LINC00578, LINC00607, LINC00657, LINC0Q678, ί INC ^' 00702. LINC00886, LINC0096I, LINCOlOl 1, LL CO! 118, LINC01204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMODl, LOC400927, LONP1, LOX, LPHN1, LRBA, LRCH4, LRIG1, LRI>4, LRP8, LRRC1, LRRC32, LRRC39, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, l.YRMI. LZTS2, MACROD2, MAFB, MAGED4, MAGED4B, MAMDC2, MA 1A2,

MAN2A1, MAN2C1, MANE A, MAP4K4, MAPKI0, MAPK13, MARCH7, MARCH8,

M.ASP1, MB, MB21D2, MBD1, MBO.AT7, MC4R, MCM10, MDM2, MDN1, MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl, MEPCE, MFGE8, MFN2, MI AT, MICAL2, ΜΓΝΡΡ1, MIR6 2, MKL1, MKLN , MKNK2, ML.LT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MN1, MORF4L1, MOXD1, MPPE1, MPZL1, MRPL3, MRPL45, MRPL55, MRPS28, MRVIl, MSANTD3, MSG, MSI 12, MSI 14. MSH6, M:SL3, MSMOl, MSRB3, MTAP, MTERF3, MTERFDl, MTHFD1L, MTMR3, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MY ADM, MYB, MYCBP2, MYLK, MYOID, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAEI, NAGS, NASP, NAVI, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOI, NEURL1B, NF2, NFASC, NFE2L1, NFX1, NGF, NGFR, NHLH1, NIDI, NID2, ΝΪΡΑ1, NKX3-1, LGN1, NLN, NOLIO, NOM03, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRDl, NREP, NRG I, NRROS, NSUN4, NT5C2, NT5E, NTNG1 , NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, OCLN, ODF2, OLRl, OS9, OSBPL3, OSBPL6, OSBPLIO, OSMR, OXCT1, OXCT2, P4HA1, IMS IB. PABPC l, PAIP2B, PAK4, PAPD4. PARD3, PARN, PAR 14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCCB, PCDH10, PCDHGB3, PCGF3, PCML

PCMTD2, PCNXL2, PCSK9, PDE1 C, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1, PDXDC2P, PEAR1, PELIL PEPD, PEX5, PFKP, PHACTR3, PHF 19, PHF8, PHRF1, PHTF2, PI4 2A, PIEZ01 , PIGN, PIGU, PIK3C2B, PI 3CD, PI 3R1 , PIKFYVE, ΡΓΜ2, ΡΓΓΡΝΑ, PITPNB, PITPNMl, ΡΓΓΡΝΜ3, PLAU, PLEC, PLEK2,

PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1, PMSl, PNISR, PGDN, POLE3, POLN, PQLR A, POLR3D, POM 1 2. POSTN, POU2F1 , PPAPDC l A, PPARA, PPARG, PPFIBPl, PPIP5K1, PPIP5K2, PPMIE, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKCA, PRKDC, PRKG1, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRU E2, PSMA4, PSMC l, PSMD6, PSMD6-AS2, PTCHl, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF I, RALB, RAPIGDS I, RAPGEFI, RARG, RARS, RARS2, RASIPl, RASSF8, RBBP8, RBCKl, RCOR3, RBFOX2, RBKS, RBMIO, RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGL1, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF 130, RNF144A, RNF213, RNF38, RNFTl, ROR1, ROR2, RPA1, RPF2, RPL10, RPS 10, RPS6KB2, RPS6KC1 , RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCOl, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61 A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1 , SF3B3, SGiP , SGK3, SGMS 1, SGOL2, SGPL1, SH2B3, SH3RF1, SH3YL1, SHROOM3, SIGLEC 10, SKA2, SKIL, SKP1, SLC12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A1 I, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A1 1, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1 , SMG , SMG1P3, SMOX, SM ³ D4, SM I N, SMYD3, SMYD5, SXAP23, SNED1, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCSl, SORCS2, SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPIN 5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBFl, SRGAPl, SRRMl, SRSF3, SSBP1 , STAC2, STARD4, STAT1, STAT3, STAT4, STAUl , STC2, STEAP2, STK32B, STRAD8, STRIP 1, STRN4, STS, STX16, STXBP4, STXBP6, SULF1, SUPT20H, SVEP1 , SYNE1 , SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC 1, TAF2, TAGL 3, TANC2, TANG06, TARBP1, TARS, TASPl, TBC1D15, TBCA, TBL1XR1, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1, TENM2, TEP1 , TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAP1, TGM2, THADA, THAP4, TUBS 2, THRB, TIAM1 , TIMP2, TJAP1, TJP2, TLE3, TLK 1, TMC3, TMEM67, TMEM102, TMEM119, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAJP8L3, TNFRSF12A, TNFRSF14, TNIPl, TNKS1BP1, TNP03, TNRC18P1, TNS1, TNS3, TNXB, TOE1, TOMM40, TO\IM . TOPORS, TP53A1P1, TP53INP1, TPRG1, TRAF3, IRA I , TRAPPC12, TRIBJ , TRIM2, TRIM23, TRIM20, TRIM28, TRIM65, TRIM60, TRMT1L, TRPC4, TRPS 1 , TSC2, TSHZ 1 , TSHZ2, TSPAN1 1 , TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B,

TUBB2C, TUBB3, TUBE1, TXNIP, TXNL1 , TXNL4B, TXNRD 1 , TYW5, U2SURP,

UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC13B, UNC5B, URGCP, URGCP-MRPS24, USP19, USP7, USP27X, UVRAG, VANGLl, VARS2, VAV2, VCL, VDAC2, VIM-AS1, VIPAS39, VPS 13 A, VPS29, VPS41 , VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPFl, VVISPI, WNKl, WNT5B, W XT I OB, WSBl, WWTR1, XDH, XIAP, XRN2, YAP1, YDJC, YESl, YPEL5, YTFIDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEBl, ZEB2, ZFAND1, ZFA D5, ZFP82, ZHX3, ZMIZ1, ZMIZl-AS l, ZMIZ2, ZMYM2, ZNF12, Z F138, ZNF148, Z F208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, Z F350, Z F37A, Z F37BP, Z F395, Z F426, ZNF431, ZNF583, ZNF618, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, Z F680, ZNF730, ZNF74, ZNF764, Z F777, Z F778, ZNF780A, Z F7804A, ZNF79, ZNF827, ZNF836, Z F837, Z F839, ZNF91 and ZSCAN25.

[00439] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exoi is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3 ' order; an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is not SMN2.

[00440] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is not selected from ABHD10, ADAMI2, AKTl, ANXAl l, APLP2, APPL2, ARMCX6, ATG5, AXINl, BAIAP2, CCNBIIPI, CCT7, CEP57, CSF 1, DLGAP4, EPNl, ERGIC3, FOXM1, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN1B1, MRPL39, PCBP4, PPHLN1, PRKACB, RAB23,

RAP 1 A, RCCl, SREKl, STRN3 and TNRC6A.

[00441] In a particular aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5' to 3' order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a branch point, and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is not selected from ABHD10, ADAMI2, AKTl, ANXAl l, APLP2, APPL2, ARMCX6, ATG5, AXINl, BAIAP2, CCNBIIPI, CCT7, CEP57, CSF1 , DLGAP4, EPNl , ERGIC3, FOXM1 , GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN IB 1, MRPL39, PCBP4, PPHLN1, PRKACB, RAB23,

RAP1 A, RCCl, SMN2, SREKl, STRN3 and TNRC6A. [00442] In certain aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is primary ceil(s) or cell(s) from a cell line. In some aspects, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a fibroblast(s), an immune ceil(s), or a muscle celi(s). In some enbodiments, the celi(s) contacted or cultured with a compound of Formula (I) or a form thereof is a cancer cell . Non-limiting examples of cell lines include 3T3, 4T1, 721 , 9L, A2780, A172, A20, A253, A431, A-549, ALC, B 16, B35, BCP-1 , BEAS-2B, bEnd.3, BHK, BR 293, BT20, BT483, BxPC3, C2C 12, C3H-10T1/2, C6/36, C6, Cal-27, CHO, COR-L23, COS, COV-434, CML Tl, CMT, CRL7030, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6, FM3, I f i 299, 1169, HB54, HB55, IICA2, HD-1994, ! ! !)!· . HEK-293, He! .a. Hepalclc7, i l l . -60. HMEC, Hs578T, HsS78Bst, I I I -29, HTB2, HUVEC, Jurkat, J558L, JY, K562, Ku8 I2, KCL22, KG1, KYOI, LNCap, Ma-Mel, MC-38, MCF-7, MCF-IOA, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK, MG63,

X 1OR/0 2R. MONO-MAC 6, MRC5, MTD- 1A, NCI-H69, NIH-3T3, NALM-1, NS0, NW-145, OPCN, OPCT, PNT-1A, PNT-2, Raji, RBL, RenCa, RIN-5F, RMA, Saos-2, Sf21, Sf9,

SH-SY5Y, SiHa, SKBR3, SKOV-3, T2, T-47D, T84, THP1, U373, U87, U937, VCaP, Vero, VERY, W138, WM39, WT-49, X63, YAC-1, and YAR cells. In one aspect, the cells are from a patient. In another aspect, the patient cells are GM03813 cells. In another aspect, the patient cells are GM04856, GM04857, GM09I97, GM04281, G\ 104022. GM07492 cells.

[00443] In certain aspects described herein, the cell(s) i s contacted or cultured with a compound of Formula (I) or a form thereof with a compound of Formula (I) or a form thereof for a period of 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours or more. In other aspects described herein, the cell(s) is contacted or cultured with a compound of Formula (I) or a form thereof with a compound of Formula (I) or a form thereof for a period of 15 minutes to 1 hour, 1 to 2 hours, 2 to 4 hours, 6 to 12 hours, 12 to 18 hours, 12 to 24 hours, 28 to 24 hours, 24 to 48 hours, 48 to 72 hours.

[00444] In certain aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 0.01 μΜ, 0.05 μΜ, 1 μΜ, 2 μΜ, 5 μΜ, 10 μΜ, 15 μΜ, 20 μΜ, 25 μΜ, 50 μΜ, 75 μΜ, 100 μΜ, or 150 μΜ. In other aspects described herein, the cell(s) i s contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 175 μΜ, 200 μΜ, 250 μΜ, 275 μΜ, 300 μΜ, 350 μΜ, 400 μΜ, 450 μΜ, 500 μΜ, 550 μΜ 600 μΜ, 650 μΜ, 700 μΜ, 750 μΜ, 800 μΜ, 850 μΜ, 900 μΜ, 950 μΜ or 1 ηιΜ. In some aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 5 nM, 10 M, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 450 nM, 500 nM:, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, or 950 nM. In certain aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is between 0,01 μΜ to 0.1 μΜ, 0. J μΜ to 1 μΜ, 1 μΜ to 50 μΜ, 50 μΜ to 100 μΜ, 100 μΜ to 500 μΜ, 500 μ.Μ to 1 nM, 1 M to 10 nM, 10 nM to 50 nM, 50 nM to 100 nM, 100 nM to 500 nM, 500 nM to 1000 nM. In certain aspects described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof that results in a substantial change in the amount of an RNA transcript (e.g., an mRNA transcript), an alternatively spliced variant, or an isoform of a gene (e.g., a gene described herein, infra).

[00445] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript contains in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second Y splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3 ' splice site.

[00446] In one aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. [00447] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REIMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript contains in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00448] In a particular aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene in a subject, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS (for example, an endogenous intronic REMS or a non-endogenous intronic REMS), the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent, and wherein the gene is selected from ABCA1 , ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM 12, AD AMI 5, ADAM 17, ADAM23, ADAM33, ADAMTS1, ADAMTS 19, ADCY3, ADD1 , ADGRG6, ADH6, ADHFE1 , AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC 1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP3, AKAP8L, AKAP9, AKNA, AKT1, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, ANK3, ANKFY1, ANKHD 1 -EIF4EB P3 , ANKRA2, ANKRD13C, ANKRD17,

ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA1 1 , ANXA6, AP2B 1, AP4B1-AS1, APAF , APIP, APLP2, APOA2, APP, API ³ !.2, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARMCX6, ARSJ, ASAP1, ASIC1 , ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C 1, ATXNI, ATXN3, AURKA, AXIN1, B3GALT2, B3GNT6, B4GALT2, BACE1 , BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYR 1 , BECNl, BEND6, BUM 1 2, BICDl, BIN1, BIN3, ΒΪΝ3-ΓΠ, BIRC3, BIRC6, BNC1, BNC2, BRCA1, BRCA2, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1QTNF9B- AS 1, Clorf27, Clorf86, C 10orf54, Cl lorBO, Cl lorf70, Cl lorf73, Cl lorf76, Cl lorf94, C12orf4, C12orf56, C14orfl32, C17orf76-ASl , C19orf47, C2orf47, C3, C4orf27, C5or£24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orfB8, C9orf69, CA13, CA3, CAB 39, CACNA2D2, CACNB1, CACNB4, CADM1, CADM2, CALU, CAM K1 , CAND2, CAP S1, CASC3, CASP7, CASP8AP2, CAV1 , CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDHl l, CDH13, CD! 1 18. CDKl lB, CDK16, CDKALl , CDKNI C, CECR7, CELSRl, CEMIP, CENPI, CEP 112, CEP162, CEP170, CEP192, CEP57, CEP68, CFH, CFLAR, CHD8, CHEK1, CHRM2, CIITA, CIZ1 , CL.DN23, CLIC K CLK4, CLTA, CMAHP, CNGA4, CNOT1 , CNRIP1, CNTDI, CMSSI, CNOT7, CNRIPI, CNTNl, COG1, CGL1A1, COL11A1,

COL12A1 , COL14A1, COL15A1 , COL5A1, COLS A3, COL6A1, COL6A6, COL8A1 ,

COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF l, CRLS 1 , CRTAP, CRX, CRYBG3, CRYL 1 , CSDEl, CSNK1A1, CSNK IE, CSNK1G1 ,

CTDSP2, CTNND1, CTRC, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRDl, CYGB, CYP1B1, CYP51AI, DAAMl, DAB2, DACTl, DAGLB, DARS, DA X. DCAF 10, DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN 1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDRl, DDX39B, DDX42, DDX50, DEGSI, DENNDIA, DENNDIB, DENND4A, DENND5A, DEPTOR, DET1 , DFNB59, DGCR2, DGK1, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DLGAP4, DMD, DM XL ! , DNAH8, DNAH11, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP 8, DSEL, DST, DSTN, DYNC1I1, DYRK1A, DZIP1L, EBF1, EEAl, EEF1A1, EFCAB14, EFEMP1 , EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, ENAH, ENG, ENOX1, ENPP1, ENPP2, ENSA, EP300, EPNl, EPTl , ERCl, ERC2, ERCCl, ERCC8, ERGIC3, ERLIN2, ERRFH, ESMl, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADS1, FADS2, FAF1, i AIM, FAMl l lA, F 4I26A, FAM13A, F 4I60AI, FAM162A, F AM 174 A, FAM195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARP1, FBLN2, FBN2, FBXL 16, FBXL6, FBX09, FBXO10, FBX018, FBX031 , FBX034, FBX09, FCHOl, FDFT1 , FDPS, FER, FEZ1 , FGD4, FGD5- AS1, FGFR2, FGFRLl, FGL2, FHOD3, FLU, FLNB, f- L I 1. FN1 , FNBP1, FOCAD, FOS, FOSB, FOSL1, FOX 1, FQXMl, FRAS1, FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBPl, GCFC2, GLCE, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRCSA, GPRC5B, GPSM2, GREMl, GRK6, GRTPl, GSEl, GTF2H2B, GTSFl, GUCAIB, GULP1, GXYLT1, HAPLNl, HAPLN2, HAS2, HA S3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, FIEY1, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGBl, HMGCR, HMGN3-AS1, HMGCSl, HMGXB4, HQOK3, HOXB3, FIMOX1, HNMT, HNRNPR, HNKNPUL1, HP1BP3, HPS1, !lRlii . HSD17B12, HSD17B4, HSPAIL, HTATIP2, HTT, IARS, IDHl, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, DBKAP, IL16, IL6ST, IN A, INHBA, ΓΝΟ80, IPP4B, ΓΝΡΡ5Κ, INSIGl, INTU, INVS, IQCE, IQCG, ITCH, ITGAll, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ΓΓΡΚΑ, ITSN1, rVD, KANSL3, KAT6B, KCNK2, KCNSl, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA 199, KIAAI456, KIAA1462, KIAA1522, KIAA1524, KIAA1549,

KIAA1715, KIAA1755, KIDINS220, KIF14, IF2A, KIF21A, KIF3A, KIT, KLC1, KLC2, KLF17, K !.]· ^" (:», KLHL7, KLRG1, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB1, LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMSl, LINC0034I, LINC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINCOIOI 1, LINCOl 118, LINC01204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, I. MOD! LOC400927, LONP , [.OX. LPHN1, LRBA, LRCH4, LRIG1, LRP4, LRP8, LRRC1, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRMl, LZTS2, MACROD2, MADD, MAFB, MAGED4,

MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C 1 , MANEA, MAP4K4, MAPK10, MAPK13, MARCH7, MARCH 8, MASPl, MB, MB21D2, MBDl, MBOAT7, MC4R, MCM O, MDM2, MDN1, MEAF6, MECP2, MEDl, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl, MEPCE, MFGE8, MFN2, MIAT, MICAL2, ΜΓΝΡΡ1, MIR612, MKL1, MKLN1, MKN 2, MLLT4, MLLT10, MLST8, M:MAB, MMPIO, MMP24, MMS19, MMS22L, MN1, MORF4L1, MOXD1, MPPEI, MPZLI, MRPL3, MRPL39, MRPL45, MRPL55, MRPS28, MRVIl, MSANTD3, MSG, MSI 12, MSII4. MSI 16, MSL3, MSMOl, MS B3, MTAP,

MTERF3, MTERFDl, MTHFDIL, MTMR3, MTMR9, MTRR, MUMl, MVD, MVK, MXRA5, MY ADM, MYB, MYCBP2, MYLK, MYOID, MY09B, MYOF, NA, AA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl, NEURL1B, NF2, NFASC, NFE2L1, NFX1 , NGF, NGFR, HLHl , NIDI, NID2, NIPAl, NK X - L NLGN1, NLN, NOL10, NOM03, NGTCH3, NOTUM,

NOVA2, NOX4, NPEPPS, NRD1 , NREP, NRG1, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NIJP35, NUP50, NUPLl , NUSAPl, OCLN, ODF2, OLRl, OS9, OSBPL3, OSBPL6, OSBPL10, OSMR, OXCTl, OXCT2, P4HA1, P4I1B, PABPC1, PAIP2B, PA 4, PAPD4, PARD3, PARN, PARP14, PARP4, PARYB, PAX6, PBLD, PBX3, PCBP2, PCBP4, PCCB, PCDH10, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDEIC, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC 1 , PDXDC2P, PEAR1, PELI1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZOl, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, ΡΪΜ2, PITPNA, ΡΓΓΡΝΒ, PITPNM1, PITPN 13, PLAU, PLEC, PLEK2, PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCRl, PLSCR3, PLXNB2, PLXNCl, PMSl , PNISR, PGDN, POLES, POLN, POLRI A, POLR3D, POMT2, POSTN, POU2F1, PPAPDC IA, PPARA, PPARG, PPFIBPl , PPHLNl , ΡΡΓΡ5Κ1 , PPIP5K2, PPMIE, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKGl, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTCH1, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF l, RALB, RAPl A, RAPIGDSI, RAPGEFl, RARG, RARS, RARS2, RASIPl, RASSF8, RBBP8, RBCKl, RCOR3, RBFOX2, RBKS, RBM10, RCCl, RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGLl, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF130, RNF144A, R.NF213, RNF38, RNFT1, ROR1, ROR2, RPAl, RPF2, RPL10, RPS 10, RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCOl, SDCBP, SEC14L1 , SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPDSE2, SF1, SF3B3, SGIP1, SGK3, SGMSl , SGOL2, SGPL1, SH2B3, SH3RF 1, SH3YL1, SHROOM3, SIGLECIO, SKA2, SKIL, SKP1, SLC12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8,

SLC7A1 1 , SLC9A3, SLITS, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1 , SMG1 , SMG1P3, SMN2, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, S X14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1, SORCS2,

SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPINK5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREKl , SRGAPl, SRRMl, SRSF3, SSBP1, STAC2, STARD4, STAT1, STAT3, STAT4, STAL L STC2,

STEAP2, ST 32B, S TRAD 8, STRIPl , STRN3, STRN4, STS, STX16, STXBP4, STXBP6, SULFl, SUPT20H, SVEP1, SY E1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC L TAF2, TAGLN3, TANC2, TANG06, TARBP1, TARS, TASPl, TBC1D15, TBCA, TBL1XR1, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1 , TENM2, TEPL TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBRL TGFBRAP 1 , TGM2, THADA, THAP4, THBS2, THRB, TIAM1 , TIMP2, TJAP1 , TJP2, TLE3, TL.K1 , TMC3, ! Ail 167. TMEM102, TMEM1 19, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, T MEM256 -PL S CR 3 , TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAIP8L3, TNFRSFI2A, TNFRSF14, TNIPl, TNKSIBPI, TNP03, TNRC 18P1, TNRC6A, TNS1, TNS3, TNXB, TOEl, TOMM40, TOMM5, TOPORS, TP53AIP1, TP53INP1, TPRG1, TRAP 3, TRAK1, TRAPPC 12, 1 RIB L TRIA12, TRIM23, TRIM26, TRIM28, TRTM65,

TRIM66, TRMTIL, TRPC4, TRPS1, TSC2, TSHZL TSFIZ2, TSPANl l, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBE1, TXNIP, TXNLl , TXNL4B, TXNRD1, TYW5, U2SURP, LIBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHM 1, UHRF1BP1 L, UNC13B, UNC5B, URGCP, URGCP-MRPS24, LISP 19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VDAC2, VTM-AS l, VIPAS39, VPS 13 A, VPS29, VPS41 , VPS51 , VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPFl, WISPl, WNK1, WNT5B, WNTIOB, WSB I, WWTRl , XDH, XIAP, XRN2, YAPl, YDJC, YESl, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC l 1, ZEB l, ZEB2, ZFANDl , ZFAND5, ZFP82, 71 1X3. ZMIZ I, ZMIZl-ASl, ZMIZ2, ZMYM2, ZNF12, ZNF138, ZNFT48, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431 , ZNF583, ZNF618, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF730, ZNF74, ZNF764, ZNF777, ZNF778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 and ZSCAN25. [00449] In a specific aspect of the foregoing, the precursor RNA transcript contains in 5' to 3 ' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect of the foregoing, the precursor RNA transcript contains in 5' to 3' order; a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect of the foregoing, the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00450] In another specific aspect of the foregoing, the gene is selected from ABCAl, ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABHD10, ABL2, ABLIM3, ACACA,

ACADVL, ACAT2, ACTA2, A DAL ADAM 12, AD AMI 5, ADAM 17, ADAM33, ADAMTS !, ADCY3, ADD1 , ADGRGo, ADH6, ADHFEI , AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC 1, AHRR, AJUBA, AK021888, AK3 I0472, AKAP1, AKAP3, AKAP9, AKNA, ALCAM, ALDH4A1 , AMPD2, ANK.1 , ANK2, ANK3, ANKFY1 , ANKHD1 - EIF4EBP3, A RA2, A KRD17, A RD33B, ANKRD36, A S6, ANP32A, ANXAl 1, ANXA6, AP2B 1 , AP4B 1-AS1, APAF 1, APIP, APLP2, APP, APPL2, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15,

ARMCX3, ARMCX6, ASAPl, ASIC1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C1, ATXN1, ATXN3, AURKA, AXIN1, B3GALT2, B3GNT6, B4GALT2, BACEl, BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYRN1, BECN1 , BEND6, BHMT2, BICDl , BIN1 , ΒΙΝ3-ΓΠ , BIRC3, BIRC6, BNC1, BRD2, BRPFl, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, Clorf86, C 10orf54, Cl lorOO, Cl lorf70,

CI l orf73, CI lorf94, C12orf4, C12orf56, C14orfl32, C17orf76-ASl, C19orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CA13, CA3, CAB 39, CACNA2D2, CACNB 1, CADMl, CALU, CAMKK1, CAND2, CAPNS 1, CASC3, CASP7, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH1 1 , CDH 13, CDKl lB, CDK16, CDKALl, CECR7, CELSRl, CEMIP, CENPI, CEP 112, CEP170, CEP 192, CEP68, CFH, CFLAR, CHD8, CHEK1, CUT A, CIZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CNOTI , CNRIPl , CNTDI , COG1, COLlAl , COLl l Al, COL12A1 , COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1, COLEC 12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1, CRTAP, CRYBG3, CRYL1, CSDE1, CSNK1A1, CSNKIE, CSNK1G1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYP1B1, CYP51A1, DAB2, DACT1, DAGLB, BARS, DAXX, DCAF10, DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAH1 , DDAH2, DDHD2, DDIT4L, DDR1 , DDX39B, DDX42, DDX50, DEGS1,

DENND1A, DE ND1B, DENND5A, DEPTGR, DFNB59, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1,

DOCK ! 1, DPP 8, DSEL, DST, DSTN, DYNCIH, DYRK1A, DZIP1L, EBF 1, EEA1, EEF1A1, EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELN, ELP4, EMX20S, EN AH, ENG, ENPPl, ENPP2, ENSA, EP300, EPNl, EPTl, ERCl, ERCCl, ERCC8, ERGIC3, ERLIN2, ERRFIl, ESM , ETV5, EVC, EVC2, EXOl, EXTL2, EYA3, F2R, FADS 1, FADS2, FAF 1, FAIM, FAMI I IA, FAM126A, Ι- ΛΜ Ι 3 Λ. FAM160A1, FAM162A, FAM174A, FAM198B, FAM20A, FAM219A, FAM219B, FAM3C, FAM46B, FAM65A, FAM65B, FAP, FARPl, FBLN2, FBN2, FBX09, FBXL6, FBXO10, FBX018, FBX031, FBX034, FBX09, FCHOl , FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFR2, FGFRL1 , FGL2, FHOD3, FLU, FLNB, FLT1, FN1, FNBPl, FOCAD, FOS, FOSB, FOSL1, FOXK1 , FOXM1, FRASl, FSCN2, FUS, FYN, GABPBl, GAL3ST4, GALC, GALNTl, GALNT15, GAS7, GATA6, GBA2, GBGT1, GCFC2, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB 1, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM1 , GR 6, GRTP1 , GSEl, GTF2H2B, GUCAIB, GULP1, GXYLTl, HAPLN1, HAPLN2, HAS2, HAS3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1 , HEG1 , HEPH, HEY1 , HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB 1, HMGCR, HMGN3-AS1, HMGCSl, HOOK3, HMOX1, HNMT, HNRNPR, HNRNPULl, HP1BP3, HPS1, HRHl, HSD17B 12, HSD 7B4, HSPAlL, ΗΤΑΊΊΡ2, H I T, IARS, IDHl, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IL16, IL6ST, INA, INHBA, INPP5K, INSIGl, INTU, IQCE, IQCG, ITGAl 1, ITGA8, ITGAV, ITGB5, ITGB8, ITIHl, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1 I43, KIAAI I99, KIAA1456,

KIAA1462, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIAA1755, KIF 14, KIF2A, KIF3A, KIT, KLCl, KLC2, KLFI7, KLF6, KLHL7, KLRGl, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAP1 -5, KRTAP2-3, L3MBTL2, LAMA2, LAMB 1 , LAMB2P1 , LARI>4, I.A P7, LATS2, LDLR, LEMD3, LETM2, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINCQG341, LINC00472, LINC00570, LINCQG578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC0096L LINCOlOl l, LINC01118, LINC012Q4, LMAN2L, LM07, LMOD1, LOC400927, LONP1, LOX, LRBA, LRCH4, LRIG1 , LRP4, LRP8, L.RRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRM1, LZTS2, MADD, MAFB, MA.GED4, MAGED4B, MAMDC2, MAN1A2, MAN2A1, MA.N2C1, MAP4K4, MAPK13, MASP1, MB, MB21D2, MBD1, MBOAT7, MC4R, MCM10, MDM2, MEDl, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl , MEPCE, MFGE8, MFN2, MIAT, MICAL2, ΜΓΝΡΡ1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMPIO, MMP24, MMS 19, MMS22L, MN1 , MOXD1, MPPEi, MPZL1, MR P! .3. MRPL45, MRPL55, MR S 28, MRVI 1, MSANTD3, MSG, MSH2, MSH4, M SI 16, MSL3, MSMOl, MSRB3, MTAP, MTERF3, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MY ADM, MYCBP2, MYLK, MYOID, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NELFA, NEOl, NEURL1B, NF2, NFE2L1, NFX1, NGF, NGFR, NHLH1, NIDI, NID2, NffAl, NKX3-1, NLN, N( )] . ! (). NOM03, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRDl, NREP, NRGl, NRROS, NSUN4, NT5C2, NT5E, NTNGl , NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, OCLN, ODF2, OLR1, OS9, OSBPL6, OSBPL10, OSMR, OXCT1, OXCT2, P4HAL P4HB, PABPC1, PAIP2B, PAK4, PAPD4, PARD3, PARN,

PARP14, PARP4, PARVB, PBLD, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1 , PCMTD2, PCNXL2, PCSK9, PDEIC, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1 , PEAR1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1 , PHTF2, PI4K2A PIEZOl, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNMl, PITPNM3, PLAU, PLEC, PI I K . PLEKHAl , PLEKHA6, PLEKHB2, PLEKITH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1, PMSl , PNISR, PGDN, POLE3, POLN, POLR1A, POLR3D, POMT2, POSTN, POU2F1, PPAPDCIA PPARA, PPARG, PPHLN1, PPIP5K1, PPIP5K2, PPM1E, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKGl, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1 , PSMD6, PSMD6-AS2, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKL RAB23, R.AB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF 1 , RALB, RAP1 A, RAP1 GDS1, RAPGEF1 , RARG, RARS, RARS2, RASSF8, RBBP8, RBCK1, RBFOX2, RBKS, RBMIO, RCCl, RDX, RERE, RFTN1 , RFWD2, RF ^' X3-AS1 , RGCC, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFTl, ROR1, ROR2, RPA1 , R I. I O. RPS10, RPS6KB2, RPS6KC1, RRBPL RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1 , SCOl, SDCBP, SEC14L1 , SEC 22 A, SEC24A, SEC24B, SEC61A1, SE P6, SEPT9, SERGEF, SERPL E2, SFL SGK3, SGOL2, SH3RF1 , SH3YL1 , SHROOM3, SIGLEC10, SKA2, SKIL, SLC12A2, SLC24A3, SLC25A17, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMPD4, SMTN, SMYD3, SMYD5, SN P23, SNED 1, SNHG16, SNX7, SNX14, SOCS2, SON, SORBS2, SORCS2, SOS2, SOX7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPRED2, SPRYD7, SOLE, SQRDL, SQSTM1, SRCAP, SREBFL SREK1, SRGAP1, SRRM1, SRSF3, STAC2, STARD4, STAT1, STAT3, STAT4, STAU1 , STC2, STEAP2, STK32B, STRIP 1, STRN3, STRN4, STS, STX16, STXBP6, SULFL SUPT20FL SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACCL TAF2, TAGLN3, TANC2, TANG06, TARBPI, TARS, TASPL TBC1D15, TBL2, TCF12, TCF4, TCF7L2, TENCL TENM2, TEP1 , TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAPL TGM2, THADA, 1 1 1 MM. THBS2, S1 IRB. TLAM1, TIMP2, TJP2, TLE3, TLK l , TMC3, TMEM102, TMEM119,

TMEM134, TMEMI54, TMEMl 89-UBE2V1 , TMEM214, TMEM256-PL SCR3 , TMEM47, TMEM50B, TMEM63A, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, Ί XI· SI 14, TNIPl , TNKS1BP1, TNP03, TNRC18P1, TNRC6A, TNSL TNS3, TNXB, TOE1, TOMM40, TOMM5, TOPORS, TP53AIPL TP53INP1, TPRG L TRAF3, TRAK1 , TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMTIL, TRPC4, TRPSL TSC2, TSHZ1, TSHZ2, TSPAN1 1, T SPAN 18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TlJBEl, TXNTP, TXNLl, TXNRDI, TYW5, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UFIMKl , UHRF IBPIL, UNC5B, URGCP, LISP 19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VTM-AS1, VIPAS39, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR91, WIPFL WISP1, WN 1, WNT5B, WNT10B, WSBL WWTR1, XIAP, XRN2, YAP1, YDJC, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTBIO, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC 1 1 , ZEB1 , ZEB2, ZFAND1 , ZFAND5, ZFP82, ZHX3, ZMIZ1, ZMIZ1-AS1, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF431, ZNF583, ZNF62L ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF79, ZNF827, ZNF837, ZNF839 and ZNF91 .

[00451] In another specific aspect of the foregoing, the gene is selected from ABCAl, ABCB7, ABCC1, ABHD10, ABL2, ABLIM3, AC AC A, ACADVL, ACAT2, ADAM 12, ADAM 15, AD AM 7, ADAM33, AFF2, AGK, AGPAT3, AGPS, AHCYL2, ΛΙ ΙΙΧΊ . AHRR, AJUBA, AK021888, AK310472, AKAP1 , AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK2, ANKFY1, ANKUD 1 -EIF4EBP3 , ANKRD17, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, APAF 1, APLP2, APP, APPL2, APTX, ARHGAP22, ARID 1 A, ARID2, ARMCX3, ASAP1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG9A, ΑΤΜΪΝ, ATP2C1, ATXN3, AURKA, AXINl, B4GALT2, BACEl, BAG2, BASPl, BC03328L BCAR3, BEND6, BICDl, BINl, BNCl , BRD2, BRPF , BSCL.2, BTBDIO, BZWl, C I l orf30, CI l orf73, C17orf76-ASl , C4orf27, C5orf24, C6orf48, C9orf69, CAB39, CALU, CAMKK1, CAPNSl, CASC3,

CASP8AP2, CAV1, CCAR1, CCDC77, CCDC88A, CCDC92, CCT6A, CD276, CD46,

CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK I 6, CDKALl, CEP68, CFLAR, CFID8, CIZI, CLICl, CLK4, CNOT1, COG1, COL 12A1, COLl Al, COL6A1, COPS7B, CPEB2, CREB5, CRLSl , CRTAP, CSDE1, CSN 1A1 , CTDSP2, CTNNDl, CUL2, CUL4A, CUX1, CYB5B, CYBRD1, CYP5 IA1, DAB2, DACT1, DARS, DAXX, DCAFIO, DCAF1 1 , DCBLD2, DCUN1D4, DDAH1, DDAH2, DDHD2, DDR1, DDX39B, DDX42, DENNDIA, DENND1B, DENND5A, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1 , DIAPH3, DIS3L, DKFZp434M1735, DKK3, DLCI , DNM2, DOCK1 , DPP8, DSEL, DST, DSTN, EBFl, EEAl, EEFIAI, EFCAB14, EGRl, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ENG, ENPP2, ENSA, EPNl, EPT1, ERC1, ERGIC3, ETV5, EXOl , EXTL2, EYA3, FADS1, l ^; ADS2. FAFl, FAMl l lA, FAM198B, FAM219A, FAM219B, FAM3C, FAM65 A, FBXO10, FBX018, FBX031, FBX034, FBX09, FDFT1, 1 DPS, FER, FEZ 1, FGD5-AS1, FGFRL1, FHOD3, FLU, FLNB, FN1, FNBPl, FOCAD, FOS, FOSB, FOSL1, FOXKI, FOXM1, FUS, FYN, GABPB 1, GALC, GALNTI, GAS7, GBA2, GCFC2, GGCT, GHDC, GIGYF2, GJC1, GMIP, GNA13, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASPl, GPR1, GPR89A, GPSM2, GREMI, GRK6, GSE1, GTF2H2B, HAS2, HAT1, HAUS3, HAUS6, HDAC7, HEG1 , HLA-A, HLA-E, HLTF, HMGA1 , HMGB1, HMGCR, HMGCS l , HMOXl, HNRNPR, HNRNPULl, HP1BP3, HRHl , HSD17B12, HSD 1 7B4, HTT, IARS, IDHI, IDIl, IGF2BP2, IL6ST, INHBA, INSIGl, IQCE, ITGAV, ITGB5, ITM2C, ITSNl, KANSL3, KCNK2, KIAAI033, KIAA1 143, KIAA1199, KIAA1522, KIAAI 524, KIAA1549, KIAA1715, ΚΙΠ 4. KIF2A, KIF3A, KLC1 , L.C2, KLF6, KLFIL7, KRT18, KRT19, KRT34, KRTAP2-3, LAMA2, LAMBl, LARP4, LARP7, LATS2, LDLR, LEMD3, LGALS8, LIMS1, LINC00341, LINC00657, LMAN2L, LM07, [.ON P L LOX, LRCH4, LRIG1 , LRP8, LRRC8A, LSS, LTBR, LUC7L2, LZTS2, MADD, MAGED4, MAGED4B, ΜΑΝΊΑ2, MAP4K4, MBD l , MBOAT7, MDM2, MED I, MED AG, MEF2D, MEIS2, MEMOl , MEPCE, MFGE8, MICAL2, ΜΓΝΡΡ1 , MKL1, M LN1, MKNK2, MLLT4, MLST8, MMAB, MMS19, MMS22L, MPP ! , MPZL1 , MRPL3, MSANTD3, MSG, MSH2, MSI 16, MSL3, MSMOl, MSRB3, MTAP, MTERFDl , MTHFD 1 L, MTMR9, MTRR, MUM1, MVD, MVK, MY ADM, MYLK, MYOID, MY09B, MYOF, NAA35, NADK, NASP, NAVl, NAV2, NCOAL NCOA3, NCOA4, NCSTN, NELFA, NEOl , NEURL1 B, NF2, NFE2L1, NFX1 , NIDI, NID2, ΝΓΡΑ1 , NKX3-1 , NO 1.10, NOM03, NPEPPS, NRD1, NREP, NRG1, NSUN4, NT5C2, NT5E, NTNGl, NUDT4, NUPI53, NUP35, NUP50, NUPL1, NUSAP1, ODF2, 0S9, OSBPL6, OSMR, P4HA1, P4HB, PABPCl , PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1 , PCMTD2, PCNXL2, PCSK9, PDE4A, PDE7A, PDLIM7, PDXDCL PEPD, PEX5, PFKP, PHF19, PHF ^: 8, PHRF ^' l , PHTF2, PI4K2A, PIEZOl, PIGU, PIK3C2B, PITPNA, PITPNB, PITPNMl, PLAU, PLEC, PLEKHB2, PLSCR3, PLXNB2, PLXNCl, PMSl, POLE3, POLR3D, POSTN, POU2F 1 , PPAPDC 1 A, PPARA, PPHLN1 , PPIP5K1 , PPP1 R12A, PPP6R1 , PPP6R2, PRKACB, PRKDC, PRMTl, PRNP, PRSS23, PSMA4, PSMC 1, PSMD6, PTK2B, PTPN14, PUF60, PUS7, PVR, PXN, QKI, RAB23, RAB2B, RAB34, RAD1 , RAD23B, RALB, RAP I A, RAPIGDSl, RARG, RASSF8, RBCK1, RBFOX2, RBM10, RCC1, RFTNL RFWD2, RGSIO, RGS3, RIF l , RNF14, RNF 19A, RNF38, RNFTl, RPL10, RPS6KC1, RRBPl, RWDD4, SAMD9, SAMD9L, SARI A, SA T3, SCAF4, SCAF8, SCD, SCLT1, SCOl, SDCBP,

SEC14L1, SEC22A, SEC24B, SEC61A1, SEPT9, SERPINE2, SF 1, SGOL2, SH3RF1, SKIL, SLC25A17, SLC39A3, SLC41A1, SLC4A4, SLC7A6, SLC7A8, SMARCA4, SM.\ C( 2, SMC4, SMC6, SMCHD1, SMG1, SMN2, SMPD4, SMYD3, SMYD5, SNAP23, SNHG16, SNX14, SOCS2, SON, SOS2, SPATA20, SPATS2, SPG20, SPRED2, SQLE, SQRDL,

SQSTM1, SRCAP, SREBFl, SREK1, SRSF3, STARD4, STATl, STAT3, STAU1, STC2, STEAP2, STRIP!, STRN3, SIX 16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TACC 1 , TAF2, TANC2, TARBP1, TARS, TBC1D15, TBL2, TCF7L2, TENC 1 , ΊΈΝΜ2, TEP1, TET3, TFCP2, TGFBI, TGFBR1, TGFBRAP1, THADA, THAP4, TURB, ΊΊΜΡ2, TJP2, TLE3, TLK1, TMEM154, TMEM47, TMEM63A, TNC, TNFAIP3, TNFRSF12A, I MP I . TNKS 1BP1, TNP03, TNS1, TNS3, TOE1, TOMM40, TOMM5, TOPORS, TP53INP1 , TRAF3, I RAK I , TRAPPC12, TRIB l, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRMT1L, TRPS1, TSC2, TSHZ1 , TSPAN2, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRD1, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRFIBPIL, UNC5B, USP19, USP7, VANGL1, VARS2, VCL, VIPAS39, VPS 13 A, VPS29, VPS51, VWA8, WDR19, WDR37, WDR48, WIPF1, WNT5B, WSB1, WWTRl , XIAP, XRN2, YAPl, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB IO, ZBTB24, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC l l, ZEBl, ZEB2, ZFAND1, ZFAND5, ZHX3, ZMIZ1 , ZMYM2, ZNF12, ZNF 148, ZNF219, ZNF227, ZNF24, ZNF268, Z F28, XX! 28 1 , Z F335, ZNF37A, Z F37BP, Z F395, ZNF583, ZNF621, ZNF652, ZNF655, ZNF674, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF827, Z F839 and Z F91.

[00452] In another specific aspect of the foregoing, the gene is selected from ABCB8, ANKRD36, APLP2, ARHGAP12, ARMCX6, ASAP1, ATG5, ΑΧΪΝ1, BIRC6, Clorf86, CDC42BPA, CLTA, DYRKIA, ERGIC3, FBXL6, FOXMl, GGCT, KAT6B, KDM6A, KIF3A, KMT2D, LARP7, LYRM1, MADD, MAN2C1, MRPL55, MYCBP2, MY09B, PNISR, RAP A, RAPGEF1, SENP6, SH3YL1, SLC25A17, SMN2, SREK1, STR 3, TAF2, TlViEM134, VPS29, ZFAND1 and ZNF431 ,

[00453] In another specific aspect of the foregoing, the gene is selected from ABCB8, ANKRD36, ARHGAP12, ARMCX6, ATG5, BIRC6, ClorfSo, CLTA, DYRK I A, FBXL6, KAT6B, KDM6A, KMT2D, LYRM1, MAN2C1, MRPL55, MYCBP2, PNISR, RAPGEF1, SENP6, SH3YL1, TMEM134 and ZNF431.

[00454] In another specific aspect of the foregoing, the gene is selected from ABCA I O, ABCC1, ACTA2, ADAL, AD AM 12, ADAMTS1, ADAMTS5, ADD1 , ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPS, AKAP3, ANK1, ANK2, ANK3, ANKRD33B, ANXAl l, ANXA6, AP4B 1-AS1, ARHGEF16, ARID5B, ARL9, ARMCX3, ASAP1, ASIC1, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYRN1 , ΒΙΝ3-ΓΠ , BIRC3, BTG2, C10orf54, Cl orf70, Cl lorf73, Cl lorf94, C 12orf56, C19orf47, C3, C4orf27, C7orf31, C8orf34, CAB, CA3, CACNA2D2, CACNB1 , CADM1 , CAND2, CCDC79, CCER2, CCNF, CDCA7, CDKAL1 , CELSRl, CEMIP, CEP170, CFH, CIITA, CLDN23, CMAHP, CNGA4, CNTDl, COLl lAl , COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP,

CPA4, CPQ, CRISPLD2, CRLFl, CRYL1, CUXL CYB5B, CYB5R2, CYGB, CYP1B1, DCLK1, DCN, DDIT4L, DDX42, DDX50, DEGS1, DENND1 A, DE ND5A, DEPTOR, DFNB59, DGKA, DHFR, DIAPH3, DIRAS3, DIS3L, DLG5, DNAH8, DNAJC27, DOCK1, DOCKl 1, DYNC1I1, DZIPIL, EBF1, EFEMP1, EGR3, EIF2B3, ELN, ELP4, EMX20S, ENPP1, ERCC8, ESM1, EVC2, F2R, FAM160A1, FAM198B, FAM20A, FAM46B, FA.\ii>5B, FAP, FARPl, FBLN2, FBN2, FBX09, FCHOl, FER, FGFR2, FGL2, FLT1, FRASl, FSCN2, GAL3ST4, GALC, GALNT15, GATA6, GBGTl, GCNT , GDF6, GNAQ, GOLGBl, GPR183, GPR50, GPRC5A, GPRC5B, GRTPl, GUCAIB, GXYLT1, HAPL l, HAPLN2, HAS3, HAVCR2, HDAC5, HECTD2-AS1, HEPH, HEY 1 , HLTF, HMGN3-AS1, HMOX1, HOOK3, HSD17B12, HSPAIL, HTATIP2, HTT, IGDCC4, IGF2R, IGFBP3, IL16, IN A, INTU, IQCG, ITGA11, ITGA8, ITGB8, ΠΊΗ1, ITPKA, KCNS1, KCNS2, K.DM6A, KDSR, KIAA1456, KIAA1462, KIAA1524, KIAA1715, KIAA1755, KIT, KLF17, KLRG1, KRT7, KRTAPl-1, KRTAP!-5, L3MBTL2, LAMB2PI, LGI2, LGR4, LFIX9, LINC00472, LINC00570,

LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINCOlOll, LINCOl 118, LINC01204, LMODl, LRBA, I RIM, LRRC32, LRRC39, LSAMP, LUM, LYPDl, LYRM , MAFB, MAMDC2, MAN1A2, MAN2A1, MARK 13. MASPl, MB, MC4R, MEDAG, MEGF6, MEMO I, MIAT, MIR612, MLLT10, MMP10, MMP24, \IMS19. MNI, MOXD1, MR VII, MSI 14, MTERF3, MXRA5, MYOID, NA, NAALADL2, AEl, NAGS, NDNF, NEURLIB, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, NTNG1, OCLN, OLR1, OSB LIO, OXCT2, PAIP2B, PAPD4, PBLD, PCM1, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PDXDC1, PEAR1, PEPD, PHACTR3, PI4K2B, PIK3R1, PIM2, PITPNB, PITPNM3, PLAU, PLEK2, PLEKHA6, PLEKI-U:I2, PLXNCl, PMSl, PGDN, POLN, POLRIA, POSTN, PPMIE, PPP3CA, PRKCA, PRKDC, PRKG1, PRPH2, PRRG4, PRUNE2, PSMD6- AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RCCI, RDX, RFWD2, RFX3-AS1, RGCC, RNFT1, ROR1, ROR2, RWDD4, SCARNA9, SCOl, SEC22A, SHROOM3, SIGLECIO, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SMYD3, SNED1, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, SQRDL, STAC2, STAT I, STAT4, STEAP2, STK32B, STRN4, STS,

STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNP02, SYNP02L, TAGLN3, TANG06, TARBP1, ΊΈΧ21Ρ, TGFA, TGFB2, TGFB3, TGM2, THADA, TFJBS2, THRB, TMEM102, TMEM119, TMEM256 -PL S CR3 , T MEMS OB, TNC, TNFAIP8L3, TNFRSF14, TNRC18P1, TNS3, TNXB, TP53AIPL TPRG1, TRAF3, TRIM66, TRPC4, TSHZ2, TSPAN11, T SPAN 18, TSPAN7, TSSK3, TXNIP, UNC5B, USP27X, UVRAG, VIM-AS1, VPS41, VSTM2L, VWA8, VWF, WDR91, WISP1, WNTIOB, XRN2, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-ASL ZNF212, ZNF350, ZNF660, ZNF79 and ZNF837,

[00455] In another specific aspect of the foregoing, the gene is selected from ABCA10, ACTA2, ADAL, ADAMTS 1 , ADAMTS5, ADD1, ADGRG6, ADH6, ADHFEl, AFF3, AKAP3, ANK1, ANK3, ANKRD33B, AP4B1-AS1, ARHGEF16, ARID5B, ARL9, ASIC1 , ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYRN1 , ΒΓΝ3-ΓΠ, BIRC3, BTG2, C10orf54, C l lorf70, Cl lorf94, C12orf56, C19orf47, C3, C7orf31 , C8orf34, CAB, CA3, CACNA2D2, CACNB 1, CADMl, CAND2, CCDC79, CCER2, CCNF, CELSRl, CEMIP, CEP170, CFH, CIITA, CLD 23, CMAHP, CNGA4, CNTD1, COL11A1 , COL14A1, COL15A1 , COL5A1, COL5A3, CGL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLFl, CRYL1, CTO5R2, CYGB, CYP1B1, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, D IRA S3, DLG5, DNAH8, DNAJC27, DOCK1 1, DYNC1I1, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX20S, ENPP1, ERCC8, ESM1 , EVC2, F2R, FAM160A1, FAM20A, FAM46B, FAM65B, FAP, FARP l , FBLN2, FBN2, FBX09, FCHOl, FGFR2, FGL2, FLT1, I ^' AS L FSCN2, GAL3ST4, GALNT15, GATA6, GBGTl, GCNTl, GDF6, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1 , GUCA1 B, GXYLT1, HAPLN1 , HAPL.N2, HAS3, HAVCR2, HDAC5, HECTD2-AS 1, HEPH, HEY1, HMGN3-AS1, HOOK3, HSPA1L, ΗΤΑΤΓΡ2, IGDCC4, IGF2R, IGFBP3, IL16, IN A, INTO, IQCG, ITGA1 1 , ITGA8, ITGB8, ΓΓΊΗ1, ITPKA, KCNS1 , K.CNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRGl, KRT7, KRTAPl- 1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, LINC00472, LINC00570,

LINC00578, LINC00607, L1NC00678, LINC00702, LINC00886, LINC00961, LINCO l Ol l, LINC01 118, LINC01204, LMODI, LRBA, I R IM, LRRC32, LRRC39, LSAMP, LUM, LYPDl, MAFB, MAMDC2, MAN2A1, MAPK13, MASP1, MB, MC4R, MEGF6, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MGXD1, MRVTL MSH4, MTERF3, MXRA5, NA,

NAALADL2, AEl, NAGS, NDNF, NGFR, NHLI-Il, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRRGS, OCLN, OLRl, GSBPLIO, OXCT2, PAIP2B, PBLD, PDEIC, PDE5A,

PDGFD, PDGFRB, PDS5B, PEAR1 , PHACTR3, PI4K2B, PIK3R1 , PIM2, ΡΓΓΡΝΜ3, PLEK2, PLEKHA6, PLEKHH2, PGDN, POLN, POLRIA, PPMIE, PPP3CA, PRKCA, PRKGl, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS,

RBBP8, RBKS, RDX, RFX3-AS1, RGCC, RORl, ROR2, SCARNA9, SHROOM3, SIGLECIO, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A1 1 , SLC6A15, SLC7A1 1 , SLC9A3, SLIT3, SMG1P3, SMTN, S ED1, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, STAC 2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1 , SYNGR2, SYNPO, SYNP02, SYNP02L, TAGLN3, TANG06, TEX21P, TGFA, TGFB2, TGFB3, TGM2, THBS2,

TMEM102, TMEM1 19, TMEM256 -PL S CR3 , TMEM50B, TNFAIP8L3, TNFRSF14,

TNRC18P1, TNXB, TP53AIP1, TPRG1, TRTM60, I RPC4, FS) 1/2, TSPAN11, T SPAN 18, TSPAN7, TSSK3, TXNIP, USP27X, UVRAG, VTM-AS1, VPS41, VSTM2L, VWF, WDR91, WISP1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1 -AS1 , ZNF212, ZNF350, ZNF660, ZNF79 and ZNF837.

[00456] In another specific aspect of the foregoing, the gene is selected from ABCB8, ABCC3, ADAM 17, ADCY3, AGPAT4, ANKRA2, ANXAl 1, APIP, APLP2, ARHGAPl, ARL15, ASAPl, ASPH, ATAD2B, ATXN1, AXINI, BECNI, BHMT2, BICD l , BTN3A1, Cl lorOO, Cl lorf73, C 12orf4, C14orfl32, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP 112, CEP192, CHEK1, CMAHP, CNRIPl, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DC AF 17, DCUN1D4, DDX42, DENNDIA, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNIVIBP, DOCK I, DYRK1 A, EIF2B3, EN AH, ENOX1, EP300, ERC1 , ERCC1, ERGIC3, ERLIN2, ERRFI1 , EVC, FAF1, FAIM, FAMI26A, F AMI 3 A, FAMI62A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1 , GPSM2, GULPl, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B 12, HSD17B4, HTT, IFT57, ΓΝΡΡ5Κ, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, l.YRM L MADD, MB21D2, MCM10, MED13L, MEDAG, MEMOl, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC l , PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS 1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1 R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAFl, RAP I A, RAPGEFl , RARS2, RBKS, RERE, RFWD2, RNFT1, RPAl, RPS10, RPS6KB2, SAMD4A, SARI A, SCOl , SEC24A, SENP6, SERGEF, SGK3, SH3YL1 , SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SXAP23, SNHG16, SNX7, SOS2, SPAT A 18, SPATA5, SPIDR, SPRYD7, SRGAP1 , SRRM1, ST ATI, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCP 12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29,

WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP and ZNF680.

[00457] In another specific aspect of the foregoing, the gene is selected from ABCB8, ABCC3, ADCY3, AGPAT4, ANKRA2, APIP, ARHG AP 1 , ARL15, ATXNI, BEC 1, BHMT2, BTN3A1, C12orf4, C14orfl32, C8orf44, C8orf44-SGK3, C8orf88, CASP7, CCDC122, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAIIP, CNRIPl, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNKIGI, DAGLB, DCAF17, DLGAP4, DNAJC13, DNMBP, DYRKl A, ENAH, EP300, ERCCl, ERLTN2, ERRFH, EVC, FABVi, FAM126A, FAM13A, FAM162A, F AMI 7 A, FBN2, GGACT, GLCE, GULP1, GXYL.T1, HDX, HMGA2, HNMT, HPS!. IFT57, INPP5 , LVD, KDM6A, LETM2, LOC400927, LRRC42, LYRMI, MB21D2, MCMIO, MED13L, MFN2, MRPL45, MRPS28, MTERF3, MYCBP2, NGF, OXCT1, PDS5B, PIGN, PIK3CD, PIK3R1, PIKFYVE, PLEKHA1, PLSCRl, POM 12, PPARG, PPIP5K2, PPP1R26, PRP! 3 I. PRUNE2, PXK, RAFl, RAPGEF1, RARS2, RBKS, RERE, RP Al, RPSIO, RPS6KB2,

SAMD4A, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC44A2, SNX7, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRMl, STXBP6, TASP1, TCF12, TCF4, TIAM1, TMC3, TMEM189-UBE2V1 , TMEM214, TNRC6A, TTC7B, TUBE1, TYW5, URGCP, VAV2, WDR27, WDR91, WXKI. ZCCHC8, ZFP82, ZNF138, ZNF232 and ZNF680.

[00458] In another specific aspect of the foregoing, the gene is selected from ABHD10, ADAL, ADAM 17, ADAM23, ADAMTS19, AGPAT4, AGPS, AKAP8L, AKTl, ANKRD13C, ANXA1I, APIP, APPL2, ARHGAP1, ARHGAP5, ARL15, ARL5B, ARSJ, ASAPl, ATF6, BECN1, BHMT2, BIN , BNC2, BTBD10, C1QTNF9B-AS1, Clorf27, Cllorf30, Cllorf73, CI lori-76, C12orf4, C2orf47, CACNBl, CACNB4, CADM2, CCNL2, CDH18, CENPI,

CEP 162, CEP 170, CEP 192, CEP57, CHE 1, CHRM2, CMAI!P, CMSSl, CNOT7, CNRIPl, CNTNI, COPS7B, CRISPLD2, CRYBG3, CUXI, DAAMl, DC AF 17, DCUN1D4, DDX42, DENNDIA, DENND4A, DENND5A, DET1, DGK1, DHFR, DIAPH3, DLG5, DMXLl, DNAJA4, DNMBP, DYRKl A, DZIPIL, ELM02, ENAH, ENOXl, EP300, ERCl, ERC2, EVC, EXOC3, EXOC6B, F AM 162 A, F AM 74 A, FAM195B, FAM208B, FAM49B, FAM69B, FBN2, FBXL16, FBX09, FGD4, FHOD3, GALC, GBP1, GLCE, GNG12, GOLGB1, GTSF1, GXYLT1, HDAC5, HDX, HMGXB4, HOXB3, HSD17B4, HIT, IFT57, IKBKAP, INO80,

ΓΡΡ4Β, INVS, ITCH, IVD, KDM6A, KDSR, KIAA1524, KIAA1715, KIDINS220, KIF2IA, L3MBTL2, L.GALS3, LINCR-0002, LING02, LOC400927, LPHN1, LRRCl, L.RRC42, LYRM1, MACROD2, MANE A, MAPK10, MARCH7, MARCH8, MDN1, MEAF6, MEMOl, MFN2, MLLT10, MMS19, MORF4L1 , MRPL39, MRPL45, MR S 28, MTMR3, MYB, MYCBP2, MYLK, NEDD4, NFASC, NGF, NIPAl, NLGN1, NLN, NREP, NSUN4, NUPLl, OSBPL3, PAPD4, PBX3, PCDHIO, PDE3A, PDE7A, PDXDCl, PDXDC2P, PELI1, PIGN, PITPNB, PMS1 , PNISR, POMT2, PPARG, PPFIBP l , PRPF3 1 , PSMA4, PXK, RAB23, RAF1, RAPGEFl, RASIPl, RBBP8, RC0R3, RE RE, RGL1, RNF 130, RNF144A, RNF213, RPF2, RPS10, SAMD4A, SCO l , SENP6, SF3B3, SGIP1, SGMS 1 , SGPL1, SH2B3, SKP1, SLC12A2, SLC25A16, SLC25A17, SMOX, SNAP23, SNX24, SNX7, SOCS6, SOGA2, SORCS1, SPIDR, SPRYD7, SREK1, SSBPl , STRAD8, STXBP4, STXBP6, SUPT20H, TAF2, TARBP1 , TASP1, TBCA, TBLIXRI, TCF4, TEKT4P2, TET1, TIAMl, TJAP1, TJP2, TMEM214, TMX3, TNRC6A, TRAF3, TRIM65, TSPAN7, TXNL4B, UBE2D3, UBE2L3, UBN2, UNC13B, URGCP-MRPS24, UVRAG, VDAC2, WDR27, WDR90, WHSC2, WNK1, XRN2, ZFP82, ZMIZ2, ZNF138, ZNF208, ZNF212, ZNF280D, ZNF350, ZNF37BP, ZNF426, ZNF6I8, ZNF680, ZNF730, ZNF777, ZNF7804A, ZNF836 and ZSCAN25.

[00459] In another specific aspect of the foregoing, the gene is selected from APOA2, ASA , BRCA l, BRCA2, CDKN1 C, CRX, CTRC, DENND5A, DIAPH3, DMD, DNAH l, EIF2B3, GALC, HPS1, HTT, IKBKAP, KIAA1524, LMNA, MECP2, PAPD4, PAX6, PCCB, PITPNB, PTCH1, SLC34A3, SMN2, SPINK5, SREK1, TMEM67, VWF, XDH and XRN2, [00460] In another specific aspect of the foregoing, the gene is selected from ABCA1, ABCA!O, ABCB7, ABCB8, ABCCl, ABCC3, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM 1 5, AD AM 7, ADAM23, ADAM33, A OA M l S i , ADAMTS19, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AS IDC i , AHRR, AJUBA, AK021888, AK310472, A AP L AKAP3, AKAP8L, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANKL ANK2, ANK3, ANKFY1, ANKHD1- EIF4EBP3, ANKRA2, ANKRD13C, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA6, AP2B 1, AP4B 1-AS1, APAFl, APIP, APOA2, APP, APTX, ARHGAPl, ARHGAPl 2, ARHGAP22, ARHGAPS, ARHGEF 16, ARIDIA, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARSJ, ASAPl, ASICl, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG9A, ATMIN, ATP2A3, ATP2C1, ATXN1, ATXN3, AURKA, B3GALT2, B3GNT6, B4GALT2, BACEI, BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYRNl, BECN1, BEND6, BHMT2, BICDl , BIN1 , BIN3, ΒΙΝ3-ΓΠ , BIRC3, BIRC6, BNC1 , BNC2, BRCA1 , BRCA2, BRD2, BRPFl, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1QTNF9B-AS1, CIorf27, Clorf86, C10orf54, Cl lorOO, C 1 1 orf70, CI l orf73, CI l orf76, CI l orf94, C12orf4, C12orf56, C14orfl32, C17orf76-ASl, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orB4,

C8orf44, C8orf44-SGK3, C8ori¾8, C9orf69, CA13, CA3, CAB 39, CACNA2D2, CACNB i, CACNB4, CADMl, CADM2, CALU, CAMKK1 , CAND2, CAPNS1, CASC3, CASP7,

CASP8AP2, CAV1, CCARl, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CC L2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42B A, CDCA7, CDH1 1 , CDH13, CDH18, CDK11B, CDK16, CDKALl, CDKN1C, CECR7, CELSR1, CEMIP, CENPL CEP112, CEP162, CEP 170, CEP192, CEP68, CFH, CFLAR, CHD8, CHE 1, CHRM2, CUT A, CIZ1, CLDN23, CLIC l, CLK4, CLTA, CMAHP, CNGA4, CNOTl, CNRIP1, CNTDl, CMSSl, CNOT7, CNRIP1 , CNTN1, COG1, COL1A1, COM 1 Al, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1 , COLEC12, CQMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF 1 , CRLS 1, CRTAP, CRX, CRYBG3, CRYL1, CSDE1, CSN 1A1, CSNK1E, CSNKI GI, CTDSP2, CTNND1, CTRC, CUL2, CUL4A, CUXl, CYB5B, CTO5R2, CYBRDl, CYGB, CYPIBI, CYP51AI, DAAMl, DAB2, DACT1, DAGLB, DARS, DAXX, DCAF10, DCAF1 1 , DCAF17, DCBLD2, DCLK.1 , DCN, DCUN1D4, DDAHI, DDAH2, DDHD2, DDIT4L, DDRI, DDX39B, DDX42, DDX50, DEGSl, DENND1 A, DENNDIB, DENND4A, DENND5A, DEPTOR, DET1, DFNB59, DGCR2, DGK1, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLCl, DLG5, DMD, DMXLl , DNAH8, DNAH1 1, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK! 1, DPP 8, DSEL, DST, DSTN, DY CIH, DYRK1A, DZIP1L, EBF 1, EEAl, EEF1A1, EFCAB14, EFEMP1, EGR1 , EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, EN AH, ENG, ENOXl, ENPP1, ENPP2, ENSA, EP300, EPT1, ERC1, ERC2, ERCC 1, ERCC8,

ERLIN2, ERRFI1 , ESM1 , ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADS l, FADS2, FAFl, FAIM, FAM111 A, FAM126A, F AMI 3 A, FAM160A1,

FAM162A, F AM 174 A, FAM195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAR. FARP1, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXO10, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFT1, FDPS, FER, FEZ l, FGD4, FGD5-AS1, FGFR2, FGFRLl, FGL2, FHOD3, FLU, FLNB, FLTl, FN1 , FNBP1 , FOCAD, FOS, I ^' OSB FOSL1 , FOXK1 , FRAS1 , FSCN2, FUS, FYN, GABPB l, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBP1, GCFC2, GLCE, GCNTl , GDF6, GGACT, GHDC, GIGYF2, GJC1 , GLCE, GMIP, GNA 13, GNAQ, G AS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGB l , GORASP L GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREMl, GRK6, GRTPl, GSEl, GTF2H2B, GTSF1, GUCA1B, GULP1, GXYLT1, HAPL 1, HAPLN2, HAS2, HA S3, HATl , HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEGl, HEPH, HEY1 , HLA-A, HLA-E, HLTF, HMGA1 , HMGA2, HMGB 1, HMGCR, HMGN3-AS1 , HMGCSl, HMGXB4, HOOKS, HOXB3, HMOX1, HNMT, HNRNPR, HNRNPULl, HP1BP3, HPSl, HRH1,

HSD17B12, HSPA1 L, ΗΤΑΤΪΡ2, HIT, IARS, IDH1, IDIl, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, IL16, IL6ST, INA, INHBA, ΓΝΟ80, IPP4B, ΓΝΡΡ5Κ, INSIGL INTU, INVS, IQCE, IQCG, ITCH, ITGAl l, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1 199, KIAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549,

KIAA1715, KIAA1755, KIDINS220, KIF 14, KIF2A, KIF21A, KIF3A, KIT, KLC l , KLC2, KLF17, KLF6, KLHL7, KLRGI, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAP1 -5, KRTAP2-3, L3MBTL2, LAMA2, LAMB1, LAMB2P1, LARP4, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINC003 1, LINC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LTNC0096I, LINCOIOl 1, LINC01 118, LTNC01204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMODl, LOC400927, LONPl, LOX, LPHNI, LRBA, LRCH4, LRIGl, LRP4, LRI>8, LRRC1, LRRC32, LRRC39, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPDl, LYRM1, LZTS2, MACROD2, MAFB, MAGED4, MAGED4B, MAMDC2, MAN1 A2,

MAN2A1, MAN2C1, MANEA, MAP4K4, MAPKI O, MAPK13, MARCH7, MARCH8, MASPI, MB, MB2ID2, MBDl, MBOAT7, MC4R, MCM10, MDM2, MDN1, MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMOl , MEPCE, MFGE8, MFN2, MIAT, MICAL2, MINPP1, MIR6I2, MKL1, MKLNI, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MM P K), MMP24, MMS19, MMS22L, MM MORF4L1, MOXD1, MPPE1, MPZLl, MRP1.3. MRPL45, MRPL55, MRPS28. MRVH, MSANTD3, MSG, MSH2, MSH4, MSH6, MSL3, MSMOl, MSRB3, MTAP, MTERF3, MTERFD1, MTHFDIL, MTMR3, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MY ADM, MYB, MYCBP2, MYLK, MYOID, M:Y09B, MYOF, NA, NAA35, NAALADL2, NADK, NAEl , NAGS, NASP, NAVl , NAV2, NCOA1, NCOA3, NCOA4, NCSTN, D F, NEDD4, NELFA, NEOL NEURL1B, NF2, NFASC, NFE2L1, NFX1, NGF, NGFR, NHLH1, NIDI , NID2, ΝΪΡΑ1 , NKX3-1 , NLGN1, NLN, NOL10, NOM03, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRDl, NREP, NRGI, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPLL NUSAP1, OCLN, 0DF2, OLR1 , 0S9, OSBPL3, OSBPL6, OSBPL10, OSMR, OXCT1, OXCn... P4HA1, P4HB, PABPC l, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCCB, PCDH10, PCDHGB3, PCGF3, PCM1 ,

PCMTD2, PCNXL2, PCSK9, PDE1C, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1, PDXDC2P, PEAR1 , PELI1 , PEPD, PEX5, PFKP, PHACTR3, PHF 19, PHF8, PHRFL PHTF2, PI4K2A, PIEZOl, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNM1, PITPNM3, PLAU, PLEC, PLEK2,

PLEKHAl , PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNCl, PMS1, PNISR, PGDN, POLE3, POLN, POLRIA, POLR3D, POMT2, POSTN, POU2F1 , PPAPDC IA, PPARA, PPARG, PPFIBPl, PPIP5K1, PPIP5K2, PPMIE, PPP1R12A, PPP1R26, PPP3CA, PPP6RL PPP6R2, PRKCA, PRKDC, PRKG1, PRMTL PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PR.UNE2, PSMA4, PSMC 1, PSMD6, PSMD6-AS2, PTCH1, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR., PXK, PXN, QKI, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF 1 , RALB, RAP1GDS 1 , RAPGEF1 , RARG, RARS, RARS2, RASIP1, RASSF8, RBBP8, RBCKL RCOR3, RBFOX2, RBKS, RBMIO, RDX, RERE, RFTNl, RFWD2, RFX3-AS1, RGCC, ROL L RGSIO, RGS3, RIF1, RNF14, RNF 19 A, RNF130, RNF 144 A, RNF213, RNF38, RNFT1, ROR1, ROR2, RPA1, RPF2, RPL10, RPS10, RPS6KB2, RPS6KC 1 , RRBPl, RWDD4, SA M 1)4 A . SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCO, SCLT1, SCOl, SDCBP, SEC14L1, SEC22A, SEC 24 A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SF3B3, SGIP1, SGK3, SGMS1, SGOL2, SGPL1, SH2B3, SH3RF1 , SB3YL1 , SHROOM3, SIGLEC 10, SKA2, SKIL, SKP1, SLC12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3,

SLC39A10, SLC4A4, SLC4A1 1 , SLC41 A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMOX, SMPD4, SM I N, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, S X24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCSl, SORCS2, SOS2, SOX7, SPAT A 18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPIN 5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBFl, SRGAPl, SRRMl, SRSF3, SSBP1, STAC2, STARD4, STAT1, STAT3, STAT4, STAUl, STC2, STEAP2,

STK32B, STRAD8, STRIP 1, STRN4, STS, STX16, STXBP4, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC1, TAF2, TAGLN3, TANC2, TANG06, TARBP1, TARS, TASPl, TBC1D15, TBCA, TBL1XR1, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENCl, TENM2, TEP1, TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAPl, TGM2, THADA, THAP4, THBS2, THRB, TIAM1, ΤΓΜΡ2, TJAP1, TJP2, TLE3, TLKl, TMC3, TMEM67, TMEM102, TMEM119, TMEM134, TMEM154, TMEM 89-UBE2V 1 , TMEM214, TMEM256-PLSCR3 , TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFATP3, TNFATP8L3, TNFRSF12A, I N! RSI 14. TNIPl, TNKS1BP1, TNP03, TNRC18P1, TNSl, TNS3, TNXB, TOEl, TOMM40, TOMM5, TOPORS, TP53AIP1, Τ 53ΓΝΡ1, TPRG1, TRAF3, TRAK1, TRAPPC12, TRJB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMTIL, TRPC4, TRPS1, TSC2, TSHZ1, TSHZ2, TSPANll, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B,

TUBB2C, TUBB3, TUBEl, TXNIP, TXNLl, TXNL4B, TXNRDl, TYW5, U2SURP,

UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHM l, UHRF1BP1L, UNC13B, UNC5B, URGCP, URGCP-MRPS24, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VDAC2, VIM-AS1, VIPAS39, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPFl, WISPl, WNKI, WNT5B, WT10B, WSBl, WWTRL XDH, XIAP, XRN2, YAP1, YDJC, YES l , YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEBl, ZEB2, ZFANDl, ZFAND5, ZFP82, ZHX3, ZMIZ1, ZMIZ1-AS1, ZMIZ2, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431, ZNF583, ZNF618, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF730, ZNF74, ZNF764, ZNF777, ZNF778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 andZSCAN25. [00461] In another aspect, the gene is not SMN2.

[00462] In another aspect, the gene is not selected from ABHD10, ADAM 12, AKT1,

ANXA1 1 , APLP2, APPL2, ARMCX6, ATG5, ΑΧΪΝ1, BAIAP2, CCNB 1IP1 , CCT7, CEP57, CSFI, DLGAP4, EPN1, ERGIC3, FOXM1, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN IB 1, MRPL39, PCBP4, PPHLNl, PRKACB, RAB23, RA 1A, RCC1, SREK1 , STRN3 and TNRC6A.

[00463] In another aspect, the gene is not selected from ABHDIO, ADAM 12, AKT1,

ANXA 1 , APLP2, APPL2, ARMCX6, ATG5, AXIN1, BAIAP2, CCNB 1IP1, CCT7, CEP57, CSFI, DLGAP4, EPNl, ERGIC3, FOXM1, GGCT, GRAMD3, HSD17B4, LARP7, LRRC42, MADD, MAN IB 1, MRPL39, PCBP4, PPHLNl, PRKACB, RAB23, RAPIA, RCC1, SMN2, SREK1, STRN3 and TNRC6A.

[00464] In another particular aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene in a subject, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS (for example, an endogenous intronic REMS or a non-endogenous intronic REMS), the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript contains in 5' to 3 ' order; a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00465] In another particular aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene in a subject, wherein the precursor RNA transcript transcribed from the gene comprises a non- endogenous intronic REMS, the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript contains in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00466] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition compri sing a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript contains in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00467] In another aspect, provided herein are methods for modifying RNA splicing in order to modulate the amount of one, two, three or more RNA transcripts of a gene described herein, comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein.

[00468] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or a protein) in a subject, wherein the gene comprises a DNA nucldeotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00469] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5' to 3' order: a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00470] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure

IA, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00471] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure

IB, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00472] In another aspect, provided herein is a method for modifying RNA splicing in order to modulate the amount of a product of a gene (such as an RNA transcript or protein ) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DN A nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00473] In a specific aspect, the gene is a gene described in a table in this disclosure.

[00474] In certain aspects, a compound of Formula (I) or a form thereof contacted or cultured with a cell(s), or administered to a subject is a compound described herein.

[00475] Table 3 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value,

[00476] Table 3

Table 3

ABCA1, ABCA10, ABCB7, ABCB8, ABCC1, ABC C ABHDIO, ABL2, ABLEV13,

ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM 12, AD AMI 5, AD AMI 7, ADAM23, ADAM33, ADAMTS 1, ADAMTS19, ADCY3, ADD1, ADGRG6, ADH6, ADHFEl, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK 021888, AK310472, AKAP1, AKAP3, AKAP8L, AKAP9, AKNA, AKT1, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, A K3, ANKFY1, ANKHD 1 -EIF4EBP3 , ANKRA2, A KRD13C, AN RD17, AN RD33B, ANKRD36, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, AP4B1-AS1, APAFl, APIP, APLP2, APOA2, APP, APPL2, APTX, ARHGAPl,

ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, ARL15, ARL5B, ARMCX3, ARMCX6, ARSJ, ASAP1, ASIC l, A SI . , ASNS, ASPH,

ATAD2B, ATF6, ATF7IP, ATG5, ATG9A, ΑΤΜΓΝ, ATP2A3, ATP2C1, ATXN1, ATXN3, AURKA, AXIN1 , B3GALT2, B3GNT6, B4GALT2, BACE1, BAG2, BASP1 , BC033281, BCAR3, BCL2L15, BCYRN1, BECN1, BEND6, BHMT2, BICDl, B IN 1 , BINS, ΒΓΝ3-ΓΠ, BIRC3, BIRC6, BNC1 , BNC2, BRCA1, BRCA2, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1 , C1 QTNF9B-AS1 , Clorf27, Clorf86, Cl()orf54, Cl lorGO, Cl lorfZO, Cl lorf73, Cl lorf76, C l lorf94, C12orf4, C12orf56, C14orfI32, C17orf76-ASl, CI9orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31 , C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf(59, CA13, CA3, CAB39, CACNA2D2, CACNBl, CACNB4, CADM1, CADM2, CALU, CAMKKl, CAND2, CAPNS 1, CASC3, CASP7, CASP8AP2, CAVl, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDHl l, CDH13, CDH18, CDK11B, CDK16, CDKAL1, CDKN1C, CECR7, CELSRl, CEMIP, CENPI, CEP 112, CEP162, CEP170, CEP192, CEP57, CEP68, CFH, CFLAR, CHD8, CHE 1, CHRM2, CIITA, CIZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CNOT1, CNRIP1, CNTDl, CMSS1, CNOT7, CNRIP1, CNTN1, COG1, COL1A1, COL1 1A1, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1, COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1, CRTAP, CRX,

CRYBG3, CRYL1, CSDE1, CSNK 1 A1, CSN 1 E, CSNK1 G1, CTDSP2, CTNND1 , CTRC, Table 3

CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYP1B1, CYP51A1,

DAAM1 , DAB2, DACT1 , DAGLB, BARS, DAXX, DC F10, DCAF11, DCAF17, DCBLD2, DCLK1 , DCN, DCUN1D4, DDAITl, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGS1, DENND1 A, DENND1B, DENND4A, DENND5A, DEPTOR, DET1, DFNB59, DGCR2, DGK 1, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1 , DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DLGAP4, DMD, DMXLL DNAH8, DNAH11, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP8, DSEL, DST, DSTN, DYNC1I1 , DYRK 1 A, DZIP1L, EBF 1 , EEA1, EEF1 A1,

EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4GI, EIF4G2, EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, ENAH, ENG, E OX1 , ENPP1, ENPP2, ENSA, EP300, EPN1, EPT1, ERC1 , ERC2, ERCC1 , ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADS1, FADS2, FAF 1, FAIM, FAM111A, F AM 126 A, FAM13A, FAM160A1 , FAM 162A, F AMI 74 A, FAM 195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARP1, FBLN2, FBN2, FBXL16, FBXL6, FBX09, FBXO10, FBX018, FBX031, FBX034, FBX09, FCHOl, FDFT1 , FDPS, FER, FEZ 1 , FGD4, FGD5-AS1, FGFR2, FGFRLL FGL2, FHOD3, FLU, FLNB, FLTl, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FRAS1, FSCN2, FUS, FYN, GABPBl, GAL3ST4, GALC, GALNT1, GALNT 5, GAS7, GATA6, GBA2, GBG 1, GBP1, GCFC2, GLCE, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJCL GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASPl, GPR1 , GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM1, GRK6, GRTPl, GSE1, GTF2H2B, GTSF1, GUCA1B, GULP1, GXYLTl, HAPLN1, l i \Pl.N2, HAS2, HA S3, HAT 1 , HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEYl, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB 1, HMGCR, HMGN3-AS1, HMGCSl, HMGXB4, HOO 3, HOXB3, HMOX1, H MT, HNRNPR, H RNPUL1, HP1BP3, HPS ! , ! !Rl l i . HSD17B12, HSD17B4, HSPA1L, HTATIP2, HTT, LARS, 11)1 I I . IDI1, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, IL16, IL6ST, IN A, ΓΝΗΒΑ, ΙΝΌ80, IPP4B, ΓΝΡΡ5Κ, INSIG1 , INTU, INVS, IQCE, IQCG, ITCH, ITGA l l , ITGA8, ITGAV, ITGB5, ITGB8, ITIHl, ITM2C, ITPKA, ITSNl, IVD, KANSL3, KAT6B, KCNK2, KCNS l , KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1199, KIAA1456,

KIAA1462, KIAA1522, KIAA 1524, K.IAA1549, KIAA1715, KIAA1755, KIDINS220, KIF14, KIF2A, KIF21A, KIF3A, KIT, KLCl, KLC2, KLF 17, KLF6, KLHL7, KLRGl, KMT2D, KRT7, KRT 8, KRT19, R 1 4. KRTAPl-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB l, LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS l, LINC00341, LLNC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINCOlOl l, LINC011 I8, LINC0I204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMOD1, LOC400927, LONP1, LOX, LPHN1, LRBA, LRCH4, LRIG1, LRP4, LRI>8, LRRC l, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1 , LYRM1, LZTS2, MACROD2, MADD, MAFB, MAGED4, MAGED4B, MAMDC2,

MAN1A2, MAN2A1, MAN2C1, MANEA, ΜΛΡ-Ι 4. MAPK10, MAPK13, MARCH7, MA CH 8, MASPl, MB, MB21D2, MBD1, MBOAT7, MC4R, MCMIO, MDM2, MDN1, MEAF6, MECP2, MED1, MED13L, MED AG, MEF2D, MEGF6, MEIS2, MEMO I, MEPCE, MFGE8, MFN2, M l AT. MICAL2, MINPP1 , M R612, M L1, MKLN1 , MKNK2, MLLT4, Table 3

MLLTIO, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MN1, MORF4L1, MOXD1 , MPPE1 , MPZL1, MRPL3, MRPL39, MRPL45, MRPL55, MRPS28, MRVIl, MSANTD3, MSG, MS! 12, MSH4, MSH6, MSL3, MSMOl, MSRB3, MTAP, MTERF3, MTERFD1, MTHFD1L, MTMR3, MTMR9, MTRR, MUMl, MVD, MVK, MXRA5, MY ADM, MYB, MYCBP2, MYLK, MYOI D, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAEL NAGS, NASP, NAVL NAV2, NCOAl, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl, NEURL1B, NF2, NFASC, NFE2L1, NFX1, NGF, NGFR, NHLH1, NIDI , NID2, NIPAl, NKX3-1, NLGN1 , NLN, NOL10, NOM03, NOTCH3, NOTUM, NGVA2, NOX4, NPEPPS, NRDL NREP, NRGl, NRROS, NSUN4, NT5C2, NT5E, NTNGl, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, OCLN, ODF2, 01. R L OS9, OSBPL3, OSBPL6, OSBPLIO, OSMR, OXCT1, OXCT2, P4HA1 , P4HB, PABPCl, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCBP4, PCCB, PCDH10, PCDHGB3, PCGF3, PCXi L PCMTD2, PCNXL2, PCSK9, PDE1C, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDCL PDXDC2P, PEAR1, PELI1, PEPD, PEX5, PFKP, PHACTR3, PF£F19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZOl, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1 , PKFYVE, PIM2, PITPNA, PITPNB, PITPW ! L PITPNM3, PL AU, PLEC, PLEK2, PLEKHA1, PLEKHA6, PLEKHB2,

PLEKHH2, PLSCRl , PLSCR3, PLXNB2, PLXNCl, PMSL PNISR, PGDN, POLE3, POLN, POLR1A, POLR3D, POMT2, POSTN, POU2F1, PPAPDC 1A, PPARA, PPARG, PPFIBPl, PPHLN1, PPIP5K1, PPIP5K2, PPM IE, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKGl, PRMT1, PRNP, PRPF31 , PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTCH1, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD , RAD9B, RAD23B, RAF1 , RALB, RAP1A, RAP1GDS 1 , RAPGEF 1 , RARG, RARS, RARS2, RASIP1, RASSF8, RBBP8, RBCKL RCOR3, RBFOX2, RBKS, RBM10, RCCl , RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGL1, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF130, RNF 144A, RNF213, RNF38, RNFT1 , ROR1, ROR2, RPAL RPF2, RPLIO, RPS 10, RPS6KB2, RPS6KC1, RRBPl, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLTl , SCOl, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SF3B3, SGIP1, SGK3, SGMS1, SGOi.2. SGPL1, SH2B3, SH3RF1, SH3YL1 ,

SHROOM3, SIGLECK), SKA2, SKIL, S P1 , SLC12A2, SLC24A3, SLC25A16, SLC25A17, PTCHL SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A1 1, SLC41A1, SLC44A2, SLC46A2, SLC6A 15, SLC7A6, SLC7A8, SLC7A11, SLC9A3, SLIT3, SMARCA4,

SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1 , SORCS2, SOS2, SOX7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPINK 5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTMl, SRCAP, SREBFl, SREKI, SRGAPl, SRRMI, SRSF3, SSBPl, STAC2, STARD4, STAL L STAT3, STAT4, STAU1, S IX 2 STEAP2, STK32B, STRAD8, STRIP1 , STRN3, STRN4, STS, STX16, STXBP4, STXBP6, SULF1, SUPT20H, SVEP1, SY E1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACCl , TAF2,

TAGLN3, TANC2, TANG06, TARBP1, TARS, TASPl , TBC1D15, TBCA, TBL1 XR1, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1, TENM2, TEP1, TET1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAPl , TGM2, THADA, THAP4, Table 3

THBS2, THRB, TIAM1, TIMP2, TJAPl, TJP2, TLE3, TLKl, TMC3, TMEM67, TMEM102, TMEM1 19, TMEM134, TMEM154, TMEM 189-UBE2V1 , TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAIP8L3, TNFRSF 12 A, TNFRSF14, T IP1, TNKS1BP1 , TNP03, TNRC18P1, TNRC6A, TNS1, TNS3, TNXB, TOE1, TOMM40, TOMM5, TOPORS, TP53AIP1 , TP531NP1 , TPRG1 , TRAP 3, I RAK I , TRAPPC12, TRIB 1, TRIM2, T IM23, T IM26, TRIM28, T IM65, TRIM66, TRMT1L, TRPC4, TRPS1, TSC2, TSHZ1, FS1 1/2, TSPAN11, T SPAN 18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBEl , TXNIP, TXNL1, TXNL4B, TXNRD1, TYW5, U2SURP, UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1, UBN2, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC13B, UNC5B, URGCP, URGCP-MRP S24, USP19, USP7, USP27X, UVRAG, VANGLl , VARS2, VAV2, VCL, VDAC2, VIM-AS l, VTPAS39, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, WAS, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR91, WHSC2, WIPF1 , WISP1, WN 1, WNT5B, WNT10B, WSB1, WWTR1, XDH, XIAP, XRN2, YA 1, YDJC, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB 10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC l, ZEBl, ZEB2, ZFANDl, ZFAND5, ZFP82, ZHX3, ZMIZl, ZMIZl -AS 1, /M IZ2. ZMYM2, ZNF12, ZNF138, ZNF148, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431, ZNF583, ZNF618, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF730, ZNF74, ZNF764, ZNF777, ZNF778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 and ZSCAN25

[00477] Table 4 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isofomi abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

Table 4

ABCA1, ABCB7, ABCC1 , ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ADAM 12, AD AMI 5, AD AMI 7, ADAM33, AFF2, AGK, AGPAT3, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, A 02 i 888. Λ 10472. AKA l , Λ ΛΡ , AKNA, ALCAM, ALDH4A1, AMPD2, ANK2, ANKFY1, ANKHD1 -EIF4EBP3, ANKRD17, ANK.S6, ANP32A, ANXA11, ANXA6, AP2B 1, APAF1, APLP2, APP, APPL2, APTX, ARHGAP22, ARID 1 A, ARID2, ARMCX3, ASAP1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG9A, ATMIN, ATP2C 1, ATXN3, AURKA, AXIN1, B4GALT2, BACE1, BAG2, BASP1 ,

BC033281, BCAR3, BEND6, BICDl, BINl, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BZW1, CI l orOO, CI l orf73, C17orf76-AS l , C4orf27, C5orf24, C6orf48, C9orf69, CAB39, CALU, CAMKKl, CAPNSl, CASC3, CASP8AP2, CAVl, CCARl, CCDC77, CCDC88A, CCDC92, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK l I B, CD 16, CDKAL1, CEP68, CFLAR, CHD8, CIZ1, CLIC1 , CL 4, Table 4

CNOTL COG1, COL 12 A 1, COL1A1, COL6A1, COPS7B, CPEB2, CREB5, CRLSL CRTAP, CSDE1, CS K1 A1 , CTDSP2, CTNND1, CUL2, CUL4A, CUX1 , CYB5B,

CYBRD1, CYP51A1, DAB2, DACT1, BARS, DA XX. DCAF10, DCAF11, DCBLD2, DCUN1D4, DDAH1, DDAH2, DDHD2, DDR1, DDX39B, DDX42, DENNDIA,

DE ^' NNDIB, DENND5A, DGCR2, DG A, DHCR24, DHCR7, DIIFR, DHX9, DIAPH1, DIAPH3, DIS3L, DKFZp434M1735, DKK3, DLCl, DNM2, DOCK1, DPP 8, DSEL, DST, DSTN, EBF , EEA1, EEF1A1, EFCAB14, EGR1, EHMT2, EIF2B3, EIF4G1, EIF4G2, E1F4G3, ELF2, ENG, ί·ΛΡΡ2, ENS A, EPN1, I P Ί 1. ERC1 , ERGIC3, ETV5, EXOl, EXTL2, EYAS, FADS1, FADS2, FAF1, FAM1 11 A, FAM198B, FAM219A, FAM219B, FAM3C, FAM65A, FBXO10, FBX018, FBX031, FBX034, FBX09, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFRLI, FHOD3, FLU, FLNB, FNl , FNBPI, FOCAD, FOS, FOSB, FOSL l, FOXKl, FOXM1, FUS, FYN, GABPB l, GALC, GALNTl, GAS7, GBA2, GCFC2, GGCT, GHDC, GIGYF2, GJCl, GMIP, GNA13, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGBl , GORASP1, GPR1 , GPR89 A, GPSM2, GREM1, GRK6, GSE1, GTF2H2B, HAS2, HAT 1 , HAUS3, HAUS6, HDAC7, HEG1, HLA-A, HLA-E, l il. i l·, HMGA1, HMGB1, HMGCR, HMGCSl , HMOXl , HNRNPR, HNRNPULl, HP1BP3, HRH1 , HSD17B 12, HSD17B4, HTT LARS, IDH1, IDI1, IGF2BP2, IL6ST, INHBA, INSIGL IQCE, ITGAV, ITGB5, ITM2C, ITSN1, KANSL3, KCNK2, IAA1033, IAA 143, KIAA1 199, KIAA1522,

IAA1524, KIAA1549, KIAA1715, KIF 14, KIF2A, IF3A, KLC1, KLC2, KLF6, KLHL7, KRT18, KRT19, KRT34, KRTAP2-3, LAMA2, LAMBl, LARP4, LARP7, LATS2, LDLR, LEMD3, LGALS8, LIMSl , LINC00341 , LINC00657, LMAN2L, LM07, LONP1, LOX, LRCH4, LRIG1 , LRP8, LRRC8A, LSS, LTBR, LUC7L2, LZTS2, MADD, MAGED4, MAGED4B, MA 1A2, MAP4K4, MBDl, MBOAT7, MDM2, MED1, MEDAG, MEF2D, MEIS2, MEMOl, MEPCE, MFGE8, MICAL2, MINPP1 , MKL1 , MKLN1, MKNK2, MLLT4, MLST8, MMAB, MMS19, MMS22L, MPPE1, MPZL1, MRPL3, MSANTD3, MSC, MSH2, MSH6, MSL3, MSMOl, MSRB3, MTAP, MTERFDl, MTHFDIL, MTMR9, MTRR, MUM1 , MVD, MVK, MY ADM, MYLK, MYOID, MY09B, MYOF, NAA35, NADK, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NELFA, XI ·.() ! .

NEURL1 B, NF2, NFE2L1, NFX1 , NIDI, NID2, NIPA1, NK.X3-1, NOL10, NOM03, NPEPPS, NRD1, NREP, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAPl, ODF2, OS9, OSBPL6, OSMR, P4HA1, P4HB,

PABPC1, PAK4, PAPD4, PARD3, PAR.N, PARP14, PARP4, PARVB, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE4A, PDE7A, PDLIM7, PDXDC l , PEPD, PEX5, PFKP, PHF 19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZOl, PIGU, PI 3C2B, PITPNA, PITPNB, PITPNMl, PLAU, PLEC, PLEKHB2, PLSCR3, PLXNB2, PLXNCL PMS1, POLE3, POLR3D, POSTN, POU2F1, PPAPDC1A, PPARA, PPHLN1, PPIP5K 1, PPP1R12A, PPP6R1, PPP6R2, PR ACB, PRKDC, PRMT1, PRNP, PRSS23, PSMA4, PSMC1, PSMD6, PTK2B, PTPN14, PUF60, PUS7, PVR, PXN, QKI, RAB23, RAB2B, RAB34, RAD1, RAD23B, RALB, RAP1A, RAP1GDS1, RARG, RASSF8,

RBCK1 , RBFOX2, RBMIO, RCC1 , RFTN1, RFWD2, RGSI O, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFTl, RPLIO, RPS6KC1, RRBP1, RWDD4, SAMD9, SAMD9L, SARI A, SART3, SCAF ^' 4, S( AI 8, SCD, SCLTl , SCOl, SDCBP, SEC14L1, SEC22A, SEC24B, SEC61A1, SEPT9, SERPINE2, SF1, SGOL2, SH3RF 1, SKIL, SLC25A17, SLC39A3, SLC41A1, SLC4A4, SLC7A6, SLC7A8, SMARCA4, SMARCC2, SMC4, SMC 6, SMCHD1, SMG1 , SMN2, SMPD4, SMYD3, SMYD5, SNAP23, SNHG16, SNX14, SOCS2, SON, SOS2, SPATA20, SPATS2, SPG20, SPRED2, SQLE, SQRDL, SQSTML SRCAP, SREBF 1 , SREK1, SRSF3, STARD4, ST ATI , STAT3, STAU1, STC2, STEAP2, STRIP1, STR.N3, STX16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TACC1, TAF2, TANC2, TARBP1, TARS, TBC1D15, TBL2, TCF7L2, TENC1, TENM2, ΊΈΡ1, TET3, TFCP2, TGFBI, TGFBR1 , TGFBRAP1 , THADA, THAP4, THRB, TIMP2, TJP2, TLE3, TLK1 , TMEM154, TMEM47, TMEM63A, TNC, TNFAIP3, TNFRSF12A, TNIPl, TNKSIBPI, TNP03, TNS1, TNS3, TOE1, TOMM40, TOMM5, TOPORS, TP53INP1, TRAP 3, TRAKl, TRAPPC12, TRIB 1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRMT1L, TRPSl, TSC2, TSHZ1, TSPAN2, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRDL U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRFIBPIL, UNC5B, USP19, USP7, VANGL1, VARS2, VCL, VIPAS39, VPS 13 A, VPS29, VPS51, VWA8, WDR19, WDR37, WDR48, WIPF1, WNT5B, WSBL WWTR1, XIAP, XRN2, YAPl, YES1 , YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB7A, ZC3H 12C,

ZC3H14, ZC3H18, ZCCHC 1 1 , ZEB l , ZEB2, ZFANDl, ZFAND5, ZHX3, ZMIZ l, ZMYM2, ZNF12, ZNF148, ZNF219, ZNF227, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF37A, ZNF37BP, ZNF395, ZNF583, ZNF621 , ZNF652, ZNF655, ZNF674, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF827, ZNF839 and ZNF91

[00479] Table 5 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value,

[00480] Table 5

Table 5

ABCAl, ABCCl, ABL2, AC AC A, ACAT2, AFF2, AHRR, AK021888, AK310472,

AKAP1, ANK2, ANKUD 1 -EIF4EBP3 , AP2B1, APAFl , ΛΡ1.Ρ2, ARID 1 A, ARMCX3, ASAP1, ASPI-I, ATAD2B, ATF7IP, ATG9A, ΑΧΓ 1, BACE1, BI 1, BNC1, BRPF l , BZW1, Cl lorGO, C l lorf73, C17orf76-ASl, C4orf27, C6orf48, CAB 39, CAMKKl,

CCDC88A, CCDC92, CDC25B, CDC42BPA, CDCA7, CDH1 1 , CDH13, CEP68, CFLAR, COPS7B, CREB5, CUL2, CUL4A, CUXl, CYP51A1 , DCUN1D4, DDRl , DDX39B, DDX42, DENNDIA, DENND5A, DGKA, DHCR24, DHCR7, DIAPH1, ()SAPS I3. DNM2, DOCKl, EFCAB 14, EIF2B3, EPN1, EPT1 , ERC1, ETV5, FADS1 , FADS2, FAF1 ,

FAM198B, FAM219B, FBXOIO, FBX09, FDFT1, FDPS, FER, FEZ1, FHOD3, FLU, FLNB, FNBP1, FOS, FOSB, FOXM1, FYN, GABPB l, GALC, GAS7, GGCT, GJC 1, GPSM2, GRK6, HAS2, HAT1, ITLTF, ITMGA1, HMGB 1, HMGCR, HMGCS 1, 1-IMOXl, HP1BP3, HSDI7B 12, HTT, IDI1, ΓΝΗΒΑ, INSIG1, KANSL3, KIAA1199, KIAA1524, KIAA1715, KIF3A, KLF6, KRT19, KRT34, KRTAP2-3, LAMA2, LARP7, LDLR, LEMD3, LMAN2L, LRCI-I4, LRP8, LSS, MAGED4, MAGED4B, MAN! A2, MEDAG, MEF2D, MEMOl, MFGE8, MICAL2, MMAB, MMS19, MMS22L, MSL3, MSMOl, MTAP,

MTERFD1, MVP, MVK, NASP, NAV2, NEURLI B, FE2L1 , NIDI, NPEPPS, NREP, RGl, NSUN4, NT5C2, NUP153, P4HA1, PABPC 1, PAPD4, PCBP2, PCM1, PCSK9, PDXDC1 , PEPD, PHF19, PHF8, PHTF2, PIK3C2B, PITP B, PLEC, PMS1, POU2F1, PPHLN1, PRKDC, PRSS23, PSMCl, PTPN14, PUF60, PVR, RAB23, RAD23B, R AP I A. RASSF8, RBM10, RCC1, RFWD2, RNFT1, RWDD4, SAMD9L, SART3, SCAF4, SCD, SEC22A, SEC61A1 , SERPINE2, SF 1 , SLC25A17, SLC7A6, SLC7A8, SMN2, SMYD3, SMYD5, SNAP23, SNHG16, SQLE, SQRDL, SQSTM1, SRCAP, SREBFl, STARD4, ST ATI, S TAL L STEAP2, STRN3, SYNE1, TACC1, TAF2, TANC2, TARBPl, TBC1D15, TEP1 , TFCP2, TGFBRAP1, THADA, TIMP2, TLKl, TMEM154, TNS3, T0MM5, TRAF3, TRAKl, TRAPPC12, TRIM2, TRJM26, TRJM65, TSPAN2, U2SURP, UBAP2L, UBE2V1, UCHL5, UHRFIBPIL, VANGLl, VARS2, VPS 13 A, VPS29, VWA8, WSB 1, ΧΪΑΡ, XR 2 YPEL5, ZAK, ZC3H18, ZFAND5, ZMIZl, ZMYM2, ZNF219, ZNF227, ZNF24, ZNF37A, ZNF37BP, Z F395, ZNF652, ZNF674, ZNF74 and Z F778

[00481] Table 6 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TRIM23, TRIM65, TRMT1L, TRPS 1, TXNL1, TXN D1, U2SURP, UBE2G2, UBE2V1 UHMK1 , USP7, VPS29, VWA8, WDR19, WDR37, WiPF l , YPEL5, YTHDF3, Z24749, ZBTB 10. ZBTB7A. ZFAND5. ZMIZL ZNF12. ZNF 148. ZNF335. ZNF395. ZNF583.

[00483] Table 7 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isofomi abundance as a result of iExon or eExon generation in RNA having ititrotiic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

[00484] Table 7

Table 7

ABCB7, ABHD10, ABLIM3, ACACA, ADAM 12, ADAM 17, ADAM33, AGK, AGPS, AHCYL2, AHDC1, AHRR, AK021888, A 310472, AKAP1 , AKAP9, A NA, AMPD2, ANKRD17, ANKS6, ANP32A, ANXA11, ANXA6, APLP2, APP, APPL2, APTX,

ARHGAP22, ARMCX3, ASAP1, ASNS, ASPH, ATG9A, ATP2C , AURKA, ΑΧΓΝ1, B4GALT2, BACE1, BASPl, BEND6, BICDl, BIN1, BRD2, BRPF1, BTBD10, CI l orOO, Cl lorf73, C17orf76-ASl, C4orf27, C6orf48, CAB39, CAPNS1, CASC3, CCDC77,

CCDC88A, CD46, CDC40, CDC42BPA, CDCA7, CDH13, CDK lB, CEP68, CIZ1, CLK4, CNOT1 , COG1, CQL12A1 , COL1A1, COL6A1, COPS7B, CSDE 1 , CSNKIAI, CUXl , CYB5B, CYBRDl, DAB2, DARS, DCBLD2, DCUN1D4, DDAH2, DDR1, DDX39B, DDX42, DENND1A, DENND1 B, DENND5A, DG A, DHFR, DHX9, DIAPH1 , DIAPH3, DIS3L, DNM2, DOCKl, DPP 8, DSEL, EEAl , EFCAB14, EIF2B3, EIF4G1, EIF4G3, ELF2, ENG, ENPP2, EPN1, EXTL2, EYA3, FAF1, FAM198B, FAM3C, FBXO10, FBX018, FBX031 , FBX09, FER, FEZ1, FHOD3, FLU, FN1 , FNBP1, FOCAD, FOSL1, FOXM l , GABPB 1, GALC, GALNTl, GCFC2, GGCT, GIGYF2, GMIP, GNAS, GNL3L, GOLGB1, GPR89A, GPSM2, GREM1, GRK6, GTF2H2B, HAT1, HAUS3, HEG1, HLA-A, HLTF, HP1BP3, HRH1, HSD17B 12, FISD17B4, HIT, LARS, IDH1, IGF2BP2, ITM2C, KCNK2, KIAA1033, KIAA1143, KIAA1522, KIAA1524, KIAA1715, KIF3A, KLHL7, LAMA2, LARP4, LARP7, LATS2, 1.IMS 1. LI C00341, 1.IXC00657, LMAN2L, LM07, LRCH4, LRIGl, LRRC8A, LTBR, LUC7L2, LZTS2, MADD, MAGED4B, MAN1A2, MAP4K4, MEDl, MED AG, MEF2D, MEIS2, MEMO , MICAL2, MKLN1, MLLT4, MMS19,

MPZL1 , MSANTD3, MSG, MSL3, MTAP, MTERFD1, MTHFD1L, MY ADM, MYLK, MY09B, MYOF, NASP, NAV2, NCOA3, NCOA4, ELFA, NEOl, NEURLIB, NF2, NID2, NOL10, NPEPPS, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUP153, NUP35, NUP50, NUSAP1, ODF2, OS9, OSBPL6, P4HA1, P4HB, PABPC l, PAPD4, PARN, PARP4, PCBP2, PCBP4, PCDHGB3, PCGF3, PCMl, PCMTD2, PDE7A, PDXDC l, PEPD, PFKP, PHF19, PHRF1 , PHTF2, PIEZOl, PIGU, ΡΓΓΡΝΑ, ΡΓΓΡΝΒ, PITPNM1 , PLAU, PLSCR3, PLX C l, PMS1, POU2F1, PPAPDCIA, PPHLN1, PPIP5K1, PPP1R12A,

PRKDC, PRMTl , PRSS23, PSMA4, PTK2B, PUF60, PVR, RAB23, RAB2B, RAD1,

RAD23B, RAP ! A, RAPIGDSI, RARG, RASSF8, RBC l, RCC1, RFWD2, RGS3, RNF14, RNFTl, RPL10, RRBPl, RWDD4, SARI A, SCAF4, SCAF8, SCLT1, SCOL SDCBP, SEC22A, SEPT9, SFI , SGOL2, SLC25A17, SLC4A.4, SLC7A6, SMARCC2, SMC4, SMC6, SMCHD1, SMN2, SMPD4, SMYD3, SNAP23, SNUG 16, SOCS2, SOS2, SPATA20, SPATS2, SPG20, SQRDL, SREBFl , SREK1, SRSF3, ST ATI , STAU1, STEAP2, STRN3, STX16, SUPT20H, SYNE1 , SYNE2, SYT15, SYTL2, TAF2, TARBP1 , TARS, TBL2, TCF7L2, TENC1, TUXM2. TEP1, TET3, TGFBR1, THADA, THRB, TJP2, TLE3,

TMEM47, TMEM63A, TNFAIP3, IMP I . TNP03, TNS1, TNS3, TOE1, ΊΌΜΜ5,

TP53INP1, TRAF3, TRAPPC 12, TRIM2, TRIM23, TRIM65, TSC2, TSPAN2, TUBB2C, TXNRD1, UBAP2L, UBE2V1, UCHL5, USP19, VANGL1, VIPAS39, VPS29, VPS51, VWA8, WDR48, WNT5B, WSBl, WWTRl, XRX2, YAPl , YES1, YPEL5, YTHDF3, Z24749, ZBTB24, ZC3H14, ZFANDl, ZFAND5, 71 1X3. ZMIZ1, ZMYM2, ZNF219, ZNF268, ZNF395, ZNF827 and ZNF91

[00485] Table 8 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

[00486] Table 8

Table 8

AC AC A, ACADVL, AFF2, AHCYL2, AHRR, AKAP1, ALDH4A1, ANKRD 17, AP2B1, APL.P2, ASL, ASPH, ATG9A, ATMIN, ATXN3, BAG2, BASP1 , BRPFl, BSCL2,

Cl lorf30, Cl lorf73, C 17orf76-ASl, C6orf48, C9orf69, CAB39, CALU, CDC25B,

CDC42BPA, CDKALl, CLIC1, COL12A1, COL1A1, COL6A1, CSNK 1A1, CTDSP2, CUL2, CUL4A, DAXX, DCAF10, DDAH1, DDR1 , DDX39B, DENND1 A, DGCR2, DKFZp434M1735, DKK3, DNM2, DST, EEF 1A1, EFCAB 14, EHMT2, EIF4G1, EIF4G2, EIF4G3, ENSA, EXOl , FAM1 1 1A, FAM198B, FAM65A, FBX034, FEZ l, FGD5-AS1, FGFRLl, FIJI, FN1, FOXK1 , FOXM1, FUS, GALC, GAL-NT 1, GAS7, GCFC2, GGCT, GJCi, GNA13, GNL3L, GOLGA4, GPRl, GREMl, HEGl, HLA-A, HLA-E, HLTF, HNRNPR, HNRNPUL1 , IQCE, ITGB5, ITSNl, KIAA1033, KIF2A, KIF3A, KLC2, LATS2, I IMS ! , LINC00341, LINC00657, LONP1, L-OX, L-UC7L2, MBD1, MBOAT7, MEF2D, MEIS2, MICAL2, MKL1, MKNK2, MLST8, MPPEl, MSL3, MSRB3, MTRR, MY ADM, MYLK, MYOID, NAA35, NAV1 , NAV2, NCOA l, NFX1, NKX3-1, NOM03, NRG I , XI. DT I, NUPL1, NUSAP1, OSMR, P4HA1, P4HB, PAPD4, PARD3, PARN, PARP14, PARVB, PCBP2, PCBP4, PCGF3, PDLIM7, PDXDCl, PEX5, PFKP, PHRF1, PI4K2A, POLE3, POLR3D, POSTN, PPARA, PPP6R1, PPP6R2, PRNP, PXN, RAB34, RAD23B, RALB, RAP1A, RASSF8, RBCK1, RBFOX2, RGS IO, RIF l, RNF14, RNF 19A, SAMD9, SCAF4, SDCBP, SERPINE2, SF I , SH3RF 1 , SKIL, SLC25A17, SLC4A4, SMG1, SMN2, SNHG16, SREBF l , STATS, STC2, STEAP2, STRN3, SYNEl, SYNE2, TACC1, TARS, TGFBI, TMEM47, TNC, TNFRSF 2 A, TNS1, TRAF3, TRIM28, TSC2, TSHZ1, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRD1, UBE2G2, UBE2V1 , UBQLN4, UNC5B, US PI 9, VARS2, VCL, VPS29, WDR37, WIPF 1, WWTR1, ZC3H12C, ZCCHC11, ZEB 1, ZEB2, ZFA D1 , ZFAND5, ZMIZ1, ZNF28, ZNF281 , ZNF655, ZNF764 and ZNF839

[00487] Table 9 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically si nificant p value.

[00489] Table 10 shows genes that demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having an intronic REMS sequence in cells treated with Compound 64 24 nm and 100 nm) resulting in a statistically significant adjusted Fisher's Exact Test p value.

[00491] Table 11 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value,

[00492] Table 11

Table 11

APOA2, ASAP1, BRCAl , BRCA2, CDKN1 C, CRX, CTRC, DENND5A, DIAPH3, DMD, DNAH1 I, EIF2B3, GALC, HPS1, H IT, IKBKAP, KIAA1524, LMNA, MECP2, PAPD4, PAX6, PCCB, PITPNB, PTCH1, SLC34A3, SMN2, SPINK5, SREKl, TMEM67, VWF, XDH and XRN2

[00493] 'Table 12 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon or formation of an eExon with a corresponding change in isoform abundance as a result of iExon or eExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

[00494] Table 12

Table 12

ABCA1, ABCAIO, ABCB7, ABCB8, ABC C L ABCC3, ABL2, ABLIM3, ACACA,

ACADVL, ACAT2, ACTA 2, A DA L AD AMI 5, AD AM I 7, ADAM23, ADAM33,

ADAMTSl, ADAMTS19, ADCY3, ADDl, ADGRG6, ADH6, ADHFEl, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1 , AHRR, AJUBA, AK021888,

AK 10472, AKAP1, AKAP3, AKAP8L, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, ANK3, ANKFY1, ANKUD 1 -EIF4EBP3 , ANKRA2, ANKRD13C,

ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA6, AP2B1, AP4B 1 -AS1 , APAFl, APIP, APOA2, APP, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGAP5, ARHGEF16, ARID 1 A, ARID2, ARID5B, ARL9, AR1 . 1 5. ARL5B, ARMCX3, RSJ.

ASAPl, ASICl, ASL, ASNS, ASPH, ATAD2B, ATF6, ATF7IP, ATG9A, ATMIN, ATP2A3, ATP2C1, ATXNL ATXN3, AURKA, B3GALT2, B3GNT6, B4GALT2, BACE1, BAG2, BASP1 , BC033281 , BCAR3, BCL2L15, BCYRN1 , BECN1, BEND6, BHMT2, BICDl, BIN1, BIN3, BIN3-IT1, BIRC3, BIRC6, BNC 1 , BNC2, BRCAl, BRCA2, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1QTNF9B-AS1 , Clor£27, Clorf86, C10orf54, C I l orf30, C I lorf70, C I lorf73, Cl lor†76, Cl lorf94, C12orf4, C12orf56, C14orfl 32,

C17orf76-AS l, C19orf47, C2orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CA13, CA3, CAB39, CACNA2D2, CACNB l, CACNB4, CADM:1 , CADM2, CALU, CAMK 1, CAN 1)2 CAPNS1 , CASC3, CASP7, CASP8AP2, CAVL CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCNL2, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, ( 1)1 1 1 1 , Table 12

CDH13, CDH18, CDK11B, CDK16, CDKALl, CDKN1C, CECR7, CELSR1, CEMIP, CENPI, CEP1 12, CEP 162, CEP 170, CEP 192, CEP68, CFH, CFLAR, CHD8, CHEK1, CHRM2, CIITA, CIZ 1, CLDN23, CLIO, CLK4, CLTA, CMAHP, CNGA4, CNOT1, C RIP1, CNTD1, CMSS1, CNOT7, C RIP1, CNTN1, CGG1, COL1A1, COLl lAI, COL12A1 , COL14A 1, COL15A1 , COL5A1, COL5A3, COL6A1, COL6A6, COL8A1 , COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1 , CRTAP, CRX, CRYBG3, CRYL1, CSDE1, CSNK1A1, CS 1E, CSNK1G1 , CTDSP2, CTNND1, CTRC, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1 , CYGB, CYPIB I, CYP51A1, DAAMl, DAB2, DACT1, DAGLB, BARS, DAXX, DCAFIO,

DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDRl , DDX39B, DDX42, DDX50, DEGSl, DENNDl A, DENNDIB, DENND4A, DENND5A, DEPTOR, DETl, DFNB59, DGCR2, DGK1, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPHl , DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1 , DLG5, DMD, DM XI . I . DNAH8, DNAH1 1, DNAJA4, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP8, DSEL, DST, DSTN, DYNC1I1, DYRKIA, DZIP IL, EBF1, EEA1 , EEF1A1 , EFCAB 14, EFEMP1 , EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, HI G2. EIF4G3, ELF2, ELM02, ELN, ELP4, EMX20S, EN AH, ENG, ENGX1, ENPP1, ENPP2, ENSA, EP300, EPT1, ERC1, ERC2, ERCC1 , ERCC8, ERLIN2, ERRFIl, ESM1, ETV5, EVC, EVC2, EXOl, EXOC3, EXOC6B, EXTL2, EYA3, F2R, FADSl, FADS2, FAFl, FAIM, FAMl 1 1A, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM195B, FAM198B, FAM20A, FAM208B, FAM219A, FAM219B, FAM3C, FAM46B, FAM49B, FAM65A, FAM65B, FAM69B, FAP, FARPl, FBLN2, FBN2, FBX1..16, FBXL6, FBX09, FBXO10, FBX018, FBX03 1 , FBX034, FBX09, FCHOl , FDFT1, FDPS, PER, FEZ 1, FGD4, FGD5-AS1 , FGFR2, FGFRL1, FGI.2, FHOD3, FLU, FLNB, FLT1 , FN1 , FNBP1 , FOCAD, FOS, FOSB, FOSL1, FOXK1, FRAS1, FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GBP1, GCFC2, GLCE, GCNT1, GDF6, GGACT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNG12, GNL3L, GOLGA2, GOLGA4, GOLGB l, GORASPl, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM 1, GRK6, GRTP1 , GSE1, GTF2H2B, GTSF1, GUCAIB, GULP1, GXYLTl, HAPLNl, HAPLN2, HAS2, HA S3, HAT 1 , HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEYl, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB1 , HMGCR, HMGN3-AS1, HMGCSl , HMGXB4, HOOKS, HOXB3, HMOX1, HNMT, HNRNPR, HNRNPUL1, HP1BP3, HPSl, HRH1, HSD17B 12, HSPAIL, ΗΤΑΊΊΡ2, HTT, IARS, IDH1, IDI1, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IKBKAP, IL16, IL6ST, ΓΝΑ, ΓΝΗΒΑ, INO80, IPP4B, ΓΝΡΡ5Κ, INSIG1, MTU, INVS, IQCE, IQCG, ITCH, ITGA1 1, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1 , IVD, KANSL.3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1 199, KIAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549, KIAA1 715, KIAA1755, KIDINS220, KIF14, KIF2A, KIF21 A, KIF3A, KIT, KLC1 , KLC2, KLF17, KL.F6, KLHL7, KLRG1 , KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAPl-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB I, LAMB2P1, LARP4, LATS2, LDLR, LEMD3, LETM2, LGALS3, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINC00341, LINC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LTNC00886, LINC00961, LINCOIOl 1, LTNCOl 118, LINC01204, LINCR-0002, LING02, LMAN2L, LMNA, LM07, LMOD1, LOC400927, LONP1, LOX, LPHN1 , LRBA, Table 12

LRCH4, LRIG1, LRP4, LRP8, LRRC1, LRRC32, LRRC39, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRM1, LZTS2, MACROD2, MAFB, MAGED4, MAGED4B, MAMDC2, MA 1A2, MAN2A1, MAN2C1, MANEA, MAP4K4, MAPKIO, MAPK13, MARCH7, MARCH8, MASPL MB, MB21D2, MBDl, MBOAT7, MC4R, MCMIO, MDM2, MDN , MEAF6, MECP2, MED1, MED13L, MEDAG, MEF2D, MEGF6, MEIS2, MEM01, MEPCE, MFGE8, MFN2, MEAT, MICAL2, MINPP1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MN1,

M0RF4L1 , M0XD1, MPPE1 , MPZL1 , MRPL3, MRPL.45, MRPL55, MRPS28, M VI I, MSA TD3, MSG, MSH2, MSH4, MSH6, MSL3, MSMOl, MSRB3, MTAP, MTERF3, MTERFDl, MTHFD1L, MTMR3, MTMR9, M F . Mi. L MM), MVK, MIXRAS, MY ADM, MYB, MYCBP2, MYLK, MYOID, MY09B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCGAl, NCOA3, NCOA4, NCSTN, NDNF, NEDD4, NELFA, NEOl , NEURL1 B, NF2, NFASC, NFE2L1 , NFX1, NGF, NGFR, NHLH1, NIDI, NID2, NIPAl, NKX3-1, NLGN1, NLN, NOL10, NOM03, NOTCH3, NOTUM, NQVA2, NOX4, NPEPPS, NRDl, NREP, NRGl , NRROS, NSUN4, NT5C2, NT5E, NTNGI, NUDT4, NUP153, NUP35, NUP50, NUPLl, NUSAP1 , OCLN, ODF2, OLR1 , OS9, OSBPL3, OSBPL6, OSBPLIO, OSMR, OXCT1, OXCT2, P4HA1, P4HB, PABPC 1, ΡΑΓΡ2Β, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PAX6, PBLD, PBX3, PCBP2, PCCB, PCDH10, PCDHGB3, PCGF3, PCM1 , PCMTD2, PCNXL2, PCSK9, PDE1C, PDE3A, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLLM7, PDS5B, PDXDC1, PDXDC2P, PEAR1 , PELI1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1 , PHTF2, PI4K2A, PIEZOL PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNMl, PITPNM3, PLAU, PLEC, PLEK2, PLEKHA1 , PLEKHA6, PLEKHB2,

PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1 , PMS 1 , PNISR, PGDN, POLE3, POLN, POLRIA, POLR3D, POMT2, POSTN, POU2F 1, PPAPDC1A, PPARA, PPARG, PPFIBP1, PPIP5K1, PPIP5K2, PPM1E, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKCA, PRKDC, PRKGl, PRMTl, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMCl, PSMD6, PSMD6-AS2, PTCH1, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD , RAD9B,

RAD23B, RAF1, RALB, RAP1GDS 1 , RAPGEFl, RARG, RARS, RARS2, RASIP1,

RASSF8, RBBP8, RBCK1, RCOR3, RBFOX2, RBKS, RBM10, RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGL1, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF130, RNF144A, RNF213, RNF38, RNFT1, ROR1, ROR2, RPA1, RPF2, RPL10, RPS10,

RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SARI A, SART3, SCAF4, SCAF8, SCARNA9, SCO, SCLT1, SCOl, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SF3B3, SGIP1, SGK3, SGMS 1 , SGOL2, SGPLl , SH2B3, SH3RF1, SH3YL1 , SHROOM3, SIGLEC10, SKA2, SKIL, SKP1, SLC12A2, SLC24A3, SLC25A16, SLC25A17, SLC34A3, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A1 1 , SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1 , SMG1, SMG1P3, SMOX, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SNX24, SNX7, SOCS2, SOCS6, SOGA2, SON, SORBS2, SORCS1,

SORCS2, SOS2, SOX 7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPINK 5, SPRED2, SPRYD7, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1,

SRGAP1, SRRM1 , SRSF3, SSBP1 , STAC2, STARD4, STAL L STAT3, STAT4, STAU1 , Table 12

STC2, STEAP2, STK32B, STRAD8, STRIP 1, STRN4, STS, STX16, STXBP4, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNP02, SYNP02L, SYT15, SYTL2, TACC1 , TAF2, TAGLN3, TANC2, TANG06, TARBP1, TARS, TASP1, TBC1D15, TBCA, TBL IXRI, TBL2, TCF12, TCF4, TCF7L2, TEKT4P2, TENC1, TENM2, TEP1 , TET1, TET3, TEX21 P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1 ,

TGFBRAP1 , TGM2, THADA, TI1AP4, THBS2, THRB, TLAM1, TIMP2, TJAPI, TJP2, TLE3, TLK1, TMC3, TMEM67, TMEM102, TMEM119, TMEM134, TMEM154,

TMEM189-UBE2 VI , TMEM214, T MEM256-P L S CR 3 , TMEM47, TMEM50B, TMEM63A, TMX3, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, TNFRSF 14, TNIP1, TNKS 1BP1, TNP03, TNRC18P1, TNS1, TNS3, TNXB, ΊΌΕ1, TOMM40, TOMM5, S OPORS,

TP53AIP1, ΤΡ53ΓΝΡ1, TPRG1, TRAF3, TRAK1 , TRAPPC12, ί RIB i , TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMTIL, TRPC4, TRPS1, TSC2, TSHZ1, TSHZ2, I S PAX 1 1, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBE1, TXNIP, TXNL1, TXNL4B, TXNRD1, TYW5, U2SURP, UBAP2L, UBE2D3, UBE2G2, UBE2L3, UBE2V1 , UBN2, UBQLN4, UCHL5, UHMK1, UHRFTBPIL, UNC13B, UNC5B, URGCP, URGCP-MRPS24, USP19, USP7, USP27X, UVRAG, VA.NGL1, VARS2, VAV2, VCL, VDAC2, VIM-ASI, VIPAS39, VPS 13 A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR90, WDR9 I , WHSC2, WIPF1, WISPl, WNKl, WNT5B, WNTIOB, WSB l, WWTRl, XDH, XIAP, XRN2, YAPl, YDJC, YESl, YPEL5, YTHDF3, Z24749, ZAK, ZBTB IO, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC1 1 , ZEB 1 , ZEB2, ZFAND1 , ZFAND5, ZFP82, ZHX3, ZMIZ1, ZMIZ l-AS l , ZMIZ2, ZMYM2, ZNF12, ZNFI38, ZNF 148, ZNF208, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF280D, ZNF281 ,

ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF426, ZNF431 , ZNF583, ZNF618, ZNF62I, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF730, ZNF74, ZNF764,

ZNF777, ZN 1-778, ZNF780A, ZNF7804A, ZNF79, ZNF827, ZNF836, ZNF837, ZNF839, ZNF91 and ZSCAN25

METHODS OF PREVENTING AND/OR TREATING DISEASES

[00495] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease associated with the aberrant expression of a product of a gene (e.g., an niRNA transcript or protein), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non- human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a 5' splice site, a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3 ' order: a first 5' splice site, a first branch point, a first 3 ' splice site, an intronic REMS, a second branch point, and a second 3 ' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3 ' order: an intronic REMS, a branch point, and a 3 ' splice site.

[00496] In certain aspects, the gene is any one of the genes described herein. In certain aspects, the gene contains a nucleotide sequence encoding a non-endogenous intronic REMS. In one aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein) described herein, the methods comprising administering to a human or non- human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[00497] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease associated with aberrant expression of a product of a gene described herein (e.g., an mRNA, RNA transcript or protein), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a branch point, a 3 ' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3 ' order: a first 5' splice site, a first branch point, a first 3 ' splice site, an intronic REMS, a second branch point, and a second Y splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3 ' order: an intronic REMS, a branch point, and a 3 ' splice site.

[00498] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein) described herein, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutical ly acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a 5' splice site, a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site,

[00499] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease associated with aberrant expression of a product of a gene described herein (e.g., an niRNA, RNA transcript or protein), comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein.

[00500] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a 5' splice site, a branch point, a Y splice site and an intronic REMS, In another specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order; an intronic REMS, a branch point, and a 3' splice site.

[00501] In certain aspects, the gene is any one of the genes described herein. In certain aspects, the gene contains a nucleotide sequence encoding the non-endogenous intronic REMS. In one aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[00502] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a 5' splice site, a branch point, a 3 ' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a branch point, a 3 ' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3 ' order: a first 5' splice site, a first branch point, a first 3 ' splice site, an intronic REMS, a second branch point, and a second 3 ' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3 ' order: an intronic REMS, a branch point, and a 3 ' splice site.

[00503] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RN A transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a 5' splice site, a branch point, a 3 ' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript contains in 5' to 3' order: a first 5' splice site, a first branch point, a first 3 ' splice site, an intronic REMS, a second branch point, and a second 3 ' splice site. In another specific aspect the precursor RNA transcript contains in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00504] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene described herein is benefi cial to the prevention and/or treatment of the disease, the methods comprising

administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, one, two, three or more RNA isoforms encoded by a gene described herein are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein.

[00505] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which a change in the level of expression of one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a 5' splice site, a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript comprises in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site. [00506] In certain aspects, the gene is any one of the genes described herein. In certain aspects, the gene contains a nucleotide sequence encoding a non-endogenous intronic REMS. In one aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

[00507] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a 5' splice site, a branch point, a 3 ' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript compri ses in 5 ' to 3 ' order: a branch point, a 3 ' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3 ' order: a first 5 ' splice site, a first branch point, a first 3 ' splice site, an intronic REMS, a second branch point, and a second 3 ' splice site. In another specific aspect the precursor RNA transcript comprises in 5' to 3 ' order: an intronic REMS, a branch point, and a 3 ' splice site.

[00508] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent, in a specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a 5' splice site, a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. In another specific aspect, the precursor RNA transcript comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an intronic REMS, a second branch point, and a second 3' splice site. In another specific aspect the precursor RNA transcript comprises in 5' to 3' order: an intronic REMS, a branch point, and a 3' splice site.

[00509] In another aspect, provided herein are methods for modifying RNA splicing in order to prevent and/or treat a disease in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene described herein is beneficial to the prevention and/or treatment of the disease, the methods comprising

administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific aspect, one, two, three or more RNA isoforms encoded by a gene described herein are decreased following administration of a compound of Formula (!) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes described herein,

[00510] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent, treat or prevent and treat a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is benefi cial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject,

[00511] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent, treat or prevent and treat a di sease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5' to 3 ' order: a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3 ' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject,

[00512] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent, treat or prevent and treat a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1 A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00513] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent, treat or prevent and treat a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure IB, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00514] In another aspect, provided herein is a method for modifying RNA splicing in order to prevent, treat or prevent and treat a disease in a subject in which the modulation (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an nitron and wherein the DNA nucleotide sequence encodes exonic and intronic elements illustrated in Figure 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

[00515] In a specific aspect, the gene is a gene described in a table in this disclosure.

[00516] In some aspects, the compound of Formula (I) or a form thereof that i s administered to a subject is a compound described herein.

[00517] In a specific aspect, the methods for modifying RNA splicing in order to prevent a disease described herein prevent the onset or development of one or symptoms of the disease. In another aspect, the methods for preventing a disease described herein prevent the recurrence of the disease or delays the recurrence of the disease. In another aspect, the methods for treating a disease described herein has one, two or more of the effects: (i) reduce or ameliorate the severity of the disease; (ii) inhibit the progression of the disease; (iii) reduce hospitalization of a subject; (iv) reduce hospitalization length for a subject; (v) increase the survival of a subject; (vi) improve the quality of life of a subject, (vii) reduce the number of symptoms associated with the disease; (viii) reduce or ameliorates the severity of a symptom(s) associated with the disease; (ix) reduce the duration of a symptom(s) associated with the disease, (x) prevent the recurrence of a symptom associated with the disease; (xi) inhibit the development or onset of a symptom of the disease, and/or (xii) inhibit of the progression of a symptom associated with the disease.

ARTIFICIAL GENE CONSTRUCTS

[00518] Also provided herein are artificial gene constructs comprising a DNA sequence encoding exons and one or more introns, wherein the nucleotide sequence encoding at least one intron comprises in 5' to 3 ' order: a nucleotide sequence encoding a branch point, a nucleotide sequence encoding a 3 ' splice site and a nucleotide sequence encoding an intronic REMS, and artificial gene constructs comprising an RNA sequence that compri ses exons and one or more introns, wherein at least one intron comprises in 5' to 3' order: a branch point, a 3' splice site and an intronic REMS. The DNA sequence described herein can be or derived from, for example, a genomic DNA sequence or a DNA analog thereof. The RN A sequence described herein can be or derived from, for example, a precursor RNA transcript or an RNA analog thereof. As used herein, the term " artificial gene construct" refers to a DNA or RNA gene construct that comprises a nucleotide sequence not found in nature.

[00519] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an iREMS, a second branch point and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, and wherein r is adenine or guanine and n is any nucleotide.

[00520] In another aspect, provide herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RN A nucleotide sequence of the intron comprises in 5' to 3' order: an iREMS, a branch point and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, and wherein r is adenine or guanine and n is any nucleotide.

[00521] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in Figure 1A.

[00522] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in Figure IB.

[00523] In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein the RN A sequence comprises exonic and intronic elements illustrated in Figure 1C.

[00524] In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3' splice site, an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, and wherein r is adenine or guanine and n is any nucleotide.

[00525] In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3' order: a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site, wherein the nucleotide sequence encoding the iREMS comprises an DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide.

[00526] In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the DNA sequence encodes exonic and intronic elements illustrated in Figure 1 A.

[00527] In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the DNA sequence encodes exonic and intronic elements illustrated in Figure IB.

[00528] In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the DNA sequence encodes exonic and intronic elements illustrated in Figure 1 C.

[00529] In one aspect, provided herein are artificial gene constructs comprising an intronic REMS. In one aspect, an artificial gene construct comprises genomic DNA or DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS, which may be upstream or downstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site, is introduced into the nucleotide sequence encoding an intron by genetic engineering. In another aspect, an artificial gene construct comprises DNA encoding exons and one, two or more introns, wherein the nucleotide sequence encoding an intron comprises a nucleotide sequence encoding an intronic REMS, a nucleotide sequence encoding a 3 ' splice site(s) and a nucleotide sequence encoding a branch point(s) sequence, wherein the nucleotide sequence encoding an intronic REMS, which may be upstream or downstream of at least one nucleotide sequence encoding a branch point and at least one nucleotide sequence encoding a 3 ' splice site, is introduced into the nucleotide sequence encoding the intron by genetic engineering. In another aspect, an artificial gene construct comprises DNA encoding exons and one, two or more introns, wherein the nucleotide sequence encoding an intron comprises a nucleotide sequence encoding a 3 ' splice site(s) and a nucleotide sequence encoding a branch point(s), wherein a nucleotide sequence encoding an intron is modified to introduce a nucleotide sequence encoding an intronic REMS, In some aspects, an artificial gene construct comprises a DNA sequence that is modified to introduce a nucleotide sequence encoding an intronic REMS, wherein the location of the intronic REMS is as illustrated in any of Figures 1 A-IC. In certain aspects, the DNA sequence chosen to be used in the production of an artificial gene construct may contain a nucleotide sequence encoding an intronic REMS and an additional nucleotide sequence encoding an intronic REMS or a branch point or a 3 ' splice site sequences are introduced. In specific aspects, the nucleotide sequence encoding an intronic REMS or a branch point or a 3 ' splice site sequence is a nucleotide sequence encoding a non-endogenous intronic REMS or branch point or 3 ' splice site sequence, i .e., a sequence not naturally found in the DNA sequence of the artificial gene construct. In certain aspects, the artificial gene construct comprises other elements, such as a promoter (e.g., a constitutive, inducible or tissue specific promoter), a Poly(A) site, a transcription termination site, and a transcription binding site(s). In certain aspects, the artificial gene construct comprises at least the sequences to encode a therapeutic protein. In some aspects, the artificial gene construct comprises at least an intronic REMS for a gene described herein. In certain aspects, the artificial gene construct comprises at least the exons of a detectable reporter gene, such as green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein, beta galactosidase, renilla luciferase, firefly luciferase, etc.

[00530] In certain aspects, an artificial gene construct is produced as follows: a nucleotide sequence encoding an intronic REMS is introduced into a nucleotide sequence encoding an existing intronic branch point and intronic 3 ' splice site of genomic DNA or DNA, wherein the DNA encodes two or more exons and one or more introns, and wherein the nucleotide sequence encoding the intronic REMS is upstream of a nucleotide sequence encoding a branch point and a 3' splice site. In some aspects, an artificial gene construct is produced as follows: a nucleotide sequence encoding an intronic REMS is introduced upstream of a nucleotide sequence encoding a branch point and a 3' splice site of genomic DNA or DNA, wherein the DNA encodes two or more exons and an intron(s). In a specific aspect, the nucleotide sequence encoding the intronic REMS is introduced internally within a nucleotide sequence encoding an intron. In certain aspects, an artificial gene construct is produced as follows: a nucleotide sequence encoding an intronic REMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3' splice site are introduced into a cDNA, wherein the nucleotide sequence encoding the intronic REMS may be upstream of the branch point and 3' splice site, respectively, or may be downstream of the 3' splice site and branch point, respectively. The nucleotide sequence encoding the intronic REMS functions as a 5' splice site. In certain aspects, the nucleotide sequence encoding the intronic REMS is internally within an intron. In a specific aspect, the genomic DNA or DNA chosen for use in the production of an artificial gene construct does not contain one or more of a nucleotide sequence encoding an intronic REMS or a nucleotide sequence encoding a branch point or a nucleotide sequence encoding a 3' splice site. In certain aspects, the genomic DNA or DNA chosen for use in the production of an artificial gene construct contains an intronic REMS and an additional intronic REMS is introduced. In some aspects, care should be taken to introduce a nucleotide sequence encoding an intronic REMS into a DNA sequence so as not to disrupt an open reading frame or introduce a stop codon. The introduction of a nucleotide sequence encoding an intronic REMS into a DNA sequence may or may not result in an amino acid change at the protein level. In certain aspects, the introduction of a nucleotide sequence encoding an intronic REMS into a DNA sequence results in an amino acid change at the protein level. In some aspects, this amino acid change is a conservative amino acid substitution. In other aspects, the introduction of a nucleotide sequence encoding an intronic REMS into a DNA sequence does not result in an amino acid change at the protein level. Techniques known to one of skill in the art may be used to introduce an intronic REMS and other elements, such as a branch point sequence or 3' splice site sequence into a DNA sequence, e.g., gene editing techniques such as the CRISPR-Cas approach, Transcription Activator-Like Effector Nucleases (TALENs), or Zinc finger nucleases (ZFNs) may be used.

[00531] In certain aspects, an artificial gene construct comprises an RNA sequence

comprising exons and one, two or more introns, wherein an intronic REMS 5' splice site, which is downstream of a 3' splice site, is introduced into an intron by genetic engineering. In another aspect, an artificial gene construct comprises an RNA sequence comprising exons and one, two, or more introns, wherein an intron comprises a 5' splice site(s), a 3' splice site(s) and a branch point(s), wherein an intronic REMS, which is upstream of a 3' splice site, is introduced into an intron by genetic engineering. In another aspect, an artificial gene construct comprises an RNA sequence comprising exons and one, two, or more introns, wherein an intron comprises a 3 ' splice site(s) and a branch point(s), wherein an intron is modified to introduce an intronic REMS. In specific aspects, the intronic REMS is non-endogenous, i.e., not naturally found in the RNA sequence of the artificial gene construct. In certain aspects, the artificial gene construct comprises other elements, such as a promoter (e.g., a tissue-specific promoter or constitutive! y expressed promoter), 5' untranslated region, 3' untranslated region, a binding site(s) for RNA binding protein(s) that regulate splice site (5' and 3') recognition and cataly sis, a small molecule RNA sensor(s), e.g., riboswitches, stem-loop structures, and/or internal ribosome entry sites (IRES) and the like. In certain aspects, the artificial gene construct comprises at least the introns of a gene encoding a therapeutic protein. In some aspects, the artificial gene construct comprises at least the introns of a gene described herein. In a specific aspect, the RNA transcript chosen to be used in the production of an artificial gene construct does not contain an intronic REMS. In certain aspects, the RNA transcript chosen to use in the production of an artificial gene construct contains an intronic REMS and an additional exonic or intronic REMS is introduced. In other aspects, the artificial gene construct comprises at least one intron and two exons of a detectable reporter gene, such as green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein, beta gaiactosidase, renilia luciferase, firefly luciferase, etc.

[00532] In certain aspects, an artificial gene construct is produced as follows: an intronic REMS is introduced into an existing 5' splice site of precursor RNA, wherein the RN

comprises two or more exons and one or more introns, and wherein an intronic REMS is upstream of a branch point sequence and a 3' splice site sequence. In some aspects, an artificial gene construct is produced as follows: an intronic REMS is introduced upstream of a 3' splice site of a precursor RNA, wherein the RNA comprises two or more exons and an intron(s). In a specific aspect, the intronic REMS is introduced internally within an intron. In certain aspects, an artificial gene construct is produced as follows: a branch point, a 3 ' splice site and an intronic REMS are introduced into an mRNA, wherein the REMS may be either downstream or upstream of the branch point and 3 ' splice site. The intronic REMS functions as a 5' splice site. In certain aspects, the intronic REMS is located in an intron. In some aspects, care should be taken to introduce an intronic REMS into an RNA sequence so as not to di srupt an open reading frame or introduce a stop codon. The introduction of an intronic REMS into an RNA transcript may or may not result in an amino acid change at the protein level . In certain aspects, the introduction of an intronic REMS into an RNA transcript results in an amino acid change at the protein level . In some aspects, this amino acid change is a conservative amino acid substitution. In other aspects, the introduction of an intronic REMS into an RN A transcript does not result in an amino acid change at the protein level. Techniques known to one of skill in the art may be used to introduce an intronic REMS and other elements, such as a branch point or 3 ' splice site into an RNA transcript.

[00533] In some aspects, an artificial gene construct is present in a viral vector (e.g., an adeno-associated virus (AAV), self-complimentary adeno-associated vims (scAAV), adenovirus, retrovirus, lentivirus (e.g., Simian immunodeficiency virus, human immunodeficiency virus, or modified human immunodeficiency virus), Newcastle disease virus (NDV), herpes virus (e.g., herpes simplex virus), alphavirus, vaccina virus, etc.), a plasmid, or other vector (e.g., non-viral vectors, such as iipoplexes, liposomes, polymerosomes, or nanoparticles).

[00534] In some aspects, the artificial gene construct is an RNA molecule modified to enable cellular uptake. In certain aspects, the artificial gene construct is an RNA molecule containing pseudouridine or other modified/artificial nucleotides for enhanced cellular uptake and gene expression ,

[00535] The use of an artificial gene construct described herein in gene therapy allows one to regulate the amount and type of a protein produced from the construct depending on the presence of a compound described herein. The compound is essentially a tunable switch that, depending on the amount and duration of the dose of the compound, regulates the amount and type of protein produced.

[00536] In certain aspects, an RNA transcript transcribed from an artificial gene construct that is DNA would not produce or produce substantial ly less functional protein in the presence of a compound described herein than the amount of functional protein produced in the absence of a compound described herein. For example, if the artificial gene construct comprises a nucleotide sequence encoding an intronic REMS, which is downstream of an intronic nucleotide sequence encoding a 3' splice site, then the creation of an intronic exon would ultimately result in less amount of the original protein {i.e., protein produced when KNA splicing is not modified) being produced in the presence of a compound described herein. Alternatively, in certain aspects, an RNA transcript transcribed from an artificial gene construct that is DNA would produce or would produce substantially less functional protein in the presence of a compound described herein than the amount of functional protein produced in the absence of a compound described herein,

[00537] In certain aspects, an artificial gene construct or vector comprising an artificial gene construct is used in cell culture. For example, in a cell(s) transfected with an artificial gene construct or transduced with a vector comprising an artificial gene construct, the amount and type of a protein produced from the artificial gene construct can be modulated or modified depending upon whether or not a compound described herein is contacted with the transfected ceil(s). For example, if the artificial gene construct comprises a nucleotide sequence encoding an intronic REMS, which is downstream of a nucleotide sequence encoding a Y splice site, then the likelihood of producing an intronic exon would be less in the absence of the compound relative to in the presence of the compound . Thus, the use of an artificial gene construct described herein allows one to regulate the amount and type of a protein produced from the construct depending on whether or not a compound described herein is present. In other words, a compound described herein is essentially a switch that regulates the amount and type of protein produced. This regulation of the production of protein could be useful, e.g., when trying to assess the role of certain genes or the effects of certain agents on pathways. The amount of the protein produced can be modified based on the amount of a compound described herein that is contacted with the transfected cell and/or how long the compound is contacted with the transfected cell.

[00538] In certain aspects, an animal {e.g., a non-human animal, such as a mouse, rat, fly, etc.) is engineered to contain an artificial gene construct or a vector comprising an artificial gene construct. Techniques known to one of skill in the art may be used to engineer such animals. The amount of protein produced by this engineered animal can be regulated by whether or not a compound described herein is administered to the animal. The amount of the protein produced can be titrated based on the dose and/or the duration of administration of a compound described herein to the engineered animal. In certain aspects, the artificial gene construct encodes a detectable reporter gene, such as green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein, beta galactosidase, renilla luciferase, firefly luciferase, etc. In accordance with this aspect, the engineered animal may be used to monitor development at different stages, visualize tissue function, etc. In other aspects, the artificial gene construct encodes a therapeutic gene product, such as described herein. In accordance with this aspect, the engineered animal may be used to monitor development at different stages or in functional biological studies where a certain protein or protein isoform needs to be expressed only for a period of time and not constitutively, etc,

[00539] In certain aspects, an artificial gene construct or a vector comprising an artificial gene construct are used in gene therapy. Non-limiting examples of vectors include, but are not limited to, plasmids and viral vectors, such as vectors derived from replication defective retroviruses, adenoviruses, adeno-associated viruses and baculoviruses. The vector can be an RNA vector or preferably a DN A vector.

GENE THERAPY

[00540] In another aspect, artificial gene constructs or vectors comprising an artificial gene construct may be provided for use in gene therapy. The use of an artificial gene construct described herein in gene therapy allows one to regulate the amount and type of a protein produced from the construct depending on whether or not a compound described herein is present. The compound is essentially a switch that regulates the amount and type of protein produced.

[00541] In certain aspects provided herein, an RNA transcript transcribed from an artificial gene construct that is DNA would produce substantially more functional protein in the presence of a compound descri bed herein than the amount of functional protein produced in the absence of a compound described herein. For example, an artificial gene construct or vector that comprises a nucleotide sequence encoding an intronic REMS, which is downstream of a nucleotide sequence encoding a branch point and a 3' splice site, has a lower likelihood of producing an intronic exon in the absence of a compound described herein. If the protein produced as a result of iExon inclusion is a functional protein, then the result of compound administration would ultimately result in more of the functional protein being produced from the artificial gene construct. Thus, an artificial gene construct or a vector comprising an artificial gene construct may be useful in treating and/or preventing certain conditions or diseases associated with genes when the construct or vector increases the likelihood of producing an intronic exon in the presence of a compound described herein. The conditions or diseases may include those described herein.

[00542] Alternatively, in certain aspects, an RNA transcript transcribed from an artificial gene construct that is DNA would produce substantially less functional protein in the presence of a compound described herein than the amount of functional protein produced in the absence of a compound described herein. For example, an artificial gene construct or vector that comprises a nucleotide sequence encoding an intronic REMS, has a higher likelihood of producing an intronic exon in the presence of a compound described herein. If the protein produced as a result of i Exon inclusion is not a functional protein, but the protein produced without iExon inclusion is a functional protein, then the result of compound administration would result in reduction in the production of a functional protein. However, in the absence of a compound described herein, normal splicing would occur, and the production of the functional protein would not be reduced. The amount and type of the protein produced can be titrated based on dose and duration of dosing of the compound. In a specific aspect, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3' order: a first 5' splice site, a first branch point, a first 3' splice site, an iREMS, a second branch point and a second 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, and wherein r is adenine or guanine and n is any nucleotide.

[00543] In another specific aspect, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5' to 3' order: an iREMS, a branch point and a 3' splice site, wherein the iREMS comprises an RNA sequence GAgurngn, and wherein r is adenine or guanine and n is any nucleotide.

[00544] In another specific aspect, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in Figure 1 A. [00545] In another specific aspect, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements il lustrated in Figure IB ,

[00546] In another specific aspect, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in Figure 1C.

[00547] In another specific aspect, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3 ' order: a nucleotide sequence encoding a first 5' splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3 ' splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3 ' splice site, wherein the nucleotide sequence encoding the iREMS comprises a DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide,

[00548] In another specific aspect, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding a first exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding a second exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5' to 3 ' order; a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3 ' splice site, wherein the nucleotide sequence encoding the iREMS comprises an DNA sequence GAgtrngn, wherein r is adenine or guanine and n is any nucleotide.

[00549] In another specific aspect, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the DNA sequence encodes exonic and intronic elements illustrated in Figure 1 A.

[00550] In another specific aspect, the artificial gene construct used in gene therapy compri ses a DNA sequence encoding two exons and an intron, wherein the DNA sequence encodes exonic and intronic elements illustrated in Figure I B. [00551] In another specific aspect, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the DNA sequence encodes exonic and intronic elements illustrated in Figure 1 C.

[00552] An artificial gene construct, a vector comprising the artificial gene construct, or an RNA molecule comprising an artificial gene construct modified to enable cellular uptake may be introduced into cells or administered directly to patients. In one aspect, an artificial gene construct or a vector comprising the artificial gene construct is introduced into cells ex vivo or in vivo. In a specific aspect, an artificial gene construct or vector is introduced into a cell(s) ex vivo and the cell(s) may be administered to a subject. Various techniques known to one of skill in the art may be used to introduce an artificial gene construct or vector comprising the artificial gene construct into a cell(s), such as electroporation, transfection, transformation, etc. In another aspect, an artificial gene construct or vector comprising the artificial gene construct is administered to a subject. The artificial gene construct or vector comprising the artificial gene construct may be administered to a subject by any technique known to one skilled in the art, e.g., intramuscularly, intravenously, subcutaneously, intradermally, topically, intrathecally, intraperitoneally, intratumorally, etc. In some aspects, the artificial gene construct or vector comprising the artificial gene construct is administered to a subject systemically. In other aspects, the artificial gene construct or vector comprising the artificial gene construct is administered to a subject locally.

MODIFYING- ENDOGENOUS GENES

[00553] In another aspect, provided herein are method for modifying an endogenous gene such that the resulting gene contains a nucleotide sequence encoding an intronic REMS, or contains an additional nucleotide sequence encoding an intronic REMS (in other words, an intronic REMS not naturally found in the endogenous gene, i.e., a non-endogenous intronic REMS), In a specific aspect, provided herein are methods for modifying an endogenous gene such that the resulting gene contains a nucleotide sequence encoding an intronic REMS and contains a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site upstream of the nucleotide sequence encoding the intronic REMS.

[00554] As used herein, the term "endogenous gene" refers to a gene naturally found in a cell or living subject. Techniques known to one of skill in the art can be used to introduce any one, two, or all of the following: a branch point, a 3' splice site, and an intronic REMS into an endogenous gene, e.g., the CRISPR-Cas approach, TALEN, or ZFN may be used. In certain aspects, a nucleotide sequence encoding an existing 5' splice site can be replaced with an intronic REMS or an intronic REMS may be inserted internally within an intron. In some aspects, care should be taken to introduce a nucleotide sequence encoding an intronic REMS into an endogenous gene so as not to disrupt an open reading frame or introduce a stop codon. The introduction of a nucleotide sequence encoding an intronic REMS into an endogenous gene may or may not result in an amino acid change at the protein ievel. In certain aspects, the

introduction of a nucleotide sequence encoding an intronic REMS into an endogenous gene results in an amino acid change at the protein level. In some aspects, this amino acid change is a conservative amino acid substitution. In other aspects, the introduction of a nucleotide sequence encoding an intronic REMS into an endogenous gene does not result in an amino acid change at the protein ievel.

KITS

[00555] In one aspect, provided herein are kits comprising, in a container, an artificial gene construct or a vector comprising an artificial construct. In certain aspects, the kits further comprise a compound described herein, in a separate container, and/or a negative control, such as phosphate buffered saline or a compound that does not recognize an intronic REMS, in a separate container. In a specific aspect, the kits further comprise a positive control, such as a compound described herein as a positive control. In some aspects, the kits further comprise primers and/or antibodies, in one or more separate containers, for assessing the production of an mRNA transcript from an artificial gene construct and/or protein production therefrom.

[00556] In another aspect, provided herein are kits comprising, in one or more containers, the components and/or reagents necessary to produce an artificial gene construct and/or a vector comprising an artificial gene construct. In another aspect, provided herein are kits comprising, in one or more containers, the components and/or reagents necessary to modify an endogenous gene so that it contains a nucleotide sequence encoding an intronic REMS or an additional nucleotide sequence encoding an intronic REMS (in other words, a REMS not naturally found in the endogenous gene, i.e., a non-endogenous REMS), In another aspect, provided herein are kits comprising, in one or more containers, the components and/or reagents necessar to modify an endogenous gene so that the resulting gene contains a nucleotide sequence encoding an intronic REMS and contains a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3' splice site upstream of the nucleotide sequence encoding the intronic REMS. In some aspects, the kits further comprise primers and/or antibodies, in one or more separate containers, for assessing the production of an mRNA transcript from a modified endogenous gene and/or protein production therefrom.

[00557] In another aspect, provided herein are kits comprising, in a container, a compound described herein, and instructions for use. In some aspects, the kits further comprise a negative control, such as phosphate buffered saline or a compound that does not recognize an intronic REMS, in a separate container,

EXAMPLES

[00558] To describe in more detail and assist in understanding the present description, the following non-limiting biological examples are offered to more fully illustrate the scope of the description and are not to be construed as specifically limiting the scope thereof. Such variations of the present description that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the present description and as hereinafter claimed. The example below illustrates the existence of an intronic recognition element for splicing modifier (REMS) that is important for the recognition of a compound described herein, and the binding of such a compound to the intronic REMS on a precursor RNA permits or enhances the splicing of the precursor RNA, and suggests the usefulness of the intronic REMS in combination with a compound described herein for modifying RNA splicing, and for modulating the amount of a gene product.

[00559] Materials and Methods

[00560] Cell treatment: GM04856 lymphocyte cells were diluted in a medium composed of DMEM, 10% FBS and Ix Pen/Strep to a concentration of 2.5e5 cells/mL, 2 mL (500K cells) were seeded in 6-well plates and recovered for 4h at 37°C, 5% CO?.. Compound dilutions were prepared as 2x compound stock in medium (e.g. for final 100 nM, make a 200 nM stock). After 4h recovery, 2 mL of the 2x compound stock were added to each well, resulting in 4 mL/weil with Ix final compound concentration. The cells were incubated for ~20h at 37°C, 5% CO2. After incubation, the cells were pelleted for 5 min at 1000 rpm. The supernatant was vacuum- removed and the cells were resuspended in 350 μL of RLT buffer (w/ 10 μΕ/ιηΕ beta-mercapto- ethanol, RNeasy kit). Total RNA was isolated using the RNeasy Mini Kit from Qiagen according to the manufacturer's instructions. The concentration of the resulting total RNA was determined using Nanodrop and diluted with water to a final concentration of 25 ng/^L.

[00561] Endpoint RT-PCR and RNAseq: Analysis of alternatively spliced mRNAs in cultured cells

[00562] SH-SY5Y ceils derived from a bone marrow biopsy of a female patient with neuroblastoma were plated at 600,000 cells/well in 2 mL DMEM with 10% FBS in 6-weil plates, and incubated for 4 hours in a cell culture incubator (37 °C, 5% CC , 100% relative humidity). Cells were then treated with Compound 64 at different concentrations (in 0.1% DMSO) for 24 hours. After removal of the supernatant, cells were lysed in RLT buffer with β-mercaptoethanol and total RNA was extracted according to the manufacturer's protocol (RNeasy Mini Kit, Qiagen, Inc.).

[00563] One-step RT-PCR was performed using AgPath-ID™ One- Step RT-PCR Reagents (Life Technologies, Inc.) using 50 ng total RNA as input. The following PGR conditions were used: Step 1 : 48°C (15 min), Step 2: 95°C (10 min), Step 3 : 95°C (30 sec), Step 4: 55°C (30 sec), Step 5: 68°C (1 min), repeat Steps 3 to 5 for 34 cycles, then hold at 4°C. The presence of iExons within alternatively spliced mRNAs was identified using primers listed in Tables 13 through 19, which correspond to Figures 2, 3, 4 and 5. PGR products were separated on 2% agarose E-gels (Life Technologies, Inc.), stained with ethidium bromide and visualized using a gel imager (UVP). Results for genes affected by intronic exons generated by treatment with Compound 64 are shown in Table 21 and Table 22 for SH-SY5Y cells treated with Compound 64 at 24 nm and 100 nm, respectively, and Table 23 for HD-1994 cells treated with Compound 64 at 100 nm.

[00564] For RN Aseq, SH-SY5Y cells were treated as described above. Total RNA (3 μg) was used for stranded RNA library preparation and sequencing. The mRNA was enriched using oligo(dT) beads and then fragmented randomly by adding fragmentation buffer, then the cDNA was synthesized by using mRNA template and random hexamers primer, after which a custom second-strand synthesis buffer (Iliumina), dNTPs, RNase H and DNA polymerase I were added to initiate the second-strand synthesis. After a series of terminal repair, ligation and sequencing adaptor ligation, the double-stranded cDNA library was completed through size selection and PGR enrichment. RNA libraries were sequenced in a HiSeq sequencer at >30M per sample, then 150 nt pair end reads were generated. The adapter-sequence containing reads were removed and the remaining reads were mapped to human genome (hg ^' 19) using STAR (version 2.5.1). Only uniquely mapped reads (with MAPQ>10) with <5nt/100nt mismatches and properly paired reads were used. The number of reads in the coding sequence (CDS) region of protein-coding genes and exonic region of non-coding genes were counted and analyzed using DESeq2 (Love et al., 2014). For splicing analysis, reads were counted for different exons annotated or not annotated but identified from RNA-seq. for each exon, a Pereent-Spii ced-In (PSI) value was calculated using the percent of average read number supporting the inclusion of the exon among all reads supporting either the inclusion or the exclusion of an exon. PSI differences between two samples were compared and Fisher's Exact Test was used to determine statistical significance. A PSI increase of >5% and -value <0.01 was used to select statistically significant intronic exons being included by the compound.

[00565] Results: Oligonucleotides corresponding to exons that flank the intron where an iExon is located were used to amplify total RNA purified from untreated (DMSO) or cells treated with Compound 64 (at dose levels 10 nM, 1 μΜ or 10 μΜ).

[00566] The resulting products were run on an agarose gel where the resulting bands of interest for each gene are shown by open and closed arrowheads, where an open arrowhead represents an exon isoform where endogenous wild-type splicing occured; and, where a closed arrowhead represents an exon isoform where an iExon is included in the mRNA. as shown in Figures 2A, 2B, 3 A, 3B, 4 A, 4B, 5 A, 5B and 6A. In all cases, the increase of compound concentration resulted in the appearance of a slower migrating PGR product containing the intronic-derived exon, where the additional bands seen are intermediate spliced products. The asterisk (*) in each Figure represents an event where the targeted exon was skipped.

00567] Table 13 Forward Primers for Figisre 2

Gesie Forward Primer Sequence 5'-3' SEQ ID NO:

DIAPH3 DIAP 6-25 CGGCAGAGTCTCAGTCCAAT 3642

EVC EVC 61-80-KE GGCACTGAGGCAGGAAAAGC 3643

FAM162A FAMl_54-72 GTC GGC GGAGT AGC AAGTG 3644

HIT HTT E49 For TGCCCAGTCATTTGCACCTT 3645

MMS22L MMS22Lel4Fl TGGTGTCTAAGAATGAGGAAATGGTA 3646

NIPA1 NIPAle4Rl TTTGGGGAGTGGATAATCAGCA 3647

PAPD4 PAPD 46-65-KE CCCGGAGCAGTGATGGTGAT 3648

PDXDCl PDXD 23-42 TGTGCCGTGTACCCTGTAAC 3649

RAF 1 ' RAFl 90- Ϊ Ϊ 2-ΚΕ CGACATCCACACCTAATGTCCAC 3650

SE P6 SENP_12-36-KE TCAGAGTCTAAGAGAGATGGAGGTT 3651

SF3B3 SF3B-9a_122-143-KE CTGGTTGATGAGTTGGACAGCC 3652

SF3B3 SF3B-2a 84-105-KE ACTTAACCTTGCAGAGAGCCAC 3653

TBCA TBCA 21-39- E GCCTAAATAGCCGCAGCCT 3654

UBE2L3 UBE2 18-36 GCCAGCAGGAGGCTGATGA 3655

XRN2 XRN2 28-47 TTCACATCTGATGGCTCCCC 3656

ZFAND1 ZFAN_9-32-KE CCATTTGTGTGTGATGATTGTTCA 3657

[00568] Table 14 Reverse Primers for Figure 2

Geue Reverse Primer Seqeeuee 5'-3' SEQ ID NO:

ZFAND1 ZFA.N 146-167-KE A AGTTCTCTCTCAGC AC AGTCT 3680

00569] Table 15 Forward Primers for Figure 3

00570] Table 16 Reverse Primers for Figure 3

SEQ ID

Gene Reverse Primer

Sequence 5'-3' NO:

NSUN4 NSUN 317-338-KE CTGTCGCTCCTTCTTCCTTGAC 3715

NUPL1 NUPL 306-325 AATTGAGCCCCACAGAAGGG 3716

PPIP5K2 PPIP 149-172-KE TTCACCTCCCCATTTTAGAACCAA 3717

SOS2 SOS2 281-301-KE AATGGTGTTGGGTGACCTCGT 3718

STAT1 STAT 279-300-KE TGCGAATGATGTCAGGGAAAGT 3719

STRN3 STRN 304-323-KE GAAGGGATGTGGGGCAGCTC 3720

TNS3 I N S3 96-1 16-KE CGGCTCCTTGTCCTTCAACAT 3721

WNK1 WNK1 187-207 CTGAGGACTCTGAGGTGCTGG 3722

00571] Table 17 Forward Primers for Figure 4

00572] Table 18 Reverse Primers for Figure 4 Reverse

Gene

Primer Seqeesiee 5'-3' SEQ ID NO:

DEC A 168-

DCAF 17 CCATGAGACAAGGTAGCATCTGT 3737

190- E

DHFR_209-

DHFR TGCCTTTCTCCTCCTGGACA 3738

228

DMXL 342-

DMXL1 ATGACTACCACAAAGGCACTGATAA 3739

366-KE ^"

FER 189-213-

FER TTGCCCAGTAATTCTCCCAATATGA 3740

KE

FNDC 178-

FNDC3A ACTGTGTGACTACCAGGGTGA 3741

198-KE

GALC 238-

GALC TTTCACTCGCTGGAGACCTTG 3742

258-KE

GBP1 354-

GBP1 CATTGGGCCTGTCATGTGGAT 3743

374-KE

HSD 1 164-

HSD17B 12 TGGATCTTTCCACCATGCCAG 3744

184-KE

KID I 303-

K IDINS220 ATTGCCTTGTTCGGCAGCTA 3745

322-KE

LARP 366-

LARP7 CTGCAAGCACCTGTTTAACTCG 3746

387-KE

OXCT 236-

OXCT1 AATGAAAAACACGCAGCCTGG 3747

256-KE

SREK 335-

SREK1 GTATGGGAACGAGATCGACCG 3748

355- E

SSBP 1 SSBP 300-323 TCTTTCAAGAACCAAACTGGTAGT 3749

STRA 353-

STRADB GTTACCAGTGTTCCTGTGGG 3750

372

00573] Table 19 Forward Primers for Figure 5

Gene Forward Primer Sequence 5'-3' SEQ ID NO:

ENTPD 1 ENTP 79-97-KE TTGCTTGCTGTGGGGTTGAC 3759

ERG I 128-147-

ERGIC3 GAAGGCTGCCAGGTGTATGG 3760

KE

GNAQ 143-164-

GNAQ CATGGACACACTCAAGATCCCA 3761

KE

KIAA 107-129-

KIAA 1524 GGGATTTGGAACAAAGGTTGCAG 3762

KE

KIAA1715 KIAA 2-26 TGAAGCATTGGATGATTTAAAATCC 3763

L3MBTL2 L3MB 47-67-KE TTACAAGGCTGCTCCCGTCAG 3764

LRRC42 LRCC 190-211 C C AGTG A AT AC T AGAGGGATC G 3765

MAN! 24-46-

MAN1A2 ATTGGCTGAGAAACTCCTTCCTG 3766

KE

MMSl 22-45-

MMSl 9 CAGTGTTACAAGTTGTGGAAGCCC 3767

KE

PMSl 104-127-

PMSl TCTCCTCATGAGCTTTGGTATCCT 3768

KE

POMT2 POMT 10-29 ACCCTTCCTTCCCAGTGGAG 3769

PRPF31 RPRF 50-69-KE GCCAACCGTATGAGCTTCGG 3770

SKP1 SKP1 56-75 TCTTCCTTCGCTAACGCCTC 3771

STRN 84-105-

STRN GAGAGAAAGGGGAAAAAGGGGG 3772

KE

STRN 33-52~4a~

STRN4 GAGAACAGCCCGTTGGTGTG 3773

KE

SUPT20H SUPT 8-30-KE AGCAAGGTTCAACCAGTCAAGAA 3774

TMEM214 TMEM: 55-75 CCCACTTCTGGACTTTGCCTA 3775

UBAP2L UBAP 60-79-KE CCCTTTCCAACAGCCGAGTG 3776

VDAC2 VDAC 25-48 ATTGGAGTAGGCTATACTCAGACT 3 / / /

VPS29 VPS2 12-31-KE CGACGGTGGTGGTGACTGAG 3778

00574] Table 20 - primers for Figure 5

Gene Reverse Primer Sequence 5'-3' SEQ ID NO:

DLGA 466-485-

DLGAP4 CGGGACTGGGCTCCTCTTTT 3785

KE

ELMO 229-248-

ELM02 TAATGGATGCCAGGGGCCGT 3786

KE

EN TP 198-219-

ENTPD1 AACTTGTGTGAGAAGAACCCGC 3787

KE

ERGI 321-340-

ERGIC3 CAGGGGGTTCACAATGCCTG 3788

KE

GNAQ 273-296-

GNAQ TTCTCAAAAGCAGACACCTTCTCC 3789

KE

KIAA 383-405-

KIAA 1524 GC TT AC TTC CAT AC C AG G A ACC A 3790

KE

KIAA1715 KIAA 2889-2909 TGAGTCCGGATCAAACCTTTC 3791

L3MB 447-467-

L3MBTL2 TGAGCACCTCCACCTTCATCC 3792

KE

LRRC42 LRCC_339-359 GTAAGACATTGCCTTGGTTGC 3793

MAN! 4503-

MAN1A2 AGCCCCAGTTTCGCCCTACT 3794

4522-KE

MMS1 260-280-

MMS 19 TTCTCCAGGAGCAAGGTGTGA 3795

KE

PMS1 285-308-

PMS1 AC ATGAGAGCC ATC TTGTGATC TG 3796

KE

POMT2 POMTJ 51-170 CTGATAGTGCTTCCGGGTCA 3797

RPRF 218-237-

PRPF31 TCGTTTACCTGTGTCTGCCG 3798

KE

SKP1 SKP1 290-314 TGTGA AG ATG AGTTC AGATCC AAAG 3799

STRN 277-296-

STRN GGGTCTGGAAGGTGAACCCA 3800

KE

STRN 171-190-

STRN4 TTGGACCGCATGTCGAGGAT 3801

4a- K

SUPT 216-235-

SUPT20H TGTTCTCGGCAGAGCCAAGC 3802

KE

TMEM214 TMEM__ 173-193 AAATGCCAGCACTTTCAGTCG 3803

XJBAP 218-237-

UBAP2L CTCAGCCGTCCAGAAATGCT 3804

KE

VDAC2 \TJ AC 147-168 AGCCCAACCTTGTGGCCTCCAG 3805

VPS2 203-220-

VPS29 CCGGTGTGGGATGTGCAG 3806

KE

00575] Results: The RNA-seq data iExon production (ΔΡ8Ι) according to the Fisher's Exact !¾st (FET) in SH-SY5Y cells treated with Compound 64 at 24 nM: (Table 21) and 100 nM (Table 22) and in HD-1994 human normal fibroblast line cells treated with Compound 64 at 100 nM (Table 23), providing the Log2 based fold change of gene expression (Log2FC) for each, where NA represents "Not Available." Analysis of RNA-seq data in HD1994 cells obtained from Palacino, et al., (Nat. Chem. Bio., 2015, (1 1) 51 1-517; NCBI-SRA Accession Number SRP055454).

[00576] The APSI for modulated expression of RNA transcripts identified is represented by stars in Table 21, Table 22 and Table 23, where one star (*) represents < 25% change in expression, where two stars (**) represent change in expression in a range from >25% to < 50% change, where three stars (***) represent change in expression in a range from >50% to < 75% change, and, where four stars (****) represent change in expression in a range from > 75% to < 100% change.

[00577] Table 21 Compound Effect in SHSY5Y Cells at 24 nm

Inclusion

Table 21 Gesie ΔΡ8Ι FET ΔΡ8! Log2FC

Position

CADM2 14 * 1 0.1

CDH18 14 ** 2.00E-04 0.0

CENPI 119 0.6 -0.1

CEP 162 12 * 3.00E-04 0.1

CEP 170 ilO * 5.0QE-15 -0.2

CEP 192 il3 * 7.00E-04 0.1

CHEK1 i 13 ** 2.00E-26 -0.3

CHRM2 14 * 2.00E-05 -0.2

CMAHP 16 * 3.00E-04 -0.3

C EJP1 12 * 5.00E-44 0.1

CNTN1 il * 7.00E-15 -0.6

CRYBG3 117 1 -0.1

CUX1 Ό ^' * 8.0QE-Q7 -0.1

DAAM1 il5 * 0.1 -0.1

DCAF17 12 * 7.00E-04 0.1

DCAF17 i6 * 0.4 0.1

DCUN1D4 19 * 0.5 0.1

DDX42 18 * 2.00E-14 0,0

DENNDIA ilO * 0.2 -0.1

DENND4A 130 * 4.00E-05 -0,1

DENND5A i8 * 8.00E-04 -0.1

DET1 il * 0.08 0,0

DET1 il 1 0.0

DGKI 119 * 0.4 -0,2

Dl 11 R i5 ** 3.00E-07 -0.3

1)1 U 15 ** 3.00E-11 -0,3

1)1 PI 13 115 * 9.00E-11 -0.4

DLAPH3 127 * 5.00E-05 -0,4

DLG5 120 * 6.00E-08 -0.1

DYRK1A 13 * 6.00E-05 0.1

DZIP1L 115 * 0.02 -0.2

^ sjc ί}ϊ ί

ELM02 13 0.004 0,0

EN AH 11 * 1.00E-17 0.3

ENOX1 15 * 0.3 0,0

ERC2 16 1 -0.1

EVC 15 * 2.00E-11 -0.1

FAM162A 11 * 4.00E-26 0.1 liicliisiosi

Table 21 Gesie ΔΡ8Ι FET ΔΡ8! Log2FC

Position

FAM174A * 2.0QE-Q4 0.0

FAM195B 15 0.8 0.0

FAM208B il * 0.006 0.1

FAM69B 11 * 9.00E-05 0.1

FBXL16 i9 * 5.0QE-Q9 -0.4

FGD4 11 * 0.1 -0.1

FHOD3 121 * 2.0QE-Q7 -0.9

GALC 16 * 0.09 -0.2

GLCE Ό ^' 1 0.0

GOLGB 1 114 * 0.1 -0.2

GTSFl 1? * 0.003 0.0

GXYLT1 17 * 7.00E-43 0.1

FID AC 5 114 * 0.09 -0.3

HDX 11 ** l .OOE-11 0.2

HIT 149 * l .OQE-21 -1.0

IFT57 15 * 2.00E-15 0.2

INO80 127 * 6.00E-05 0.0

INVS 13 * 3.00E-07 0,0

KDM6A 127 * l .OOE-16 0.2

K !!)[\S220 12 * 0.008 0,0

KIF21A 11 * l .OOE-21 0.0

L3MBTL2 15 * 0.09 -0,4

LINCR-0002 11 * 1.00E-07 0.0

LING02 16 * 3.00E-05 -0,2

LOC400927 13 ** 0.02 0.0

LPHN1 13 * 5.001·- ! 1 0,0

LRRC1 11 1 * 0.02 -0.1

LRRC42 12 ** 3.00E-35 0,0

LYRM1 12 * 2.00E-12 0.2

MACROD2 11 * 0.01 -0.1

MAPKI O 12 * 0.1 0.0

MARCH 8 16 * 1 .00E-04 0,0

MDN1 191 * 0.1 0.0

MEAF6 18 ** 1 .00E-12 0.1

MEMO! 16 * 1.00E-17 -0.1

MFN2 11 * 2.00E-08 0,0

MLLT10 117 * 4.00E-11 0.0 liicliisiosi

Table 21 Gesie ΔΡ8Ι FET ΔΡ8! Log2FC

Position

MRPL39 110 * 3.0QE-Q6 0.1 RPi.45 14 * 1.00E-09 0.1

MRPS28 i9 * 6.0QE-12 0.1

MTMR3 i6 * 0.05 0.0

MYB ill * 0.03 0.1

MYCBP2 155 ** 2.00E-08 0.0

MYCBP2 i80 * 0.01 0.0

MYLK i5 1 -0.1 LGN1 14 1 -0.1

NSUN4 i5 * 0.5 0.0

MJPL1 il * 5.0QE- 5 0.2

OSBPL3 il * 0.3 0.0

PAPD4 : n ** l.OQE-24 -0.4

PCDH10 il * 0.002 -0.2

PDE3A Ό ^' * 6.001··· 12 -0.1

PDE7A Ϊ2 ** 4.00E-40 0.2

PDXDC1 n * 3.00E-21 -0.1

PDXDC2P 0.01 0,0

PELI1 il * 3.00E-05 0.0

PITPNB n * 3.00E-10 -0,5

PMS1 i5 * 0.2 0.0

POMT2 ill ** 5.00E-76 0,0

PSMA4 i4 * 3.00E-26 0.2

RAB23 il * 0.2 0,2

RAF 1 * l.OOE-28 0.0

RASIP1 i3 1 0,0

RCOR3 ilO * 3.00E-07 0.0

RERE il3 * 0.04 0.1

RNF130 i8 * 0.05 0.1

RNF144A i2 * 0.008 -0.1

RNF213 i26 * 0.3 -0.3

RPF2 il * l.OOE-10 0.3

RPS10 i5 * 0.02 0.0

SCOl i4 * 6.00E-06 -0.1

SENP6 i2 * 2.00E-23 0.1

SF3B3 ;o * 5.00E-164 0,0

SGMS1 \2 * 0.5 0.1 liicliisiosi

Table 21 Gesie ΔΡ8Ι FET ΔΡ8Ι Log2FC

Position

SGPL1 i3 * 0.5 -0.1

SLC25A16 16 * 0.04 0.0

SLC25A17 i3 * 7.00k- H) 0.0

SNX24 i l * 5.00E-08 -0.1

SNX7 18 * 4.00k- 12 0.1

SORCS1 126 * 0.03 -0.2

SPIDR il * 3.00E-07 0.0

SPRYD7 i4 * 5.00E-06 -0.1

SREK1 : n * 2.0QE-Q8 -0.2

SSBP1 i2 * 3.00E-104 0.1

STRADB 14 * 6.0QE-Q6 0.0

STXBP4 116 1 0.0

SUPT20H 124 * 4.00E-08 0.0

TAF2 123 ** 4.00E-42 0.1

TARBP1 113 * .2 0.0

TASP1 113 * 1.00E-04 -0.1

TBCA 11 * 6.00E-88 0.1

TCF4 14 * 7.00E-50 -0, 1

TEKT4P2 12 0.9 0.0

TET1 18 * 3.00E-09 -0,2

TIAM1 14 * 1.00E-07 -0.1

TJP2 1 * 8.00E-06 0,2

TMEM214 18 * 6.00E-06 0.0

TNRC6A 14 * 1.00E-27 0,0

TRAF3 18 * 0.1 0.0

TRIM65 15 ** 1.00E-22 0,0

TSPAN7 11 * 0.02 -0.3

UBN2 16 * 0.6 -0.1

URGCP-MRPS24 11 * 7.00E-06 0.0

UVRAG 15 * 0.006 -0.1

WDR27 19 ** 1.00E-29 -0.1

WDR90 19 * 6.00E-06 -0.2

WNK1 123 * 4.00E-31 0.0

XRN2 116 * l .OOE-24 -0.5

ZFP82 14 * 5.00E-16 0.1

ZMLZ2 11 * 0.001 0,0

ZNF138 13 * 1.00E-05 0.1 Inclusion

Table 21 Gene ΔΡ8Ι FET ΔΡ8Ι Log2FC

Position

ZNF208 13 * 0.4 0.0

ZNF212 11 * 0.01 0.1

ZNF280D 119 * 0.2 0.0

Z F37BP i4 1.00E-31 0.0

ZNF426 14 * 0.01 0.2

Z F618 il l * 2.00E-09 -0.1

Z F680 * 2.0QE-Q9 0.1

Z F730 13 * 0.04 0.1

^

ZNF836 * 0.08 -0.1

ZSCAN25 12 * 0.02 0.0

00578] Table 22 Compoinid Effect in SHSY5Y Cells at 100 em

Table 22 Inclusion

APS. FET APS! Log2FC Gene Position

CE PI il9 * l .OOE-10 0.0

CEP 162 i2 * l .OOE-10 0.2

CEP 170 ilO * 5.00E-43 -0.6

CEP 192 il3 * 0.002 0.1

CHEK1 i 13 ** 9.00E-34 -0.6

CHRM2 i4 ** 9.00E-14

CMAHP i6 ** 2.00E-05 -U.3

CNRIP1 i2 * 7.00E-122 0.1

CNTNl i l * 3.00E-61 0.0

CRYBG3 il7 * 6.00E-08

CUX1 * 1.00E-33 -u.1

DAAM1 i lS * 6.00E-05

DCAF17 i? * 7.00E-14 0.1

DCAF17 i6 * 5.00E-08 0.1

DCUN1D4 i9 * 9.00E-06 0.0

DDX42 i8 * 1.00E-54 -0.2

DENNDIA ilO * 5.00E-12 -0.3

DENND4A i30 ** 3.00E-19 0.0

DENND5A i8 * 7.00E-35 -0.6

DET1 il * 0,002 0.0

DET1 i l * 6.00E-04 0.0

DGKI il9 * 2.00E-05 -0.3

DHFR i5 ** 2.00E-10 -0.8

DHFR i5 ** 4.00E-17 -0.8

DIAPH3 i l 5 * 5.00E-19 -1 . 1

DLAPH3 1Z / * 1.00E-27 -1.1

DL.G5 i20 * 2.00E-43 -0.4

DYRK1A i3 * 2.001 10 0.1

DZIP1 L i l 5 * 5.00E-05 -0.2

ELM02 i3 sjc 5.00E-04 0.0

EN AH i l * 8.00E-71 0.2

ENOXl i5 * 2.00E-07 0.0

ERC2 i6 9.00E-05 -0. 1

EVC iS ** 5.00E-27 -0.2

FAM162A i l * 9.00E-88 0.1

F AM 174 A * 8.00E-10 0.0

FAM195B i5 * 5.00E-08 -0.2 Table 22 Inclusion

APS. FET APSJ Log2FC Gene Position

FAM208B il * 7.00E-06 0.1

FAM69B il * 8.00E-06 -0.1

FBXL16 i? * 5.00E-13 -0.5

FGD4 i l * 4.00E-17 0.0

FHOD3 i21 ** _* 5.00E-37 -1.2

GALC i6 * 4.00E-05 _n

GLCE * 0.001 u. l

GOLGB1 il4 * 2.00E-04

GTSF1 1 -u.1

GXYLT1 ** 2.00E-103

HDAC5 i l4 * 9.00E-07 -0.5

HDX il ¾ ¾ % 1.00E-37 0.3

HTT i49 ** _* 9.00E-62 -1.4

IFT57 i5 * 3.00E-45 0.1

INO80 j?7 * 6.00E-15 -0. 1

INVS i3 * 2.00E-10 0.1

KDM6A i27 ¾ % 3.00E-47 0.3

KIDI S220 i2 * 2.00E-12 0.1

KIF21A i l * 3.00E-79 -0. 1

L3MBTL2 i5 * 3.00E-11 -0.9

I I NCR -0002 i l * 7.00E-12 0.0

LING02 i6 * 1.00E-05 0.0

LOC400927 ¾ %

LI 3.00E-06 0.0

LPHNi i3 * 2.00E-20 -0.2

LRRC1 i l l * 3.00E-09 -0.3

LRRC42 i2 ^ ¾ % 1.00E-92 0.0

LYRM1 i2 * 1 .00E-56 0.4

MACROD2 il ^ ¾ % 3.00E-06 0.1

MAPK10 i2 * 4.00E-07 -0. 1

MARCH8 i6 * 5.00E-04 0.1

MDN1 i91 * 2.00E-10 -0. 1

MEAF6 i8 ^ ¾ % 3.00E-23 0.0

MEMO 1 i6 ** 1 .00E-62 -0.5

MFN2 il * 1.00E-33 0.0

MLLT10 i l 7 * 3.00E-41 -0.2

MRPL39 ilO * 3.00E-32 0.2

MRPL45 i4 * 3.00E-26 0.1 Table 22 Inclusion

APS. FET APS! Log2FC Gene Position

MRPS28 i2 * 1.00E-29 0.0

MTMR3 i6 * 1.00E-05 0.0

MYB ill * 8.00E-07 -0.1

MYCBP2 155 ** 5.00E-13

MYCBP2 i80 * 3.00E-08 u.1

MYLK i5 * 9.00E-06

NLGNl i4 * 4.00E-04 -U.2

NSUN4 i5 * 2.00E-10

NUPL1 il ** 2.00E-125

OSBPL3 il * 2.00E-05

PAPD4 il ** _* 3.00E-58 -u. /

PCDH10 il * i. ooiv lo ~Ό .2

PDE3A i? * 2.00E-39 0.0

PDE7A i2 *** 1.00E-122 0.3

PDXDC1 ** 4.00E-67 -0.3

PDXDC2P i7 **** 1.00E-05 0.0

PELI1 il * 5.00E-11 0.0

ΡΓΓΡΝΒ i7 * 2.00E-28 -1.5

PMS1 i5 * 8.00E-22 -0.4

POMT2 ill **** 4.00E-165 -0.2

PSMA4 i4 * 5.00E-69 0.2

RAB23 il * 7.00E-07 0.1

RAF 1 i7 * ! .001 104 0.0

RASIPl i3 **** 0.01 0.0

RCOR3 i 10 * 5.00E-19 -0.2

RERE i!3 * 3.00E-19 -0.1

RNF130 i8 * 2.00E-04 0.1

RNF144A i2 * 2.00E-17 0.1

RNF213 i26 * 0.002 -0.1

RPF2 il * 2.00E-41 0.2

RPS10 \S * 0.005 0.0

SCOl Ί4 * 3.00E-21 -0.4

SENP6 2 ** 1.00E-103 0.0

SF3B3 12 * 0 -0.1

SGMS1 2 * 5.00E-05 0.1

SGPL1 i3 * 3.G0E-04 0.1

SLC25A16 16 * 7.00E-06 -0.1 Table 22 Inclusion

APS. FET APSJ Log2FC Gene Position

SLC25A17 i3 * 2.00E-39 0.0

S X24 il * .0i ⁾ lv 16 0.1

SNX7 i8 * 1.00E-75 u. l

SORCS1 i26 * 5.00E-05 -0.3

SPIDR i l ** 1.00E-29 0.0

SPRYD7 i4 * 2.00E-12 ~Ό .2

SREK1 il * 6.00E-32 -0.6

SSBP1 Ϊ2 * 0 0.0

STRADB i4 * 8.00E-16 u. l

STXBP4 i l6 * l .OOE-10 0.1

SUPT20H i24 * 9.00E-24 0.0

TAF2 i23 ^ ¾ % 3.00E-99

TARBP1 i 13 * 0.005 -0.2

TASP1 i 13 * 2.00E-07 0.0

TBCA i l * 5.00E-244 0.1

TCF4 i4 * 8.00E-125 0.0

TEKT4P2 * 0.007 0.0

TET1 i8 *** 3.00E-18 -0.4

TIAMl i4 ¾ % 4.00E-22 -0. 1

TJP2 il * 2.00E-25 -0.1

TMEM214 i8 * 3.00E-50 -0. 1

TNRC6A i4 ** 6.00E-90 0.0

TRAF3 i8 * 4.00E-10 -0.2

TRIM65 i5 ** 6.00E-28 -0.1

TSPAN7 i l * 2.00E-06 -0.4

UBN2 i6 * 0,003 -0.2

URGCP- MRPS24 il ** 2.00E-19 0.0

UVRAG i5 * 9.00E-06 ™(J .2

WDR27 i9 ** _* 9.00E-64 -U.2

WDR90 i9 ** 2.00E-16 ~Ό .2

WNK1 Ϊ23 * 3.00E-86 0.0

XRN2 il6 * 3.00E-78 -1.1

ZFP82 i4 ** 2.00E-38 0.4

ZMIZ2 il * 1.00E-20 0.1

ZNF138 * 2.00E-20 0.1

ZNF208 i3 * 0,005 0.0 Table 22 Inclusion

APS. FET APS! Log2FC Gene Position

ZNF212 il * 2.G0E-10 0.0

ZNF280D il9 * 0.007 0.0

ZNF37BP i4 6.00E-49 0.1

ZNF426 i4 * 2.00E-18 0.3

ZNF618 i l l ** 3.00E-37 0.0

ZNF680 i3 ** 7.00E-35 0.2

ZNF730 * 5.00E-08 u. l

ZNF836 13 * 1.00E-04 0.1

ZSCAN25 i2 * 2.00E-10 0.0

00579] Table 23 Compound Effect in HD-1994 Cells at 100 nm

Inclusion

Table 23 Gene APSI FETAPSI Log2FC

Position

Cl lorf73 ** 2.00E-12 -0.9

C12orf4 il 9.00E-137 0.0

Clorf27 il 3.00E-52 0.1

C1QTNF9B-AS1 il * 0.002 0.1

CC L2 15 * 0.003 0.0

CDH18 i4 ** 1.00E-07 -0.7

CENPI il9 ** 7.00E-24 -0.1

CEP 57 il * 6.00!·- 1 3 -0.2

CMS SI il * 2.00E-27 -0.1

CNOT7 i2 * 1.00E-04 0.0

COPS7B i2 * 1.00E-16 -0.5

CRISPLD2 il * 3.00E-Q6 -0.6

CUX1 i2 * 6.00E-12 -0.3

DCAF17 i2 ** 3.00E-14 -0.9

DDX42 i8 * 1.00E-32 -1.7

DENND4A i30 ** 9.00E-16 0.2

DENND5A i8 * 1.00E-43 -1.9

DENND5A i3 * 4.00E-22 -1.9

DET1 i l * 7.00E-04 0.0

DLG5 i20 * 2.00E-13 -1.5

DMXL1 i25 * 3.00E-06 0.0

DNAJA4 i2 * 0.001 -0.3

D MBP i l * 4.00E-05 -0.1

EN AH il 9.00E-267 0.2

EP300 i l * 2.00E-16 0.2

ERC1 il 8 * 9.00E-29 -0.4

EVC i5 1 .00E-54 0.2

EXOC3 il 2 * 4.00E-14 -0.6

EXOC6B i21 ** 1 .00E-20 0.0

F AM 162 A il ** 1.00E-50 -0.2

F AMI 74 A i2 ** 3.00E-22 0.5

FAM208B il ** 2.00E-08 0.2

FAM49B i l * 3.00E-10 -0.2

FBN2 i5 * 2.00E-78 -0.6

GBP1 i l * 7.00E-14 -0.2

GNG12 * 2.00E-152 -0.1

GXYLTl i7 5.00E-86 -1.0

Inclusion

Table 23 Gene APSI FETAPSI Log2FC

Position

FASC 128 * 1.00E-12 0.0

NGF il ^ ¾ ^ 4.00E-150 0.4

NIPA1 * 3.00E-04 0.0

NLN il2 * 5.00E-15 -1.4

^

NREP * 1.00E-13 -0.3

NUPL1 il ^ ¾ ^ 4.00E-146 0.3

OSBPL3 il * 3.00E-11 -0.1

PAPD4 ^ ¾ ^ 6.00E-61 -1.9

PBX3 i8 * 1.00E-09 -0.2

PDE7A i2 ^ ^ ^ 9.00E-25 -0.5

PIGN i22 * 8.00E-24 0.1

PITP B 1 * 2.00E-Q4 -4.0

PNISR il * 2.00E-17 -0.1

POMT2 il l *** * 1.00E-182 0.0

PPARG i4 * 5.00E-09 -0.5

PPFIBP 1 i2 * 8.00E-13 0.0

PRPF3 ί i l l * 6.00E-27 0.1

PSMA4 i4 * 2.00E-14 0.1

PXK i l * 2.00E-08 -0,2

RAB23 il * 1.00E-16 -0.7

RAF I i7 * 2.00E-102 -0.1

RAPGEF l il l * 2.00E-18 0.0

RBBP8 i6 * 5.00E-16 -1.4

RERE il.3 *** 3.00E-48 -0.1

RGL1 i l * 3.00E-05 -0.2

RPF2 il * 1.00E-51 0.1

SAMD4A i3 * 3.00E-18 -0.2

SCOl i4 * 8.00E-26 -1.3

SENP6 i2 % j 3.00E-77 -0.5

SF3B3 *** 0 -0.1

SGIPl i l * 7.00E-12 -0.1

SH2B3 * 2.00E-07 0.1

SKP1 i l * 2.00E-1 15 -0.7

SLC12A2 il O * 1.00E-08 -0.1

SLC25A17 i3 ** 7.00E-66 -0.4

SMOX il * 9.00E-06 0.0

SXAP23 i3 * 2.00E-27 -0.7 Inclusion

Table 23 Gene APSI FETAPSI Log2FC

Position

SNX24 il ** 7.00E-27 0.1

SNX7 i8 ** 8.00E-203 -0.1

SOCS6 il * 0.001 -0.1

SOGA2 il5 * 2.00E-05 NA

SPIDR il ** 7.00E-19 -0.3

SSBP1 i2 * 7.00E-75 -0.3

STRADB 14 ** 2.00E-27 0.2

STXBP6 il 1.00E-39 -0.5

STXBP6 i2 * 4.00E-21 -0.5

SUPT20H i24 * 2.00E-23 -0.5

TAF2 i23 3.00E-58 -0.6

TAF2 i20 * 2.00E-Q7 -0.6

TASP1 il3 ** 5.00E-12 -0.3

TBCA il *** * 6.00E-246 -0.3

TBL1XR1 i l * 7.00E-09 -0,2

TCF4 i4 ** 3.00E-42 0.0

TJAP1 i3 * 0.003 0.1

TIP2 il * 1.00E-22 0.0

TMEM214 i8 ** 0 0.0

TMX3 i5 * 2.00E-39 -0.7

TNRC6A i4 % % 9.00E-54 0.0

TXNL4B il * 4.00E-06 -0.1

UBE2D3 i l ** 9.00E-07 -0.1

UBE2L3 il *** * 9.00E-54 0.2

UNC13B n * 4.00E-04 0.0

URGCP-MRPS24 il *** 7.00E-45 0.1

VDAC2 i 10 1 .00E-08 0.1

WHSC2 il * 5.00E-14 NA

WNK1 i23 *** 1 .00E-152 0.0

XRN2 il o ** 3.00E-26 -3.9

ZFP82 i4 1 .00E-26 0.8

ZNF138 i3 8.00E-12 -0.2

ZNF350 i4 *** 5.00E-07 0.8

ZNF37BP i4 1.00E-05 -0.2

ZNF61 8 i l l ** 9.001 ·- ! 2 -0.2

ZNF680 i3 2.00E-06 -0.4

ZNF777 i l ** 0.001 -0.1 Inclusion

Table 23 Gene APSI FETAPSI Log2FC

Position

ZNF804A il * 3.00E-08 -0.1

ZSCAN25 12 * 2.00E-Q4 -0.1

[00580] Details on the location of the iExon produced in affected genes from Table 21, Table 22 and Table 23 are shown in Table 24.

[00581] Table 24 Gene Coordinates

Gene Coordinates (hgl9) Refseqid Description

APIP chr 1 x34933660: M_015957

34933520 APAF1 interacting protein

APPL2 chr!2 : 105625259: NM_018171 adaptor protein, phosphotyrosine

105625147 interaction, PH domain and leucine zipper containing 2

ARHGAP 1 chrl 1 x46718619: NM 004308

46718571 Rho GTPase activating protein 1

ARHGAP5 chrl4:+:32619665: \M 001 173

32619772 Rho GTPase activating protein 5

ARL15 chr5:-:53603776: M_019087

53603718 ADP-ribosylation factor-like 15

ARL15 chr5x 53212951 : NM_019087

53212826 ADP-ribosylation factor-like 15

ARL5B chrl 0:+: 18963389: NMJ 78815

18963454 ADP-ribosylation factor-like 5B

ARSJ chr4:~: 114894867: NM 024590

1 14894796 arylsuffatase family, member J

ASAP1 chr8x 131173039: M OO 1247996 ArfGAP with SH3 domain, ankyrin

131 173031 repeat and PH domain I

ASAP1 chr8x 131 135828: M_001247996 ArfGAP with SH3 domain, ankyrin

131 35650 repeat and PH domain 1

ATF6 chrl : · : ! (> 1840762: M 007348

161840851 activating transcription factor 6

BECN1 chrl7:-:40963348: NM 003766

40963310 beclin 1, autophagy related

BHMT2 chr5:+:78374568: NM_017614 betaine— homocysteine S- 78374655 methyltransferase 2

BIN3 chr8:-:22501255: NM_018688

22501165 bridging integrator 3

BNC2 chr9x 16672136: NM 017637

16672064 basonuclin 2

BTBD10 chrl 1 : 13440890: M_032320

13440824 BTB (POZ) domain containing 10

C10orf76 chr!Ox 103608231 : NM 0245 1 chromosome 10 open reading frame

103608157 76

Cl lorOG chrl 1 : · : 76259972: NM 020193 chromosome 11 open reading frame

76260061 30 Gene Coordinates (hgl9) Refseqid Description

Cl l orf73 chrl l :+:86037555: R_024596 chromosome 1 1 open reading frame

86037718 73

C12orf4 chrl2 :4646680: NM_020374

4646546 chromosome 2 open reading frame 4

Clorf27 chrl :+: 1863476 8: NM_017847

186347702 chromosome I open reading frame 27

C1 QTNF9B- chrl3 :+:24463289: NM_001014442 C1QTNF9B and sense RNA 1 (non¬

AS1 24463692 protein coding)

C2orf47 chr2:+:200826550: M 024520

200826651 chromosome 2 open reading frame 47

CACNB 1 chrl 7:-:37342662: XM 000723 calcium channel, voltage-dependent,

37342603 beta 1 subunit

CACNB4 chi2:-: 152728639: NM 000726 calcium channel, voltage-dependent,

152728497 beta 4 subunit

CADM2 chr3 :+:85895854: NM_001256504

85895996 cell adhesion molecule 2

CCNL2 chrl 1328183 : NM_030937

1326677 cyclin L2

CDH18 chr5 19938439: NM_001291956

19938387 cadherin 18, type 2

CENPI chrX:+: 10041151 1 : NM_006733

100411544 centromere protein I

CEP 162 chr6x84932759: NM_014895

84932696 centrosomal protein 162kDa

CEP 170 chrl :-:243340118: XM 0148 1 2

243340004 centrosomai protein 170kDa

CEP 192 chri S: : 1 3038 14 : XM 032 142

13038578 centrosomal protein 192kDa

CEP57 chri i : .95527385: NM_001243776

95527523 centrosomai protein 57kDa

CHEK1 chrl l :+: 125526101 : NM_001114121

125526230 checkpoint kinase 1

CHRM2 chr7:+: 136686610: NM_001006626

136686804 cholinergic receptor, muscarinic 2

CMAHP chr6:-:25107418: NR 002174 cy tidine m onophospho-N-

25107336 acetylneuraminic acid hydroxylase, pseudogene Gene Coordinates (hgl9) Refseqid Description

CMSS1 chr3 :+:99770076: M_032359

99770147 NA

CNOT7 chr8:-: 17101054: NM_013354 CCR4-NOT transcription complex,

17100951 subunit 7

CNRIP1 chr2:-:68542975: NM_001 111101 cannabinoid receptor interacting

68542840 protein 1

CNTN1 chrl2:+:41263098: NM_001843

41263196 contactin 1

COPS7B chr2:+:232655632: M 022730 COP9 constitutive photomorphogenic

232655883 homolog subunit 7B (Arabidopsis)

CRISPLD2 chrl 6:+:84869783 : XM 0 1476 cysteine-rich secretory protein LCCL

84870041 domain containing 2

CRYBG3 chr3 :+:97635177: NM /l 53605 beta-gamma crystallin domain

97635237 containing 3

CUX1 chr7:+: 101592135: M_001202543

101592250 cut-like homeobox 1

DAAM1 chrl4:+:59801 175: NM_001270520 dishevelled associated activator of

59801315 morphogenesis 1

DCAF17 chr2:+: 172298369: XM 025000 DDB1 and CUL4 associated factor

172298546 17

DCAF17 chr2:+: 172309926: X\! 025000 DDB1 and CUL4 associated factor

172309987 17

DCUN1D4 chr4:+:52775086: M 001287757 DCN1, defective in cuilin

52775141 neddvlation 1, domain containing 4

DDX42 chrl 7:+:61883354: XM 007372 DEAD (Asp-Glu-Ala-Asp) box

6188351 1 helicase 42 ("DEAD" disclosed as

SEQ ID NO: 3807)

DENND1 A chr9:-: 126385380: XM 020946 DENN/MADD domain containing

126385322 1A

DENND4A chrl 5x65957563 : NM _ 001 144823 DENN/MADD domain containing

65957537 4A

DENND5A chrl l :-:9198449: M_001243254 DENN/MADD domain containing

9198319 5A

DENND5A chrl 1 x9227781 : XM 0152 13 DENN/MADD domain containing

9227736 5A

DET1 chrl 5:-:89087925: XM 01 7996

89087842 de-etiolated homolog 1 (Arabidopsis) Gene Coordinates (hgl9) Refseqid Description

DET1 chrl5:-:89088400: M_017996

89088342 de-etiolated homolog 1 (Arabidopsis)

DGKI chr7:-: 137249412: NM_004717

137249362 diacylglycerol kinase, iota

DHFR chr5:-:79929807: XM 000791

79929696 dihydrofolate reductase

DHFR chr5---7 ^Q 928121 : NM 000791

79928051 dihydrofolate reductase

DIAPH3 chrl3 :60548266: M 001042517

60548219 diaphanous-related formin 3

DIAPH3 chr! 3 x00266972: NM 001042517

60266851 diaphanous-related formin 3

DLG5 chrlQ:-:79572531 : NM 0Q4747

79572471 discs, large homolog 5 (Drosophila)

DMXL1 chr5:+: 118508106: M_005509

118508210 Dmx-like 1

DNAJA4 chrl5:+:78557823 : NM_018602 DnaJ (Hsp40) homolog, subfamily A,

78558635 member 4

DNMBP chrl Ox 101762780: NM_015221

101762699 dynamin binding protein

DYRK1A chr21 :+:38794884: XM 101 395 dual-speci fi city tyrosi ne-( Y)~

38794954 phosphorylation regulated kinase 1 A

DZIPIL chr3 :-: 137783162: NMJ73543 DAZ interacting zinc finger protein

137783023 1-like

ELM02 chr20:-:45023043 : XM 13 1 71

45022947 engulfment and cell motility 2

ENAH chrl :-:225788060: XM 0 1008493

225787910 enabled homolog (Drosophila)

EN AH chrl :-:225788064: M_001008493

225787910 enabled homolog (Drosophila)

ENOX1 chrl3 :43984398: NM_017993

43984311 ecto-NOX disulfide-thiol exchanger 1

EP300 chr22:+:41496302: NM_001429

41496407 El A binding protein p300

ERC1 chrl2:+ _: 1536281 : NR 027948 ELKS/RAB6-interacting/CAST

1536343 family member 1

ERC2 chr3 x56159162: NM_015576 ELKS/RAB6-interacting/CAST

56159019 family member 2 Gene Coordinates (hgl9) Refseqid Description

EVC chr4;+:5743061 : M_153717

5743168 Ellis van Creveld protein

EXOC3 chr5:+:466496: NM_007277

466667 exocyst complex component 3

EXOC6B chr2:-:72410034: NM_015189

72410023 exocyst complex component 6B

FAM162A chr3 :+: 122120223 : NM 014367 family with sequence similarity 162,

122120382 member A

FAM174A chr5:+:99917051 : NM_198507 family with sequence similarity 174,

99917108 member A

FAM195B chrl 7:-:79781381 : M_001288798 family with sequence similarity 195,

79781288 member B

FAM208B chrl0:+:5751493 : NM 017782 family with sequence similarity 208,

5751626 member B

FAM49B chrSx 130937848: M_016623 family with sequence similarity 49,

130937794 member B

FAM69B chr9:+: 139611405: NM_ 152421 family with sequence similarity 69,

13961 1665 member B

F:BN2 chr5x 127850450: NM_001999

127850370 fibrillin 2

FBXL16 chrl6:-:746433 : NM_153350 F-box and leucine-rich repeat protein

746287 16

FGD4 chrl2:+:32664764: NMJ39241 FYVE, RhoGEF and PH domain

32664843 containing 4

FHOD3 chrl 8:+:34322340: NM 001281740 formin homology 2 domain

34322431 containing 3

GALC chrl4:-:88447791 : \\ l 001201402

88447758 galactosylcerami dase

GBP1 chrl :-:89530504: M_002053 guanylate binding protein 1 ,

89530384 interferon-inducible

GLCE chrl5:+:69517534: NM_015554

69517591 glucuronic acid epimerase

GNG12 chrl :-:68179430: NM_018841 guanine nucleotide binding protein

68179375 (G protein), gamma 12

GOLGB1 chi-3 :~: 12140!81 Q: NM 0Q1256486

121401764 golgin Bl

GTSF1 chr!2 : 54862737: NMJ44594

54862609 gametocyte specific factor 1 Gene Coordinates (hgl9) Refseqid Description

GXYLT1 chrl2:-:42489016: M_173601

42488953 glucoside xylosyltransferase 1

HDAC5 chrl7:-:42163619: NM_001015053

42163517 histone deacetylase 5

HDX chrX:-:83756519: NM_001 177479

83756437 highly divergent homeobox

HMGXB4 chr22:+:35663361 : \ ^' R 027780

35663507 HMG box domain containing 4

HOXB3 chrl7 :46648520: M 002146

46648451 homeobox B3

HSD17B4 chr5:+: 1 18792986: NM 001199291 hydroxysteroid (17-beta)

118793063 dehydrogenase 4

HTT chr4:+:3215349: NM 0021 11

3215463 huntingtin

1FT57 chr3 :-: 107911373 : M_018010

107911323 intraflagellar transport 57

IKBKAP chr9x 1 1 1695687: NM_003640 inhibitor of kappa light polypeptide

111695551 gene enhancer in B-cells, kinase complex-associated protein

INO80 chrl 5 :-:41305472: M_017553

41305408 INO80 complex subunit

INPP4B chr4:-: 143190586: \\ l 003866 inositol polyphosphates-

143190485 phosphatase, type II, l OSkDa

!NVS chr9:+: 102970748: NM_183245

102970845 inversin

ITCH chr20:+:32980543 : NM_001257137 itchy E3 ubiquitin protein ligase

32980720 homolog (mouse)

IVD chrl 5:+:40706571 : NM_002225

40706723 isovaleryl-CoA dehydrogenase

KDM6A chrX:+:44965787: NM 001291415

44965894 lysine (K)-specific demethylase 6A

KDSR chrl8:-:61002332: M_002035

61002156 3-ketodihydrosphingosine reductase

KIAA1524 chr3 :-: 108284925: NM 020890

108284745 IAA1524

KIAA 71 5 chr2:-: 176835145: M_030650

1 76834927 KIAA1715 Gene Coordinates (hgl9) Refseqid Description

KID1NS220 chr2:-:8961232: NM_020738 kinase D-interacting substrate,

8961097 220kDa

KIF21A chrl2:-:39835889: NM_001173464

39835764 kinesin family member 21 A

L3MBTL2 chr22:+:41613520: NM_031488

41613848 l(3)mbt-like 2 (Drosophila)

LGALS3 chrl4:+:55596173 : \\! 001 177388

55596365 lectin, galactoside-binding, soluble, 3

LINCR- chr3 :+: 191191340: NR_120606

0002 191 191477 uncharacterized LincR-0002

LING02 chr9:-:28080976: M_001258282 leucine rich repeat and Ig domain

28080822 containing 2

LOC400927 chr22 :38766050: NR 002821 TPTE and PTEN homologous

38765991 inositol lipid phosphatase pseudogene

LPHN1 chrl9:-: 1428421 1 : M_001008701 adhesion G protein-coupled receptor

14284108 LI

LRRC1 chr6:+:53784070: NM_018214

53784138 leucine rich repeat containing 1

LRRC42 chrl :+:54413535: NM_001256409

54413654 leucine rich repeat containing 42

LYRM1 chrl6:+:20922505: NM 001 128301

20922586 LYR motif containing 1

MACROD2 chr20:+: 13976991 : M 080676

13977165 MACRO domain containing 2

MANEA chr6:+:96029731 : M_024641

96029787 mannosidase, endo-alpha

MAPK10 chr4:-:87168720: \M 002753

87168646 mitogen-activated protein kinase 10

MARCH7 chr2:+: 160619771 : M_022826 membrane-associated ring finger

160619867 (C3HC4) 7

MARCH8 chrl0:-:45955325: NM_001282866 membrane-associated ring finger

45955 188 (C3HC4) 8, E3 ubiquitin protein ligase

MDN1 chr6:-:90366293 : NM 01461 i

90366095 midasin AAA ATPase 1

MEAF6 chrl :-:37959764: R_073092

37959741 MYST Esal -associated factor 6 Gene Coordinates (hgl9) Refseqid Description

MEMO! chr2:~:32 12156: M_015955

321 12104 Methvlation modifier for class I HLA

MFN2 chrl :+: 12041867: NM_014874

12041910 mitofusin 2

MLLT10 chrl0:+:22017561 : NM_004641 myeloid/lymphoid or mixed-lineage

22017604 leukemia; translocated to, 10

MMS19 chrl 0x99241240: NM_022362 MMS19 nucleotide excision repair

99241106 homolog (S. cerevisiae)

MORF4L1 chrl5:+:79184787: NMJ206839

79184819 mortality factor 4 li ke I

MRPL39 chr21 :-:26960065: NM 080794

26960013 mitochondrial ribosomai protein L39

MRPL45 chrl7:+:36468550: NM 03235 !

36468624 mitochondrial ribosomai protein L45

MRPS28 chr8:-:80915355: M_014018

80915234 mitochondrial ribosomai protein S28

MTMR3 chr22:+:30384868: NM_021090

30384916 myotubularin related protein 3

MYB chr6:+: 135520664: NM_001 161656 v-myb avian myeloblastosis viral

135520719 oncogene homolog

MYCBP2 chrl3 :-:77692630: X\! 01 5057 MYC binding protein 2, E3 ubiquitin

77692475 protein iigase

MYCBP2 chrl3 :77628 42: NM_015057 MYC binding protein 2, E3 ubiquitin

77628054 protein ligase

MYLK chr3 :-: 123459382: M_053025

123459323 myosin light chain kinase

MZT1 chrl3 :-:73299916: XM 001071775

73299780 mitotic spindle organizing protein 1

NEDD4 chrl5:-:56132413 : M_006154 neural precursor cell expressed,

56132348 deveiopmentaliy down-regulated 4

NFASC chrl :+:204980621 : NM_001005388

204980739 neurofascin

NGF chrl :-: 115843104: NM_002506 nerve growth factor (beta

1 15843018 polypeptide)

IPA1 chrl5:-:23053780: M_ 001 142275 non imprinted in Prader-

23053689 Wilii/Angelman syndrome 1

NLGN1 chr3 :+: 173946047: M 014932

173946101 neuroligin I

- All - Gene Coordinates (hgl9) Refseqid Description

NLN chr5:+:651 18355: NM_020726 neurolysin (metallopeptidase M3

651 18497 family)

REP chr5:-: 1 1 1086122: NM_001142476

111086049 NA

NSUN4 chi :+:46823248: NR_045789

46823331 NOP2/Sun domain family, member 4

NUPL1 chrl3 :+:25877240: NM_014089

25877293 nucleoporin 58kDa

OSBPL3 chr7x2493834Q: NM 015550

24938132 oxy sterol binding protein-like 3

PAPD4 chr5:+:78937278: M_001 14393

78937340 PAP associated domain containing 4

PBX3 chr9:+: 128726317: NM 006195

128726477 pre-B-cell leukemia homeobox 3

PCDHIO chr4:+: 134074437: M_032961

134074588 protocadherin 10

PDE3A chrl2:+:20755159: NM_000921 phosphodiesterase 3A, cGMP-

20755255 inhibited

PDE7A chr8:-:66693182: NM_001242318

66693079 phosphodiesterase 7 A

PDXDC l chrl6:+ _: 15103356: \\! 001 285447 py ri doxal -dependent d ecarb oxy 1 ase

15103418 domain containing 1

PDXDC2P chrl6x 7006515 1 : NR_003610 pyridoxal-dependent decarboxylase

70065089 domain containing 2, pseudogene

PFi,n chr2:-:64339806: NM 02065 1

64339697 pellino E3 ubiquitin protein iigase 1

PIGN chrl8:-:59764997: M_176787 phosphatidylinositol giycan anchor

59764914 biosynthesis, class N

PITPNB chr22:-:28290410: M_012399 phosphatidylinositol transfer protein,

28290364 beta

PITP B chr22:-:28288318: NM_012399 phosphatidylinositol transfer protein,

282881 17 beta

PMSl chr2:+: 190683464: NM_000534 PMSl homolog 1, mismatch repair

190683555 system component

PNISR chr6:-:99868460: NM 032870 PNN-interacting serine/arginine-rich

99868399 protein

POMT2 chrl4:-:77753614: NM 013382

77753576 protein-O-mannosyltransf erase 2 Gene Coordinates (hgl9) Refseqid Description

PPARG chr3 :+: 12427535: M_138712 peroxi some prol i ferator-acti vated

12427591 receptor gamma

PPFIBP1 chrl2:+:27769294: NM_003622 PTPRF interacting protein, binding

27769423 protein 1 (liprin beta 1)

PRPF31 chrl9:+:54632112: NM_015629 PRP31 pre-mRNA processing factor

54632180 31 homolog (S, cerevisiae)

PSMA4 chrl5:+:78834918: NM_ 001 102667

78834987 proteasome subunit alpha 4

PXK chr3 :+:58321084: NM_017771 PX domain containing

58321 179 serine/threonine kinase

RAB23 chr6:-:57086244: NM 001278666 RAB23, member RAS oncogene

570861 17 family

RAB23 chr6:-:57086244: NM 016277 RAB23, member RAS oncogene

57086141 family

RAF 1 chr3 :-: 12645036: M_002880 Raf-1 proto-oncogene,

12644977 serine/threonine kinase

RAPGEF1 chr9:-: 134479440: NM_005312 Rap guanine nucleotide exchange

134479348 factor (GEF) 1

RASIP1 chrl9:-:49241364: NM_017805

49241141 Ras interacting protein 1

RBBP8 chrl8:+:20557753 : NM_002894

20557850 retinoblastoma binding protein 8

RCOR3 chrl :+:211478332: M 001136223

21 1478493 REST corepressor 3

RERE chrl :-:8456591 : NM 012 102 arginine-glutamic acid dipeptide (RE)

8456504 repeats

RGL1 chrl :+: 183708924: XM 01 5 149 ral guanine nucleotide dissociation

183709042 stimulator-like 1

RNF130 chrSx 179390561 : M_018434

179390471 ring finger protein 130

RNF144A chr2:+:7114066: NM_014746

7114154 ring finger protein 144 A

RNF213 chrl 7:+:78316103 : NM_001256071

78316182 ring finger protein 213

RPF2 chr6:+: l 1 1305510: XM 032 194 ribosome production factor 2

1 11305566 homolog

RPS10 chr6:-:34385674: M 001204091

34385575 ribosomal protein S10 Gene Coordinates (hgl9) Refseqid Description

SAMD4A chrl4:+:55204147: M_015589 sterile alpha motif domain containing

55204227 4A

SCO! chr!7 : 10594966: NM_004589 SCOl cytochrome c oxidase

10594907 assembly protein

SENP6 chr6:+:76331643 : NM_015571

76331687 SUMOl/sentrin specific peptidase 6

SF3B3 chrl6:+:70561279: \\! 01 2426

70561332 splicing factor 3b, subunit 3, 130kDa

SGIPl chrl :+:67051355: NM 032291 SH3 -domain GRB2-like (endophilin)

6705153 interacting protein 1

SGMS1 chrl 0:-:52328405: MJ47156

52328298 sphingomyelin synthase 1

SGPL1 chrl i): : 726042 : NM 003901

72604395 sphingosine-1 -phosphate lyase 1

SH2B3 chrl2:+: l 1 1859705: M_005475

11 1859739 SH2B adaptor protein 3

SKP1 chr5x l33511076: NM_ 170679

133510975 S-phase kinase-associated protein 1

SLC12A2 c r · : 1274788 1 8: NM_001046 solute carrier family 12

127478874 (sodium/potas sium/ chl ori de

transporters), member 2

SLC25A16 chrl0:-:70250796: \M 1 52707 solute carrier family 25

70250680 (mitochondrial carrier), member 16

SLC25A17 chr22:-:41193340: \ ^' R 104235 solute carrier family 25

1 193288 (mitochondrial carrier; peroxisomal membrane protein, 34kDa), member 17

SMOX chr20:+:4133445: NM_175842

4133558 spermine oxidase

SNAP23 chrl5:+:42805372: M 003825 synaptosomal-associated protein,

42805407 23kDa

SNX24 chr5:+: 122233837: M_014035

122233931 sorting nexin 24

SNX7 chrl :+:99204216: M_015976

99204359 sorting nexin 7

SOCS6 chrl8:+:67981331 : M_004232

67981476 suppressor of cytokine signaling 6 Gene Coordinates (hgl9) Refseqid Description

SOGA2 chrl8:+:8828355: M_015210

8828467 NA

SORCS1 chrlO:-: 108337396: NM_001206572 sortilin-related VPS 10 domain

108337339 containing receptor 1

SPIDR chr8:+:48185929: NM_001080394 scaffolding protein involved in DNA

48186042 repair

SPRYD7 chrl3 x50492357: \\! 020456

50492229 SPRY domain containing 7

SRE.K1 chr5:+:65460436: NM 001270492 splicing regulatory glutamine/lysine-

65460505 rich protein 1

SSBPi chr7:+: 1414411 10: NR 046269 single- stranded DNA binding protein

141441259 1, mitochondrial

STRADB chr2:+:202335632: NM 018571

202335834 STE20-related kinase adaptor beta

STXBP4 chrl7:+:53193279: M_178509

53193304 syntaxin binding protein 4

STXBP6 chrl4x25457178: NM_014178

25457092 syntaxin binding protein 6 (amisyn)

STXBP6 chrl4:-:2541 1028: NM_014178

25410930 syntaxin binding protein 6 (amisyn)

SUPT20H chrl3 :-:37585794: NM OOIO 14286 suppressor of Ty 20 homolog (S.

37585696 cerevisiae)

TAF2 chr8x 120757276: NM 003184 TAF2 RNA polymerase II, TATA

120757121 box binding protein (TBP)-associated factor, 150kDa

TAF2 chr8:-: 120771346: NM_003184 TAF2 RNA polymerase II, TATA

120771264 box binding protein (TBP)-associated factor, 150kDa

TARBP1 chrl :-:234571617: NM_005646

234571386 TAR (HIV-1) RNA binding protein 1

TASP1 chr20 : 13395909: \M 01 7714

13395770 taspase, threonine aspartase, 1

TBCA chr5:-:77070041 : \\! 004607

77070009 tubulin folding cofactor A

TBL1XR1 chr3 :-: 1 76865407: NM 024665 transducin (beta)-iike 1 X-linked

176865310 receptor 1

TCF4 did 8x53202868: NM 001243226

53202790 transcription factor 4 Gene Coordinates (hgl9) Refseqid Description

ΊΈΚΤ4Ρ2 chr21 :-:9963254: R_038328

9963195 tektin 4 pseudogene 2

TET1 chrl0:+:70440629: NM_030625

70440724 tet methylcytosine dioxygenase 1

TIAM1 chr21 :-:32641011 : NM_003253 T-celi lymphoma invasion and

32640727 metastasis 1

TJAP1 chr6:+:43453391 : NM 001 1460 8 tight junction associated protein 1

43453466 (peripheral)

TJP2 chr9:+:71792959: M 004817

71793045 tight junction protein 2

TMEM214 chr2:+:27260130: N M 01 7727

27260168 transmembrane protein 214

TMX3 chrl8:-:66368055: NM 019022 thioredoxin-reiated transmembrane

66367951 protein 3

TNRC6A chrl6:+:24769760: M_014494

24769920 trinucleotide repeat containing 6A

TRAP 3 chrl4:+: 103356688: NM_ 145725

103356763 TNF receptor-associated factor 3

TRIM65 chrl7:-:73887957: NM_173547

73887894 tripartite motif containing 65

TSPAN7 chrX:+:38425575: \\! 004615

38425608 tetraspanin 7

TXNL4B chr!6 : 72127025: M 001142318

72126872 thioredoxin-like 4B

UBE2D3 chr4:-: 103774240: N M 181 890

103774195 ubiquitin-conjugating enzyme E2D 3

UBE2L3 chr22:+:21933070: R_028436

21933127 ubiquitin-conjugating enzyme E2L 3

UBN2 chr7:+: 138949929: M_173569

138950208 ubinuclein 2

UNC13B chr9:+:35291066: NM_006377

35291 101 unc-13 homolog B (C. elegans)

URGCP- chr7:-:43945050: NM_001204871

MRPS24 43944971 URGCP-MRPS24 readthrough

UVRAG chrl l :+:75603173 : NM 003369

75603437 UV radiation resistance associated

VDAC2 chrl0:+:76990177: M 001184783

76990208 voltage-dependent anion channel 2 Gene Coordinates (hgl9) Refseqid Description

WDR27 chr6:~: 170061846: M_182552

170061799 WD repeat domain 27

WDR90 chrl6:+:702156: NM_ 145294

702218 WD repeat domain 90

WHSC2 chr4x 1993796: NM_005663 Wolf-Hirschhorn syndrome candidate

1993723 2

WNK1 chrl2:+ _: 1004327: NM_ 001 184985 WNK lysine deficient protein kinase

1004362 1

XRN2 chr20:+:21326472: M 012255

21326525 5 -3' exoribonuclea.se 2

ZFP82 chrl 9:-:36891305: NM 133466

36891187 ZFP82 zinc finger protein

ZMIZ2 chr7:+:44790571 : NM 031449

44790690 zinc finger, MIZ-type containing 2

ZNF138 chr7:+:64277652: M_001160183

64277713 zinc finger protein 138

Z F208 chrl9 :22168468: NM_007153

22168407 zinc finger protein 208

ZNF212 chr7:+: 148945885: NM_012256

148945948 zinc finger protein 212

ZNF280D chrl5:-:56935772: NM_001288588

56935673 zinc finger protein 280D

Z F350 chrl9x 52470649: M 021632

524705 1 zinc finger protein 350

ZNF37BP chrl0:-:43046910: XR 026777

43046848 zinc finger protein 37B, pseudogene

ZNF426 chrl9:-:9645012: XM 02 106

9644915 zinc finger protein 426

ZNF618 chr9:+: 116797471 : M_133374

116797515 zinc finger protein 618

Z F680 chr7x64002295: NM_178558

64002108 zinc finger protein 680

ZNF730 chrl 9:+:23321296: NM_001277403

23321357 zinc finger protein 730

Z F777 chr7 : 149154134: NM 015694

149153846 zinc finger protein 777

Z F804A chr2:+: 185677213 : NM_194250

185677264 zinc finger protein 804A Gene Coordinates (hgl9) Refseqid Description

ZNF836 chrl9:-:52668638: M_001102657

52668509 zinc finger protein 836

ZSCAN25 chr7:+:99216410: NM_145115 zinc finger and SCAN domain

99216516 containing 25

[00582] The sequences for iExons produced in certain affected genes at the indicated coordinates from Table 24 are shown in Table 25. In certain instances, detection and analysis of the amount and type of iExon sequences are useful biomarkers produced as a result of contacting a cell with a compound as described herein or administering to a subject in need thereof a compound as described herein.

[00583] Table 25 Gene Sequences

Gene Sequence SEQ ID NO:

AKAP8L GTGAAAACAGCTCCAGCGTGAGTTTTGGCACCACACTG 3817

GTAGAAAACACTTGGTGTTCAGACCCTTTTGGACCTGG

GGGAATTGCAGA

AKTl GTGGCCACTTCTTGACTGCTTTGAGTCCCTCATCCGAGC 3818

GAAGGGCGGACGGAGTCCGTTGGTGGGGGTCCGGTTGC CTCTCCCGGGAGCTGTGTAGACTTCTCATACACCAGGGT

TCTGGAGGCAGATGGAGGAGCCCTTTCGAAAACAGA

A KRD13 GGAAACCAAGAATACCAACTCACTTTGCCTTGTCTGTG 3819

C ATGAGAACTGAAAAACCTACAGA

ANXA1 1 AGTATCTCCTGCATGCCAGCAAGCTATGGACATCTGGA 3820

AGAAGCCACATGCCTTGCCCTCAAGTTGCTTAGGGTGG AAGGAAATGATTAGAAATGAGCCAAGCCGAGCCTGCAC TCTTAGA

ANXA1 1 CAAGCTATGGACATCTGGAAGAAGCCACATGCCTTGCC 3821

CTCAAGTTGCTTAGGGTGGAAGGAAATGATTAGAAATG AGCCAAGCCGAGCCTGCACTCTTAGA

APIP CTCTGAAATTAAATCCCTACTGACTGGCCCTTGAACTGA 3822

TTTTTTCTAACATCAGCAAAAGTCAAGGAGTGTTTCCCT AAAAAAGAAAGCATTTACTCAGAAACCGTATATTGAAG TCCAGGCTGAAAAATGCAAACATGA

APPL.2 TAAAATGAAGTTAATGGAACCATGGAATCTACCTTGGA 3823

GAGTTGCTAGAAGAATTAAATGAAGTCACATATGTTTA GTGCCCAGCACAGCGTCCAGCACATAGGTGGTACAGA

ARHGAP1 GGCCGTCAACCTTTCCACCTTGAAACTGGTGTCAGGAG 3824

CACCCTGCAGA

ARHGAP5 TTCTAGAGGCTGGTAAGTTCAGGGTCAAGGAGGCCTCA 3825

TCAGGTGAGGGCCTTTTTGCAAAGTCATTCCATGACCGA

AGGTGGAAGGGCAAGAGAGCACACTCAGAGA

ARL15 GGAAAAAAAATGCTCCTTTCATTCCAAGTTTGACTCCAG 3826

ATTTTGCTGAATGGATTAGA

ARL15 GGGCCTTCCAGAGAACAAATGGCTGGTCCTTTTCCAAG 3827

GGGACAGATTTTCCTACCTGATGCTTTTGTTCTCCAGCA AGAAAAGAAAATGAAAACTGTTGTCTTCCCCTAGAATA TTGAGTCCAGA

ARL5B GAAGCTTGAAAGAAATTTCACATTTTCTGCAAGGACTT 3828

AAACCTGAGCTCTCAGCTTTCTGCAAGA

ARSJ GTAATTAGCTGAGAAGGAAGATCTGAAGGTTTAACGAG 3829

AGAGGGCGAGAGATACAAAATATCTGCTAGGAGA

ASAP ! TCTAGGAGA 3830 Gene Sequence SEQ ID NO:

ASAP1 AGCAAACCCCATTGTCAGGGGAAAGCAGAACAAAGAA 3831

AAGTATTTAGAAATGTATTTCCGGGATGCACAGATTCTT

TTCACCCTCACCTTCCCCTAGGTTGTTGCAGCTGCGCAC

CTGCTCTGTGAAGCACAGATTGTCATGGGGGCAGTTCTC

TCAAAAACATGGCATATTGTGATGA

ATF6 GTTGTATGCTTTCTCTGTGCAGGGATAAAGTCTATTCAT 3832

TCTGTTTTGTCTTTTACAAGATCTATTGCAATGCATTGC AGGCTCGGCAGA

BECN1 GATCCCATTGATGGATGGAAACTCTAGTTTTTACTTAGA 3833

BHMT2 GATGTTTTCATCTGGCCCAAGAAGAACTTGTTCTTAATG 3834

TTAAAAGACCTTTTTGCTAAACTGGGAAGAAAGTGCTG

GAATAACAAGA

BIN3 AGCTCTCAAAAGTACAGGAAAGAGATTGCTTCAGTGTG 3835

GTGAGAAGTTTGGCACACATCTGACCAATGGCTCCATC

TCTAGCAAATCCAGA

BNC2 GAGTGCCCCAGATCTCCCTGTTTCACCTGTGATTATCTG 3836

TGATGCCATAGCAACACCCCTTGCTGTTAGCAGA

BTBD10 ATGAAAGAACTGAGCTTTGGAGGCTAAATTACTTGTCC 3837

CAAGTTAATACAGCTTAGAAAGTGATAGA

C 10orf76 GCAATCTACACAGCTATTTCCTGTGGGGAAATCTCCTTG 3838

AAGAGTCTGCCAGATTCCTCTTGGAACCCTCTCAGA

Cl lorf30 GCCTTGTTCAAAGCTCTGGGCATCTAGCAATGAGTAAG 3839

ATAGTCAAGATCTGTGCTCTGTCCACGTTCTCTTGGAGC TTACATTTTAAGA

Cl lorf73 GTAATTATTGAACATCTACTTGCTGCCTACTTTCAACAT 3840

CTGCATGTGTGTGTGAATATTAAATATCACACCAAGAC

ATTGTTCAGAGGAGACAGAATAGTGAGCTGAGATAAAT

GAGAATCTCTCTATGGAAGATTAGACTGGAGCATGAAC

TTGAAATATGA

C 12orf4 TGAGCACCATAAAATAAAAACGCCATACAATCCAACAA 3841

TTATTTATTAGTTCTTGCCATTCGCAACATCCTGCCTAAT

ACATGGAATACAAGACAGTATTCCTTCCACTTCAAGAA

GACTGTTTTCTAGCCAAGA

C lorf27 CTATAGAAATGCAAATCAAAGGAGCATAAGCCAATAGA 3842

GGGAATGAATATACTGACTTCCATCCACAGACCAGAGG

GAAAACAGA Gene Sequence SEQ ID NO:

C 1QTNF9B GTCCAAGCGGCTGCCCTGGGGCTTGACATTGAAGGCGG 3843

-ASl CGCCCACGGGAGACCAGCTGGTGCTGACCCTTCGGGCC

CGGATCCCGGCTTCGAGGCTTCCCCGGCCCGCCCGGCG

GGGCGGCAGAGCTGCTGCTCTGGCTCCCAAGCCGCCCA

GCCTTCCGACGCACAGCATTCTAGCACCAGAGCAGTCC

CTTCCTCCAACGCAGATCCCTGCCCTGCTGCTTTCGCTG

GGAGCGCGCGCTCCGCGTTTCCAAGGCAGCAGCCCACG

CCGCCCCACGTGACGGCCCCGCTTCCGGGTCTGGGCGC

GGCCTCAGGACGTGGGCACGTTGTCGTCCAGAGAGCAA

GAGCGTCGCTCCCCCTCGCCTTCTCGGCCGCCCTCCCGG

TTTACCGCCCCCTGTGTCCAGA

C2orf47 TGCCAACATCCCCAGTGAAACTTTAAGAGGAGCCAGTG 3844

TATTCCAGGTTAAGTTGGGGAATCAGAATGTGGAAACT AAACAACTTCTTAGTGCAAGCTATGA

CACNB1 TAGGAAACACCCCAATCCTGAGTCCCCCAAGCACATGC 3845

AGTGGTTCCCCCTCCATGAAGA

CACNB4 GAACGGACAGAGTTTAAGATGGTGAAGGCCAATAAAA 3846

AAAGGAAAAAAATGATGCAGACTCTCAAGAAAATGCT GTTTTCAGTCTCCATGTGGAATTTCAGGATGTATTAGTA CAGCCCGAGCTGGAAGGGTTGAAGCAGAGA

CADM2 ATTAAAAAAATCAGCCGATGTGGTGGTGCATGCCTGTA 3847

GTCCCAGGTAATTGGGAGGCTGAGGCAGGAGGATTGTT

TGAGCCCAGGAGTTCAAGTCTGCAGTGAGCTATGATCA TGCCACAGTACTCCAGTCTGCGTGACAGA

Gesie Sequence SEQ ID NO:

CC L2 GGTAGCCTCTGAGGGTAAGTGACTAAGACTTCTCCTCTG 3848

CTGTCCAAGCGCTTTGGTGCAGGGACAGCGGCATCTTC

AGCCAATCCAGTGCAGGCTCTCCACCGAAGGCTGGCTC

TAGACTGGTGGTACGCACATAGCATAGCCATGGCCGAC

TCCTGCTGTGGTTCTCTGACGATTGTGCTTCTTGTTAATC

CTCTGTCGTGCTTTGGTAATCGTATTGATTAGAGTTGGT

AACTGTCTTGACTTGAATTTTGTCCCTTTAAAACTGCTG

TACCTGTATGATAAAGATGCAGTACCTTTCTCTTAAAAA

AAAATGCTATGGAAAGCTGTGAGAATTGAAGAGACAA

ATTGGCTGTGTCAGTGTGGGGTTATGTCATGATTTCTAG

AAGCCCTGAAGTTGCTCTTTTGAGCAGCTTTGCATGACA

CGCTCTGGTAAAAGGTGTGCATCTTTAAATTATTTCATG

GATACTTTGAAAAATATTGTATCACTTCAAATACAGCA

ATAAGTTTATATGTTCTCAAGATTTCATTTGTTTTTAAG

AATTTTAAGTTCGTGGATTAATATCACTACTTGAATACT

GACAGTTGTTGATTAGACACCGAAAGGTTACTGATTGTT

GAATGTATCTGTGTTAGAGCTGTGCACTGGCACGCTTGC

ATCAGGGGCTGGGGCCACACGGCCGCCACACAGATTCC

CCCGTGATGCCTGGAGCTGCTTCCAGAGCCGGGTGTCTC

CAAGAGGCACCTGTAGGACTTCCCATTTAGAAATCTCTT

GAGTGGGTTTGTATGTTACCTTCTCCAAGGTTTATTTAG

GAC AGAGAT ATTGCTGGA AGGTC ATGGGTC AGATTCCC

TCACAACCCACCTCGTCTGCGGGTGCAGCCCCACTCCA

AGGCTCCCCGTTATTGGGGTATGTGAGGAGCAGTAAAT

ATAAAACCAGTTCAACTGTCCTCATGGAATCACCCTTTC

TGTTTTTGCAGTATTCATAAAGCTAGTGTAAGGTCTGGT

TTTAGTCTATTAAATCTTAGAGATCTAAAGGAAATGCTC

AAAATGTAGCCAGGTTTTAAATGCTTTAACTTTTAAAAA

ATGTAAATTTTTGTATGTTTATAGCTTCTAAATATGAAA

GTTAAAGAATGTACTGTGATGAAATGTTCAGTATTATGT

TGCTTCTCAGTATCATGTTGCTTCTCAGTATTGTGTTGCT

TCTGATTCTATGAATGTTCATTTTAAGACCCCTTGTTGA

AATGGGACAGTTGGCAGCGGCTCTGATGAGCCCGAGAA

GAGGCCTGCCCTTGGGTGCGGAGTCTCCCTCCGCACGA

TGCTCCCACGCGTCCAACTTGCACCCAAGGGGCTTTTCC

CTCTTCCAAGTGGACTCCTTCAAGGAAGCTGCAGCTCG

GTCAGCAGAGAAGGGGCCTGCCGCCAGCGCCCTGGAGG

AAGAGGAAGAGGAACCCAAGAGGATGGCTTGTCTCCCA

GCAGCCACACCGGCTTTGTGCTCAGCCAGTTCATTTGA

CDH18 TCAGGAAGTCTGAAGTCTAAAGGATATGAGCAGAAGTT 3849

AACCATGACAATAGA

CENPI: GTTTTTGGGGAACAGGTGCTATTTGGTTACATGA 3850

CEP 162 ATAAATTGAAAA AATGGGAGGAAAGAGAAATGGAACA 3851

CCTCAAGGTGATACTGAAGTTTAGAGA Gene Sequence SEQ ID NO:

CEP 170 GTGACAGCCTCTTCTTTTTATAAGCTCCTTTATCAGACG 3852

TAACCTCCTCAAAAGCAAAGACTGTCATACAGATTTTGT

AATCCCCTGCAGTGGCTAGCCAAGTAGCCTGTGGAGA

CEP 192 GAGAGTTCTTTGCTCAAAGATCTGAAGCTCTTGGTTGCC 3853

TTGGTGGTGGTAACAATGTGAAAAGA

CEP 57 ACCAGAGGCTGGGCTCTGGATTACAGCTCAGTAGTGGG 3854

TCATGGAATATGTACTGTGACTCAACCCGTATCATTTTC

AAGAAAGAAGAGAGAGAAAATCGTTCAGCAAATATAA CTGAATGAATTATCTGGTTCACAGA

CHEKI GTTGAGGCCTTGGCTCCTGCCTGTAGTCCCAGCTACTTA 3855

GGAGGCTGAGAGAGGAGGATCGCGTGAACCTGGAAGT TTGAGGCTGTAGTGAGCTATGATTGCACCAGTGCACTCC AGCTTGGATGACAGA

CHRM2 CCAGTCTCAGCAGAAGAGTAACATGACATGAGAGATTG 3856

GGAAACTGTCCTTCTGTGGGGTTCTTCAGACAACCTAAG CCATCTCCTACATCCTACACTCGCTGAACATAGAATGGT TGAAGGAAAGAATGAATACATATGTAGAAGAGAAGAA

TCTTGCTAAAAGGAATGAAGTTGTCAAGATAAATAATT AAGA

CMAHP AATGAACACTCCATGAGAGCAGGGACCTGCTTTGCCTT 3857

GTTCACCACTTTATTCCCAGTGGCTAGAACCACGTCTGA CACAGA

CMS S I GTTTTTAAAACTCATTTGGACACCCACCTCAATATATGC 3858

TGTGCAATTAGAATAATCCAGAAGACTGAAAGA

CNOT7 TTCTTCAAGAAACTTGGTTTTAGCATTGGAATACTGTGA 3859

GCATCATTTCATGTATCCTTTGGGAGACAGGAATTTATG ATTTTCCCCCCTTTCTTGGTTATAGA

CNR!Pl TTAACCGGGTGTGGTGATACCACACCTGTAGTGCCAGC 3860

AACTTGGGAGGCTGAGGCAGGAGGATCACTTGGATCCA GGAGGTTGAGGCTGCAGTGAGCTATGATCACACCACTG CACTCCAGCCTCGGTGACAAGA

CNTNl GGTCTTTGTCACCCAGGCTGGAGTGCAGTGGAGCTATC 3861

ACAGCCCACTACAGCCTTGCCCTCCCTGGGATCAAGTG ATCCTCCCAACTCAGTCGCCAGA

COP STB TAGAGACGGGGTTTCACCTTGTTAGCCAGGATGGTCTC 3862

GATCTCCTGACCTCATGATCCACCCGCCTCGGCCTCCCA

AAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGC

CCACGTTTGTGATTTAAACAACAACAACAACAACAACA

ACCAGTTAACGTAATTGACAGCAGAGAAGTTCCAGGCA

GAACAGTGGCTCTTTCGTTTTTCTTCTACACATGGCTTTT

TGCCATCAGCATCAGTGAAGA Gesie Sequence SEQ ID NO:

CRISPLD2 ATTGGGTCTTATCCCCAAGATATCTCATTATGTACATGC 3863

AAATCAGCGGAGCATCGTCATGACACCAGGAGGACACC

CCGTGACGCCGATTACCGCACTCTCAACCTCAACCCAG

CGTCAGAGTTTTCTGGCATCTCTTCTTTGAGCCTGGCCG

CCTGCAGCTGGAAATGCTCATATATGGTGGTGTGACTA

ACCTGAGAGAGAGAGATCAGGGATCCTGAGAAGTTCTG

CATTCTTGGTCTGCTTCCCAGTGGGACGA

CRYBG3 GGCCTTTCTGTCTGGTGTGTGCAGAATGATCTGGGTCAC 3864

CTCTGAGGCCCATATTTATAGA

CUXl CAGAGAAATCTCAGGAGGCACCATGCCAGGCCACTGTG 3865

CCCCTGCAAGTGTGTCTGAGTATGGCCCAGGACCCTGC CCATCACTGGTCTGCAACAAGATAAGCACAGAAGTTCA GA

DAAM1 AGTCATGACACCCTGTTCAAACTCTCTGGACTTCAGCCA 3866

GTTGTTTGGCTAGATACAATTCTCAGAGAGGCAAAGGA

ACATTACAAAGGTAATGGCATGAATACCATTACCTGTA

TGCATGCAACAGGAACCCTGCACAGA

DCAF17 TTTTGCCAAGGAGTTTGTCCACAGAGCTCTTCATGCCCT 3867

CATGCTGGAAGTGGAAATCTGGACATGTTATCTTATCAT

GTCATTATCACACCTAGGAAAATGAGCAACAATTCTTC

AGGATCATTTAATGTCAAGTTTATAACTTCCTGCTTTAA

CTTAAAAAAAAAATTAAATTAGA

DCAF17 GTGGATCATATTGGATACCTGTGGTCATTAACAAACTAC 3868

TATGTTATGAAATTACAAAATGA

DCUN1D4 GCCGAAGATGGTGTTAGTGATTGCGAGCTGCTGGCTGG 3869

C ACC C TTGC A G A GC AGG A

DDX42 GTGCAGTTTGAACAGGGCTTGACAGTGGCTGGACCATC 3870

ACTAAGTGAGACTTTAATTCATCAAGCATAACTGAAAA TGGAGGCAGTAGATTATATCTTGGTAGCCAGCATGTGT AGACTTGTCTTATTTGGAGCCCACTTGGAATTTTCATTT

CAAGA

DENND1A CTGTGGCATAAGAATGAAAAGAAAAGAAACAAAAGCA 3871

GATGGCAGAGAAAACGAAAGGA

DENND4A GTCAAAGTCGTACTCTTTTGTTTGAGA 3872

DENND5A GCCAAAATCATATTATATGATCAACCTCAAGTGCATGG 3873

GAAGCTGTGAAAGTGAACATTGAACTGGGTATAATGTT

ACCCTGAACAGTATGAAGGTCTATGAGCAAGAAAGAAG GGGTGAATGAATTATGA

DENND5A ATAGGACAGCATTTAAAAATCTCATGTGGAAGAATATA 3874

CCACTAGA Gene Sequence SEQ ID NO:

DET1 GAGTGATGAATCTAAGCAGGAATGCCATCCACCTTCAG 3875

AGCC ATTGGCGTGAGGATGACGGTGTGAAGTCT ^' l Γ TCA

AAGCAGGA

DET1 TACATAATTTAGGATGAGAAGCACGAGTTACCGAATGA 3876

AGATCTGGTTGATCCCCCAGA

DGKI ATAAAATTCTGGAACAGACAATTATGTCCTTACAAACA 3877

ACAACATTTGAGA

DHFR CCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAA 3878

GGATCATGCAAGACTTTGAAAGTGACACGTTTTTTCCAG AAATTGATTTGGAGAAATATAAACTTCTGCCAGA

DHFR GCATGTACTAACATAACATCATAACAGCCTCTTTAATGG 3879

AATGGAGGGAATTCTCTAACGGGAGACCTAGA

DIAPH3 GGTTTTGTTCCTAATGTCACATGTTTCCTAAGTAATTCA 3880

GCATAAAGA

DIAPH3 GTAAATTAGACCCAAAATAACTCCCAGGGAGCAATACA 3881

CAGCCTGGAAAACATGAAACAAGGAGCGGCTGTTTGGT GTAATAAAGGAGGAGCACCAGGCTGAATTTTCAGAGGC CTAATAGA

DL.G5 GATGGAATGTCATCCCAGGAGCCATCTCTTTTCCTCGGA 3882

GGGCATCTCAAGACCCCCCAGA

DMXL1 GATAGGCAGTACTTTGTGAACCAGCTACAACAGAATCA 3883

GCTGCAGTGCTTGTTAAAAGTCTGGATTCTCAAGTTCAC TCCAAACTTATTCAATCAGTTTGTGAGA

Gene Sequence SEQ ID NO:

DNAJA4 GGACACGGACATCTGCAACCTGACATCAGCTTGTACTC 3884

ATATTCTGGGTTTTCGGTGACAAGTGACACACAGTTGAT

CATAAGTACCAATCATAGACTGAAAATGCTCTGCATTTT

AGAGACAGAAGTTAAAAGCTTTTCCATCCTGTTTACAG

AAAGTTTGCTTTTTATCTCTAAAGAGGCTCATGACCCAC

CTGAATAGGTGAATTGAAGGATGAGGCATTGCAAGGAA

AGGCTGCTAACCCTCCCGTTCCTCCTTTCACTTCTTGCC

ATTTTCTTACAAAACTTTGGTTGTTCCGCATGGGTCTTG

AGAGGTGGGGCCGTTATAGTAGCTGATAGCAGTGTCAC

TTGGGCCACGTTTGAAACCACACCAATCACCCATGTAG

CATTTAAGACCTGTGGAAACGACGCTGGAATCAAAATA

CCTGTCTGTGTTAGTTGTTCCAAGCTGGAGAAAGCTACT

TC A GG AC GGTTGGC TG A A TGGC A A C AGTG A TGG A A TAT

TTATATTTAGCCACATGTGCTGAATGTGGCTGTCACAAG

TTTAAAATGCTTTCCTGTAAGACCATTTGTCTGTTACTC

ACTTGCGTTCTTTCTCATCTATATTTAGATGGCTTACTGT

AGCTTTTAAAGGCACTGGCGTTTTACATGGTGCTGGTGA

TTCATCCACCTGCTCCCTACATTCATTGTGGTCCGCTTCT

GACAGTCTCCTTTAAGGAGAGCTTGTAGGCTTCTAATTT

CACATTTCAGCAAGCTGGCTAAAGACATGTGGGAAAGC

CTGACCCTGGATTCAGGTCAAATCTCAGCACTCACAAG

A

DNMBP CATTGGCCAGGACTACTAGAACTGTGTCAAAACAGCTG 3885

CTACACTAACGGGCATCTTTGTCTTGTTCTCAGTCTTAA

DYRK1A GTTCAGGGATGCTGGAAAGGACACTGAAGTAGGCCTTG 3886

GCTGATGGGCCTTTCAGAAGTGAACACTTAAGA

DZIP1L CAGCTGCTCTTCCAGCCCGGTCTCATCCCACAGTGGGCT 3887

CCTCCCCAGTCCCTCACTCTGCCATGGACCCTAACACAA

TATGTGTGTGGAGCGGACTCCCCCAAGGGTGGTACTGG AGTGGCCTCGCATAGCACATCAGA

ELM02 GTATGCTCCTGAAGTGAGAAGCAGTGGTTCAAGGAAAG 3888

GCACCTGGGGAGTGCATGGCAGAGGACATCTTGAGGGA TGGGGACCACCGGCATCAAGA

EN AH AGTCTGACTGTTGCCCAGGCTGGAGTGCAATGGCACCA 3889

ACATGGCTCACTGCAACCTTGACCTCCTGGGCTCAAGTG ATCCTCCCGGCCTCCGTCTCCCGAATAGCGGTCTTACTC ATTTTCTACGTGTGTGTTGAGTGCACCATTTGAGA

EN AH ACAGAGTCTGACTGTTGCCCAGGCTGGAGTGCAATGGC 3890

ACCAACATGGCTCACTGCAACCTTGACCTCCTGGGCTCA

AGTGATCCTCCCGGCCTCCGTCTCCCGAATAGCGGTCTT ACTCATTTTCTACGTGTGTGTTGAGTGCACCATTTGAGA Gene Sequence SEQ ID NO:

ENOX1 CTGCCTAATTGAAATATTCAGAGAGCAGAAGTTACTTA 3891

CTCTCGTCTCACCTCCTACTTCTCTCAGAAAATGTAGTA CGACTTCTAGA

EP300 GTGTTTGAAATGGCAGAAAATGAAACGGGGTAAGGATG 3892

AACTCCTGTATAGATAGACTGGATAAAGAGAAAGCCAA GTGCATGATGTTCATAGAGGAGTCTTAAGA

ERC1 ACAGACCCTTCCAGAACCAGATGACCATCAAGACAAAA 3893

GC AT AC TC A AGC AGAC A AG A A AGG A

ERC2 GCTGAAGCAGATTCAATATGGACTTGTTAAAACGTATG 3894

TTTTGTAAATTGAGTTTATCTAAATCCCAGTCTAGAAGA AGGAAGCTCATTTTCTCTAGAAAGTGAATTTCAAAGTA AAACCACATGTTGGATGAAATACAATAGA

EVC TTCCATACAACTATCCCGCTGATTCTTTCTTCAAAGAAG 3895

CAAACCCTCCTTTGCTTTTTATATTTTCTTCACACATGGA

AATGGGGGATGTGGAGGGCCTTGCACAGA

EXOC3 GGGCCACCTCCATGGCTGCAGCCGCGTCACCTCCGTCCC 3896

ATCATCTCGCTGGTTAAACGTGGAAAAACGGGGTCTTG

AGCTCTCCACGGTCTCCCCTCTGGTTGGGCCGGAACAA

AGATTTATAAAAGCAGTGTTGAAAAATCTTTCTGCAATT

GGATTGAGAAAAGACAGA

EXOC6B GATATCTAGAGA 3897

FAM162A GTTGGTTCATGTGATCCTGGTTAATGGAACATAAGTGA 3898

GATTTTATGGGTGACAGGGAGAGAGATCAGGCTTGACT

TGAGAGCACGTGGGAAAAGAAGGGGGCTATCTCTTCGC

AAAGATTTAAGTATCTTATAAGAACTGTTTGCCAGTGCA

ATTATGA

FAM174A ACTGCTGTGGAATTCCTGAGAAAGAGCAACTGAGGGAT 3899

AGCAACATGGATTTCACTGA

FAM195B GGTGTGGAGCGAGACCTGCGAGGCCAGGTGCCGGGTGG 3900

CGAGCGGGGCCTGGTGGAGGAGTATGTGGAGAAGGTCC C T A AC CCC AGCC TGA AGA

FAM208B CATTTATGACATTAACAGAGAACAGGACTATGTCAAGA 3901

ATTCTGAGGGTATACTTGGTGAAAATGAATTAAGACCA CCCTCCCAGCTACATTCTCTCTTAGAGAAGATCGAGACA GGGTCCCTATCAGAAAAGA

FAM49B ATCACATGAGGGCCACCTGAGAGAAGTGAGACCACATG 3902

AGGGAAAACCCAAAAGA Gene Sequence SEQ ID NO:

FAM69B GCACAGTGGCTCACACCTGTAATCCCAGCACTTTGGGA 3903

GGCCAAGGCAGGTAGATCACCTGAGGTCCGGAGTTCAA

GACCAGCCTAGTCAACATGGTGAAACCCCGTCTCTACT

AAAAATACAAAAATTAGCTGGTCGTGGTGGTGCATGCC

TGTAGTCCCAGTTACTCGGGAGGCTGACGCAGGAGAAT

CACTTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCGAG

ATCGCGCCACTGCACTCCAGCCTGGGCTACAGA

FBN2 GATTAATTACCGTTAATGTCTTGGAGACTATAACGTACA 3904

CTGCACGTTGTAATAACACAAAAGGACAAGCAAGATGT AAGA

FBXL16 AAATTAGCCAGGCCTGGTGGTGGGCACCTGTAGTCCCA 3905

GCTACTTGGGAGGACACTGAGGCAGGAGAATCGCTTGA ACCCGGGAGGCGGGGGGTACAGTGAGCTGAGATCATGC CACTGCACTCCAGCCTGGGACCTGGGCAACAGA

FGD4 AAAAAGACAGTCTACAGCCATACCACCCGGAATGTGCT 3906

CAATCTCATCTAATCTCAGAAAAAGACAAATTTCCACG

AAGA

FHOD3 GACAAAAAGCAAAGAAGAAGACTGTGGTCTAGAAGCC 3907

GAAGGAAGATGAGAAGGAAGAGTGTCCGAGGAGTCAG

CCACAGCCAGAAAGGAGA

GALC GTTTTTGGAGAATAGGTGGTATTTGGTTACATGA 3908

GBP1 GGATATGATTACATTTCCATCGTCAGTGATGGACTGAAT 3909

CCTGCTTCTATGCAGCTAAGAAATGGAAGAGTTACAAA

CGGGTTCTTTTCATGGAAGGAAAGAACAGCAAATGAGA

AGCAGA

GLCE GGCAGAGGTGGAGAGGGGTTAGATTATTTCATCTGCCC 3910

TACAGTTGGCATAATAAAGA

G G12 AAGAGGCAGATAAAGAGCTAGAGAAAGACATTGAAAG 391 1

TTGAAGGC AAGAC C AG AG A

GOLGB1 AGGTGCCTGATGCTGTTAATTCCTGAGCCTTTTGAAGAT 3912

TCTGCAGA

GTSF1 CCACATTTTTTTTTTCTTAAATATCACCTGGGAGTGTGTT 3913

GGAAATGGACAATCTCAGCGCTCATCCCAGACCTACTG AATCAGAATCAGCACTTTAACACAGTCCCTAAGTGATG TAACACCTGGAGA

GXYLT1 GGATTGTTTGTATTCCTGCCAATGATTTGTGAGACAGTC 3914

TGTTCCCCACATCCTCGTCAACAGA

HDAC5 GTCTGGGATGAGACCAGAGTCCTCTTCCCTATGAAGCT 3915

GCCACAGGCTGGGCTCTGGGGGGACACAGACGTGCCTG

AGGGTGGCCCTGTATCACCCGTGGAGA Gene Sequence SEQ ID NO:

HDX GAGC TC TGATTTGAGGTGAC AATGATTTTGAAC CTT AAA 3916

TTCTTTGGAAAGACTCAGAATGAAGTCCATTGTGGAGG

CTCAGA

HMGXB4 AATTTCCAGTCTAGTGACGTGATAATGCCATGGACTAAT 3917

CATCCAGTGCTGAATGTCGGAGCACAGGGTCAGGGAAA GCTTGAAGAAGGAGAAGGTTTCAGTGGAAGTGGACGCA TGGAGGCAGAGAGATGTTCAGGAAGCAGCAGA

HOXB3 CAAGAAAGTGCTCGGCTCGCGATCAGGCGCTTGTTTATT 3918

TGAACGTGGACATTCCCAGGATCCGAAAAGA

HSD17B4 CTTTCTGACATCTTAACGAGGCAATACAGAGAGACGAA 3919

TTTTCATCAGTTTGTTCAGGGAGACACATATAACAAAA GA

HIT AGGCAAGCCCTGGTGCTGTGGGAGCCCCAAGGAAGAGC 3920

CTCTGGCCTGGTGGCCACGTAGCCCAGGAGAGATTTCT

ACAGGAGCCCACAGCGCTGAAGGAGAGAGAGGCAGCA GA

IFT57 ATCCATACATACTTAATGCTGAAATGTGAAGGGCTGAG 3921

AAAAAAGAAAAGA

IKBKAP TGGCTGAGTAATCTTCAGATCCCAGTACTTAGCAAGTGC 3922

TCAGTCGGTGTTGGATGTAGGCCACAAACCGGATCGTA

AAGAATTCAACTGTATATTGACAGCCACGGAACTAATC

AATGAATAGATCCGTATGAAGA

INO80 GATTTTCCTTTTTCTCTTGAAATCGTATACCCTCTTCAAA 3923

GAGAGAAAGAAATGCTTCCAATAGA

INPP4B GTTGAGGCTGCACCTGGGAAAAAACACAAATTAGAGGA 3924

GCATCTGTGACCCCTGCCTTTTCCAAAGAGGGTTTTGAG GACTCCGATATGTAAAAGAGAAAGA

INVS AAATCCCATCCATAGTGTGGAACTGAAGTAGAGAAGGC 3925

AAAAGATGGATTCAATCAGTTGTTTGAAACAGGTCCCC

CAAAGGCACACATCTTCGCAGA

ITCH GGTCTTCCTCTGTTGCCCAGGCTGGAGTACAGTGGTGTG 3926

ATCATAGCTCACTGCAGACTTGACCTCCTGGTTGGGGA

GTGGTGGTGTGCACCAGTGGTCCCAGCTACTCAGGAGG

CTGAAGCAGAAGGACCCCCCCAGCCCGGGAGGCGCTCC

AGAACACCCCAGCTTGGGTGACAGA

IVD GCCATCCAGTCTCCTGGCTTTACTGGGTGGAGAGGTGCT 3927

CAGCAGCTTCTGTCACTAGCTCTGAATGGCCTGTCTCCT GGACAAAGAAGCTTTCACGGACTACTCTGCAGGGAGGT

GAC ATTGGACC AGAGCTG ACTCC ACCTGGGGG AA AG A Gesie Sequence SEQ ID NO:

KDM6A GATATTTTCATTGTCTCCGAATTTTAGAGCTGAAAAGTG 3928

CCTTAGAGATCATCTAGTTCAACCTCTCCGTTCAAATGG AGAACCTGAGCCACTAAGATTCACAGGAGA

KDSR GAATGAGTAAATAGGTTAAAGATATAACTTCAGGAATT 3929

TAGAATGGCAAGAAGTCTTCAGTGCCGGGCCTTGCAGA

TAGAGAAATAAAACACCGTATCTGCTGTTGAGGTGTTA

ACCTGGATTTTCACCTAAGAACCACTGCTCCAATGTGTT

TTGAAAATGGAATACTCCTCTAGA

KIAA1524 GTCAGGAATTATGGTTAAAGGTGGATTTTCACTGATGGT 3930

AATAAGATATTACTTTATACCCCTTCCCTCCTCATGAAT TAAGTCCATCTAATCTTTACTGAGGACCTGCTGAGTGGT AGACACTATGATTTGTTTCTGTTTCCACAGATGTCACAA TTGTCAGTAATTGTGGACCTTTAGA

KIAA1715 TTCTCAGGTTTTCTTGACACCAAGAAAGAGAGGGAATC 3931

AAGAAGATCGGTTGTAAGAGAGCAATTCAACATGAAAA TACTGAAGAAGAGATGGGAGAGAGAGAGAGATAATTG TTTTCTTCAGAGTTTTCCACTTTCTATCAGTAACTCTGAT C AC ATGGATATCT ATTGTGGGGCTAGTTG ATGC ATCCCT TCAGATGTGTTGGAAAGAGGACCAAGA

KIDINS220 AAACACTTACCTATGTGAACATCTGAAATGTAACTGTG 3932

ACCCAGAGCGTAAACAGAAAACTTCCCTGAGTCTTTGG AATTATAATTTTGAAAACTGTGATGTAAAATTGATGTAT

TCTCAGGACTGTGGATTTAGA

KIF21A GCACGAGTATTCGATGTAATTTCGGCTGTTTTGATACTT 3933

ATCAAGAAGGAAAGC r rGATAGTTGCTCATGGAAAAT

TGCAACATCATCACACTGTGTGAAAAATTAATGAAGCA TTCATCCTAGA

L3MBTL2 CATTTTCCCATGGAAAGCAGGGTGCTTCTGTAGCTGGCC 3934

TGGGCCCCXJ-TGGGCCCCGAGAGGCAGATGTGGATGCTC

CTGGAGCCACTTCTGTAAAAGGCTCCTCGATGCGGATC

ATGTAAAAGCCAGAACGAAGGGCAAGGCCCTTAGGGG

CGGGGCTTGAGCGCAAGAACCGAATATCCAGCAGCTGT

GACGTGTGGAGCCTGCAGGCCGGGAGAGCAGAGCCCA

CAACAGCACTCTTGTTTTGTCTTCACACCACGTCCCTAA

GCTCCGGGAAATCCAGGAGGAGGCCTCTTTAGTCTTGA

GGAAGTAGGGAGTCTTTTACCCAGA

LGALS3 GAGCGGGGCGGCGGGCAGCGATCTGGGCCCGGGGCAG 3935

TCGCCTTTGATTATCGAGGGCGCTGGCGTTCGGGGAAG

GTTGGCAGCACCTTACGAGACCCACACACGTCCCCGGG

GCGGCACGGGCCACCTTCTGCGGAGCCTCGTGGGCTTC

GCCGCCGTCGCACCTCCGCCGCCTGCGCTCTGCGGCCCC

AGA Gene Sequence SEQ ID NO:

LINCR- AAGTGGGAACAGAGGCCTATGGTAGTAGTTTACTTGTC 3936

0002 CAAAGACTCAGAGCTAGTGACTGATGAAGTTGGGACTC

AAATCCTACATTCTACCTCTTAAACCAGGAAACTTCCCT CTACACCCCACTGCTTCTGAAGA

LL GQ2 GCTACCTTCTCCTGCCACAGATACTCTATCCCATTTGCT 3937

GTCATCCAACGACTAACACCGTTTTCACTTCAGAACGTC

AAGCCTTTTCTGTTCTCTTCATGGCCTCCTCCCATTAAA GCTGAAAGTATCTGCTATCAGTCATTTGTCCTAACTGA

LOC400927 AATGTTAGAACGACTTTCCAAGTTTGAAGTTGGAGATG 3938

CTGAAAATGTTGCTTCATATGA

1 PI IN 1 GCACAGCTAGATGCGGTGGCTCATGCCTGTAATCCCAG 3939

CACTTCGGGAAGTCGAGACTACAATGAGCCATGATCAC ACCGCTGCTCTCCGTCCTGGGCAATAGA

LRRCl GTTCTAATGGGAGAAGTGAGAGCAGAAAAGGGAAGCA 3940

CAGGAACCTACTGAGGAATCCACTTGCAAAGA

LRRC42 GTTGATGTCATATTTTTAGTCTTGAGAAACAGCATCATG 3941

CCAAGGAAAGAGCTTGAGCTTTGGAGTAATGCGGCCCT

GAGATTGAATTCTGGCTCTGCCACTTATTAGCTCTGTTC TAGA

l.YRM i GTGAAGTAGTATTTGAAGCTTTTCATCAGTTGGCTCATT 3942

CTTTACTCAAGAATAAACCTCAAGAAACGTCATCAGGG

TCAGA

MACROD2 GTTTCCTTCCTTCGCTGCCGCAGCGTGACTTTTGAAACC 3943

TGGAACTCTAGGGGAGCCCTAAAACGAGCGTGTTGTCC

GTGAGGATAAGTGCCTTCAGAGAAGTCTGAATGGGCTG

TTCTCCCAACAGTGTGTTTCTCTGTATTCCATCCCCATTC

ATGGGCTGAAGTTGCTCAGA

MANEA AATACCTATCCAAATGTTTTCCTTCTGAAGTATTATGTT 3944

CTACTTTTAGAAAACAGA

MAPK10 ACCTTAATTCTATGAGAGTAGGGGCTGTGACTCATTTAT 3945

CTGACTAAATCATGGCCTAACGATGCCTCAGACAGA

MARCH 7 AATTGGAAACATCGAGGGAAAATGGGCTTTTTATTATT 3946

AAAACAAAACCTCAGTATTATCACTTAGAAACCTGAAA TTGAACTCCAAAAGCCAAAGA

MARC) 18 TAAATGAAAAAGAAAGTCTGGCTATTTGGAGTAAATTA 3947

ATGAGCTCCTAGAGGAGATGGGACTAGCAGAGT TGCT

TGTACCAGGAACTCTTAGCGTCGATTTCGAGCTGTTGCT GCCAAAGTAGCAAGGACCAAAGA Gene Sequence SEQ ID NO:

MDN1 ATATGATAGCAGCCTTGGTGAGCAGACCACGACCATGG 3948

GGTTTACCCAGTGGGATCCCGTCACGGCTTCTTCCCTGC CTGTGTCTCTCCCCGACCCCTGATTCCGGCCATGAAGTC TTAAGAGCCAAGTGCTGTGTGCGGCTGCCCAGCACAAA CCGTCTCACTCTTTTCATTGTCCATAGGCTTTTGCTTTTT TAAGA

MEAF6 GGTCAAACAACTGTTCTGCCGAGA 3949

MEMOl AAAGCGTGCTCTGGAATGGATTCACAAATGAGCTACCC 3950

TCCTTCCCTCAAAGA

MFN2 GGCACTTCCTCACATGCCAGCGCAACTCCCCAATACCTC 3951

AATGA

MLLT10 GAACCCTCCCTCAAGCATGGTGTTAGACTGGGTGACAA 3952

TGGAGA

MMS19 CATTAATTTACAGAAATACACGTATTCTCCTTGTTTTGG 3953

TGGAAGCTGCAGCTGCCAATCATCTCTCAAACCCTGTG

GGTAGCTGCTAAGCTGTATTTCAGAGGAATGTCACAAT CATACCACTGGGGAGAAAGA

MORF4L1 AGGCTGAACACTTTAGAACTACTACCAGAAAGA 3954

MRPL39 TCATTCTTCACTACCTCGCCTGAGTCGTACCTCCTCCAT 3955

GGAACAGTCTCAGA

MRPL 5 GTCTGGGTGGTGGCTCATACCCGTAATCCAGCACTTTTG 3956

GAGGCCGAAGTGGGAGGATTGTTTCTGGGCAGCAGA

MRPS28 ATGGGACCTGCAAAGGATAAACTGGTCATTGGACGGAT 3957

CTTTCATATTGTGGAGAATGATCTGTACATAGATTTTGG TGGAAAGTTTCATTGTGTATGTAGAAGACCAGAAGTGG

ATGGAGA

MTMR3 AGGCGTGTGTGTATGTGTGTGTGTGTTTCTTTTCCTGAA 3958

CAGATTGAGA

MYB ATAGGACCTCTTCTGACATCCCCAGGAATATTATATGAT 3959

TAGAAGCCAAGGGATGA

MYCBP2 GTGACCAACTGAGTGCCATATTGAATTCCATTCAGTCAC 3960

GACCCAATCTCCCAGCTCCTTCCATCTTTGATCAAGCTG CAAAACCTCCCTCTTCCCTAGTACACAGCCCATTTGTGT TCGGACAGCCCCTTTCCTTCCAGCAGCCTCAGCTTCAGA

MYCBP2 GCATCTAGCATAGAACTCCCTATTCTGCATTATGACTAC 3961

TGGACCACTTATCTCTCTGCCCTACTTGATAAGTTCCAT GAGGACAAAGA

MYLK CTTGCTGCTACTTGCCAGGCCTTAAGTGGAAGAATGGA 3962

GTGTTGATTGTGTCAGTCAAGA Gene Sequence SEQ ID NO:

MZT1 GATCCCATTTGAACAGAAAACTCACATTTTCTCTGGTGG 3963

AATCACTGATGTACAATTGAGAACTGATGGTTTGTGTTG GCTGCATCATCAAGATCTCTTCTGAGAAAACTTGGTGTG

AAATGAAGATTATAAAGAGA

NEDD4 ATTTACTTTATCACATACCTATCTGTCTATCCATCAGTCT 3964

GTCTTAGTTTCTTCATGCATTTCAGA

NFASC GTGGAAGTGGAATACTGGAAGAACCCAGCAGATCAACT 3965

CTGAGCTGCCCTTTGCCCTTTCAGAAAGTATCTCATTCC

AAACAGTTCTTCGAAACTAACCTCTTGCCCTCCAGCTAC

AGA

NGF GTTGGTAGAGGTGCAGCAATTTTTGCAGTGAAACTGAA 3966

GTCCAGCTGCTCAAACAGAAATGGCCTCATCTAATGGA CACTTTAATGA

NIPAl GTATTAAAGGAAGTAATCCGGTCCATACCTGAGCCTGG 3967

TATGCCCTCCTCCCGGACGTTCCTGTTTTCTGATCGTCTT CAGCACAGACATGA

NLGN1 TGACTGCTCATGAAAGAAATTAAAATGATACATCATCA 3968

GTGGATCTTCCTGTAGA

NLN CTCACTGCTTAGAATCTAAGGAGACAAGACCATAATAA 3969

AGGACAGTGTAGAAGACCTGAAGTTTTAAGCTCCAAAT CTCTTAGCTACCAAAATAAATAAATACTACAGAGCTGT

TTGTGAGCAAGAGAAAACATCTAGACAGA

NREP TGTTCCAGGGCGCCATTAACGATTGGAGTTGGCACAAA 3970

ATTTGAAACTAGAAGTGGACTATTTGCTCCTTGAGA

NSUN4 GGGCTCAGGAGTCCAGCGGTCCTAAGTATACCTTGCAG 3971

CCATCTTCCTAAAAGTTCTGACCATGACTGAGGACACTG AGAAGGA

NUPL1 ATGAAAACTACTCCAATCAACTTCTTCAATCTGTTCTGC 3972

CACATTTTAGCCAGA

OSBPL3 TGATGACAAATAAATGGTTCCAGCCTAAACTGACAGCC 3973

AGATACCATTGTCCAGCTTTTTGTCTCATGGAAGCCGCA

CGCTTCAAATATGCACCAGGTGCATTTCTGTTGCTGGAT

TGGGCTCTGAGCAATCTGATGTCCCCTGAAGAAGTGGA

TTGTGAAGGCCATGGATGGAGCAGGGAATAGAAATGG

AT A C T C T ATT GT G C C A G A

PAPD4 AGCTCTACCTCTGTTTTGAAATGTCATTAGTTTGGATAT 3974

GTTACCAGGATGCAGCAAAGAAGA Gene Sequence SEQ ID NO:

PBX3 TGTTTTGAAATGCTTCAGAGAATGTGCGATATCCTTATC 3975

AACATGATAAAATATGAAACTGTGATTGCCTGCAGCAT

TTTACAGACATGAATTCCATCTTCACTGATGAGGCTTGA

TAAGGCGCTGTTGTATAATACAGTGCATAATCTCAAAC

CACCAGA

PCDH10 TGAACAAGTTACCAGATCCTTCTCCTCTGAACTCGGGTT 3976

GCAAAAAAAGCCTTCAGTTCGGCTCTGGACAGCATTTA CAGACGCTCTTGAAGCCGAGCGCCCACACAGTGTGAAT TTGAATGAAGCTGCGTTGGCACAAACCCCTGTTAAGA

PDE3A CTACATCATCTTTTCTAATTAAGAGAAAGAGAGAAAAC 3977

CAGCGTGCAACTTAAAGACAGCTAAGGTTATCTTCTGA AAGATGCGGGTTCTTACTAGA

PDE7A CATGAAGGAATGGCCACAGGACAGGTGACTAGTCATTG 3978

TGGGATGGAATTATAGTCGATGAAGTGAGCCTTGGAGG AAGTCATGGTCCTACTCAGAGAAACAGA

PDXDC1 TCTTCAAGGAAAACTATTTGATTTTCACATCTATGATGA 3979

GAGAAAACAGAAAAATTGTCAAGA

PDXDC2P TCTTCAAGGAAAACTATTTGATTTTCACATCTATGATGA 3979

GAGAAAACAGAAAAATTGTCAAGA

PELI1 ATTATCAAATACAGAAGTAGAAGCCAAGATTGAATGTG 3980

TTCCTGTGATTGAAACTTTGATGTCACTGATAAAATATC

CCCAGATAAGGCCTTCTAAGAGATCTAAGCAGA

PIGN GGGCATACTGCAACTGTCAGTGCATACTTTACGGTGGG 3981

AAAACTTGGAGAAGGAATGGGTTAGGAAAAAATCAGTT TCTGAGGA

PITPNB TGAGCTTGGAGTGAAGTCTAGTACGTCTGTGCAGCAAA 3982

GAGACCAGA

PITPNB GCGAAAATGGGCAGTGTTTACAGGCATGAATGCTGGTG 3983

GAAAGAGCAGAGTAAGGGCAGATTGCACAAGAACCGT

GGAGGCCCTGGTTCCCATCACCTCCACCTCAGCACAGA

CTTCAGAGAGGAGAGGAGGCACTGGATGCATGACAGC

AGCACTTGAGATAGGTGCTCCAGGTGGAAGGCACTGCA

CATGCAAAGGCTGA

PMS1 GGATTCCCCCAGCAGACGTTTTTCATCTAAGAAATGGCT 3984

TGAGTGCTTCCTTTTATCGGGTGCTGTGATAGATTCTCA

AAATATGAAAATGA

P ISR ATTTTGCATTTGTTGGATTTGTTAGTAGTGAAGATACTA 3985

TGGTGAAGATGAAGGAAGAAAGA

P0MT2 ATGTCCACTTAAAAAAATCTGGCGATGGGAGCAGAAAG 3986

A Gene Sequence SEQ ID NO:

PPARG ATGGTGACTGATGCATCTCTAACACACCACATCACAGA 3987

CTTCCTGATCATCAGAAGA

PPFIBP1 CCCTGTAATCTCTTCAAGAGATGATGATCTTTGATGGCA 3988

TTTTGGGGGTGATGTTCAGGTGGCAGCCAGATTGGAGG GGACCGTGGAGCAGACTGTGTGACTACTCATTCCAAGG GCATCATTGTGGAGA

PRPF31 GACCGAACTCAGAGGCCACCTCATCCTATTAAACCTGTT 3989

CTGGTTCCTGACATCCCCCGACCCACACGA

PSMA4 CAGAGAGACGCAACATCCACAAGCTTCTTGATGAAGTC 3990

TTTTTTTCTGAAAAAATTTATAAACTCAATGA

PXK CTGTAAAGTTTGACTGAGAAATGTTGCATCAGCCCTGA 3991

AGTTTATTGAGAAAATCTTACGCTGATGCAAACTTTTTG

GACTGTTAGTGTCTTATGA

RAB23 AGTGCTGGAATATGAATGAGCCAAATTGTGCTGTTCCA 3992

TTGACACTGGTTGCTACAGAATTAACTTTACTCGGAGAT CCGAGGAGCCATCGGCAGTTCCCAGGAGTAAGAACCTG AGAGC GTGTG A G A

RAB23 AGTGCTGGAATATGAATGAGCCAAATTGTGCTGTTCCA 3993

TTGACACTGGTTGCTACAGAATTAACTTTACTCGGAGAT CCGAGGAGCCATCGGCAGTTCCCAGGA

RAF1 AATAACAACCTGAGTGCTTCTCCCAGGGCGTGGTCCAG 3994

ACGATTTTGTTTGAGGGGAAGA

RAPGEF 1 AGTGAAAACGCCAGTGAGGAAGCTGGTGAGGGTGAAT 3995

ATGTCAATCTGTATTCCTCTGGCCAGAGCAGCGAGGAG CTGGCTCCCTCTCGAGGA

RASIPl CCGAGCGTGGTGACGCATGCCTGTAATCCCAGCTACTC 3996

GGGAGGCCGAGACATGAGAATAATTTGAACCCAGGAG GCAGAGGCTGCAGTGAGCCAAGATCGCGCCACTGAACT CCAGCCTGGGGGACAGAGCGAGACTTCGTCTCGAAAAA

ACAAACAAACAAACAAACAAAAAACTGTCCTCCAGAA AAAGAAAAAGGAATTGGAGACCTAGGAGCCGGAAGA

RBBP8 GACCATCTTAAGCAAGTCTCTTCTCCTGTGCTACTTGAC 3997

G AC TC TTTTG AT AC ATGA AG AC AGCT ATC ATGGCC CTCC TGAGTCTTGTTTTC TC T AGA

RCOR3 GTTAACTACTGTGAGATAGTGGGGCCCCAATGAAACAT 3998

ATAAGCATACCTTTTAAAATGTTGCCAAATAGTCTTCAG

AGAACATACTTAATACAAAAATGCTGTGCAGACATCAT TCCGATTGATCGACTGATGGATGACTCCGCAGTTTGGAT

TAG AG AG A Gene Sequence SEQ ID NO:

RERE CTGAAAAGGAGATGAAGATCCTGCTTGTAGCTGAGCAG 3999

TCTTTAGAAGTCTGCTGCATTCTTCCCAAATTCCATCAC

TCTAGTCAAGA

RGL1 GGTGAGGAGCAATCTGTGGGAAGTCAGTGCACAGTAGA 4000

GTTCAGTCTTCCAACGCTGAAAATTTGCCAACTTTCACC

CACACTGTGGAGATGAGAAAGCAGCTGTGGGCAGACA

GTAGA

RNF130 AATGGTTTATTATTGCCAGTTTTGGCCTCCTCAGTGCCC 4001

TCACACTCTGCTACATGATCATCAGAGCCACAGCTAGCT

TGAATGCTAATGA

RNF144A GAAGACTTTGCCAGTCTCTGGTCCACACTGTTACTGGAC 4002

TTCAGGATAGCACATTGTTCACCACAGAAGGAAAGATG TGGAAATTAAGA

RNF213 AACGTGTCCCTAGTGCTAAGTGGCGCGGGACTCTGCTTT 4003

GCCTGCTGTCCTGCGGAGGCAGGAGGTGACCAGGAGAG TGA

RPF2 GGTACAGGATACAGTTTGACTACTTAAAGTTTGAAGAA 4004

AAAAGAAGAGTAAGAAAGA

RPS10 GTCCTCATAGCACACGATTGCTCTCAGATAATGTCATTT 4005

GTAAAAAGGAAGCATGTACAGTAGAAACGGTCCAATCC TGGTGCTGGATGCTTTCATAGGA

SAMD4A AACTCCAGGTTGACCATGGCAGAAAGGGCTCAGATTCC 4006

CCTTCCAGTGCTTCTTGCCAAAATCTGGGAAATAGGAA CCAGA

SCOl AGAAAGGATTTGAACTTGGCCTTCATGTATCAACTAAG 4007

TTAATCGAGCCTTGAATTGAGA

SE P6 GCATTCTGTTCAGGCAGCAATTTGGAAATCCACCATTTA 4008

TCATGA

SF3B3 ATTTAACATTTTTGAGTCAATCCAAGTAATGCAGGAGGT 4009

TCATGATTGTGTAGA

SGIP1 TAGAAACAGGGTTTCGTCGTGTTGGCGAGGCTGGTCTT 4010

GAGCTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCC CAAAGTGCTGAGATTACAAGCATGAGACACTGTGCCAG GCCAAGAGCTTTGGAGTTTTCTAAGGAATCCAGTGAAT ACCAAGTTCCATGCTTATGAAAGA

SGMS1 GCTCTTCTGGAACCCTGGACTCAAGTGATCCTCCTGCCT 401 1

CAGCCTCCTGAGTAGCTGGAACTATAGGCACAAGCCAC

AGCACCGCCTTCAGTCTTTGCTTTGAGTAGA Gene Sequence SEQ ID NO:

SGPL1 GCCTTTGAGCCCTACTTAGAGATTTTGGAAGTATACTCC 4012

ACAAAAGCCAAGAATTATGTAAATGGACATTGCACCAA GTATGAGCCCTGGCAGCTAATTGCATGGAGTGTCGTGT

GGACCCTGCTGATAGTCTGGGGATATGAGTTTGTCTTCC AGCCAGAGA

SH2B3 GTGGATTCCTAGAAGTGGCATTGCTCAGTCATAGA 4013

SKP1 GGACAACTGCATTATTGGCAAGCGCTAAGCAACATGGA 4014

GAAGCAGACATGTTTGTGAATCGCAAAGTGAAATCTGA TTCTCTCCAACTATGGATGAGTGAGA

SLC12A2 TCAGCATTTTGTAGTTTTCAGCATATACGTCCTGTATGT 4015

ATTTTGTTAGATTTACGA

SLC25A16 CCAGGCTTGGTGGTCCCAGCTACTTGAGAAGCTGAGTT 4016

AAGAGGATTGCCTGAGCCTAGGAGGTTGAGGCTTCAGC

GAGCTGTGATCATGCCACTCTACTCCAGCCTGAATGAC

AGA

SLC25A17 ATTTGTTCAAGTTGAAATTGTAAACCTATGCCAGAACTT 4017

GCATGAAGAGATGA

SMOX CTGGGAAGACTGAGGCACAGTCATACAGCTAAATAGTG 4018

ACAGAATGAGGATTGAATCCAAACATTTTACAGACGGG AGGACTGAGTCATAGTCATACAACTAAATAATAACAGA

SNAP23 TATTGGAATATGACAGGGAAGATGAATTCACTATGA 4019

SNX24 AAGAATGTTCCTTTTGTGAAGAATGACTTAAGGAAGAT 4020

TCATGATGACTGAGTGTGCCCGTGTGGAACTTTAGGAC

ATAGATGCACTCCTACAGA

SNX7 AGTTTGCAAAGGAAGGAAAGGAGCAGAGACTTGAATG 4021

AGCAGAAAATCATTTCAGGGCCTGTTCTCTATGTCCTTG CTATCCCTGTCTTCTGTAGCTATTCTGAAACCATCAACA AAGGAGC AC AC C ATTC C ATC AGC A A A AGA

SOCS6 AATCCACAAAAATTAGCCGGGTGTGGTGGCACACACCT 4022

GTAATGCCAGCTACTCGGGAGGCTGAGGCAGGAGAATC

GCTTGAACCCGGGAGTCAGAGGTTGCAGTGAGCTGAGA TGGCACCACCACACTCCAGCCTGGGCGACAGA

SOGA2 TTCAGCAGTGCAGAGAGAAGCCGTGAGGAGTTCCGGTG 4023

TGAAGAGAAAGAATCTGAAAATGGAATGCTCTTCCTCC

CTCCCCTAAGTGGAAAATGTGAGGGGAACTTTTTAGA

SORCSl ATATCGCAGCACATTGCAAAGTCTCTGACACCTTTCCCT 4024

TTCCAGTGTCATTAAATGA Gene Sequence SEQ ID NO:

SPIDR GTATTCAGTAGAAGCAGATGAACAGCCAGATGAAGAG 4025

ATGGATAGAGCAAGACATGGACATTATAAAGGAATTCA

ATAGAAGCACATGAACGGCCAGATGAAGAGATGGATA GA

SPRYD7 GTGTGGTTGTACGTGCCTGTAGTCCCAGCTACTTGAGAG 4026

GCTGAGCTGAGAGGATCTCTTGAGCCGGGGAGGTCAAG

TCTCCTGTGAGCAGTGATCATCGTGCCGCTGCACTCCAG CCTTGGCACCAGA

SRE 1 GGTGGCTGCACTCAACGAGTTTATGCAATGACTTTCTTG 4027

GATGTTTCTGAAGGAGGAGGATGTACAGAGA

SSBP1 GAGGCGGATCTTGGTCAGTAATGCTTGCTCGCTGCTTGC 4028

TGCTCACCTCCTGCTGTGCAGCCAGGTTCCTAACAGGCC ACAGAACTCTACTAGTCCTCAGCCCTGGAGGTTGGGGA

CTCTCCTCTAACTGGCTGTTCGTTATGCCTGAGA

STRADB AACTAGGCTTGGAAGAAGCCAAGAGAAGCTGCATGAC 4029

AAGGACCAGGACTGTGGAATAGGAGCAGCCTAGTGAAT

GTACTGCCCGCCACCAGACGCTGGCCCCCTGCTGATAG

CTCTGACGACTGCTGCTGCTTTGTCCTTCACTCCGTACT

CCAGTTGGCCAAGCATAGGTCGCATGCCAGGGTCAAGG

AGACTAAGGGAGA

STXBP4 GTTTAACCATGGTTGGAAATGACAGA 4030

STXBP6 AATGTAAGCTCCATGAGGGAAAGTACTTTGTTGCTCTTC 4031

TTCTCCTCAGTATCCTCAGCGTTAGGACAATGCAGTGAT ATTGAATGA

STXBP6 GTGGTCCCTGAGTTAAGAACATGCAATGGCACTCTCTC 4032

AAGGAGAGGAAGGAGCCAAAGAAGAAAGAGGTCCAAA GCAGAAAAGAGCAGACAGCTAAGA

SUPT20H TTGAAGACGATAATTCTAACTTCCTGTCAGTTGAAGACG 4033

ATAATTCTAACTTCCTGTCAGTTGAAGACGATAATTCTA ACTTCACACTTAATTAAAAGA

TAF2 GAAGATGATCACCTTGCCAAGGAAGCATCATGTAATAT 4034

ATCAGCTCATCAGCAGGGAGTGAAGAGGAAGTCTGATA

CACCACTGGGGTCCCCACTAGAACCTGGTCAAATACTG GAGAAGAATGAGGATAGCAGTAAAGTCAAACTCAAAA TCAGA

TAF2 TTTTGAGATCCACCAAATATGTCATTGTTGCCAGTCTTC 4035

TTTCCCAAGATGTATGGATAGTTTTTAATGTCTCATAAA

TATGA Gesie Sequence SEQ ID NO:

TARBP1 CCGATTTCAGCCTACCAATGTGAGGCCACTGAGTTGGA 4036

AAGAGATATGATCTTCGGTCTTTGCGATGCTGGCTGGGT

CTGCTGCTACGCCGCTGCCTGTCTTAGTTCACAGAGGAA ATAGTGGCTGTCAGGCTGGAATGCTCTCAATTTCCAGTT GCCAGATGTATGGACTTACGCTATATGCTCAACCACAC

CTGAATTCATCCTCCCTGTCTTCCCTTTGTTACAAGAGA

TASP1 CTTTGGACCTTCCTCTCCCTCTGGTTTCCTGACTTCTATA 4037

AAAGAATAGTTGAACTAACTAGTGGCATACCTGTTCAG CATCATGACTGGTTTCCGAAACATGTTCCTCCATAATGT TGAGAGCCGTGGTAGCGAAATGA

TBCA ATCCCGCTATCTGTCCTGTGATGCCATACTAGA 4038

TBL1XR1 ATTCCAGAATGAAGAAGATGCCTGTAGCCAACCTGTAG 4039

CTGACAACAAAAATGAGAAATACATTTTGCGCTGTCTG

TTGAACCCAAGACCCTTTCAGA

TCF4 GATTTGCCTCCAAGAAAAAATATATTTTATTGCCACATT 4040

TTCTCAATTGATCCAGTAGAGTTCACAGACAATGAAAA

GA

TEKT4P2 TTGAAGAGATACCATTTGACATTTTAGAGATGGCTGCAT 4041

GCAAACTCTTAAAACATTTGA

TET1 AGATCATGCGTAATATTCCTGTTTCATGGGCCATAAGGA 4042

CATGTGTTTAATTCATAAGGACATATGGATTCCATTTGA

AACAGGATCTCACACAGA

TIAM1 ATACCAGAGAAGCGTGAACATATTGCTTTGAAATCTAC 4043

TTGCTCCTAGTAAAAAAGAGATTGTCTTTATTGGAAAAT

TCCCTCTGAGATTCCTGTGATGTGTGACCTGGTGGGGAA

TATTCCAGCCTGGGAACAGCTTAACATCTGGTGTCTGTA

TGAGTTACCCCTGAACTCACTGGAACATTCAATGGAGG

GTTTCCCTTTGTGTTGCCACAAATTTTATTTCAGTGAAG

ATGTGCTGGTGAGAGTTTCAGCAACGTTTTAGCCTGAAC

AGTGGAATTATAGA

TJAPl GAGTAAGATCTTCTGTCTCTGAAGCTTCTTAGGGGCAAG 4044

CTTTTTTACTGAAGGCCAAGCATTTAGGCACTATAGA

TJP2 GGATTGGTGTCTCTATCATCCAGCTGGCCATTAAACAAC 4045

CAAAGCTTCATCATCCTAGATAACCTGTGAGCTCTCAGA

GGAGACAGA

TMEM214 CCATCCTAGATCTGAGATTTGCAACCTGGAAGTTCAAG 4046

A

TMX3 GGAAGGTAATGAGAATTATAGTACTTTAATTTTCCAAG 4047

CTCTTGACCATGAATGTGTAGATTATTTTTCAGAAGGCG

TAGATACAATGCAGTTATCAAATGCAGA Gene Sequence SEQ ID NO:

TNRC6A GATGGGAGAGAGAAGAGCATGAAAGAAGCGGTTGGGA 4048

TTAGCCTTCTTCAGTAACATACCCTGGGGTCGTCCTTTG

GAATTTCATGGTTATTGTGGTGTATGTGACCACATTTAG

AGTGCACTGCCTCAGACCTGCCTTAAAGCTGTGTCATAG

GATAAGA

TRAP 3 CACCAATACATTATTATGAAGTCAGTACAGAGAGATTG 4049

GCATCTTAGTATTTTCTGAGGAAGAGAACAGCCAAAGA

TRIM65 GCCCCAGGTCCCCTGGCACCGGTCCCAAGCACAGTTTG 4050

TCCACTGAGGAGGAAACTCTGGCAGA

TSPAN7 GTCTATAGAAGAGGAGGGAAAAACACACCTAGGA 4051

TXNL4B TTGTGGCGCGCGCCTG AGGTTCC AGCTACTCGGGAGGC 4052

TGAGGCGGGAGGATTGCTTGAGCCTGGGGAGTTGAGAC CAGCCTGGGCAACATAGCGAAACCCCGCCTCAGAAAAA GAGAGGGAGAGAGGAAAGCAGTGGAGTTATTGGTCAA

AGA

UBE2D3 GTGCTGTATAAACAGATGAGAGTGCCCCCACAGCATTG 4053

TTATTAGA

UBE2L3 AATGACCACCTGAGAAGGAGTGTGCTGTAACCTCTGAG 4054

AAGCACTGTGCTGTGATAGA

UBN2 GATCACAACTTTTACAGATTTTTAAAATATTGGCCGGGC 4055

GCAGTGGCCCACACCTGTAATCCCAGCACTTTGGGAGG

CTGAGGCAGGAGATCAAGACCATCCTGGCTAACACGAT

GAAATCCCGTCTCTACTGAAAATACACAAAATTAGCCA

GGCGTGGTGACACACACCTGTAGTCCCAGCTACTTGGG

AGGCTGAGGCAGGAGGATCACCTAAACCCGGGAGGTG

GAGATTGCAGTAAGCCGAGATCGCGCCACTGCACTCCA

GCCTGGGCGACAGA

UNC13B GTCACTGGACCTATTTGGGCTGGGGAGAACAACAGA 4056

URGCP- GCTTTGGGGCAGTGGTCATTTCCGGGACCAGGCCTTTTC 4057

MRPS24 ATTGCCAGCTGACTACCCAGCACTTTGAGCTCATGAATA

GA

UVRAG GAACAAAGCCTGAGCCTCCAAGCCAGAAGCAAAGTTTG 4058

TATGCGTGGTTAGACAGGTTGTTTCTGATTGGAGAGAA

CCTGGAAAGAATTAAGCCAGTCACACACAGGTCCATCT

CTGAAGCCCAGCCATCAGATCAGTCATCTGCTGGTCCTG

GAGAGGAGTGAGTGGAGGACACAGAGAAACTGCAGAT

GCTCCTTTCATGACCTTTTCTCCTGAGAAATGGAGTGGG

GCATTTGTCTCCTGTGTGGGAACATGGGAATGCAGA

VDAC2 ACATGGCAGCCCCTAGCATGTGTATCCTAAGA 4059

WDR27 AGCTGCCCCTGGAGCAGAATATTCCCTGCTTGGTCCAA 4060

ACCACAGAGA Gesie Sequence SEQ ID NO:

WDR90 CCTCCTGGCAAGGAGCAGAGCTGGCGGGAGGCGGCTTT 4061

GGGGAAGAATC TC TGTCC AC A AAGA

WHSC2 GCTTTCTGCGGGAGCAGTGGTGGCCCCGGCTTCTCACCC 4062

TTCAGGTTTTCTTGCATCTGCGCACCGGTGGAAGA

W ^' N i GTTGTCCAACATGTGAGCATTTTCTGGCTGGGGAGA 4063

XRN2 CCATCAACAACTCTTAGCTGAAAGAGGGATAAGGCCCA 4064

AGCAAGGATAGAGAGA

ZFP82 ATCTTTGTACATTATCCCTGTGTTGAAATGCAAATAGGA 4065

CTTCCCTGGAACCAAATCTTCTATATCCCAGAACTTCTT GTATCAACAAAGTAAGATGGTTGATACAGTGCCCAAAT AGA

ZMIZ2 GGGCACAGGGTCAAGGATACCAGACCTGGAGACTGGA 4066

AGTCTTTTCAGAGAGACTGTCCTCAGAGAGGAGACCAG AGGCATGAGTTCGGGTCGGCAGGAAATCCCCCTGTGCA

GTGAAGA

ZNF 138 GCCTCTGGAAGAGCAGGACCTCTCCCAGACTGTGATTG 4067

GGAGGAGTTTGGGATGGTTACAGA

ZNF208 GCTTCTGGAAGACAAAGACCTCTCACAGACTGTGGCTG 4068

GGAGGAGTTTGGGATGGTTACAGA

ZNF212 GAGGATGTATTTAAGCTTTTGTCTCATGTGTTCCATGAT 4069

GAATTAACTGACTTGAGTAACTAGA

ZNF280D AAATCAAGAAGTTTTAATATTTGAGCAGTGCTTATGGA 4070

GGTTTTAAAGAGAATATATTCCTCAAAATTCTAATTACT

TCTGTGATTTTACTGCCTCCAGA

ZNF350 AGTCTTGCTCTGTGCCCAGGCTGGAGCGCAATGGTGTG 4071

AACTTGGCTCACCGCAACCTCCACCTCCTGGATTCAAGC

GATTCTTGTGCCTATCCCCAACACCAGCACCATACCTGG

CACACGGTGATCATTCAGTAAGA

ZNF37BP AGTCAAGAACAGACACTGAGTCGCTTGAGGACTCAGGC 4072

AGGTGTTTGCTGCATTGACAACAGA

ZNF426 CTACTCAGGAGGCTGAAGCAGGAGAGTTGCTTGAACCT 4073

GGGAGGTGGAGGTTGCAGTGAGCCAAGATTGCACCAGT GCACTCCAGCCTGGGCAACAGA

ZNF618 AAACTGCAAGTCCCCTGATTTCCAACCCTTTCCCTCTCC 4074

TACAGA

ZNF680 GCAGAACTGGCCGTGAACTGTGGCTCAGGGAGCTGGAA 4075

CTGAGTCATCGAACTGCTTCAGAAACCACAGTAAAGGA

CAAGGTCTGCAGGCCTGCCTGCGTGGCTATAAATGGCT

GTCTTCCTCCAGGCCTCTGGAAGGGCACGGTCTCTCCCA

GACTGTGGCTGGGAGGAGTTTGGGATGATTAGAGA Gene Sequence SEQ ID NO:

ZNF730 GCCTCTGAAAAGGCAGGACCTCTTCCAGACTTTGGCTG 4076

GGAAGAGTTTTGGATGGTTTCAGA

ZNF777 GCCTCACTACTTCCTCATTCCCCATGTCGGAAACCCCAG 4077

GGTGGAACCCAGACCACCTGAGCACACCTGCTGCAATG

GACTGCTGCCCACTCCTAGGAGTGGTTGAATTGCCTGCC

TTCACCTGCCTCGATGTCTCGCTCTGCTTATAGCAGAAG

CCAGGCCAGAATACCCAGAAGCCCGTTCAGCCTCTACA

GCAGGGGCCGGGCACATAGAAGATGTTTCCAAGTCAAA

CATACATATACCATACTGACTCATTGATATGAGTCTGCA

ATGCAACTGTTATCAAAGA

ZNF804A CTCTCTGTGTCAGATTTGACCTTGGAAGATCACAGAGG 4078

AAAAGCGAGAAGGA

ZNF836 TGCCTAAATGAAGACGTATGGGTCTTTTACTGTTTTTTG 4079

CTGTTACAAAGAATGTCACCGTGGCTGCCTGTATGCATG

CTATCTTTACCACAGATGTCTGAAGTTTCCTCCAGGTTG

GGCAGTTTAAAGA

ZSCAN25 GCTCTGGGTGATCTGGTTTCTGTCTGCCTCTGCCACCTC 4080

TTCTGGTGCAGCTCTGCTCGTCACTGCTGAAGCCACACT GGGATATGGCTTGTTCTTGGACACCCAGA

[00584] Results: For certain genes, where the values for splicing modification may have been considered statistically insignificant, the values in those instances prompted manual examination of RNAseq data for the likelihood of iExon production inclusion. Those events that

demonstrated qualitative reads to support iExon inclusion were subsequently validated by end- point PGR. As demonstrated herein, the presence of an iExon has been demonstrated and validated for numerous targets,

[00585] It will be appreciated that, although specific aspects of the invention have been described herein for purposes of illustrati on, the invention described herein is not to be limited in scope by the specific aspects herein disclosed. These aspects are intended as illustrations of several aspects of the invention. Any equivalent aspects are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description, which modification also intended to be within the scope of this invention.

[00586] All references cited herein are incorporated herein by reference in their entirety and for all puiposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.